CA3139526A1 - Triaryl compounds for treatment of pd-l1 diseases - Google Patents

Triaryl compounds for treatment of pd-l1 diseases Download PDF

Info

Publication number
CA3139526A1
CA3139526A1 CA3139526A CA3139526A CA3139526A1 CA 3139526 A1 CA3139526 A1 CA 3139526A1 CA 3139526 A CA3139526 A CA 3139526A CA 3139526 A CA3139526 A CA 3139526A CA 3139526 A1 CA3139526 A1 CA 3139526A1
Authority
CA
Canada
Prior art keywords
methyl
methoxy
compound
group
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3139526A
Other languages
French (fr)
Inventor
Pingchen Fan
Christopher Lange
Venkat Reddy Mali
Darren J. Mcmurtrie
Viengkham Malathong
Sreenivas Punna
Rajinder Singh
Ju Yang
Yibin Zeng
Penglie Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemocentryx Inc
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of CA3139526A1 publication Critical patent/CA3139526A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/195—Radicals derived from nitrogen analogues of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Description

TRIARYL COMPOUNDS FOR TREATMENT OF PD-Li DISEASES
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application is an application claiming benefit under 35 U.S.C.
119(e) of U.S.
Provisional Application No. 62/848,114 filed May 15, 2019, which is incorporated herein by reference in its entirety.
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER
FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
[0002] NOT APPLICABLE
REFERENCE TO A "SEQUENCE LISTING," A TABLE, OR A COMPUTER
PROGRAM LISTING APPENDIX SUBMITTED ON A COMPACT DISK
[0003] NOT APPLICABLE
BACKGROUND OF THE DISCLOSURE
[0004] Programmed cell death protein -1 (PD-1) is a member of the CD28 superfamily that delivers negative signals upon interaction with its two ligands, PD-Li or PD-L2. PD-1 and its ligands are broadly expressed and exert a wide range of immunoregulatory roles in T cell activation and tolerance. PD-1 and its ligands are involved in attenuating infectious immunity and tumor immunity, and facilitating chronic infection and tumor progression.
[0005] Modulation of the PD-1 pathway has therapeutic potential in various human diseases (Hyun-Tak Jin et al., Curr Top Microbiol Immunol. (2011); 350:17-37). Blockade of the PD-1 pathway has become an attractive target in cancer therapy. Therapeutic antibodies that block the programmed cell death protein -1 (PD-1) immune checkpoint pathway prevent T-cell down regulation and promote immune responses against cancer. Several PD-1 pathway inhibitors have shown robust activity in various phases of clinical trials (RD Harvey, Clinical Pharmacology and Therapeutics (2014); 96(2), 214-223).
[0006] Agents that block the interaction of PD-Li with either PD-1 or CD80 are desired.
Some antibodies have been developed and commercialized. A few patent applications disclosing non-peptidic small molecules have been published (WO 2015/160641, WO
2015/034820, and
7 and W02018/009505 from BMS; WO 2015/033299 and WO 2015/033301 from Aurigene; WO 2017/070089, US 2017/0145025, WO 2017/106634,US2017/0174679, W02017/192961, W02017/222976, W02017/205464, W02017/112730, W02017/041899 and W02018/013789 from Incyte, W02018/006795 from Maxinovel and W02018/005374 from us, ChemoCentryx). However there is still a need for alternative compounds such as small molecules as inhibitors of PD-L1, and which may have advantageous characteristics in term of oral administration, stability, bioavailability, therapeutic index, and toxicity.
BRIEF SUMMARY OF THE DISCLOSURE
[0007] In one aspect, provided herein are compounds having formula (I):
R7 R1 a R2a R6 R8 Rid R3 `R2b Z¨A R1 b R4 Ric (R3a)n (I) or a pharmaceutically acceptable salt thereof; wherein A, Z, Xi, Ria, RR, Rid, R2a, R2b, R3, R3a, R4, R6, R7, ¨8, and the subscript n are as defined herein.
[0008] In addition to the compounds provided herein, the present disclosure further provides pharmaceutical compositions containing one or more of these compounds, as well as methods associated with preparation and use of such compounds. In some embodiments, the compounds are used in therapeutic methods to treat diseases associated with the PD-1/PD-L1 pathway.
BRIEF DESCRIPTION OF THE DRAWINGS
[0009] NOT APPLICABLE

DETAILED DESCRIPTION OF THE DISCLOSURE
Abbreviation and Definitions
[0010] The terms "a," "an," or "the" as used herein not only include aspects with one member, but also include aspects with more than one member. For instance, the singular forms "a," "an,"
and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a cell" includes a plurality of such cells and reference to "the agent"
includes reference to one or more agents known to those skilled in the art, and so forth.
[0011] The terms "about" and "approximately" shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements. Typical, exemplary degrees of error are within 20 percent (%), preferably within 10%, and more preferably within 5% of a given value or range of values. Alternatively, and particularly in biological systems, the terms "about" and "approximately" may mean values that are within an order of magnitude, preferably within 5-fold and more preferably within 2-fold of a given value.
Numerical quantities given herein are approximate unless stated otherwise, meaning that the term "about" or "approximately" can be inferred when not expressly stated.
[0012] The term "alkyl", by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain hydrocarbon group, having the number of carbon atoms designated (i.e. C1-8 means one to eight carbons). Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. The term "alkenyl" refers to an unsaturated alkyl group having one or more double bonds. Similarly, the term "alkynyl" refers to an unsaturated alkyl group having one or more triple bonds. Examples of alkenyl groups include vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl and 3-(1,4-pentadieny1). Examples of alkynyl groups include ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers.
The term "cycloalkyl" refers to hydrocarbon rings having the indicated number of ring atoms (e.g., C3-6 cycloalkyl) and being fully saturated or having no more than one double bond between ring vertices. "Cycloalkyl" is also meant to refer to bicyclic and polycyclic hydrocarbon rings such as, for example, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, etc. The bicyclic or polycyclic rings may be fused, bridged, spiro or a combination thereof. The term "heterocycloalkyl" or "heterocycly1" refers to a cycloalkyl group that contain from one to five heteroatoms selected from N, 0, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. The heterocycloalkyl may be a monocyclic, a bicyclic or a polycylic ring system. The bicyclic or polycyclic rings may be fused, bridged, spiro or a combination thereof It is understood that the recitation for C4-12 heterocyclyl, refers to a group having from 4 to 12 ring members where at least one of the ring members is a heteroatom.
Non limiting examples of heterocycloalkyl groups include pyrrolidine, imidazolidine, pyrazoli dine, butyrolactam, valerolactam, imidazolidinone, tetrazolone, hydantoin, dioxolane, phthalimide, piperidine, 1,4-dioxane, morpholine, thiomorpholine, thiomorpholine-S-oxide, thiomorpholine-S,S-oxide, piperazine, pyran, pyridone, 3-pyrroline, thiopyran, pyrone, tetrahydrofuran, tetrahydrothiophene, quinuclidine, and the like. A
heterocycloalkyl group can be attached to the remainder of the molecule through a ring carbon or a heteroatom.
[0013] The term "alkylene" by itself or as part of another substituent means a divalent group derived from an alkane, as exemplified by -CH2CH2CH2CH2-. An alkylene group can be linear or branched. An examples of the latter are -CH2C(CH3)2CH2-, -CH2C(CH3)2- or -CH(CH3)CH2CH2-. Typically, an alkyl (or alkylene) group will have from 1 to 12 carbon atoms, with those groups having 8 or fewer carbon atoms being preferred in the present disclosure. Similarly, "alkenylene" and "alkynylene" refer to the unsaturated forms of "alkylene"
having double or triple bonds, respectively.
[0014] The term "heteroalkyl," by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon group, or combinations thereof, consisting of the stated number of carbon atoms and from one to three heteroatoms selected from the group consisting of 0, N, Si and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) 0, N and S may be placed at any interior position of the heteroalkyl group. The heteroatom Si may be placed at any position of the heteroalkyl group, including the position at which the alkyl group is attached to the remainder of the molecule.
Examples include -CH2-CH2-0-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH3, -CH2-CH2,-S(0)-CH3, -CH2-CH2-S(0)2-CH3, -CH=CH-0-CH3, -Si(CH3)3, -CH2-CH=N-OCH3, and -CH=CH-N(CH3)-CH3. Up to two heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3 and -CH2-0-Si(CH3)3. Similarly, the terms "heteroalkenyl" and "heteroalkynyl" by itself or in combination with another term, means, unless otherwise stated, an alkenyl group or alkynyl group, respectively, that contains the stated number of carbons and having from one to three heteroatoms selected from the group consisting of 0, N, Si and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) 0, N and S may be placed at any interior position of the heteroalkyl group.
[0015] The term "heteroalkylene" by itself or as part of another substituent means a divalent group, saturated or unsaturated or polyunsaturated, derived from heteroalkyl, as exemplified by -CH2-CH2-S-CH2CH2- and -CH2-S-CH2-CH2-NH-CH2-, -0-CH2-CH=CH-, -CH2-CH=C(H)CH2-0-CH2- and -S-CH2--. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like).
[0016] The terms "alkoxy," "alkylamino" and "alkylthio" (or thioalkoxy) are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively. Additionally, for dialkylamino groups, the alkyl portions can be the same or different and can also be combined to form a 3-7 membered ring with the nitrogen atom to which each is attached. Accordingly, a group represented as -Nine is meant to include piperidinyl, pyrrolidinyl, morpholinyl, azetidinyl and the like.
[0017] The terms "halo" or "halogen," by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
Additionally, terms such as "haloalkyl," are meant to include monohaloalkyl and polyhaloalkyl. For example, the term "Ci-4haloalkyl" is meant to include trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
[0018] The term "hydroxyalkyl" or "alkyl-OH" refers to an alkyl group, as defined above, where at least one (and up to three) of the hydrogen atoms is replaced with a hydroxy group. As for the alkyl group, hydroxyalkyl groups can have any suitable number of carbon atoms, such as C1-6. Exemplary hydroxyalkyl groups include, but are not limited to, hydroxymethyl, hydroxyethyl (where the hydroxy is in the 1- or 2-position), hydroxypropyl (where the hydroxy is in the 1-, 2- or 3-position), and 2,3-dihydroxypropyl.
[0019] The term "C1.3 alkyl-guanidinyl" refers to a C1-3 alkyl group, as defined above, where at least one of the hydrogen atoms is replaced with a guanidinyl group (-NHC(NH)NH2).
[0020] The term "aryl" means, unless otherwise stated, a polyunsaturated, typically aromatic, hydrocarbon group which can be a single ring or multiple rings (up to three rings) which are fused together or linked covalently. The term "heteroaryl" refers to aryl groups (or rings) that contain from one to five heteroatoms selected from N, 0, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. A heteroaryl group can be attached to the remainder of the molecule through a heteroatom.
It is understood that the recitation for C5-10 heteroaryl, refers to a heteroaryl moiety having from 5 to 10 ring members where at least one of the ring members is a heteroatom. Non-limiting examples of aryl groups include phenyl, naphthyl and biphenyl, while non-limiting examples of heteroaryl groups include pyridyl, pyridazinyl, pyrazinyl, pyrimindinyl, triazinyl, quinolinyl, quinoxalinyl, .. quinazolinyl, cinnolinyl, phthalazinyl, benzotriazinyl, purinyl, benzimidazolyl, benzopyrazolyl, benzotriazolyl, benzisoxazolyl, isobenzofuryl, isoindolyl, indolizinyl, benzotriazinyl, thienopyridinyl, thienopyrimidinyl, pyrazolopyrimidinyl, imidazopyridines, benzothiaxolyl, benzofuranyl, benzothienyl, indolyl, quinolyl, isoquinolyl, isothiazolyl, pyrazolyl, indazolyl, pteridinyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiadiazolyl, pyrrolyl, thiazolyl, furyl, thienyl and the like. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below.
[0021] The term "carbocyclic ring," "carbocyclic" or "carbocycly1" refers to cyclic moieties with only carbon atoms as ring vertices. Carbocyclic ring moieties are saturated or unsaturated and can be aromatic. Generally, carbocyclic moieties have from 3 to 10 ring members.
.. Carbocyclic moieties with multiple ring structure (e.g. bicyclic) can include a cycloalkyl ring fused to an aromatic ring (e.g. 1,2,3,4-tetrahydronaphthalene). Thus, carbocyclic rings include cyclopentyl, cyclohexenyl, naphthyl, and 1,2,3,4-tetrahydronaphthyl. The term "heterocyclic ring" refers to both "heterocycloalkyl" and "heteroaryl" moieties. Thus, heterocyclic rings are saturated or unsaturated and can be aromatic. Generally, heterocyclic rings are 4 to 10 ring members and include piperidinyl, tetrazinyl, pyrazolyl and indolyl.
[0022] When any of the above terms (e.g., "alkyl," "aryl" and "heteroaryl") are referred to as 'substituted' without further notation on the substituents, the substituted forms of the indicated group will be as provided below.
[0023] Substituents for the alkyl groups (including those groups often referred to as alkylene, alkenyl, alkynyl and cycloalkyl) can be a variety of groups selected from: -halogen, -OR', -NR'R", -SR', -SiR'R"R", -0C(0)R', -C(0)R', -CO2R', -CONR'R", -0C(0)NR'R", -NR"C(0)R', -NR'-C(0)NR"R", -NR"C(0)2R', -NH-C(NH2)=NH, -NR'C(NH2)=NH, -NH-C(Nth)=NR', -S(0)R', -S(0)2R', -S(0)2NR'R", -NR'S(0)2R", -CN and -NO2 in a number ranging from zero to (2 m'+1), where m' is the total number of carbon atoms in such group. R', R" and R" each independently refer to hydrogen, unsubstituted C1-8 alkyl, unsubstituted heteroalkyl, unsubstituted aryl, aryl substituted with 1-3 halogens, unsubstituted C1-8 alkyl, C1-8 alkoxy or C1-8 thioalkoxy groups, or unsubstituted aryl-C1-4 alkyl groups.
When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 3-, 4-, 5-, 6-, or 7-membered ring. For example, -NR'R" is meant to include 1-pyrrolidinyl and 4-morpholinyl. The term "acyl" as used by itself or as part of another group refers to an alkyl group wherein two substitutents on the carbon that is closest to the point of attachment for the group is replaced with the substitutent =0 (e.g., -C(0)CH3, -C(0)CH2CH2OR' and the like).
[0024] Similarly, substituents for the aryl and heteroaryl groups are varied and are generally selected from: -halogen, -OR', -0C(0)R', -NR'R", -SR', -R', -CN, -NO2, -CONR'R", -C(0)R', -0C(0)NR'R", -NR"C(0)R', -NR"C(0)2R', -NR'-C(0)NR"R", -NH-C(NH2)=NH, -NR'C(NH2)=NH, -NH-C(NH2)=NR% -S(0)R', - S (0)2R' , -S(0)2NR'R", -NR' S(0)2R", -N3, perfluoro(C1-C4)alkoxy, and perfluoro(C1-C4)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R', R" and R"
are independently selected from hydrogen, C1-8 alkyl, C3-6 cycloalkyl, C2-8 alkenyl, C2-8 alkynyl, unsubstituted aryl and heteroaryl, (unsubstituted aryl)-C1-4 alkyl, and unsubstituted aryloxy-C1-4 alkyl. Other suitable substituents include each of the above aryl substituents attached to a ring atom by an alkylene tether of from 1-4 carbon atoms.
[0025] Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -T-C(0)-(CH2)q-U-, wherein T and U are independently -NH-, -0-, -CH2- or a single bond, and q is an integer of from 0 to 2.
Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH2),-B-, wherein A and B are independently -CH2-, -0-, -NH-, -S-, -5(0)-, -S(0)2-, -S(0)2NR'- or a single bond, and r is an integer of from 1 to 3. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the sub stituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -(CH2),-X-(CH2)t-, where s and t are independently integers of from 0 to 3, and Xis -0-, -NR'-, -S-, -5(0)-, -S(0)2-, or -S(0)2NR'-. The substituent R' in -NR'- and -S(0)2NR'-is selected from hydrogen or unsubstituted C1-6 alkyl.
[0026] As used herein, the term "heteroatom" is meant to include oxygen (0), nitrogen (N), sulfur (S) and silicon (Si).
[0027] The disclosure herein further relates to prodrugs and bioisosteres thereof. Suitable bioisosteres, for example, will include carboxylate replacements (phosphonic acids, phosphinic acids, sulfonic acids, sulfinic acids, and acidic heterocyclic groups such as tetrazoles). Suitable prodrugs will include those conventional groups known to hydrolyze and/or oxidize under physiological conditions to provide a compound of Formula I.
[0028] The terms "patient" and "subject" include primates (especially humans), domesticated companion animals (such as dogs, cats, horses, and the like) and livestock (such as cattle, pigs, sheep, and the like).
[0029] As used herein, the term "treating" or "treatment" encompasses both disease-modifying treatment and symptomatic treatment, either of which may be prophylactic (i.e., before the onset of symptoms, in order to prevent, delay or reduce the severity of symptoms) or therapeutic (i.e., after the onset of symptoms, in order to reduce the severity and/or duration of symptoms).
[0030] The term "pharmaceutically acceptable salts" is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present disclosure contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of salts derived from pharmaceutically-acceptable inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc and the like.
Salts derived from pharmaceutically-acceptable organic bases include salts of primary, secondary and tertiary amines, including substituted amines, cyclic amines, naturally-occuring amines and the like, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperadine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like. When compounds of the present disclosure contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, malonic, benzoic, succinic, suberic, fumaric, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge, S.M., et al, "Pharmaceutical Salts", Journal of Pharmaceutical Science, 1977, 66, 1-19).
Certain specific .. compounds of the present disclosure contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
[0031] The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present disclosure.
[0032] Certain compounds of the present disclosure can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present disclosure.
Certain compounds of the present disclosure may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present disclosure and are intended to be within the scope of the present disclosure.
[0033] Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers, regioisomers and individual isomers (e.g., separate enantiomers) are all intended to be encompassed within the scope of the present invention. When a stereochemical depiction is shown, it is meant to refer to the compound in which one of the isomers is present and substantially free of the other isomer.
'Substantially free of' another isomer indicates at least an 80/20 ratio of the two isomers, more preferably 90/10, or 95/5 or more. In some embodiments, one of the isomers will be present in an amount of at least 99%.
[0034] The compounds of the present disclosure may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (3H), iodine-125 (1251) or carbon-14 (14C). All isotopic variations of the compounds of the present disclosure, whether radioactive or not, are intended to be encompassed within the scope of the present disclosure. For example, the compounds may be prepared such that any number of hydrogen atoms are replaced with a deuterium (2H) isotope. The compounds of the present disclosure may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. Unnatural proportions of an isotope may be defined as ranging from the amount found in nature to an amount consisting of 100% of the atom in question. For example, the compounds may incorporate radioactive isotopes, such as for example tritium (3H), iodine-125 (1251) or carbon-14 (14C), or non-radioactive isotopes, such as deuterium (2H) or carbon-13 (13C). Such isotopic variations can provide additional utilities to those described elsewhere within this application. For instance, isotopic variants of the compounds of the disclosure may find additional utility, including but not limited to, as diagnostic and/or imaging reagents, or as cytotoxic/radiotoxic therapeutic agents. Additionally, isotopic variants of the compounds of the disclosure can have altered pharmacokinetic and pharmacodynamic characteristics which can contribute to enhanced safety, tolerability or efficacy during treatment.
All isotopic variations of the compounds of the present disclosure, whether radioactive or not, are intended to be encompassed within the scope of the present disclosure.
COMPOUNDS
[0035] In one aspect, the present disclosure provides compounds having formula (I):
R7 Ria R2a R6 Rs Rid R3 =R2b Z¨A R1 b (R3a)n (I) or a pharmaceutically acceptable salt, prodrug or bioisostere thereof, wherein:
Ria, Rib, Ric and ¨ ld x are each independently selected from the group consisting of H, halogen, C1-3 alkyl, C1-3 haloalkyl, C1-3 alkoxy and CN;
Xi is C1-3 alkylene, optionally substituted with one or two C1-2 alkyl or CO2H;
R2a and R2b are each independently selected from the group consisting of H, C1-8 alkyl, C1-8 haloalkyl, -Y, -X2-C(0)2Ra, -X2-0Ra, -x24RaRb, _x2_coNRaRb, _v_so2Ra, -X2-SO2NRaRb, -X2-SO3Ra and ¨X2-Y wherein each X2 is C1-6 alkylene and any Ci-galkyl or C1-6 alkylene, is optionally further substituted with one or two members independently selected from OH, SO2NH2, CONH2, C(0)NHOH, P03H2, COO-Ci-8alkyl or CO2H, and each Y is selected from the group consisting of C3-6 cycloalkyl, C4-8heterocycly1 and 5-to 6-membered heteroaryl, each of which is optionally further substituted with one to four substituents independently selected from the group consisting of oxo, OH, Ci-4alkyl, C1-4 haloalkyl, Ci_4hydroxyalkyl, C1-4 alkoxy, C1-4haloalkoxy, C1-4 hydroxyalkoxy, SO2NH2, CONH2, C(0)NHOH, P03H2, COO-Ci-galkyl, SO3H and CO2H;

or R2a and R2b are combined to form a 4- to 10-membered ring or spirocyclic ring, optionally having one or two additional ring vertices selected from 0, N or S;
wherein the ring formed by combining R2 and R2b, is substituted with 0 to 4 substituents independently selected from the group consisting of oxo, C1-8 alkyl, C18 haloalkyl, Ci_ghydroxyalkyl, -X3-C(0)2Ra, -x3-0R', -X3-NRaRb, -X3-CONRaRb, -X3-S02Ra, -X3-SO2NRaRb, and ¨X3-SO3Ra; wherein X3 is a bond or C1-6 alkylene;
R3 and R4 are each independently selected from the group consisting of F, Cl, CN, CH3, OCH3, CH2CH3 and CF3;
the subscript n is 0, 1, 2 or 3;
each R3a is independently selected from the group consisting of H, F, Cl, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 haloalkoxy, C2-3 alkenyl and CN;
R6, R7 and le are each independently selected from the group consisting of H, F, Cl, CN, CH3, OCH3, CH2CH3 and CF3;
A is a member selected from the group consisting of ¨N(Ra)-, ¨C(=0)N(Ra)-, ¨S(0)N(Ra)-, and ¨S(0)2N(Ra)-;
Z is selected from the group consisting of:
i) a monocyclic, bicyclic, or spirocyclic non-aromatic heterocyclic ring, optionally substituted with one or two oxo groups and optionally substituted with up to four IV
and/or Rb;
ii) a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three Rc; and iii) a fused bicyclic heteroaryl ring, optionally substituted with one to three Rc;
wherein when A is ¨N(Ra)-, then Z is a fused bicyclic heteroaryl ring optionally substituted with one to three Rc;
each IV is independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C1-6hydroxyalkyl, C1-6 alkylene-CO2H, C1-6alkylene-S03H;
each Rb is independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C1.6hydroxyalkyl, C1.6 alkylene-CO2H, and C1-6 alkylene-S03H, each of which is optionally further substituted with one or two members independently selected from OH, SO2NH2, CONH2, C(0)NHOH, P03H2, COO-C1-8 alkyl and CO2H;

and Ra and Rb, when attached to the same nitrogen atom, are optionally combined to form a 4- to 8-membered ring or spirocyclic ring, optionally substituted with halogen, OH, SO2NE12, CONE12, C(0)NHOH, P03H2, COO-C1-8 alkyl or CO2H;
each RC is independently selected from the group consisting of H, halogen, CN, C1-6 alkyl, C1-6 haloalkyl, -Yl, C(0)2Ra, -0-X4-C(0)2Ra, -X4-OR', -x4 _NRaRb, _x4_ c omtaRb, -0-X4-CONRaRb, -X4- SO2Ra, -X4-SO2NRaRb, -X4-SO3Ra, and -N(Ra)-x4_c(0)2Ra, wherein each X4 is a bond or C1-6 alkylene, and each Yl is selected from the group consisting of C3-6 cycloalkyl and C4-8 heterocyclyl; and optionally two RC on adjacent ring vertices are combined to form a fused 5- or 6-membered heterocyclic ring.
[0036] In one aspect, the present disclosure provides compounds having formula (I):
R7 R1 a R2a R6 R8 R 1 d X1 ¨Nr R3 \R2b Z¨A R1 b R4 R1 c (R3a)n (I) or a pharmaceutically acceptable salt, prodrug or bioisostere thereof, wherein:
Ria, Rib, Ric and ¨ ld x are each independently selected from the group consisting of H, halogen, C1-3 alkyl, C1-3 haloalkyl, Ci-3 alkoxy and CN;
Xi is C1-3 alkylene, optionally substituted with one or two Ci-2 alkyl or CO2H;
R2a and R2b are each independently selected from the group consisting of H, C1-8 alkyl, C1-8 haloalkyl, -Y, -X2-C(0)2Ra, -X2-OR', -x24RaRb, _v_coNRaRb, _v_so2Ra, -X2-SO2NRaRb, -X2-SO3Ra and ¨X2-Y wherein each X2 is C1-6 alkylene and any C1-8 alkyl or C1-6 alkylene, is optionally further substituted with one or two members independently selected from OH, SO2NE12, CONE12, C(0)NHOH, P03H2, COO-C1-8 alkyl or CO2H, and each Y is selected from the group consisting of C3-6 cycloalkyl, C4-8 heterocyclyl and 5-to 6-membered heteroaryl, each of which is optionally further substituted with one to four substituents independently selected from the group consisting of oxo, OH, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, Ci-4 alkoxy, Ci-4 haloalkoxy, C1-4 hydroxyalkoxy, SO2NH2, CONI-12, C(0)N1-10H, P03H2, COO-Ci_galkyl, SO3H and CO2H;

or R2a and R2b are combined to form a 4- to 9-membered ring or spirocyclic ring, optionally having one or two additional ring vertices selected from 0, N or S;
wherein the ring formed by combining R2 and R2b, is substituted with 0 to 4 substituents independently selected from the group consisting of oxo, C1-8 alkyl, C1-8 haloalkyl, Ci_g hydroxyalkyl, -X3-C(0)2Ra, -x3-0R', -X3-NRaRb, -X3-CONRaRb, -X3-S02Ra, -X3-SO2NRaRb, and ¨X3-SO3Ra; wherein X3 is a bond or C1-6 alkylene;
R3 and R4 are each independently selected from the group consisting of F, Cl, CN, CH3, OCH3, CH2CH3 and CF3;
the subscript n is 0, 1, 2 or 3;
each R3a is independently selected from the group consisting of H, F, Cl, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 haloalkoxy, C2-3 alkenyl and CN;
R6, R7 and le are each independently selected from the group consisting of H, F, Cl, CN, CH3, OCH3, CH2CH3 and CF3;
A is a member selected from the group consisting of ¨N(Ra)-, ¨C(=0)N(Ra)-, ¨S(0)N(Ra)-, and ¨S(0)2N(Ra)-;
Z is selected from the group consisting of:
i) a monocyclic, bicyclic, or spirocyclic non-aromatic heterocyclic ring, optionally substituted with one or two oxo groups and optionally substituted with up to four IV
and/or Rb;
ii) a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three Rc; and iii) a fused bicyclic heteroaryl ring, optionally substituted with one to three Rc;
wherein when A is ¨N(Ra)-, then Z is a fused bicyclic heteroaryl ring optionally substituted with one to three Rc;
each IV is independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkylene-CO2H, C1-6 alkylene-S03H;
each Rb is independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, C1.6 hydroxyalkyl, C1.6 alkylene-CO2H, and C1-6 alkylene-S03H, each of which is optionally further substituted with one or two members independently selected from OH, SO2NH2, CONH2, C(0)NHOH, P03H2, COO-C1-8 alkyl and CO2H;

and Ra and Rb, when attached to the same nitrogen atom, are optionally combined to form a 4- to 8-membered ring or spirocyclic ring, optionally substituted with halogen, OH, SO2NH2, CONH2, C(0)NHOH, P03H2, COO-C1-8 alkyl or CO2H;
each RC is independently selected from the group consisting of H, halogen, CN, C1-6 alkyl, C1-6 haloalkyl, -Y1, X _-4_ C(0)2Ra, -0-X4-C(0)2Ra, -X4-0Ra, -x4_NRaRb, _x4_coNRaRb, -0-X4-CONRaRb, -X4-SO2Ra, -X4-SO2NRaRb, -X4-SO3Ra, and -N(Ra)-x4_c(0)2Ra, wherein each X4 is a bond or C1-6 alkylene, and each Yl is selected from the group consisting of C3-6 cycloalkyl and C4-8 heterocyclyl; and optionally two RC on adjacent ring vertices are combined to form a fused 5- or 6-membered heterocyclic ring.
[0037] In some embodiments, the present disclosure provides compounds of Formula (I) represented by Formula (Ia):
R1 a R2a iIi Rld R3 'Rzb Z¨A Rlb R4 Ric (Ia) wherein the groups lea, Rib, Ric, Rid, R2a, R2b, R3, R4, A, A and Z have the meanings provided for Formula (I).
[0038] In some embodiments, the present disclosure provides compounds of Formula (I) represented by Formula (lb):
R1 a R2a Xl¨r<
R3 'R2b Z¨A Rib R4 Ric (Ib) wherein the groups lea, Rib, Ric, R2a, R2b, R3, R4, A, A and Z have the meanings provided for Formula (I).
[0039] In some embodiments, the present disclosure provides compounds of Formula (I) represented by Formula (Ic):

Ria ,R2a Xl¨N
R2b Z¨A R1 b (Ic) wherein the groups It', R, R2a, R2b, R3, R4, A, A-1 and Z have the meanings provided for Formula (I).
[0040] In some embodiments, the present disclosure provides compounds of Formula (I) represented by Formula (Id):
Rla ,R2a R3 N \
R2b Z¨A Rlb (Id) wherein the groups It', Rib, R2a, R2b, R3, R4, A, and Z have the meanings provided for Formula
[0041] In some selected embodiments, the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id) are those compounds wherein Z is a non-aromatic heterocyclic ring having a formula selected from the group consisting of:
Rbs. RN)R b N N N N
I I

Ra Ra Ra Ra Rb Rb, N
and Rb N 0 N 0 Ra
[0042] In some selected embodiments, the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id) are those compounds wherein Z is a non-aromatic heterocyclic ring selected from the group consisting of piperidinyl, morpholinyl, tetrahydropyranyl, and tetrahydrofuranyl, each of which is optionally substituted with up to four IV and/or Rb.
[0043] In some selected embodiments, the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id) are those compounds wherein Z is a fused bicyclic heteroaryl ring having a formula selected from the group consisting of:
N N
N INJ 1 1%1 N
I
/
N
N1 N NroJs.
I.,N
N N
lei N N
risi sr. I rLss 1 1 N N N N N

1 N N ssN
ss HN ss' HNIiss scFc N NH 0 Is10 N 0 Rc Ac ..

eN
Nssi il N 0 trisl N

Ric Ric Rc' Sy\
and Rc_N¨IN
[0044] In some selected embodiments, the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id) are those compounds wherein Z is a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three Itc; and said heterocyclic ring is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, oxazolyl, thiazolyl, and pyrazolyl.
[0045] In selected embodiments, including any of those noted above with respect to the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id), further embodiments are those wherein A is ¨
C(=0)N(Ra)-.
[0046] In selected embodiments, including any of those noted above with respect to the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id), further embodiments are those wherein the group lea is OCH3 and Rib is F.
[0047] In selected embodiments, including any of those noted above with respect to the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id), further embodiments are those wherein R2a and R2b are each H.
[0048] In selected embodiments, including any of those noted above with respect to the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id), further embodiments are those wherein R2a and R2b are combined to form a 4- to 9-membered ring or spirocyclic ring, optionally having one or two additional ring vertices selected from 0, N or S; wherein said ring or spirocyclic ring is substituted with 0 to 4 sub stituents independently selected from the group consisting of oxo, C1-8 alkyl, C1-8haloalkyl, Ci_g hydroxyalkyl, _x2_c (0)2Ra, _X2-0Ra, -x2_NRaRb, _x2_coNRaRb, -X2-SO2Ra, -X2-S02NRaRb, and ¨X2-SO3Ra; wherein X2 is a bond or C1-6 alkylene.
[0049] In selected embodiments, including any of those noted above with respect to the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id), further embodiments are those wherein ¨N(R2a)(R2b) is selected from the group consisting of:

EN OH EN OH 1_NCO2H EN OH
H H H H

1-N CONH2 1-N OH N N H2 N CC)211 I H <CH H H

OH
1_N CON H2 _rµj/<NH2 N OH EN SO3H

HO OH OH
/
N <OH
NOH

I
H H H

0 0 and _ u 1¨rsil -NOH N -LOH N N H2
[0050] In selected embodiments, including any of those noted above with respect to the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id), further embodiments are those wherein ¨N(R2a)(R2b) is selected from the group consisting of:

XN

I I j 11 CO2H
iNNO_N H2 rrkrµl) KN C 02H KN
INN&CO2H
co2H
OH
ss(N r3" N

H H H
4 Nj: 4 N L. 4N 4N f.10 H OH H OH H
OH H

H H H OH H
OH

H
r54.. .....--..õ.õ.õ.---., 4 4N 1 N m N NH
H r!....y and N H

OH H .
[0051] In selected embodiments, including any of those noted above with respect to the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id), further embodiments are those wherein ¨N(R2a)(R2b) is selected from the group consisting of:

&TI
/0 skNNH

NH NH N¨CH3 and
[0052] In selected embodiments, including any of those noted above with respect to the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id), further embodiments are those wherein R2a is H or C1-8 alkyl; and R2b is ¨Y or ¨X2-Y.
[0053] In selected embodiments, including any of those noted above with respect to the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id), further embodiments are those wherein R2a is H or Ci-galkyl; R2b is ¨Y or ¨X2-Y; and Y is selected from the group consisting of C3-6 cycloalkyl and C4-8 heterocyclyl, each of which is optionally further substituted with one to four substituents independently selected from the group consisting of oxo, OH, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 hydroxyalkoxy, SO2NH2, CONH2, C(0)NHOH, P03H2, COO-C1.8alkyl, and CO2H..
[0054] In selected embodiments, including any of those noted above with respect to the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id), further embodiments are those wherein A is ¨
C(=0)N(Ra)- and Z is a 5- or 6-membered non-aromatic heterocyclic ring, optionally substituted with one or two oxo groups and optionally substituted with IV and/or Rb.
[0055] In selected embodiments, including any of those noted above with respect to the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id), further embodiments are those wherein A is ¨
C(=0)N(Ra)- and Z is a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three It'.
56 [0056] In selected embodiments, including any of those noted above with respect to the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id), further embodiments are those wherein A is ¨
C(=0)N(Ra)-; Z is a 5- or 6-membered non-aromatic heterocyclic ring, optionally substituted with one or two oxo groups and optionally substituted with IV and/or Rb; and each of Ric, R6, R7 and le is H.
[0057] In selected embodiments, including any of those noted above with respect to the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id), further embodiments are those wherein A is ¨
C(=0)N(Ra)-; Z is a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three Rc; and each of Ric, R6, R7 and Rg is H.
[0058] In selected embodiments, including any of those noted above with respect to the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id), further embodiments are those wherein A is ¨
C(=0)N(Ra)-; Z is a 5- or 6-membered non-aromatic heterocyclic ring, optionally substituted with one or two oxo groups and optionally substituted with IV and/or Rb; and said non-aromatic heterocyclic ring is selected from the group consisting of piperidinyl, morpholinyl, tetrahydropyranyl, and tetrahydrofuranyl.
[0059] In selected embodiments, including any of those noted above with respect to the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id), further embodiments are those wherein A is ¨
C(=0)N(Ra)-; Z is a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three It', and said heterocyclic ring is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, oxazolyl, thiazolyl, and pyrazolyl.
[0060] In selected embodiments, including any of those noted above with respect to the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id), further embodiments are those wherein the compound is selected from Table 1. In selected embodiments, including any of those noted above with respect to the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id), further embodiments are those wherein the compound is selected from Table 2.
[0061] In selected embodiments, including any of those noted above with respect to the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id), further embodiments are those wherein the compound is selected from Table 1, having ++ or +++ activity. In selected embodiments, including any of those noted above with respect to the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id), further embodiments are those wherein the compound is selected from Table 2, having ++ or +++ activity.
[0062] In selected embodiments, including any of those noted above with respect to the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id), further embodiments are those wherein the compound is selected from Table 1, having +++ activity. In selected embodiments, including any of those noted above with respect to the compounds of Formulae (I), (Ia), (lb), (Ic) or (Id), further embodiments are those wherein the compound is selected from Table 2, having +++
activity.
[0063] In addition to the compounds provided above, pharmaceutically acceptable salts of those compounds are also provided. In some embodiments, the pharmaceutically acceptable salts are selected from ammonium, calcium, magnesium, potassium, sodium, zinc, arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanol amine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrab amine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperadine, procaine, purines, theobromine, triethyl amine, trimethylamine, tripropylamine, tromethamine, hydrochloric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, acetic, propionic, isobutyric, malonic, benzoic, succinic, suberic, fumaric, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, arginate, glucuronic acid and galactunoric acids. In some embodiments, the pharmaceutically acceptable salts are selected from ammonium, calcium, magnesium, potassium, sodium, hydrochloric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, acetic, propionic, isobutyric, malonic, benzoic, succinic, suberic, fumaric, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, arginate, glucuronic acid and galactunoric acids.
In some embodiments, the pharmaceutically acceptable salts are sodium or hydrochloric.
[0064] In addition to salt forms, the present disclosure provides compounds which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present disclosure. Additionally, prodrugs can be converted to the compounds of the present disclosure by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present disclosure when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
[0065] An ester may be used as a prodrug for the corresponding carboxylic acid. A Ci_io alkyl ester or a Ci-io haloalkyl ester may be used as a prodrug for the corresponding carboxylic acid.
The following esters may be used: tert-butyl ester, methyl ester, ethyl ester, isopropyl ester.
PHARMACEUTICAL COMPOSITIONS
[0066] In addition to the compounds provided herein, compositions of those compounds will typically contain a pharmaceutical carrier or diluent.
[0067] The term "composition" as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof
[0068] In another embodiment, a pharmaceutical composition comprising a compound of the present disclosure including a compound of Formulae (I), (Ia), (lb), (Ic) or (Id), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, is provided.
[0069] In some embodiments, the pharmaceutical composition further comprises one or more additional therapeutic agents. In some embodiments, the one or more additional therapeutic agent is selected from the group consisting of an antimicrobial agent, an antiviral agent, a cytotoxic agent, a gene expression modulatory agent, a chemotherapeutic agent, an anti-cancer agent, an anti-angiogenic agent, an immunotherapeutic agent, an anti-hormonal agent, an anti-fibrotic agent, radiotherapy, a radiotherapeutic agent, an anti-neoplastic agent, and an anti-proliferation agent. In some embodiments, the one or more additional therapeutic agent is an antagonist of a chemokine and/or chemoattractant receptor, which includes but is not limited to, CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CCR11, CCR12, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, CXCR7, C3aR, and/or C5aR.
Chemokine and/or chemoattractant receptor antagonists are known in the art and described in, for example, W02007/002667, W02007/002293, WO/2003/105853, WO/2007/022257, WO/2007/059108, WO/2007/044804, W02007/115232, W02007/115231, W02008/147815, W02010/030815, W02010/075257, W02011/163640, W02010/054006, W02010/051561, W02011/035332, W02013/082490, W02013/082429, W02014/085490, W02014/100735, W02014/089495, W02015/084842, W02016/187393, W02017/127409, WO 2017/087607, W02017/087610, W02017/176620, W02018/222598, W02018/222601, W02013/130811, W02006/076644, W02008/008431, W02009/038847, W02008/008375, W02008/008374, W02008/010934, W02009/009740, W02005/112925, W02005/112916, W02005/113513, W02004/085384, W02004/046092. Chemokine and/or chemoattractant receptor antagonists also include CCX354, CCX9588, CCX140, CCX872, CCX598, CCX6239, CCX9664, CCX2553, CCX3587, CCX3624, CCX 2991, CCX282, CCX025, CCX507, CCX430, CCX765, CCX224, CCX662, CCX650, CCX832, CCX168, CCX168-M1, CCX3022 and/or CCX3384.
[0070] The pharmaceutical compositions for the administration of the compounds of this disclosure may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy and drug delivery. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. In the pharmaceutical composition the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases.
[0071] The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions and self-emulsifications as described in U.S. Patent Application 2002-0012680, hard or soft capsules, syrups, elixirs, solutions, buccal patch, oral gel, chewing gum, chewable tablets, effervescent powder and effervescent tablets. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents, antioxidants and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as cellulose, silicon dioxide, aluminum oxide, calcium carbonate, sodium carbonate, glucose, mannitol, sorbitol, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example PVP, cellulose, PEG, starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated, enterically or otherwise, by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Pat. Nos.
4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
[0072] Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, polyethylene glycol (PEG) of various average sizes (e.g., PEG400, PEG4000) and certain surfactants such as cremophor or solutol, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil. Additionally, emulsions can be prepared with a non-water miscible ingredient such as oils and stabilized with surfactants such as mono- or di-glycerides, PEG esters and the like.
[0073] Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethyl cellulose, methyl cellulose, hydroxy-propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxy-ethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, .. or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
[0074] Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
[0075] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above.
Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
[0076] The pharmaceutical compositions of the disclosure may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.
[0077] Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. Oral solutions can be prepared in combination with, for example, cyclodextrin, PEG and surfactants.
[0078] The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid .. find use in the preparation of injectables.
[0079] The compounds of the present disclosure may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
Such materials include cocoa butter and polyethylene glycols. Additionally, the compounds can be administered via ocular delivery by means of solutions or ointments. Still further, transdermal delivery of the subject compounds can be accomplished by means of iontophoretic patches and the like. For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of the present disclosure are employed. As used herein, topical application is also meant to include the use of mouth washes and gargles.
[0080] The compounds of this disclosure may also be coupled with a carrier that is a suitable polymer for targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues.
Furthermore, the compounds of the disclosure may be coupled to a carrier that is a class of biodegradable polymers useful in achieving controlled release of a drug, for example polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels. Polymers and semipermeable polymer matrices may be formed into shaped articles, such as valves, stents, tubing, prostheses and the like. In one embodiment of the disclosure, the compound of the disclosure is coupled to a polymer or semipermeable polymer matrix that is formed as a stent or stent-graft device.
METHODS OF TREATING DISEASES AND DISORDERS
[0081] The compounds of the disclosure may be used as immunomodulators. The compounds of the disclosure may be used as agonists, antagonists, partial agonists, inverse agonists, inhibitors of PD-1 and/or PD-Li in a variety of contexts, both in vitro and in vivo. In some embodiments, the compounds of the disclosure may be used as inhibitors of the protein protein interaction. In some embodiments, the compounds of the disclosure may be used as inhibitors of PD-Li. In some embodiments, the compounds of the disclosure may be used as inhibitors of the CD80/PD-L1 protein protein interaction. In some embodiments, the compounds of the disclosure may be used to inhibit the interaction between PD-1 and PD-Li and/or PD-1 and CD80 and/or PD-1 and PD-L2 in vitro or in vivo. In some embodiments, the compounds of the disclosure may be used to inhibit VISTA and/or TIM-3. In some embodiments, the compounds of the disclosure may be inhibitors of the PD-1/PD-L1 protein protein interaction and inhibitors of VISTA and/or TIM-3. In some embodiments, in addition to being inhibitors of the PD-1/PD-L1 protein protein interaction, the compounds of the disclosure may be inhibitors of CTLA-4 and/or BTLA and/or LAG-3 and/or KLRG-1 and/or 2B4 and/or CD160 and/or HVEM and/or CD48 and/or E-cadherin and/or MHC-II and/or galectin-9 and/or CD86 and/or PD-L2 and/or VISTA and/or TIM-3 and/or CD80.
[0082] The compounds of the disclosure may be contacted with the receptor they interact with, in aqueous solution and under conditions otherwise suitable for binding of the ligand to the receptor. The receptor may be present in suspension (e.g., in an isolated membrane or cell preparation), in a cultured or isolated cell, or in a tissue or organ.
[0083] Preferably, the amount of the compounds of the disclosure contacted with the receptor should be sufficient to inhibit the PD-1/PD-L1 binding in vitro as measured, for example, using an ELISA. The receptor may be present in solution or suspension, in a cultured or isolated cell preparation or within a patient.
[0084] In some embodiments, the compounds of the present disclosure are useful for restoring and augmenting T cell activation. In some embodiments, the compounds of the present disclosure are useful for enhancing an immune response in a patient. In some embodiments, the compounds of the present disclosure are useful for treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer and infectious diseases.
[0085] In some embodiments, the compounds of the present disclosure can be used for treating patients suffering from conditions that are responsive to PD-1/PD-L1 protein protein interaction modulation.
[0086] In some embodiments, a method of modulating an immune response mediated by the PD-1 signaling pathway in a subject, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure including a compound of Formulae (I), (Ia), (lb), (Ic) or (Id), or a pharmaceutically acceptable salt thereof or a composition comprising a compound of Formulae (I), (Ia), (lb), (Ic) or (Id), or a pharmaceutically acceptable salt thereof, is provided.
[0087] In some embodiments, a method of enhancing, stimulating, modulating and/or increasing the immune response in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure including a compound of Formulae (I), (Ia), (lb), (Ic) or (Id), or a pharmaceutically acceptable salt thereof or a composition of a compound of the present disclosure including a compound of Formula (I), (Ia), (lb), (II), (IIa), or (Ilb), or a pharmaceutically acceptable salt thereof, is provided.
[0088] In some embodiments, a method of inhibiting growth, proliferation, or metastasis of cancer cells in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure including a compound of Formula (I), (Ia), (lb), (Ic), or (Id), or a pharmaceutically acceptable salt thereof or a composition of a compound of the present disclosure including a compound of Formula (I), (Ia), (lb), (Ic), or (Id), or a pharmaceutically acceptable salt thereof, is provided.
[0089] In some embodiments, a method of treating a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure including a compound of Formulae (I), (Ia), (lb), (Ic) or (Id), or a pharmaceutically acceptable salt thereof or a composition of a compound of the present disclosure including a compound of Formulae (I), (Ia), (lb), (Ic) or (Id), or a pharmaceutically acceptable salt thereof, is provided.
[0090] In some embodiments, the subject suffers from a disease or disorder selected from the group consisting of an infectious disease, a bacterial infectious disease, a viral infectious disease a fungal infectious disease, a solid tumor, a hematological malignancy, an immune disorder, an inflammatory disease, and cancer. In some embodiments, the disease or disorder is selected from the group consisting of melanoma, glioblastoma, esophagus tumor, nasopharyngeal carcinoma, uveal melanoma, lymphoma, lymphocytic lymphoma, primary CNS lymphoma, T-cell lymphoma, diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, prostate cancer, castration-resistant prostate cancer, chronic myelocytic leukemia, Kaposi's sarcoma fibrosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, angiosarcoma, lymphangiosarcoma, synovioma, meningioma, leiomyosarcoma, rhabdomyosarcoma, sarcoma of soft tissue, sarcoma, sepsis, biliary tumor, basal cell carcinoma, thymus neoplasm, cancer of the thyroid gland, cancer of the parathyroid gland, uterine cancer, cancer of the adrenal gland, liver infection, Merkel cell carcinoma, nerve tumor, follicle center lymphoma, colon cancer, Hodgkin's disease, non-Hodgkin's lymphoma, leukemia, chronic or acute leukemias including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma, ovary tumor, myelodysplastic syndrome, cutaneous or intraocular malignant melanoma, renal cell carcinoma, small-cell lung cancer, lung cancer, mesothelioma, breast cancer, squamous non-small cell lung cancer (SCLC), non-squamous NSCLC, colorectal cancer, ovarian cancer, gastric cancer, hepatocellular carcinoma, pancreatic carcinoma, pancreatic cancer, Pancreatic ductal adenocarcinoma, squamous cell carcinoma of the head and neck, cancer of the head or neck, gastrointestinal tract, stomach cancer, HIV, Hepatitis A, Hepatitis B, Hepatitis C, hepatitis D, herpes viruses, papillomaviruses, influenza, bone cancer, skin cancer, rectal cancer, cancer of the anal region, testicular cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the urethra, cancer of the penis, cancer of the bladder, cancer of the kidney, cancer of the ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, epidermoid cancer, abestosis, carcinoma, adenocarcinoma, papillary carcinoma, cystadenocarcinoma, bronchogenic carcinoma, renal cell carcinoma, transitional cell carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, wilm's tumor, pleomorphic adenoma, liver cell papilloma, renal tubular adenoma, cystadenoma, papilloma, adenoma, leiomyoma, rhabdomyoma, hemangioma, lymphangioma, osteoma, chondroma, lipoma and fibroma.
[0091] In some embodiments, a therapeutically effective amount of one or more additional therapeutic agents is further administered to the subject. In some embodiments, the one or more .. additional therapeutic agents is selected from the group consisting of an antimicrobial agent, an antiviral agent, a cytotoxic agent, a gene expression modulatory agent, a chemotherapeutic agent, an anti-cancer agent, an anti-angiogenic agent, an immunotherapeutic agent, an anti-hormonal agent, an anti-fibrotic agent, radiotherapy, a radiotherapeutic agent, an anti-neoplastic agent, and an anti-proliferation agent. In some embodiments, the one or more additional therapeutic agent is an antagonist of a chemokine and/or chemoattractant receptor, which includes but is not limited to, CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CCR11, CCR12, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, CXCR7, C3aR, and/or C5aR.
Chemokine and/or chemoattractant receptor antagonists are known in the art and described in, for example, W02007/002667, W02007/002293, WO/2003/105853, WO/2007/022257, WO/2007/059108, WO/2007/044804, W02007/115232, W02007/115231, W02008/147815, W02010/030815, W02010/075257, W02011/163640, W02010/054006, W02010/051561, W02011/035332, W02013/082490, W02013/082429, W02014/085490, W02014/100735, W02014/089495, W02015/084842, W02016/187393, W02017/127409, WO 2017/087607, W02017/087610, W02017/176620, W02018/222598, W02018/222601, W02013/130811, W02006/076644, W02008/008431, W02009/038847, W02008/008375, W02008/008374, W02008/010934, W02009/009740, W02005/112925, W02005/112916, W02005/113513, W02004/085384, W02004/046092. Chemokine and/or chemoattractant receptor antagonists also include CCX354, CCX9588, CCX140, CCX872, CCX598, CCX6239, CCX9664, CCX2553, CCX3587, CCX3624, CCX 2991, CCX282, CCX025, CCX507, CCX430, CCX765, CCX224, CCX662, CCX650, CCX832, CCX168, CCX168-M1, CCX3022 and/or CCX3384.
[0092] In some embodiments, the compounds of the present disclosure may be used to inhibit an infectious disease. The infectious disease includes but is not limited to HIV, Influenza, Herpes, Giardia, Malaria, Leishmania, the pathogenic infection by the virus Hepatitis (A, B, and C), herpes virus (e.g., VZV, HSV-I, HAV-6, HSV-II, and CMV, Epstein Barr virus), adenovirus, influenza virus, flaviviruses, echovirus, rhinovirus, coxsackie virus, cornovirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus and arboviral encephalitis virus, pathogenic infection by the bacteria chlamydia, rickettsial bacteria, mycobacteria, staphylococci, streptococci, pneumonococci, meningococci and conococci, klebsiella, proteus, serratia, pseudomonas, E. coli, legionella, diphtheria, salmonella, bacilli, cholera, tetanus, botulism, anthrax, plague, leptospirosis, and Lyme's disease bacteria, pathogenic infection by the fungi Candida (albicans, krusei, glabrata, tropicalis, etc.), Cryptococcus neoformans, Aspergillus (fumigatus, niger, etc.), Genus Mucorales (mucor, absidia, rhizophus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis and Histoplasma capsulatum, and pathogenic infection by the parasites Entamoeba histolytica, Balantidium coli, Naegleriafowleri, Acanthamoeba sp., Giardialambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondi, Nippostrongylus brasiliensis.
[0093] In some embodiments, the compounds of the present disclosure may be used to inhibit HIV infection, delay AIDS progression, deplete HIV viral reservoir or decrease the severity of symptoms or HIV infection and AIDS.
[0094] The compounds of the present disclosure may be used for the treatment of cancers and precancerous conditions in a subject.
[0095] Treatment methods provided herein include, in general, administration to a patient an effective amount of one or more compounds provided herein. Suitable patients include those patients suffering from or susceptible to (i.e., prophylactic treatment) a disorder or disease identified herein. Typical patients for treatment as described herein include mammals, particularly primates, especially humans. Other suitable patients include domesticated companion animals such as a dog, cat, horse, and the like, or a livestock animal such as cattle, pig, sheep and the like.
[0096] In general, treatment methods provided herein comprise administering to a patient an effective amount of a compound one or more compounds provided herein. In a preferred embodiment, the compound(s) of the disclosure are preferably administered to a patient (e.g., a human) intravenously, orally or topically. The effective amount may be an amount sufficient to modulate the PD-1/PD-L1 interaction and/or an amount sufficient to reduce or alleviate the symptoms presented by the patient. Preferably, the amount administered is sufficient to yield a plasma concentration of the compound (or its active metabolite, if the compound is a pro-drug) high enough to sufficiently modulate the PD-1/PD-L1 interaction. Treatment regimens may vary depending on the compound used and the particular condition to be treated; for treatment of most disorders, a frequency of administration of 4 times daily or less is preferred. In general, a dosage regimen of 2 times daily is more preferred, with once a day dosing particularly preferred. It will be understood, however, that the specific dose level and treatment regimen for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination (i.e., other drugs being administered to the patient) and the severity of the particular disease undergoing therapy, as well as the judgment of the prescribing medical practitioner. In general, the use of the minimum dose sufficient to provide effective therapy is preferred. Patients may generally be monitored for therapeutic effectiveness using medical or veterinary criteria suitable for the condition being treated or prevented.
COMBINATIONS
[0097] A concomitant medicine comprising the compounds of the present disclosure and other drug may be administered as a combination preparation in which both components are contained in a single formulation, or administered as separate formulations. The administration by separate formulations includes simultaneous administration and administration with some time intervals.
In the case of the administration with some time intervals, the compound of the present disclosure can be administered first, followed by another drug or another drug can be administered first, followed by the compound of the present disclosure. The administration method of the respective drugs may be the same or different.
[0098] The dosage of the other drug can be properly selected, based on a dosage that has been clinically used. The compounding ratio of the compound of the present disclosure and the other drug can be properly selected according to age and weight of a subject to be administered, administration method, administration time, disorder to be treated, symptom and combination thereof. For example, the other drug may be used in an amount of 0.01 to 100 parts by mass, based on 1 part by mass of the compound of the present disclosure. The other drug may be a combination of two or more kind of arbitrary drugs in a proper proportion.
[0099] The compounds described herein may be used or combined with one or more therapeutic agent such as an antimicrobial agent, an antiviral agent, a cytotoxic agent, a gene expression modulatory agent, a chemotherapeutic agent, an anti-cancer agent, an anti-angiogenic agent, an immunotherapeutic agent, an anti-hormonal agent, an anti-fibrotic agent, radiotherapy, a radiotherapeutic agent, an anti-neoplastic agent, and an anti-proliferation agent. These therapeutic agents may be in the forms of compounds, antibodies, polypeptides, or polynucleotides.
[0100] The compounds described herein may be used or combined with one or more of a therapeutic antibody, a bispecific antibody and "antibody-like" therapeutic protein (such as DARTs , Duobodies , Bites , XmAbs , TandAbs , Fab derivatives), an antibody-drug conjugate (ADC), a virus, an oncolytic virus, gene modifiers or editors such as CRISPR
(including CRISPR Cas9), zinc finger nucleases or synthetic nucleases (TALENs), a CAR
(chimeric antigen receptor) T-cell immunotherapeutic agent, or any combination thereof
[0101] Examples of chemotherapeutics include an alkylation agent, nitrosourea agent, antimetabolite, anticancer antibiotics, vegetable-origin alkaloid, topoisomerase inhibitor, hormone drug, hormone antagonist, aromatase inhibitor, P-glycoprotein inhibitor, platinum complex derivative, other immunotherapeutic drugs and other anticancer drugs.
[0102] The compounds described herein may be used or combined with a cancer treatment adjunct, such as a leucopenia (neutropenia) treatment drug, thrombocytopenia treatment drug, antiemetic and cancer pain intervention drug, concomitantly or in a mixture form.
[0103] The compounds described herein may be used or combined with a kinase inhibitor.
[0104] In one embodiment, the compounds of the present disclosure can be used with other immunomodulators and/or a potentiating agent concomitantly or in a mixture form. Examples of the immunomodulator include various cytokines, vaccines and adjuvants.
Examples of these cytokines, vaccines and adjuvants that stimulates immune responses include but not limited to GM-CSF, M-CSF, G-CSF, interferon-a, beta, or gamma, IL-1, IL-2, IL- 3, IL-12, Poly (I:C) and CPG. The potentiating agents include cyclophosphamide and analogs of cyclophosphamide, anti-TGF and imatinib (Gleevac), a mitosis inhibitor, such as paclitaxel, Sunitinib (Sutent) or other antiangiogenic agents, an aromatase inhibitor, such as letrozole, an A2a adenosine receptor (A2AR) antagonist, an angiogenesis inhibitor, anthracyclines, oxaliplatin, doxorubicin, TLR4 antagonists, and IL- 18 antagonists.
[0105] In some embodiments, the compounds described herein may be used or combined with one or more modulator of CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CCR11, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, CXCR7, ChemR23, .. C5aR, C5a, and C5. In some embodiments, the modulator is an antagonist.
[0106] In some embodiments, the compounds described herein may be used or combined with one or more chemokine and/or chemoattractant receptor antagonists described in, for example, W02007/002667, W02007/002293, WO/2003/105853, WO/2007/022257, WO/2007/059108, WO/2007/044804, W02007/115232, W02007/115231, W02008/147815, W02010/030815, W02010/075257, W02011/163640, W02010/054006, W02010/051561, W02011/035332, W02013/082490, W02013/082429, W02014/085490, W02014/100735, W02014/089495, W02015/084842, W02016/187393, W02017/127409, WO 2017/087607, W02017/087610, W02017/176620, W02018/222598, W02018/222601, W02013/130811, W02006/076644, W02008/008431, W02009/038847, W02008/008375, W02008/008374, W02008/010934, .. W02009/009740, W02005/112925, W02005/112916, W02005/113513, W02004/085384, W02004/046092. Chemokine and/or chemoattractant receptor antagonists useful in the present disclosure also include CCX354, CCX9588, CCX140, CCX872, CCX598, CCX6239, CCX9664, CCX2553, CCX3587, CCX3624, CCX 2991, CCX282, CCX025, CCX507, CCX430, CCX765, CCX224, CCX662, CCX650, CCX832, CCX168, CCX168-M1, CCX3022 and/or CCX3384.
DOSAGE
[0107] Dosage levels of the order of from about 0.1 mg to about 140 mg per kilogram of body .. weight per day are useful in the treatment or preventions of conditions involving the PD-1/PD-Li interaction (about 0.5 mg to about 7 g per human patient per day). The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient.
For compounds administered orally, transdermally, intravaneously, or subcutaneously, it is preferred that sufficient amount of the compound be administered to achieve a serum concentration of 5 ng (nanograms)/mL-10 [tg (micrograms)/mL serum, more preferably sufficient compound to achieve a serum concentration of 20 ng-1 [tg/m1 serum should be administered, most preferably sufficient compound to achieve a serum concentration of 50 .. ng/m1-200 ng/ml serum should be administered. For direct injection into the synovium (for the treatment of arthritis) sufficient compounds should be administered to achieve a local concentration of approximately 1 micromolar.
[0108] Frequency of dosage may also vary depending on the compound used and the particular disease treated. However, for treatment of most disorders, a dosage regimen of 4 times daily, .. three times daily, or less is preferred, with a dosage regimen of once daily or 2 times daily being particularly preferred. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination (i.e., other drugs being administered to the patient), the severity of the particular disease undergoing therapy, and other factors, including the judgment of the prescribing medical practitioner.
[0109] In another aspect of the disclosure, the compounds of the disclosure can be used in a variety of non-pharmaceutical in vitro and in vivo application. The compounds of the disclosure may also be used as positive controls in assays for PD-1/PD-L1 interaction activity, i.e., as standards for determining the ability of a candidate agent to bind to PD-1 and/or PD-L1, or as radiotracers for positron emission tomography (PET) imaging or for single photon emission computerized tomography (SPECT).
[0110] Also within the scope of the present disclosure are kits comprising a compound of the present disclosure or pharmaceutically acceptable salts thereof and instructions for use. The kit can further contain at least one additional reagent. Kits typically include a label indicating the intended use of the contents of the kit. The term label includes any writing, or recorded material supplied on or with the kit, or which otherwise accompanies the kit.
EXAMPLES
[0111] The following Examples illustrate various methods of making compounds of this disclosure including compounds of Formulae (I), (Ia), (lb), (Ic) or (Id). The following examples are offered to illustrate, but not to limit the claimed disclosure.
[0112] Reagents and solvents used below can be obtained from commercial sources such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA). 11-I-NMR spectra were recorded on a Varian Mercury 400 MHz NMR spectrometer. Significant peaks are provided relative to TMS
and are tabulated in the order: multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet) and number of protons. Mass spectrometry results are reported as the ratio of mass over charge. In the examples, a single m/z value is reported for the M+H (or, as noted, M-H) ion containing the most common atomic isotopes. Isotope patterns correspond to the expected formula in all cases. Electrospray ionization (ESI) mass spectrometry analysis was conducted on a Hewlett-Packard MSD electrospray mass spectrometer using the HP1100 HPLC for sample delivery. Normally the analyte was dissolved in methanol or CH3CN at 0.1 mg/mL
and 1 microliter was infused with the delivery solvent into the mass spectrometer, which scanned from 100 to 1000 Daltons. All compounds could be analyzed in the positive or negative ESI mode, using acetonitrile/water with 1% formic acid as the delivery solvent.
[0113] The following abbreviations are used in the Examples and throughout the description of the disclosure: TLC means Thin layer chromatography.
[0114] Compounds within the scope of this disclosure can be synthesized as described below, using a variety of reactions known to the skilled artisan. One skilled in the art will also recognize that alternative methods may be employed to synthesize the target compounds of this disclosure, and that the approaches described within the body of this document are not exhaustive, but do provide broadly applicable and practical routes to compounds of interest.
[0115] Certain molecules claimed in this patent can exist in different enantiomeric and diastereomeric forms and all such variants of these compounds are claimed unless a specific enantiomer is specified.
[0116] The detailed description of the experimental procedures used to synthesize key compounds in this text lead to molecules that are described by the physical data identifying them as well as by the structural depictions associated with them.
[0117] Those skilled in the art will also recognize that during standard work up procedures in organic chemistry, acids and bases are frequently used. Salts of the parent compounds are sometimes produced, if they possess the necessary intrinsic acidity or basicity, during the .. experimental procedures described within this patent.
Example 1: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((5-oxopyrrolidin-3-yl)amino)methyl)-11,1':3',1"-terphenyll-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe F

0 Me NHBoc H2N Br N-LOH Me N)LN Br ____________________________ kNO HATU, DMF kN0 H
Me Pd(dppf)C12, K2CO3-Me Hunig's Base Me Dioxane/H20, 95 C
Step a Step b OMe 0 Me opdNH

II H I NaCNBH3 NO Me Et0H
Me 0 C, 10 min 0 Step c y OMe NH
0 Me rYN
N ).LN
kN0 H
Me Me
[0118] Step a: To a mixture of 1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid (0.75 g, 4.87 mmol), 3-bromo-2-methylaniline (0.91 g, 4.87 mmol) in DMF (30 mL) was added HATU
.. (2.22 g, 5.84 mmol) and diisopropylethylamine (0.94 g, 7.30 mmol). The reaction was stirred at room temperature for 16 h. After completion of the reaction, half of the solvent was removed.
The resultant solution was diluted with water (100 ml) and the mixture was stirred for 20 min.
The solid was filtered using plastic funnel, washed with water (10 ml), and dried under vacuum to give the desired product N-(3-bromo-2-methylpheny1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. 1-EINMR (400 MHz, CD30D) ö
8.89 (s, 1H), 8.68 (s, 1H), 8.08-8.05 (m, 1H), 7.44-7.42 (m, 1H), 7.13 (td, J= 8.1, 0.7 Hz, 1H), 3.67 (s, 3H), 2.49 (s, 3H). MS: (ES) m/z calculated for Ci3Hi3BrN302 [M + H]+ 322.0, found 322Ø
[0119] Step b: To a mixture of N-(3-bromo-2-methylpheny1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide (1.2 g, 3.72 mmol), tert-butyl ((3-fluoro-5-methoxy-2'-.. methyl-3'-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-[1,1'-biphenyl]-4-y1)methyl)carbamate (1.4 g, 3.72 mmol), and 2M K2CO3 (5.6 mL, 11.2 mmol) in p-dioxane (32 mL) was added Pd(dppf)C12 complex with dichloromethane (456 mg, 0.559 mmol). The reaction mixture was degassed (N2) for 2 min and stirred under N2 at 95 C for 5 h. The reaction mixture was diluted with Et0Ac, filtered through Celite, washed with brine and dried over MgSO4.
The solvent was removed under reduced pressure and the residue was purified by silica gel flash chromatography (5 to 20% to 40% Et0Ac/hexane) to give N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a brown solid. 1-H NMR (400 MHz, CD30D) 8 10.40 (s, 1H), 8.91 (s, 1H), 8.67 (s, 1H), 8.15 (dd, J= 8.3, 1.3 Hz, 1H), 7.37-7.25 (m, 3H), 7.18 (dd, J= 7.3, 1.5 Hz, 1H), 6.99 (dd, J=
7.3, 1.5 Hz, 1H), 6.95 (s, 1H), 6.85-6.77 (m, 1H), 3.98 (s, 3H), 3.65 (s, 3H), 2.12 (s, 3H), 1.96 (s, 3H). MS: (ES) m/z calculated for C28H25FN304 [M + H]+ 486.2, found 486.2.
[0120] Step c: To a stirred solution of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide (100 mg, 0.206 mmol) and (S)-4-aminopyrrolidin-2-one (82 mg, 0.824 mmol) in ethanol (1 mL) was added acetic acid (5 drops). The reaction mixture was stirred at 70 C for 1 h. The mixture was then cooled to 0 C and NaCNBH3 (13 mg, 0.206 mmol) was added slowly. The mixture was stirred at 0 C for 10 min. The solvent was removed under reduced pressure and the residue was purified by HPLC (0 to 40% to 100% MeCN/H20) to give (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((5-oxopyrrolidin-3-yl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide. 1H NMR (400 MHz, CD30D) 8 11.41 (s, 1H), 8.92 (s, 1H), 8.68 (s, 1H), 8.13-8.10 (m, 1H), 7.38-7.21 (m, 3H), 7.20-7.13 (m, 1H), 7.01-6.97 (m, 1H), 6.96-6.94 (m, 1H), 6.91-6.88 (m, 1H), 4.37 (s, 2H), 4.26-4.21 (m, 1H), 4.00 (s, 3H), 3.88 (dd, J
= 11.6, 7.6 Hz, 1H), 3.66 (s, 3H), 3.57 (dd, J= 11.6, 3.9 Hz, 1H), 2.91 (dd, J= 17.8, 8.8 Hz, 1H), 2.55 (dd, J= 17.8, 4.7 Hz, 1H), 2.11 (s, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated for C32H33FN504 [M + 570.2, found 570.3.
Example 2: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(4(5-oxopyrrolidin-2-y1)methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe O Me fc :_t10 NLN
O H
Me Me
[0121] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a .. procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. 1-1-1NMR
(400 MHz, CD30D) 5 11.41 (s, 1H), 8.92 (s, 1H), 8.68 (s, 1H), 8.15-8.13 (m, 1H), 7.39-7.21 (m, 3H), 7.20-7.13 (m, 1H), 7.03-6.86 (m, 3H), 4.41 (s, 2H), 4.07-4.01 (m, 1H), 4.00 (s, 3H), 3.66 (s, 3H), 3.28-3.25 (m, 1H), 2.49-2.29 (m, 3H), 2.12 (s, 3H), 1.95 (s, 3H), 1.92-1.88 (m, 2H). MS: (ES) m/z calculated for C33H35FN504 [M + H]+ 584.3, found 584.3.
Example 3: (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(4(5-oxopyrrolidin-2-yl)methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe N
0 Me 0 HN
N.LN
O H
Me Me
[0122] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. 1-1-1NMR
(400 MHz, CD30D) 5 11.41 (s, 1H), 8.92 (s, 1H), 8.68 (s, 1H), 8.15-8.13 (m, 1H), 7.39-7.21 (m, 3H), 7.20-7.13 (m, 1H), 7.03-6.86 (m, 3H), 4.41 (s, 2H), 4.07-4.01 (m, 1H), 4.00 (s, 3H), 3.66 (s, 3H), 3.28-3.25 (m, 1H), 2.49-2.29 (m, 3H), 2.12 (s, 3H), 1.95 (s, 3H), 1.92-1.88 (m, 2H). MS: (ES) m/z calculated for C33H35FN504 [M + H]+ 584.3, found 584.3.
Example 4: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyh(5-oxopyrrolidin-2-y1)methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe 0 Me N ).LN F Me L

Me Me
[0123] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyl((5-oxopyrrolidin-2-yl)methyl)amino)methy1)41,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. 1H
NMR (400 MHz, CD30D) 5 11.41 (s, 1H), 8.92 (s, 1H), 8.67 (s, 1H), 8.15-8.11 (m, 1H), 7.39-7.23 (m, 3H), 7.17 (dd, J= 7.5, 1.5 Hz, 1H), 7.02-6.88 (m, 3H), 4.76-4.67 (m, 1H), 4.27 (s, 1H), 4.09-4.04 (m, 1H), 4.02 (s, 3H), 4.01 (s, 2H), 3.65 (s, 3H), 3.07 (s, 3H), 2.97-2.78 (m, 2H), 2.61-2.33 (m, 2H), 2.11 (s, 3H), 1.96 (s, 3H). MS: (ES) m/z calculated for C34H37FN504 [M + H]' 598.3, found 598.3.
Example 5: (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyh(5-oxopyrrolidin-2-yl)methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe N
0 Me 'Csto Me N )*LN
O H
Me LLJ
Me
[0124] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyl((5-oxopyrrolidin-2-yl)methyl)amino)methy1)41,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. 1H
NIVIR (400 MHz, CD30D) 8 11.41 (s, 1H), 8.92 (s, 1H), 8.67 (s, 1H), 8.15-8.11 (m, 1H), 7.39-7.23 (m, 3H), 7.17 .. (dd, J= 7.5, 1.5 Hz, 1H), 7.02-6.88 (m, 3H), 4.76-4.67 (m, 1H), 4.27 (s, 1H), 4.09-4.04 (m, 1H), 4.02 (s, 3H), 4.01 (s, 2H), 3.65 (s, 3H), 3.07 (s, 3H), 2.97-2.78 (m, 2H), 2.61-2.33 (m, 2H), 2.11 (s, 3H), 1.96 (s, 3H). MS: (ES) m/z calculated for C34H37FN504 [M + HIP
598.3, found 598.3.
Example 6: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(4(1-methyl-5-oxopyrrolidin-2-yOmethyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe Me O Me N .. rsci.l..t0 N )*LN
O H
Me Me
[0125] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((1-methy1-5-oxopyrrolidin-2-y1)methyl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. 1-14 NMR (400 MHz, CD30D) 6 11.41 (s, 1H), 8.92 (s, 1H), 8.68 (s, 1H), 8.13-8.11 (m, 1H), 7.37-7.23 (m, 3H), 7.14-7.12 (m, 1H), 7.01-6.88 (m, 3H), 4.43 (s, 2H), 4.00 (s, 3H), 3.97-3.92 (m, 1H), 3.66 (s, 3H), 3.49 (dd, J= 13.0, 3.0 Hz, 1H), 3.38-3.22 (m, 1H), 2.86 (s, 3H), 2.58-2.26 (m, 3H), 2.12 (s, 3H), 2.00-1.91 (m, 4H). MS: (ES) m/z calculated for C34H37FN504 [M + H]+
598.3, found 598.3.
Example 7: N-(4"-(4(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terpheny11-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe 0 Me N N H

Me M
e 10126] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(4"-((((2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. 11-1 NMR (400 MHz, CD30D) 6 11.41 (s, 1H), 8.92 (s, 1H), 8.68 (s, 1H), 8.13-8.11 (m, 1H), 7.66 (s, 1H), 7.34-7.22 (m, 3H), 7.20-7.13 (m, 1H), 6.99 (d, J= 7.6 Hz, 1H), 6.91 (s, 1H), 6.89-6.81 (m, 1H), 4.34 (s, 2H), 4.01 (s, 2H), 3.98 (s, 3H), 3.66 (s, 3H), 2.11 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated for C33H32FN605 [M + H]611.2, found 611.2.
Example 8: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((6-oxopiperidin-3-yl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe 0 Me Me hiJ
Me [0127] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((6-oxopiperidin-3-yl)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. 1H NMR (400 MHz, CD30D) 8 11.41 (s, 1H), 8.92 (s, 1H), 8.67 (s, 1H), 8.14-8.07 (m, 1H), 7.38-7.21 (m, 3H), 7.20-7.13 (m, 1H), 7.02-6.86 (m, 3H), 4.48-4.35 (m, 2H), 4.00 (s, 3H), 3.79-3.71 (m, 2H), 3.66 (s, 3H), 3.25 (s, 2H), 2.50 (dd, J= 7.6, 6.1 Hz, 2H), 2.42-2.35 (m, 1H), 2.11 (s, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated for C33H35FN504 [M + H]+ 584.3, found 584.3.
Example 9: (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((6-oxopiperidin-3-yl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe 0 Me rNSNH
N).LN

Me LiJ
Me [0128] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((6-oxopiperidin-3-y1)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. 1H NMR (400 MHz, CD30D) 8 11.41 (s, 1H), 8.92 (s, 1H), 8.67 (s, 1H), 8.14-8.07 (m, 1H), 7.38-7.21 (m, 3H), 7.20-7.13 (m, 1H), 7.02-6.86 (m, 3H), 4.48-4.35 (m, 2H), 4.00 (s, 3H), 3.79-3.71 (m, 2H), 3.66 (s, 3H), 3.25 (s, 2H), 2.50 (dd, J = 7.6, 6.1 Hz, 2H), 2.42-2.35 (m, 1H), 2.11 (s, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated for C33H35FN504 [M + H]+ 584.3, found 584.3.
Example 10: N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((2-(2-oxopyrrolidin-1-yl)ethyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe 0 Me N rL2 N N

Me LiJ
Me [0129] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((2-(2-oxopyrrolidin-1-ypethyl)amino)methy1)41,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. ITINMR (400 MHz, CD30D) 8 11.41 (s, 1H), 8.92 (s, 1H), 8.67 (s, 1H), 8.12 (m, 111), 7.38-7.22 (m, 3H), 7.17 (d, J=
7.5 Hz, 1H), 7.03-6.84 (m, 3H), 4.38 (s, 2H), 3.99 (s, 3H), 3.65 (m, 5H), 3.52 (t, J= 7.1 Hz, 2H), 2.42 (t, J= 8.1 Hz, 2H), 2.46-2.39 (m, 2H), 2.14-2.04 (m, 5H), 1.94 (s, 3H).
MS: (ES) m/z calculated for C34H37FN504 [M + 598.3, found 598.3.
Example 11: N-(4"-(((3-amino-3-oxopropyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe 0 0 Me N)*LN

Me tJ
Me [0130] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(4"-(((3-amino-3-oxopropyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. ITINMR (400 MHz, CD30D) 8 11.41 (s, 1H), 8.91 (s, 1H), 8.67 (s, 1H), 8.12 (m, 1H), 7.36-7.27 (m, 3H), 7.20-7.13 (m, 1H), 7.03-6.83 (m, 3H), 4.35 (s, 2H), 4.00 (s, 3H), 3.66 (s, 3H), 3.37-3.27 (m, 2H), 2.71 (t, J
= 6.2 Hz, 2H), 2.12 (s, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated for C31H33FN504 [M + H]+
558.2, found 558.3.
Example 12: N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((oxetan-3-ylamino)methyl)-11,1' :3',!' OMe 0 Me NN

Me LJ
Me [0131] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((oxetan-3-ylamino)methy1)41,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. 1H NMR (400 MHz, CD30D) 8 11.41 (s, 1H), 8.92 (s, 1H), 8.68 (m, 1H), 7.39-7.13 (m, 4H), 7.12-7.03 (m, 1H), 7.03-6.86 (m, 3H), 4.71-4.63 (m, 2H), 4.54-4.43 (m, 1H), 4.29 (m, 2H), 4.00 (s, 3H), 3.70-3.63 (m, 5H), 2.12 (s, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated for C31H32FN404 [M + H]+ 543.2, found 543.3.
Example 13: N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((tetrahydro-2H-pyran-4-yl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe 0 Me N
N)LN

Me LiJ
Me [0132] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((tetrahydro-2H-pyran-4-yl)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. 1H NMR (400 MHz, CD30D)15 11.41 (s, 1H), 8.92 (s, 1H), 8.67 (s, 1H), 8.16-8.07 (m, 1H), 7.36-7.24 (m, 3H), 7.20-7.13 (m, 1H), 7.03-6.84 (m, 3H), 4.35 (s, 2H), 4.06 (m, 2H), 3.99 (s, 3H), 3.66 (s, 3H), 3.51-3.45 (m, 3H), 2.14 (m, 5H), 1.94 (s, 3H), 1.74 (m, 2H). MS: (ES) m/z calculated for C33H36FN404 [M +
H]571.3, found 571.3.
Example 14: N-(3"-fluoro-4"-(((3-hydroxycyclobutyl)amino)methyl)-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe LzzzirOH
0 Me N

Me Me 101331 The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-(((3-hydroxycyclobutyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. ITINMR (400 MHz, CD30D) 8 8.58 (dd, J= 7.4, 2.2 Hz, 1H), 8.15 (dd, J= 8.2, 1.3 Hz, 1H), 8.00 (dd, J= 6.6, 2.2 Hz, 1H), 7.40-7.22 (m, 3H), 7.17 (dd, J= 7.5, 1.5 Hz, 1H), 7.00-6.86 (m, 3H), 6.62 (dd, J= 7.4, 6.5 Hz, 1H), 4.64-4.49 (m, 3H), 4.47-4.33 (m, 2H), 4.12-3.95 (m, 5H), 3.70 (s, 3H), 2.13 (s, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated for C32H34FN404 [M + H]557.3, found 557.3.
Example 15: N-(3"-fluoro-4"-(4(1S,2R)-2-hydroxycyclopentyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terpheny11-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe 0 Me NLNFOH
(N H
Me Me 101341 The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-((((lS,2R)-2-hydroxycyclopentyl)amino)methyl)-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. 1-EINMR
(400 MHz, CD30D) 8 11.41 (s, 1H), 8.92 (s, 1H), 8.67 (s, 1H), 8.16-8.07 (m, 1H), 7.38-7.21 (m, 3H), 7.16 (dd, J= 7.5, 1.5 Hz, 1H), 7.03-6.96 (m, 1H), 6.94-6.82 (m, 2H), 4.44-4.28 (m, 3H), 3.98 (s, 3H), 3.66 (s, 3H), 3.53-3.41 (m, 2H), 3.40-3.30 (m, 1H), 3.30-3.21 (m, 1H), 2.12 (s, 3H), 1.87 (s, 3H), 1.92-1.77 (m, 2H), 1.73-1.65 (m, 1H). MS: (ES) m/z calculated for C33H36FN404 [M +
H]571.3, found 571.3.

Example 16: N-(3"-fluoro-4"-((((1R,2S)-2-hydroxycyclopentyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terphenyl1-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe 0 Me H OH
N).LN

Me uii Me [0135] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-((((lR,2S)-2-hydroxycyclopentyl)amino)methyl)-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. ITINMR (400 MHz, CD30D) 8 11.41 (s, 1H), 8.92 (s, 1H), 8.67 (s, 1H), 8.16-8.07 (m, 1H), 7.38-7.21 (m, 3H), 7.16 (dd, J= 7.5, 1.5 Hz, 1H), 7.03-6.96 (m, 1H), 6.94-6.82 (m, 2H), 4.44-4.28 (m, 3H), 3.98 (s, 3H), 3.66 (s, 3H), 3.53-3.41 (m, 2H), 3.40-3.30 (m, 1H), 3.30-3.21 (m, 1H), 2.12 (s, 3H), 1.87 (s, 3H), 1.92-1.77 (m, 2H), 1.73-1.65 (m, 1H). MS: (ES) m/z calculated for C33H36FN404 [M +
H]571.3, found 571.3.
Example 17: N-(3"-fluoro-4"-((((1S,2S)-2-hydroxycyclopentyl)amino)methyl)-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe 0 Me H -OH
N)LN
LN.-O
H
Me LLJ
Me [0136] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-((((1S,2S)-2-hydroxycyclopentyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. ITINMR (400 MHz, CD30D) 5 11.41 (s, 1H), 8.92 (s, 1H), 8.67 (s, 1H), 8.16-8.07 (m, 1H), 7.38-7.21 (m, 3H), 7.16 (dd, J= 7.5, 1.5 Hz, 1H), 7.03-6.96 (m, 1H), 6.94-6.82 (m, 2H), 4.44-4.28 (m, 3H), 3.98 (s, 3H), 3.66 (s, 3H), 3.53-3.41 (m, 2H), 3.40-3.30 (m, 1H), 3.30-3.21 (m, 1H), 2.12 (s, 3H), 1.87 (s, 3H), 1.92-1.77 (m, 2H), 1.73-1.65 (m, 1H). MS: (ES) m/z calculated for C33H36FN404 [M +
H]571.3, found 571.3.
Example 18: N-(3"-fluoro-4"-((((1R,2R)-2-hydroxycyclopentyl)amino)methyl)-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe NLNFOH
NO H
Me Me [0137] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-((((lR,2R)-2-hydroxycyclopentyl)amino)methyl)-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. ITINMR (400 MHz, CD30D) 5 11.41 (s, 1H), 8.92 (s, 1H), 8.67 (s, 1H), 8.16-8.07 (m, 1H), 7.38-7.21 (m, 3H), 7.16 (dd, J= 7.5, 1.5 Hz, 1H), 7.03-6.96 (m, 1H), 6.94-6.82 (m, 2H), 4.44-4.28 (m, 3H), 3.98 (s, 3H), 3.66 (s, 3H), 3.53-3.41 (m, 2H), 3.40-3.30 (m, 1H), 3.30-3.21 (m, 1H), 2.12 (s, 3H), 1.87 (s, 3H), 1.92-1.77 (m, 2H), 1.73-1.65 (m, 1H). MS: (ES) m/z calculated for C33H36FN404 [M +
H]571.3, found 571.3.
Example 19: N-(3"-fluoro-4"-((((3R,4R)-3-hydroxytetrahydro-2H-pyran-4-yl)amino)methyl)-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terphenyll-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe 0 Me OH
N)kN
kN0 H
Me Me [0138] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-((((3R,4R)-3-hydroxytetrahydro-2H-pyran-4-yl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. 11-1 NMR (400 MHz, CD30D) 8 11.41 (s, 1H), 8.92 (s, 1H), 8.68 (s, 1H), 8.14-8.12 (m, 1H), 7.38-7.21 (m, 3H), 7.16 (d, J= 7.6 Hz, 1H), 6.99 (d, J= 7.6 Hz, 1H), 6.95-6.83 (m, 2H), 4.40 (d, J=
13.2 Hz, 1H), 4.31 (d, J= 13.2 Hz, 1H), 4.09-3.93 (m, 6H), 3.65 (s, 3H), 3.60-3.42 (m, 3H), 2.11 (s, 3H), 1.94 (s, 3H), 1.90-1.82 (m, 1H). MS: (ES) m/z calculated for C33H36FN405 [M +
H]587.3, found 587.3.
Example 20: N-(3"-fluoro-4"-(((2-hydroxyethyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-11,1' :3',!' OMe 0 Me OH
N)kN

Me Me [0139] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-(((2-hydroxyethyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. 1H NMR (400 MHz, CD30D) 8 11.42 (s, 1H), 8.92 (s, 1H), 8.68 (s, 1H), 8.11 (dd, J= 8.1, 1.3 Hz, 1H), 7.38-7.22 (m, 3H), 7.20-7.13 (m, 1H), 7.03-6.83 (m, 3H), 4.37 (s, 2H), 3.99 (s, 3H), 3.88-3.81 (m, 2H), 3.66 (s, 3H), 3.23-3.15 (m, 2H), 2.12 (s, 3H), 1.95 (s, 3H). MS: (ES) m/z calculated for C30H32FN404 [M +
H]531.2, found 531.2.
Example 21: (R)-N-(3"-fluoro-4"-(((1-hydroxypropan-2-yl)amino)methyl)-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe Me H
0 Me N
N)kN

Me LLJ
Me [0140] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (R)-N-(3"-fluoro-4"-(((1-hydroxypropan-2-yl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. ITINMR (400 MHz, CD30D) 8 11.42 (s, 1H), 8.92 (s, 1H), 8.68 (s, 1H), 8.14-8.07 (m, 1H), 7.38-7.21 (m, 3H), 7.16 (dd, J= 7.5, 1.5 Hz, 1H), 7.03-6.96 (m, 1H), 6.95-6.83 (m, 2H), 4.36 (s, 2H), 3.98 (s, 3H), 3.91-3.82 (m, 1H), 3.69-3.58 (m, 4H), 3.45-3.21 (m, 1H), 2.11 (s, 3H), 1.94 (s, 3H), 1.38 (d, J= 6.7 Hz, 3H). MS: (ES) m/z calculated for C3iH34FN404 [M + 545.3, found 545.3.
Example 22: (R)-N-(3"-fluoro-4"-(((2-hydroxypropyl)amino)methyl)-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe H
0 Me N
Me NN F
H
LLJ

Me Me [0141] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (R)-N-(3"-fluoro-4"-(((2-hydroxypropyl)amino)methyl)-5"-methoxy-2,2'-dimethyl -[1, l' :3 ', 1"-terphenyl] -3 -y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. 1H NMR (400 MHz, CD30D) 11.41 (s, 1H), 8.92 (s, 1H), 8.68 (s, 1H), 8.13-8.10 (m, 1H), 7.38-7.22 (m, 3H), 7.20-7.13 (m, 1H), 7.03-6.83 (m, 3H), 4.36 (s, 2H), 4.13-4.09 (m, 1H), 3.98 (s, 3H), 3.66 (s, 3H), 3.17-3.08 (m, 1H), 2.94-2.84 (m, 1H), 2.11 (s, 3H), 1.95 (s, 3H), 1.24 (d, J= 6.3 Hz, 3H). MS: (ES) m/z calculated for C31H34FN404 [M + H]+ 545.3, found 545.3.
Example 23: N-(3"-fluoro-4"-(((2-hydroxy-2-methylpropyl)amino)methyl)-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe N z0H
0 Me N N
H Me/ \Me )L

Me LLJ
Me [0142] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-(((2-hydroxy-2-methylpropyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. 1H NMR (400 MHz, CD30D) 8 11.41 (s, 1H), 8.92 (s, 1H), 8.68 (s, 1H), 8.13-8.10 (m, 1H), 7.38-7.22 (m, 3H), 7.20-7.13 (m, 1H), 7.03-6.84 (m, 3H), 4.40 (s, 2H), 4.00 (s, 3H), 3.66 (s, 3H), 3.03 (s, 2H), 2.12 (s, 3H), 1.95 (s, 3H), 1.30 (s, 6H). MS: (ES) m/z calculated for C32H36FN404 [M + 559.3, found 559.3.
Example 24: N-(3"-fluoro-4"-(4(1-hydroxycyclopropyl)methyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terpheny11-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe OH
0 ri Me N
N)LN F
H /

Me LiJ
Me [0143] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-((((1-hydroxycyclopropyl)methyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. 1H
NIVIR (400 MHz, CD30D) 8 11.41 (s, 1H), 8.92 (s, 1H), 8.67 (s, 1H), 8.13-8.10 (s, 1H), 7.38-7.22 (m, 3H), 7.17 (dd, J= 7.5, 1.5 Hz, 1H), 7.03-6.84 (m, 3H), 4.44 (s, 2H), 3.99 (s, 3H), 3.66 (s, 3H), 3.20 (s, 2H), 2.12 (s, 3H), 1.95 (s, 3H), 0.92 (t, J= 6.3 Hz, 2H), 0.78-0.70 (m, 2H).
MS: (ES) m/z calculated for C32H34FN404 [M + H]+ 557.3, found 557.3.
Example 25: N-(3"-fluoro-4"-(((1-hydroxy-2-methylpropan-2-yl)amino)methyl)-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe me me YOH
0 Me N
N)LN

Me Me [0144] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-(((1-hydroxy-2-methylpropan-2-yl)amino)methyl)-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. 1-1-1NMR
(400 MHz, CD30D) 8 11.41 (s, 1H), 8.92 (s, 1H), 8.68 (s, 1H), 8.13-8.10 (d, J= 7.6 Hz, 1H), 7.38-7.21 (m, 3H), 7.16 (d, J= 7.5 Hz, 1H), 6.99-6.82 (m, 3H), 4.30 (s, 2H), 3.98 (s, 3H), 3.67 (s, 5H), 2.12 (s, 3H), 1.94 (s, 3H), 1.42 (s, 6H). MS: (ES) m/z calculated for C32H36FN404 [M +
H]559.3, found 559.3.
Example 26: N-(3"-fluoro-4"-(42-hydroxyethyl)(methyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terpheny11-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe OH
0 Me Me N).LN

Me LLJ
Me [0145] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-(((2-hydroxyethyl)(methyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. 1H NMIt (400 MHz, CD30D) 5 11.42 (s, 1H), 8.92 (s, 1H), 8.67 (s, 1H), 8.15-8.11 (m, 1H), 7.39-7.23 (m, 3H), 7.17 (dd, J= 7.5, 1.5 Hz, 1H), 7.03-6.87 (m, 3H), 4.62 (d, J= 13.4 Hz, 1H), 4.43-4.34 (m, 1H), 4.01-3.86 (m, 5H), 3.65 (s, 3H), 3.43 (m, 2H), 2.89 (s, 3H), 2.12 (s, 3H), 1.95 (s, 3H). MS: (ES) m/z calculated for C31H34FN404 [M + 545.3, found 545.3.
Example 27: N-(3"-fluoro-4"-(42-hydroxy-2-methylpropyl)(methyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terpheny11-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe 0 Me OH
A
Me N N Me Me )( LLJ
Me M
e [0146] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-(((2-hydroxy-2-.. methylpropyl)(methyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. ITINMR (400 MHz, CD30D) 5 11.42 (s, 1H), 8.92 (s, 1H), 8.68 (s, 1H), 8.13-8.11 (m, 1H), 7.39-7.23 (m, 3H), 7.18 (dd, J= 7.5, 1.5 Hz, 1H), 7.03-6.87 (m, 3H), 4.85 (d, J= 13.2 Hz, 1H), 4.39 (d, J= 13.2 Hz, 1H), 4.00 (s, 3H), 3.66 (s, 3H), 3.42 (d, J= 13.5 Hz, 1H), 3.26 (d, J= 13.5 Hz, 1H), 2.93 (s, 3H), .. 2.12 (s, 3H), 1.96 (s, 3H), 1.40 (s, 3H), 1.36 (s, 3H). MS: (ES) m/z calculated for C33H38FN404 [M + H]' 573.3, found 573.3.
Example 28: 1-03-fluoro-5-methoxy-2',2"-dimethy1-3"-(1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamido)-11,1':3',1"-terpheny11-4-yl)methyl)azetidine-carboxylic acid OMe 0 Me N)kN CO2H

Me Me [0147] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product 143-fluoro-5-methoxy-2',2"-dimethy1-3"-(1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamido)41,1':3',1"-terphenyl]-4-y1)methyl)azetidine-3-carboxylic acid as a white solid. 1-EINMR (400 MHz, CD30D) 5 11.41 (s, 1H), 8.92 (s, 1H), 8.67 (s, 1H), 8.15-8.11 (m, 1H), 7.36-7.25 (m, 3H), 7.17 (ddd, J= 7.5, 1.5, 0.5 Hz, 1H), 7.02-6.85 (m, 3H), 4.57 (s, 2H), 4.43-4.41 (m, 4H), 3.99 (s, 3H), 3.73-3.68 (m, 1H), 3.66 (s, 3H), 2.11 (s, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated for C32H32FN405 [M + H]+
571.3, found 571.3.

Example 29: ((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamido)-11,1':3',1"-terpheny11-4-yl)methyl)glycine OMe 0 Me N CO2H
N ).LN

Me LJ
Me [0148] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product ((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamido)41,1':3',1"-terphenyl]-4-y1)methyl)glycine as a white solid. 1-EINMR (400 MHz, CD30D) 8 11.42 (s, 1H), 8.92 (s, 1H), 8.68 (s, 1H), 8.14-8.11 (m, 1H), 7.36-7.25 (m, 3H), 7.17 (dd, J = 7.4, 1.5 Hz, 1H), 7.03-6.84 (m, 3H), 4.42 (s, 2H), 3.99 (s, 3H), 3.93 (s, 2H), 3.66 (s, 3H), 2.12 (s, 3H), 1.95 (s, 3H). MS:
(ES) m/z calculated for C301-130FN405 [M + H]+ 545.2, found 545.3.
Example 30: N-(3"-fluoro-4"-(((2-hydroxyethyl)amino)methyl)-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide OMe 0 Me rY
N OH
N
NO H
Me LLJ
M
e [0149] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-(((2-hydroxyethyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide as a white solid. 111 NMR (400 MHz, CD30D) 8 8.58 (dd, J= 7.4, 2.1 Hz, 1H), 8.19-8.10 (m, 1H), 8.00 (dd, J= 6.6, 2.1 Hz, 1H), 7.38-7.21 (m, 3H), 7.17 (dd, J= 7.5, 1.5 Hz, 1H), 7.01-6.83 (m, 3H), 6.66-6.57 (m, 1H), 4.37 (s, 2H), 3.99 (s, 3H), 3.88-3.81 (m, 2H), 3.71 (s, 3H), 3.23-3.15 (m, 2H), 2.13 (s, 3H), 1.95 (s, 3H). MS: (ES) m/z calculated for C31H33FN304 [M + H]+ 530.2, found 530.2.
Example 31: N-(3"-fluoro-4"-(((2-hydroxy-2-methylpropyl)amino)methyl)-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-carboxamide OMe OH
0 Me rY N
H Me/ \Me N
NO H Me iti M
e [0150] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-(((2-hydroxy-2-methylpropyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide as a white solid. 111 NMR (400 MHz, CD30D) 8 8.58 (dd, J= 7.4, 2.2 Hz, 1H), 8.19-8.10 (m, 1H), 8.00 (ddd, J= 6.5, 2.1, 0.4 Hz, 1H), 7.38-7.22 (m, 3H), 7.17 (ddd, J= 7.5, 1.5, 0.5 Hz, 1H), 7.01-6.84 (m, 3H), 6.62 (ddd, J=
7.4, 6.5, 0.8 Hz, 1H), 4.39 (s, 2H), 4.00 (s, 3H), 3.71 (s, 3H), 3.04 (s, 2H), 2.14 (s, 3H), 1.96 (s, 3H), 1.31 (s, 6H). MS:
(ES) m/z calculated for C33H37FN304 [M + 558.3, found 558.3.
Example 32: 1-((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamido)-11,1':3',1"-terpheny11-4-y1)methyl)azetidine-3-carboxylic acid OMe 0 Me N3 NO H Me LLJ
Me [0151] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product 143-fluoro-5-methoxy-2',2"-dimethy1-3"-(1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamido)41,1':3',1"-terphenyl]-4-y1)methyl)azetidine-3-carboxylic acid as a white solid. 1-HNMR (400 MHz, CD30D) 8 8.60 (dd, J= 7.3, 2.1 Hz, 1H), 8.17-8.15 (m, 1H), 8.01 (dd, J= 6.5, 2.1 Hz, 1H), 7.37-7.25 (m, 3H), 7.18 (d, J= 7.5 Hz, 1H), 6.99-6.81 (m, 3H), 6.62 (t, J= 6.9 Hz, 1H), 4.57 (s, 2H), 4.43-4.41 (m, 4H), 3.99 (s, 3H), 3.71 (m, 4H), 2.13 (s, 3H), 1.95 (s, 3H). MS: (ES) m/z calculated for C33H33FN305 [M + H]' 570.2, found 570.3.
Example 33: ((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamido)-11,1':3',1"-terpheny11-4-yl)methyl)glycine OMe 0 Me rNCO2H
N
0 Me Me [0152] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product ((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamido)41,1':3',1"-terphenyl]-4-y1)methyl)glycine as a white solid. 1-EINMR (400 MHz, CD30D) 8 8.58 (dd, J=
7.4, 2.2 Hz, 1H), 8.19-8.10 (m, 1H), 8.02-7.99 (m, 1H), 7.38-7.22 (m, 3H), 7.18-7.16 (m, 1H), 7.01-6.84 (m, 3H), 6.64-6.61 (m, 1H), 4.42 (s, 2H), 3.99 (s, 3H), 3.93 (s, 2H), 3.71 (s, 3H), 2.14 (s, 3H), 1.95 (s, 3H). MS: (ES) m/z calculated for C311-131FN305 [M + H]+ 544.2, found 544.3.
Example 34: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((5-oxopyrrolidin-3-yl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe NH
0 Me HNN
0 N 0 Me Me [0153] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((5-oxopyrrolidin-3-y1)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 1H NMIR
(400 MHz, CD30D) 5 11.16 (s, 1H), 8.42 (s, 1H), 8.07-8.05 (m, 1H), 7.38-7.21 (m, 3H), 7.16 (dd, J= 7.5, 1.5 Hz, 1H), 7.00-6.85 (m, 3H), 4.37 (s, 2H), 4.26-4.21 (m, 1H), 4.00 (s, 3H), 3.88 (dd, J= 11.6, 7.6 Hz, 1H), 3.57 (dd, J= 11.6, 3.9 Hz, 1H), 3.35 (m, 3H), 2.91 (dd, J= 17.8, 8.8 Hz, 1H), 2.55 (dd, J= 17.8, 4.7 Hz, 1H), 2.10 (s, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated for C32H33FN505 [M + H]' 586.2, found 586.3.
Example 35: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyl((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me HN F Me ONO 0 Me Me [0154] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyl((5-oxopyrrolidin-2-yl)methyl)amino)methy1)41,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 11-INMR
(400 MHz, CD30D) 8 11.15 (s, 1H), 8.41 (s, 1H), 8.09-8.05 (m, 1H), 7.36-7.24 (m, 3H), 7.16 (dd, J= 7.6, 1.5 Hz, 1H), 7.01-6.87 (m, 3H), 4.74-4.68 (m, 1H), 4.08-4.03 (m, 1H), 4.02 (s, 3H), 4.00 (s, 2H), 3.35 (s, 3H), 3.06 (s, 3H), 2.95-2.80 (m, 2H), 2.60-2.32 (m, 3H), 2.10 (s, 3H), 1.95 (s, 3H). MS: (ES) m/z calculated for C34H37FN505 [M + H]+ 614.3, found 614.3.
Example 36: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((6-oxopiperidin-3-yl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 0 Me N NH
HN )*LN
0 N 0 Me Me [0155] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((6-oxopiperidin-3-y1)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 1-EINMR
(400 MHz, CD30D) 8 11.16 (s, 1H), 8.41 (s, 1H), 8.07-8.05 (m, 1H), 7.36-7.24 (m, 3H), 7.16 (d, J= 7.9 Hz, 1H), 7.00-6.86 (m, 3H), 4.48-4.35 (m, 2H), 4.00 (s, 3H), 3.77-3.74 (m, 2H), 3.52-3.41 (m, 1H), 3.36 (s, 3H), 2.50-2.49 (m, 2H), 2.42-2.38 (m, 1H), 2.14-2.04 (m, 4H), 1.94 (s, 3H). MS:
(ES) m/z calculated for C33H35FN505 [M + H]+ 600.3, found 600.3.
Example 37: (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((6-oxopiperidin-3-yl)amino)methyl)-11,1':3',1"-terphenyll-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me rNsNH
HN)*LN
ONO Me Me [0156] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((6-oxopiperidin-3-yl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid.
1-EINMR (400 MHz, CD30D) 8 11.16 (s, 1H), 8.41 (s, 1H), 8.07-8.05 (m, 1H), 7.36-7.24 (m, 3H), 7.16 (d, J=
7.9 Hz, 1H), 7.00-6.86 (m, 3H), 4.48-4.35 (m, 2H), 4.00 (s, 3H), 3.77-3.74 (m, 2H), 3.52-3.41 (m, 1H), 3.36 (s, 3H), 2.50-2.49 (m, 2H), 2.42-2.38 (m, 1H), 2.14-2.04 (m, 4H), 1.94 (s, 3H).
MS: (ES) m/z calculated for C33H35FN505 [M + H]600.3, found 600.3.
Example 38: N-(4"-(((3-amino-2,2-dimethy1-3-oxopropyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 0 Me NNH2 H Me Me HN )*L N
0 N 0 Me Me [0157] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(4"-(((3-amino-2,2-dimethy1-3-oxopropyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 11-1 NMR (400 MHz, CD30D) 8 11.16 (s, 1H), 8.42 (s, 1H), 8.07-8.05 (m, 1H), 7.38-7.22 (m, 3H), 7.19-7.12 (m, 1H), 7.01-6.91 (m, 2H), 6.87 (d, J= 9.9 Hz, 1H), 4.34 (s, 2H), 4.01 (s, 3H), 3.36 (s, 3H), 3.14 (s, 2H), 2.10 (s, 3H), 1.94 (s, 3H), 1.34 (s, 6H). MS: (ES) m/z calculated for C33H37FN505 [M + H]602.3, found 602.3.
Example 39: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((tetrahydrofuran-3-yl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe iC0 0 Me HN)*LN
0 N 0 Me Me [0158] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((tetrahydrofuran-3-yl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 1-EINMR
(400 MHz, CD30D) 8 11.15 (s, 1H), 8.41 (s, 1H), 8.09-8.05 (m, 1H), 7.37-7.24 (m, 3H), 7.19-7.12 (m, 1H), 6.98-6.87 (m, 3H), 4.34 (s, 2H), 4.07 (d, J= 9.7 Hz, 2H), 3.98 (s, 3H), 3.90-3.82 (m, 1H), 3.77-3.71 (m, 1H), 3.34 (s, 3H), 2.50-2.41 (m, 1H), 2.15-2.10 (m, 1H), 2.16-2.07 (m, 4H), 1.94 (s, 3H). MS: (ES) m/z calculated for C32H34FN405 [M + H]+ 573.2, found 573.3.
.. Example 40: (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((tetrahydrofuran-yl)amino)methyl)-11,1':3',1"-terphenyll-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe .00 0 Me fsr 0 N 0 Me Me [0159] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((tetrahydrofuran-3-yl)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid.
1-EINMR (400 MHz, CD30D) 6 11.15 (s, 1H), 8.41 (s, 1H), 8.09-8.05 (m, 1H), 7.37-7.24 (m, 3H), 7.19-7.12 (m, 1H), 6.98-6.87 (m, 3H), 4.34 (s, 2H), 4.07 (d, J= 9.7 Hz, 2H), 3.98 (s, 3H), 3.90-3.82 (m, 1H), 3.77-3.71 (m, 1H), 3.34 (s, 3H), 2.50-2.41 (m, 1H), 2.15-2.10 (m, 1H), 2.16-2.07 (m, 4H), 1.94 (s, 3H). MS: (ES) m/z calculated for C32H34FN405 [M + 573.2, found 573.3.
Example 41: N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((tetrahydro-2H-pyran-4-yl)amino)methyl)-11,1':3',1"-terphenyll-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe jas 0 Me HN)LN
Me Me [0160] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((tetrahydro-2H-pyran-4-yl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid.
1-EINMR (400 MHz, CD30D)15 11.15 (s, 1H), 8.41 (s, 1H), 8.09-8.05 (m, 1H), 7.37-7.20 (m, 3H), 7.15 (dd, J
= 7.6, 1.6 Hz, 1H), 6.96-6.86 (m, 3H), 4.34 (s, 2H), 4.10 /1.01 (m, 2H), 3.98 (s, 3H), 3.55-3.41 (m, 3H), 3.34 (s, 3H), 2.18-2.11 (m, 2H), 2.10 (s, 3H), 1.93 (s, 3H), 1.73 (m, 2H). MS: (ES) m/z calculated for C33H36FN405 [M + H]+ 587.3, found 587.3.
Example 42: N-(3"-fluoro-4"-(4(1R,2S)-2-hydroxycyclopentyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terphenyll-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me Nes -HN ).LN
ONO Me Me [0161] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-((((lR,2S)-2-hydroxycyclopentyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid.
1-EINMR (400 MHz, CD30D) 8 11.16 (s, 1H), 8.42 (s, 1H), 8.07-8.05 (m, 1H), 7.38-7.21 (m, 3H), 7.17-7.15 (m, 1H), 7.01-6.82 (m, 3H), 4.42-4.30 (m, 3H), 3.98 (s, 3H), 3.53-3.43 (m, 1H), 3.36 (s, 3H), 2.18-2.05 (m, 5H), 2.06-1.61 (m, 6H), 1.40-1.32 (m, 1H). MS: (ES) m/z calculated for C33H36FN405 [M + 587.3, found 587.3.

Example 43: (R)-N-(3"-fluoro-4"-(((2-hydroxypropyl)amino)methyl)-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe OH
0 Me N .
HN ).LN F
H Me 0 N 0 Me Me [0162] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (R)-N-(3"-fluoro-4"-(((2-hydroxypropyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 1-EINMR
(400 MHz, CD30D) 8 11.16 (s, 1H), 8.42 (s, 1H), 8.07-8.05 (m, 1H), 7.38-7.21 (m, 3H), 7.19-7.12 (m, 1H), 7.01-6.83 (m, 3H), 4.36 (s, 2H), 4.14-4.04 (m, 1H), 3.98 (s, 3H), 3.36 (s, 3H), 3.16-3.08 (m, 1H), 2.93-2.88 (m, 1H), 2.10 (s, 3H), 1.95 (s, 3H), 1.24 (d, J= 6.3 Hz, 3H). MS: (ES) m/z calculated for C31H34FN405 [M + H]561.2, found 561.3.
Example 44: N-(3"-fluoro-4"-(((2-hydroxy-2-methylpropyl)amino)methyl)-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me rY N /OH
Me HNN H Me Me LLJ
Me [0163] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-(((2-hydroxy-2-methylpropyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid.
1-H NMR (400 MHz, CD30D) ö 11.14 (s, 1H), 8.43 (s, 1H), 8.04-8.02 (m, 1H), 7.37-7.25 (m, 3H), 7.17-7.15 (m, 1H), 6.99-6.86 (m, 3H), 4.40 (s, 2H), 3.99 (s, 3H), 3.36 (s, 3H), 3.04 (s, 2H), 2.10 (s, 3H), 1.94 (s, 3H), 1.31 (s, 6H). MS: (ES) m/z calculated for C32H36FN405 [M + HIP
575.3, found 575.3.
Example 45: N-(4"-(((3-amino-2,2-dimethy1-3-oxopropyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terphenyll-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 0 Me NNH2 Me,N)LN H Me Me Me LJ
Me [0164] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(4"-(((3-amino-2,2-dimethy1-3-oxopropyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 11-1 NMR (400 MHz, CD30D) 8 11.16 (s, 1H), 8.63 (s, 1H), 8.09-8.05 (m, 1H), 7.36-7.25 (m, 3H), 7.17-7.15 (m, 1H), 6.98-6.86 (m, 3H), 4.34 (s, 2H), 4.02 (s, 3H), 3.55 (s, 3H), 3.39 (s, 3H), 3.15 (s, 2H), 2.10 (s, 3H), 1.94 (s, 3H), 1.35 (s, 6H). MS: (ES) m/z calculated for C34H39FN505 [M +
H]+616.3, found 616.3.
Example 46: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((tetrahydrofuran-3-yl)amino)methyl)-11,1':3',1"-terphenyll-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me Me,N.LN
0 N 0 Me Me [0165] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((tetrahydrofuran-3-yl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 1-EINMR
(400 MHz, CD30D) 8 11.16 (s, 1H), 8.62 (s, 1H), 8.09-8.06 (m, 1H), 7.36-7.21 (m, 3H), 7.17-7.15 (m, 1H), 6.98-6.87 (m, 3H), 4.34 (s, 2H), 4.10-4.03 (m, 2H), 3.98 (s, 4H), 3.89-3.82 (m, 1H), 3.78-3.71 (m, 1H), 3.54 (s, 3H), 3.37 (s, 3H), 2.48-2.38 (m, 1H), 2.15-2.10 (m, 4H), 1.93 (s, 3H).
MS: (ES) m/z calculated for C33H36FN405 [M + H]+ 587.3, found 587.3.
Example 47: (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((tetrahydrofuran-3-yl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe .00 0 Me fsr Me,N).LN
iIIIIi0 N 0 Me Me [0166] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((tetrahydrofuran-3-yl)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 1H NMR (400 MHz, CD30D) 8 11.16 (s, 1H), 8.62 (s, 1H), 8.09-8.06 (m, 1H), 7.36-7.21 (m, 3H), 7.17-7.15 (m, 1H), 6.98-6.87 (m, 3H), 4.34 (s, 2H), 4.10-4.03 (m, 2H), 3.98 (s, 4H), 3.89-3.82 (m, 1H), 3.78-3.71 (m, 1H), 3.54 (s, 3H), 3.37 (s, 3H), 2.48-2.38 (m, 1H), 2.15-2.10 (m, 4H), 1.93 (s, 3H). MS: (ES) m/z calculated for C33H36FN405 [M + H]+ 587.3, found 587.3.
Example 48: N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((tetrahydro-2H-pyran-4-yl)amino)methyl)-11,1':3',1"-terphenyll-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me N
Me ,N ).LN
Me Me [0167] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((tetrahydro-2H-pyran-4-yl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 1H NMR (400 MHz, CD30D) 8 11.17 (s, 1H), 8.63 (s, 1H), 8.09-8.05 (m, 1H), 7.36-7.24 (m, 3H), 7.16 (d, J=
7.5 Hz, 1H), 7.00-6.84 (m, 3H), 4.36 (s, 2H), 4.09-4.05 (m, 2H), 3.99 (s, 3H), 3.56 (s, 3H), 3.51-3.43 (m, 3H), 3.38 (s, 3H), 2.18-2.10 (m, 5H), 1.93 (s, 3H), 1.77-1.69 (m, 2H). MS: (ES) m/z calculated for C34H38FN405 [M + H]601.3, found 601.3.
Example 49: N-(3"-fluoro-4"-((((3R,4R)-3-hydroxytetrahydro-2H-pyran-4-yl)amino)methyl)-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terpheny11-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me Nes' H =
Me,N OH
0 N 0 Me uii Me [0168] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-((((3R,4R)-3-hydroxytetrahydro-2H-pyran-4-yl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 1H NMR (400 MHz, CD30D) 8 11.17 (s, 1H), 8.63 (s, 1H), 8.10-8.06 (m, 1H), 7.36-7.24 .. (m, 3H), 7.19-7.12 (m, 1H), 7.00-6.82 (m, 3H), 4.43-4.29 (m, 2H), 4.10-3.95 (m, 6H), 3.61-3.40 (m, 6H), 3.37 (s, 3H), 2.15-2.10 (m, 1H), 2.09 (s, 3H), 1.93 (s, 3H), 1.91-1.82 (m, 1H).
MS: (ES) m/z calculated for C34H38FN406 [M + H]617.3, found 618.3.
Example 50: N-(4"-(((3-amino-2,2-dimethy1-3-oxopropyl)amino)methyl)-2',3"-difluoro-5"-methoxy-2-methyl-11,1':3',1"-terpheny11-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 0 F N(jL NH2 Me,N H Me Me Me Li Me [0169] The compound was prepared from N-(2',3"-difluoro-4"-formy1-5"-methoxy-2-methyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(4"-(((3-amino-2,2-dimethy1-3-oxopropyl)amino)methyl)-2',3"-difluoro-5"-methoxy-2-methyl-[1,1':3',1"-terphenyl]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 1-E1 NMR (400 MHz, CD30D) 8 11.19 (s, 1H), 8.63 (s, 1H), 8.14-8.12 (m, 1H), 7.62-7.57 (m, 1H), 7.42-7.29 (m, 3H), 7.15-7.09 (m, 3H), 4.34 (s, 2H), 4.04 (s, 3H), 3.56 (s, 3H), 3.39 (s, 3H), 3.13 (s, 2H), 2.20 (s, 3H), 1.34 (s, 6H). MS: (ES) m/z calculated for C33H36F2N505 [M + H]620.3, found 620.3.
Example 51: (S)-N-(2',3"-difluoro-5"-methoxy-2-methyl-4"-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 N rrs.,.10 Me,NAN
0 N 0 Me Me [0170] The compound was prepared from N-(2',3"-difluoro-4"-formy1-5"-methoxy-2-methyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (S)-N-(2',3"-difluoro-5"-methoxy-2-methy1-4"-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 11-1 NMR (400 MHz, CD30D) 8 11.19 (s, 1H), 8.63 (s, 1H), 8.12 (t, J= 7.5 Hz, 1H), 7.61-7.57 (m, 1H), 7.42-7.29 (m, 3H), 7.17-7.08 (m, 3H), 4.40 (s, 2H), 4.08-4.02 (m, 1H), 4.02 (s, 3H), 3.55 (s, 3H), 3.38 (s, 3H), 3.27-3.22 (m, 2H), 2.46-2.34 (m, 3H), 2.20 (s, 3H), 1.96-1.88 (m, 1H).
MS: (ES) m/z calculated for C33H34F2N505 [M + H]' 618.2, found 618.3.
Example 52: (S)-N-(2',3"-difluoro-5"-methoxy-2-methyl-4"-(((5-oxopyrrolidin-3-yl)amino)methyl)-11,1':3',1"-terphenyll-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide 0 Me idNH

Me ,N ).LN
ác 0 N 0 Me Me [0171] The compound was prepared from N-(2',3"-difluoro-4"-formy1-5"-methoxy-2-methyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (S)-N-(2',3"-difluoro-5"-methoxy-2-methy1-4"-(((5-oxopyrrolidin-3-yl)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 1H NMR (400 MHz, CD30D) 8 11.18 (s, 1H), 8.63 (s, 1H), 8.12 (t, J= 7.6 Hz, 1H), 7.61-7.57 (m, 1H), 7.42-7.29 (m, 3H), 7.17-7.08 (m, 3H), 4.37 (s, 2H), 4.28-4.16 (m, 1H), 4.03 (s, 3H), 3.90-3.82 (m, 1H), 3.60-3.55 (m, 1H), 3.54 (s, 3H), 3.39 (s, 3H), 2.95-2.86 (m, 1H), 2.59-2.52 (m, 1H), 2.20 (s, 3H). MS: (ES) m/z calculated for C32H32F2N505 [M + H]604.2, found 604.3.
Example 53: (S)-N-(3"-fluoro-5"-methoxy-2,2'- dimethy1-4"-((((1-methyl-5-oxopyrrolidin-2-yl)methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide OM e Me 0 Me N
Me õN
N N
0 N 0 Me Me [0172] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((1-methyl-5-oxopyrrolidin-2-y1)methyl)amino)methyl)-[1,1':3',1"-terpheny1]-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide as a white solid. 1H NIVIR (400 MHz, CD30D) 11.08 (s, 1H), 8.10-8.06 (m, 1H), 7.35-7.26 (m, 3H), 7.17 (d, J= 7.6 Hz, 1H), 7.02 (d, J= 7.8 Hz, 1H), 6.98-6.86 (m, 2H), 4.44 (s, 2H), 4.01 (s, 3H), 3.99-3.93 (m, 1H), 3.77 (s, 3H), 3.48 (d, J= 12.7 Hz, 1H), 3.38 (s, 3H), 3.30 (s, 3H), 3.28-3.22 (m, 1H), 2.85 (s, 2H), 2.56-2.47 (m, 1H), 2.44-2.30 (m, 2H), 2.00-1.92 (m, 4H), 1.95 (s, 3H). MS: (ES) m/z calculated for C34H38FN605 [M + H]629.3, found 629.3.
Example 54: (R)-3-(((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)pyrrolidin-2-one OMe NH
ri Me NLN
H
Me [0173] The compound was prepared from 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1%
TFA) to give the desired product (R)-34(3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)41,1':3',1"-terphenyl]-4-y1)methyl)amino)pyrrolidin-2-one as a white solid.
1H NIVIR (400 MHz, CD30D) 6 9.24 (s, 1H), 9.05 (s, 1H), 7.79 (d, J= 7.1 Hz, 1H), 7.64-7.49 (m, 3H), 7.41-7.32 (m, 2H), 7.33-7.20 (m, 2H), 6.96-6.84 (m, 2H), 4.63 (d, J=
13.1 Hz, 1H), 4.39 (d, J= 13.2 Hz, 1H), 4.26-4.17 (m, 1H), 3.98 (s, 3H), 3.49-3.40 (m, 2H), 2.68-2.59 (m, 1H), 2.28-2.18 (m, 1H), 2.10 (s, 3H), 2.02 (s, 3H). MS: (ES) m/z calculated for C33H32FN602 [M + H]' 563.3, found 563.3.
Example 55: (S)-3-(((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido13,4-blpyrazin-5-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)pyrrolidin-2-one OMe NH
Me rr Nr.C"/
NLN
H
Me [0174] The compound was prepared from 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1%
TFA) to give the desired product (S)-3-(((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-y1)methyl)amino)pyrrolidin-2-one as a white solid.
1H NMR (400 MHz, CD30D) 8 9.24 (s, 1H), 9.05 (s, 1H), 7.79 (d, J= 7.1 Hz, 1H), 7.64-7.49 (m, 3H), 7.41-7.32 (m, 2H), 7.33-7.20 (m, 2H), 6.96-6.84 (m, 2H), 4.63 (d, J=
13.1 Hz, 1H), 4.39 (d, J= 13.2 Hz, 1H), 4.26-4.17 (m, 1H), 3.98 (s, 3H), 3.49-3.40 (m, 2H), 2.68-2.59 (m, 1H), 2.28-2.18 (m, 1H), 2.10 (s, 3H), 2.02 (s, 3H). MS: (ES) m/z calculated for C33H32FN602 [M + H]' 563.3, found 563.3.
Example 56: 5-((((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido13,4-blpyrazin-5-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)methyl)pyrimidine-2,4(1H,31I)-dione OMe Me rY NNH

H
Me [0175] The compound was prepared from 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1%
TFA) to give the desired product 5-((((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-y1)methyl)amino)methyl)pyrimidine-2,4(1H,31/)-dione as a white solid. MS: (ES) m/z calculated for C34H31FN703 [M + H]+
604.2, found 604.2.
Example 57: 1-(2-(((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-blpyrazin-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)ethyl)pyrrolidin-2-one OMe Me NYLNI
H
Me [0176] The compound was prepared from 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1%
TFA) to give the desired product 1-(24(3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-y1)methyl)amino)ethyppyrrolidin-2-one as a white solid. 1-E1 NMR (400 MHz, CD30D) 8 9.25 (d, J= 2.0 Hz, 1H), 9.05 (d, J= 2.0 Hz, 1H), 7.79 (d, J= 7.2 Hz, 1H), 7.64-7.49 (m, 2H), 7.40-7.35 (m, 3H), 7.30-7.22 (m, 2H), 6.97-6.84 (m, 2H), 4.39 (s, 2H), 3.99 (s, 3H), 3.66 (t, J= 5.8 Hz, 2H), 3.53 (t, J= 5.8 Hz, 2H), 3.37-3.27 (m, 3H), 2.42 (t, J= 8.1 Hz, 2H), 2.17-2.04 (m, 4H), 2.02 (s, 3H). MS: (ES) m/z calculated for C35H36FN602 [M + H]' 591.3, found 592.3.
Example 58: N-(4"-((((1H-pyrrol-2-yl)methyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-yl)pyrido[3,4-blpyrazin-5-amine OMe Me N
H I /
NN
H
Me [0177] The compound was prepared from 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1%
TFA) to give the desired product N-(4"-((((1H-pyrrol-2-yl)methyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)pyrido[3,4-b]pyrazin-5-amine as a white solid.
MS: (ES) m/z calculated for C34H32FN60 [M + H]+ 559.3, found 559.3.
Example 59: 3-0(2',3-difluoro-5-methoxy-2"-methyl-3"-(pyrido13,4-blpyrazin-5-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)-2,2-dimethylpropanamide OMe 0 N*NH2 NLILL H Me Me YLN
H
Me [0178] The compound was prepared from 2',3-difluoro-5-methoxy-2"-methy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1%
TFA) to give the desired product 3-(((2',3-difluoro-5-methoxy-2"-methy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)41,1':3',1"-terphenyl]-4-y1)methyl)amino)-2,2-dimethylpropanamide as a white solid. ITINMR (400 MHz, CD30D) 8 9.22 (s, 1H), 9.04 (s, 1H), 7.83-7.82 (m, 1H), 7.63-7.45 (m, 3H), 7.44-7.28 (m, 4H), 7.10-7.00 (m, 2H), 4.34 (s, 2H), 4.04 (s, 3H), 3.13 (s, 2H), 2.29 (s, 3H), 1.34 (s, 6H). MS: (ES) m/z calculated for C33H33F2N602 [M +
H]+ 583.3, found 583.3.
Example 60: (S)-54(02',3-difluoro-5-methoxy-2"-methyl-3"-(pyrido[3,4-b]pyrazin-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)methyl)pyrrolidin-2-one OMe H
Me [0179] The compound was prepared from 2',3-difluoro-5-methoxy-2"-methy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde using a procedure similar to the one described in Step c of Example 1. The product was purified HPLC (MeCN/H20 with 0.1%
TFA) to give the desired product (S)-5-((((2',3-difluoro-5-methoxy-2"-methy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-yl)methyl)amino)methyl)pyrrolidin-2-one as a white solid. 1H NMR (400 MHz, CD30D) 8 9.24 (s, 1H), 9.05 (s, 1H), 7.81 (d, J=
7.1 Hz, 1H), 7.68-7.37 (m, 7H), 7.17-7.12 (m, 2H), 4.41 (s, 2H), 4.06-4.03 (m, 4H), 3.27-3.23 (m, 2H), 2.44-2.32 (m, 3H), 2.23 (s, 3H), 1.94-1.89 (m, 1H). MS: (ES) m/z calculated for C33H3iF2N602 [M + H]' 581.2, found 581.3.

Example 61: 1-((3-fluoro-3"-(isoquinolin-1-ylamino)-5-methoxy-2',2"-dimethy1-11,1':3',1"-terphenyll-4-y1)methyl)azetidine-3-carboxylic acid OMe N Me Me CO2H
[0180] The compound was prepared from 3-fluoro-3"-(isoquinolin-1-ylamino)-5-methoxy-2',2"-dimethy141,1':3',1"-terpheny1]-4-carbaldehyde using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1%
TFA) to give the desired product 1-((3-fluoro-3"-(isoquinolin-1-ylamino)-5-methoxy-2',2"-dimethy141,1':3',1"-terphenyl]-4-yl)methyl)azetidine-3-carboxylic acid as a white solid. 11-1 NMR (400 MHz, CD30D) 6 8.67-8.63 (m, 1H), 8.11-7.99 (m, 2H), 7.93-7.89 (m, 1H), 7.61-7.45 (m, 3H), 7.44-7.22 (m, 5H), 6.97-6.86 (m, 2H), 4.56 (s, 2H), 4.43-4.41 (m, 4H), 3.98 (s, 3H), 3.73-3.68 (m, 1H), 2.07 (s, 3H), 2.03 (s, 3H). MS: (ES) m/z calculated for C35H33FN303 [M + H]' 562.2, found 562.3.
Example 62: 1-((3"-((1,6-naphthyridin-8-yl)amino)-3-fluoro-5-methoxy-2',2"-dimethyl-11,1':3',1"-terpheny11-4-yl)methyl)azetidine-3-carboxylic acid OMe N Me N\D CO2H
Me [0181] The compound was prepared from 3"-((1,6-naphthyridin-8-yl)amino)-3-fluoro-5-methoxy-2',2"-dimethyl-[1,1':3',1"-terphenyl]-4-carbaldehyde using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC
(MeCN/H20 with 0.1% TFA) to give the desired product 14(3"-((1,6-naphthyridin-8-yl)amino)-3-fluoro-5-methoxy-2',2"-dimethy141,1':3',1"-terphenyl]-4-y1)methyl)azetidine-3-carboxylic acid as a white solid. 1H NMR (400 MHz, CD30D) 5 9.34 (dd, J= 4.3, 1.7 Hz, 1H), 8.92 (s, 1H), 8.72 (dd, J=
8.4, 1.7 Hz, 1H), 7.97 (dd, J= 8.4, 4.3 Hz, 1H), 7.73 (s, 1H), 7.55-7.32 (m, 3H), 7.31-7.16 (m, 3H), 6.97-6.86 (m, 2H), 4.56 (s, 2H), 4.43-4.40 (m, 4H), 3.98 (s, 3H), 3.75-3.65 (m, 1H), 2.08 (s, 3H), 2.01 (s, 3H). MS: (ES) m/z calculated for C34H32FN403 [M + H]+ 563.2, found 563.3.
Example 63: 1-03-fluoro-5-methoxy-2',2"-dimethy1-3"-(quinoxalin-5-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)azetidine-3-carboxylic acid OMe Me H
Me [0182] The compound was prepared from 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(quinoxalin-5-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1%
TFA) to give the desired product 14(3-fluoro-5-methoxy-2',2"-dimethy1-3"-(quinoxalin-5-ylamino)-[1,1':3',1"-terpheny1]-4-yl)methyl)azetidine-3-carboxylic acid as a white solid. 1-EINMR (400 MHz, CD30D) 6 8.87 (s, 1H), 8.82 (s, 1H), 7.64-7.62 (m, 1H), 7.50 (dd, J= 7.9, 1.4 Hz, 1H), 7.41-7.29(m, 3H), 7.25-7.21 (m, 2H), 7.04-6.86(m, 4H), 4.57(s, 2H), 4.46-4.39(m, 4H), 3.99 (s, 3H), 3.74-3.66 (m, 1H), 2.05 (s, 3H), 2.01 (s, 3H). MS: (ES) m/z calculated for C34H32FN403 [M + H]' 563.2, found 563.3.
Example 64: 1-03-fluoro-5-methoxy-2',2"-dimethy1-3"-(quinazolin-8-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)azetidine-3-carboxylic acid OMe Me 1\10 N N Me [0183] The compound was prepared from 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(quinazolin-8-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1%
TFA) to give the desired product 14(3-fluoro-5-methoxy-2',2"-dimethy1-3"-(quinazolin-8-ylamino)-[1,1':3',1"-terpheny1]-4-yl)methyl)azetidine-3-carboxylic acid as a white solid. 1H NMR (400 MHz, CD30D) 9.41 (s, 1H), 9.20 (s, 1H), 7.58-7.46 (m, 2H), 7.45-7.29 (m, 3H), 7.29-7.09 (m, 3H), 7.01 (dd, J= 7.4, 1.3 Hz, 1H), 6.97-6.85 (m, 2H), 4.51 (s, 2H), 4.43-4.28 (m, 4H), 3.98 (s, 3H), 3.52-3.44 (m, 1H), 2.05 (s, 3H), 2.00 (s, 3H). MS: (ES) m/z calculated for C34H32FN403 [M + H]' 563.2, found 563.3.
Example 65: 14(3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,2-d1pyrimidin-4-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)azetidine-3-carboxylic acid OMe NN Me H)L CO2H
Me [0184] The compound was prepared from 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,2-d]pyrimidin-4-ylamino)41,1':3',1"-terphenyl]-4-carbaldehyde using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC
(MeCN/H20 with 0.1% TFA) to give the desired product 1-((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,2-d]pyrimidin-4-ylamino)41,1':3',1"-terpheny1]-4-yl)methyl)azetidine-3-carboxylic acid as a white solid. MS: (ES) m/z calculated for C33H31FN503 [M + H]+ 564.2, found 564.2.
Example 66: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyl(5-oxopyrrolidin-3-yl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide OMe oe6H OMe 0 eM H2N
.6H
9 Me 0 NaBH(OAc)3 HOAc DCE:Me0H
Step d N.L N el Br OMe JIIjNH kN0 H
Me Me 9 Me Me NaBH(OAc)3 4-113 Pd(dppf)C12.CH2C12 DCE/Me0H 2 M K2CO3 Step e Dioxane 90 C, 4 h Step f OMe 0 Me M
N)LN e kN0 H
Me Me [0185] Step d: To a stirred solution of 3-fluoro-5-methoxy-2'-methy1-3'-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)41,1'-biphenyl]-4-carbaldehyde (75 mg, 0.203 mmol) and (S)-4-aminopyrrolidin-2-one (41 mg, 0.406 mmol) in MeOH:DCE (2 mL) was added NaBH(OAc)3 (86 mg, 0.406 mmol) and AcOH (5 drops). The reaction mixture was stirred at room temperature for 2 h. The solvent was removed under reduced pressure and the residue was purified by silica gel flash chromatography (0% to 20% Me0H/DCM) to give (S)-4-(((3-fluoro-5-methoxy-2'-methyl-3'-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-[1,1'-bipheny1]-4-yl)methyl)amino)pyrrolidin-2-one as a yellow solid. MS: (ES) m/z calculated for C25H33BFN204 [M + H]455.2, found 455.3.
[0186] Step e: To a stirred solution of (S)-4-(((3-fluoro-5-methoxy-2'-methy1-3'-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)41,1'-biphenyl]-4-y1)methyl)amino)pyrrolidin-2-one (86 mg, 0.189 mmol) and parafomaldehyde 37% aqueous in water (78 [IL) in MeOH:DCE
(2 mL) was added NaBH(OAc)3 (201 mg, 0.945 mmol). The reaction mixture was stirred at room temperature for 16 h. The solvent was removed under reduced pressure and the residue was purified by silica gel flash chromatography (0% to 20% Me0H/DCM) to give (S)-4-(((3-fluoro-5-methoxy-2'-methy1-3'-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-[1,1'-biphenyl]-4-yl)methyl)(methyl)amino)pyrrolidin-2-one as a yellow solid. MS: (ES) m/z calculated for C26H35BFN204 [M + H]469.3, found 469.3.
[0187] Step f: To a mixture of (S)-4-(((3-fluoro-5-methoxy-2'-methy1-3'-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)41,1'-biphenyl]-4-y1)methyl)(methyl)amino)pyrrolidin-2-one (78 mg, 0.167 mmol), N-(3-bromo-2-methylpheny1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide (54 mg, 0.167 mmol) and 2M K2CO3 (0.25 mL, 0.501 mmol) in p-dioxane (5 mL) was added Pd(dppf)C12 complex with dichloromethane (20 mg, 0.022 mmol). The reaction mixture was degassed (N2) for 2 min and stirred under N2 at 95 C for 5 h. The reaction mixture was diluted with Et0Ac, filtered through Celite, washed with brine and dried over MgSO4. The solvent was removed under reduced pressure and the residue was purified by silica gel flash chromatography (0% to 20% methanol/dichloromethane) follwed by HPLC (MeCN/H20 with 0.1% TFA) to give (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyl(5-oxopyrrolidin-3-y1)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide as a white solid. lEINMR (400 MHz, CD30D) 8 8.92 (s, 1H), 8.67 (s, 1H), 8.15-8.11 (m, 1H), 7.39-7.23 (m, 3H), 7.17 (dd, J= 7.7, 1.7 Hz, 1H), 7.03-6.90 (m, 3H), 4.47 (s, 2H), 4.39 (d, J= 7.4 Hz, 1H), 4.01 (s, 3H), 3.96-3.87 (m, 1H), 3.78-3.71 (m, 1H), 3.65 (s, 3H), 2.91 (s, 3H), 2.85-2.74 (m, 1H), 2.12 (s, 3H), 1.96 (s, 3H). MS: (ES) m/z calculated for C33H35FN504 [M + H]' 584.3, found 584.3.
Example 67: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyl(5-oxopyrrolidin-3-yl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide OMe NH
0 Me N F rµlAe Ns:) Me Me [0188] The compound was prepared from N-(3-bromo-2-methylpheny1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide using a procedure similar to the one described in Step f of Example 66. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyl(5-oxopyrrolidin-3-y1)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide as a white solid. lEINMR (400 MHz, CD30D) 6 12.19 (s, 1H), 8.60 (dd, J = 7.3, 2.0 Hz, 1H), 8.17-8.14 (m, 1H), 8.02-8.00 (m, 1H), 7.38-7.24 (m, 3H), 7.19 (dd, J= 7.6, 1.6 Hz, 1H), 7.00-6.94 (m, 3H), 4.48-4.40 (m, 3H), 4.01 (s, 3H), 3.95-3.85 (m, 1H), 3.77-3.73 (m, 2H), 3.70 (s, 3H), 2.90 (s, 3H), 2.82-2.78 (m, 1H), 2.13 (s, 3H), 1.95 (s, 3H). MS:
(ES) m/z calculated for C34H36FN404 [M + H]+ 583.3, found 583.3.
Example 68: N-(4"-(aminomethyl)-3"-fluoro-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide OMe Me NHBoc el 0- B F Br /\)( OH Me ).LN Br _____________ HATU, DMF0 Me Pd(dppf)C12, K2CO3 MI e Hunig's Base Dioxane/H20, 95 C
Me Step a Step b OMe 0 Me NHBoc TFA
CH2C12, rt, 16 h N
1 Step c 1 Me OMe Me 0 Me NH2 N
NO H

Me Me [0189] Step a: To a solution of 1-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid (0.36 g, 2.35 mmol), 3-bromo-2-methylaniline (0.43 g, 2.35 mmol), in DMF (5.0 mL) was added HATU
(1.34 g, 3.52 mmol) and diisopropylethylamine (0.75 g, 5.87 mmol). The reaction was stirred at room temperature for 16 h. After completion of the reaction, half of the solvent was removed and the mixture was diluted with water (15 ml) and then stirred for 20 min.
The resultant solid was filtered using plastic funnel, washed with water (10 ml) and dried under vacuum.
[0190] Step b: To a solution of N-(3-bromo-2-methylpheny1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide (100 mg, 0.31 mmol), tert-butyl ((3-fluoro-5-methoxy-2'-methy1-3'-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-[1,1'-biphenyl]-4-y1)methyl)carbamate (146 mg, 0.31 mmol) and 2M K2CO3 (0.38 mL, 0.77 mmol) in p-dioxane (3 mL) was added Pd(dppf)C12 complex with dichloromethane (26 mg, 0.032 mmol). The reaction mixture was degassed (N2) for 2 min and stirred under N2 at 95 C for 4 h. The reaction mixture was diluted with Et0Ac, filtered through Celite, washed with brine and dried over MgSO4.
The solvent was removed under reduced pressure and the residue was purified by silica gel flash chromatography (5 to 20% to 40% Et0Ac/hexane) to give tert-butyl ((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamido)-[1,1':3',1"-terpheny1]-4-y1)methyl)carbamate.
MS: (ES) m/z calculated for C33H37FN305 [M + H]+ 586.3, found 586.2.
[0191] Step c: To a strirred solution of tert-butyl ((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamido)-[1,1':3',1"-terpheny1]-4-yl)methyl)carbamate (75mg, 0.123 mmol) in anhydrous dichloromethane (2.5 mL) at room temperature was added TFA (141 mg, 1.23 mmol) dropwise over 5 min. The reaction mixture was stirred at room temperature for 2 h. After completion of the reaction, the solvent was removed in vacuo to give a viscous residue. The material was purified by HPLC (MeCN/H20 with 0.1% TFA) to give N-(4"-(aminomethyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methyl-2-.. oxo-1,2-dihydropyridine-3-carboxamide (48 mg, 77%). 1H NMR (400 MHz, CD30D) 6 12.19 (s, 1H), 8.59 (dd, J= 7.4, 2.2 Hz, 1H), 8.14 (d, J= 8.2 Hz, 1H), 8.00 (dd, J=
2.2, 6.6 Hz, 1H), 7.38-7.21 (m, 3H), 7.15 (d, J= 7.2 Hz, 1H), 6.96 (d, J= 7.2 Hz, 1H), 6.91 (s, 1H), 6.86 (d, J=
9.8 Hz, 1H), 6.62 (ddd, J= 7.5, 6.5, 0.8 Hz, 1H), 4.22 (s, 2H), 3.97 (s, 3H), 3.71 (s, 3H), 2.12 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated for C29H29FN303 [M + H]486.2, found 486.2.
Example 69: 6-amino-N-(3"-fluoro-4"-(((2-hydroxyethyl)amino)methyl)-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-yl)nicotinamide OMe 49 Me oFi 1) (C0C1)2, DCM )*Li N Br H2N Me N 2) DCM, DIPEA H2NN
Pd(dppf)C12, K2CO3 rt, 16 h Dioxane/H20, 95 C
Step b H2N Br Me Step a OMe 0 Me NH2CH2CH2OH
N Na(0Ac)3BH, DMF.
rt, 16 h H2NN Me LJ Step c OMe OH
0 Me N
M

e [0192] Step a: To a stirred suspension of 6-aminonicotinic acid (0.75 g, 5.34 mmol) in CH2C12 (10 mL) was added oxalyl chloride (1.02 g, 8.15 mmol) at room temperature. The resulting mixture was stirred for 4 h. The solvent was removed under reduced pressure and the resultant residue was dried under vacuum and used directly in the next step.
The residue was added to a solution of 3-bromo-2-methylaniline (1.0 g, 6.41 mmol) and N,N-diisopropylethylamine (2.06 mg, 16.0 mmol) in THF (15 mL) and the mixture was stirred at room temperature overnight. After completion, the reaction was worked up by water wash and extracted with Et0Ac. The crude product was purified by silica gel chromatography (20-100%
Et0Ac/hexane) to give the desired product 6-amino-N-(3-bromo-2-methylphenyl)nicotinamide.
MS: (ES) m/z calculated for Ci3Hi3BrN30 [M + H]+ 306.0, found 306.1.

[0193] Step b: To a mixture of 6-amino-N-(3-bromo-2-methylphenyl)nicotinamide (150 mg, 0.49 mmol), 3-fluoro-5-methoxy-2'-methy1-3'-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-[1,1'-biphenyl]-4-carbaldehyde (199 mg, 0.53 mmol), and 2M K2CO3 (0.61 mL, 1.22 mmol) in p-dioxane (15 mL) was added Pd(dppf)C12 complex with dichloromethane (40 mg, 0.049 mmol).
.. The reaction mixture was degassed (N2) for 2 min and stirred under N2 at 95 C for 3 h. The reaction mixture was diluted with Et0Ac, filtered through Celite, washed with brine and dried over MgSO4. The solvent was removed under reduced pressure and the residue was purified by silica gel flash chromatography (5 to 20% to 40% Et0Ac/hexane) to give 6-amino-N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-yl)nicotinamide.
MS: (ES) m/z .. calculated for C281-125FN303[M + H]470.2, found 470.2.
[0194] Step c: To a stirred solution of 6-amino-N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethy141,1':3',1"-terpheny1]-3-yl)nicotinamide (50 mg, 0.106 mmol), and ethanol amine (26 mg, 0.42 mmol) in DMF (2 mL) was added NaBH(OAc)3 (56 mg, 0.26 mmol). The reaction mixture was stirred at room temperature for 2 h. The solvent was removed under reduced pressure and the residue was purified by HPLC (0 to 40% to 100% MeCN/H20) to give 6-amino-N-(3"-fluoro-4"-(((2-hydroxyethyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-yl)nicotinamide. 1H NMR (400 MHz, CD30D) 8 8.55-8.49 (m, 1H), 8.38 (dd, J=
9.4, 2.3 Hz, 1H), 7.38-7.21 (m, 4H), 7.15-7.02 (m, 3H), 6.94-6.82 (m, 2H), 4.36 (s, 2H), 3.98 (s, 3H), 3.88-3.81 (m, 2H), 3.19 (t, J= 5.2 Hz, 2H), 2.05 (s, 3H), 1.98 (s, 3H).
MS: (ES) m/z calculated for C30H32FN403 [M + 515.2, found 515.2.
Example 70: 1-((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrimidine-4-carboxamido)-11,1':3',1"-terphenyll-4-y1)methyl)azetidine-3-carboxylicacid OMe 0 Me 1) (C0C1)2, DCM 0 0 2) DCM, DIPEA 0 rt, rY 16 h OH
Br Pd(dppf)C12, K2CO3 Dioxane/H20, 95 C
rY-FiN lel N N N N Me H2N Br Me Step b Step a OMe HN-0 Me Na(0Ac)3BH, DMF
r N F rt, 16 h YL
N N Me Step c OMe 0 Me N N Me [0195] Step a: To a stirred suspension of pyrimidine-4-carboxylic acid (0. 5 g, 4.03 mmol) in CH2C12 (10 mL) was added oxalyl chloride (0.76 g, 6.04 mmol) at room temperature. The resulting mixture was stirred for 4 h. The solvent removed under reduced pressure and dried under vacuum, the obtained residue was used directly in the next step. The residue was added to a solution of 3-bromo-2-methylaniline (0.72 g, 3.90 mmol) and N,N-diisopropylethylamine (1.14 mg, 8.85 mmol) in THF (15 mL). The reaction mixture was stirred at room temperature overnight. After completion, the reaction was worked up by water wash and extracted with Et0Ac. The crude product was purified by silica gel chromatography (20-100%
Et0Ac/hexane) to give the desired product N-(3-bromo-2-methylphenyl)pyrimidine-4-carboxamide. MS: (ES) m/z calculated for Ci2HilBrN30 [M + H]292.0, found 292Ø
[0196] Step b: To a mixture of N-(3-bromo-2-methylphenyl)pyrimidine-4-carboxamide (150 mg, 0.49 mmol), 3-fluoro-5-methoxy-2'-methy1-3'-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-[1,1'-bipheny1]-4-carbaldehyde (199 mg, 0.53 mmol) and 2M K2CO3 (0.61 mL, 1.22 mmol) inp-dioxane (15 mL) was added Pd(dppf)C12 complex with dichloromethane (40 mg, 0.049 mmol).
The reaction mixture was degassed (N2) for 2 min and stirred under N2 at 95 C
for 3 h. The reaction mixture was diluted with Et0Ac, filtered through Celite, washed with brine and dried over MgSO4. The solvent was removed under reduced pressure and the residue was purified by silica gel flash chromatography (5 to 20% to 40% Et0Ac/hexane) to give N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-yl)pyrimidine-4-carboxamide. MS:
(ES) m/z calculated for C27H23FN303[M + H]+ 456.2, found 456.2.
[0197] Step c: To a stirred solution of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-yl)pyrimidine-4-carboxamide (50 mg, 0.106 mmol) and azetidine-3-carboxylic acid (26 mg, 0.42 mmol) in DMF (2 mL) was added NaBH(OAc)3 (56 mg, 0.26 mmol). The reaction mixture was stirred at room temperture for 2 h. The solvent was removed under reduced pressure and the residue was purified by HPLC (0 to 40% to 100%
MeCN/H20) to give 1-((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrimidine-4-carboxamido)41,1':3',1"-terphenyl]-4-yl)methypazetidine-3-carboxylic acid. 1-HNMR (400 MHz, CD 30D) 8 9.34 (d, J=
1.4 Hz, 1H), 9.09 (d, J= 5.1 Hz, 1H), 8.21 (dd, J= 5.2, 1.4 Hz, 1H), 7.80 (t, J= 8.7 Hz, 1H), 7.34 (d, J= 7.7 Hz, 2H), 7.26 (d, J= 7.9 Hz, 1H), 7.22-7.15 (m, 1H), 7.12-7.05 (m, 1H), 6.97-6.85 (m, 2H), 4.56 (s, 2H), 4.41 (d, J= 9.7 Hz, 4H), 3.98 (s, 3H), 3.69 (s, 1H), 2.09 (s, 3H), 1.96 (s, 3H). MS: (ES) m/z calculated for C311-130FN403 [M + 541.2, found 541.2.
Example 71: N-(4"-(aminomethyl)-3"-fluoro-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)nicotinamide OMe 0 Me NH2 N
LrF
Me [0198] The compound was prepared using a procedure similar to the one described in Example 68. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(4"-(aminomethyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-y1)nicotinamide as a white solid. 1-HNMR (400 MHz, CD30D) ö 9.18 (s, 1H), 8.83-8.76 (m, 1H), 8.52 (d, J= 8.1 Hz, 1H), 7.72 (dd, J= 8.0, 5.0 Hz, 1H), 7.43-7.29 (m, 3H), 7.29-7.09 (m, 3H), 6.93-6.80 (m, 2H), 4.22 (s, 2H), 3.97 (s, 3H), 2.04 (s, 3H), 1.96 (s, 3H). MS: (ES) m/z calculated for C28H27FN302 [M + H]456.2, found 456.2.

Example 72: N-(4"-(aminomethyl)-3"-fluoro-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)isonicotinamide OMe 0 Me NH2 rN
N Me [0199] The compound was prepared using a procedure similar to the one described in Example 68. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(4"-(aminomethyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-yl)nicotinamide as a white solid. 1-HNMR (400 MHz, CD30D) 8 9.18 (s, 1H), 8.82 (d, J= 5.1 Hz, 1H), 8.07 (d, J= 4.3 Hz, 1H), 7.44-7.29 (m, 3H), 7.28-7.09 (m, 3H), 6.90 (d, J= 1.3 Hz, 1H), 6.84 (d, J= 9.9 Hz, 2H), 4.22 (s, 2H), 3.97 (s, 3H), 2.03 (s, 3H), 1.96 (s, 3H). MS: (ES) m/z calculated for C28H27FN302 [M + H]456.2, found 456.2.
Example 73: N-(4"-(aminomethyl)-3"-fluoro-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-6-methylpicolinamide OMe 0 Me NH2 NVF
Me Me [0200] The title compound was prepared using a procedure similar to the one described in Example 68. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(4"-(aminomethyl)-3"-fluoro-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)-6-methylpicolinamide as a white solid. 1-HNMR (400 MHz, CD30D) 8 8.03 (d, J= 5.1 Hz, 1H), 7.95-7.86 (m, 2H), 7.49 (d, J= 7.8 Hz, 1H), 7.33 (dt, J= 7.7, 3.1 Hz, 2H), 7.28-7.14 (m, 2H), 7.04 (d, J= 7.5 Hz, 1H), 6.91 (s, 1H), 6.85 (d, J= 9.9 Hz, 1H), 4.22 (s, 2H), 3.97 (s, 3H), 2.64 (s, 3H), 2.11 (s, 3H), 1.96 (s, 3H). MS: (ES) m/z calculated for C29H29FN302 [M +
470.2, found 453.1 [M-17].

Example 74: 4"-(aminomethyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-N-(pyridin-2-y1)-11,1':3',1"-terpheny11-3-carboxamide OMe Me NH2 I ' 0 Me LJ[0201] The compound was prepared using a procedure similar to the one described in Example 68. The product was purified by HPLC (MeCN/1-120 with 0.1% TFA) to give the desired product 4"-(aminomethyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-N-(pyridin-2-y1)41,1':3',1"-terphenyl]-3-carboxamide as a white solid. 1H NMIR (400 MHz, CD30D) 8 9.18 (s, 1H), 8.82 (d, J= 5.1 Hz, 1H), 8.07 (d, J= 4.3 Hz, 1H), 7.44-7.29 (m, 3H), 7.28-7.09 (m, 3H), 6.90 (d, J= 1.3 Hz, 1H), 6.84 (d, J= 9.9 Hz, 2H), 4.22 (s, 2H), 3.97 (s, 3H), 2.03 (s, 3H), 1.96 (s, 3H). MS: (ES) m/z calculated for C281-127FN302 [M + H]456.2, found 439.0 [M-17].
Example 75: N-(4"-(aminomethyl)-3"-fluoro-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)pyrimidine-2-carboxamide OMe 0 Me NH2 Me LJ
[0202] The compound was prepared using a procedure similar to the one described in Example 68. The product was purified HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(4" -(aminomethyl)-3" -fluor o-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-yl)pyrimidine-2-carboxamide as a white solid. 1-EINMR (400 MHz, CD30D) 8 9.02 (d, J= 5.0 Hz, 2H), 7.87-7.80 (m, 1H), 7.70 (t, J = 4.9 Hz, 1H), 7.39-7.29 (m, 2H), 7.28-7.14 (m, 2H), 7.12-7.04 (m, 1H), 6.90 (s, 1H), 6.84 (d, J= 9.9 Hz, 1H), 4.21 (s, 2H), 3.97 (s, 3H), 2.10 (s, 3H), 1.96 (s, 3H).
MS: (ES) m/z calculated for C27H26FN402 [M + H]457.2, found 440.0 [M-17].
Example 76: N-(4"-(aminomethyl)-3"-fluoro-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)pyrimidine-4-carboxamide OMe 0 Me NH2 rY N
NN Me [0203] The compound was prepared using a procedure similar to the one described in Example 68. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(4"-(aminomethyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)pyrimidine-4-carboxamide as a white solid. 1H NMIt (400 MHz, CD30D) 8 9.34 (d, J= 1.4 Hz, 1H), 9.09 (d, J = 5.1 Hz, 1H), 8.21 (dd, J = 5.1, 1.4 Hz, 1H), 7.85-7.77 (m, 1H), 7.34 (t, J= 7.9 Hz, 1H), 7.28-7.21 (m, 1H), 7.18 (dd, J = 7.6, 1.1 Hz, 1H), 7.08 (dd, J= 7.8, 1.2 Hz, 1H), 6.93-6.81 (m, 2H), 4.22 (s, 2H), 3.97 (s, 3H), 2.09 (s, 3H), 1.95 (s, 3H). MS: (ES) m/z calculated for C27H26FN402 [M + H]457.2, found 440.0 [M-17].
Example 77: N-(4"-(aminomethyl)-3"-fluoro-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-yl)pyrazine-2-carboxamide OMe 0 Me NH2 NY.(N
H
Me [0204] The compound was prepared using a procedure similar to the one described in Example 68. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(4"-(aminomethyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)pyrazine-2-carboxamide as a white solid. 1H NMR (400 MHz, CD30D) 8 9.36 (d, J= 1.4 Hz, 1H), 8.85 (d, J= 2.4 Hz, 1H), 8.75 (dd, J= 2.5, 1.4 Hz, 1H), 7.76 (t, J= 8.3 Hz, 1H), 7.38-7.29 (m, 2H), 7.28-7.14 (m, 2H), 7.08 (dd, J= 7.8, 1.2 Hz, 1H), 6.93-6.81 (m, 2H), 4.22 (s, 2H), 3.97 (s, 3H), 2.08 (s, 3H), 1.96 (s, 3H). MS: (ES) m/z calculated for C27H26FN402 [M +
H]457.2, found 440.0 [M-17].

Example 78: N-(4"-(aminomethyl)-3"-fluoro-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terphenyl1-3-y1)tetrahydro-2H-pyran-2-carboxamide OMe 0 Me NH2 YLN
0 Me LJ
[0205] The compound was prepared using a procedure similar to the one described in Example 68. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(4"-(aminomethyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-yl)tetrahydro-2H-pyran-2-carboxamide as a white solid. 1-HNMR (400 MHz, CD30D) 8 7.52-7.43 (m, 1H), 7.36-7.19 (m, 3H), 7.13 (d, J= 7.4 Hz, 1H), 7.06-6.99 (m, 1H), 6.92-6.79 (m, 2H), 4.22 (s, 2H) 4.14 (dd, J= 11.4, 3.5 Hz, 1H), 3.96 (s, 4H), 3.61 (t, J= 10.1 Hz, 1H), 2.10 (d, J= 13.4 Hz, 1H), 1.96 (s, 3H), 1.96 (s, 3H), 1.71-1.58 (m, 4H) 1.53 (d, J= 11.7 Hz, 1H). MS:
(ES) m/z calculated for C281-132FN203 [M + H]+ 463.2, found 463.2.
Example 79: ((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrimidine-4-carboxamido)-11,1':3',1"-terpheny11-4-yl)methyl)glycine OMe 0 Me NCO2H
rYLN
NN Me [0206] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-yl)pyrimidine-4-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1%
TFA) to give the desired product ((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrimidine-4-carboxamido)-[1,1':3',1"-terpheny1]-4-yl)methyl)glycine as a white solid. 1-HNMR (400 MHz, CD30D) 8 9.35 (d, J= 1.4 Hz, 1H), 9.09 (d, J= 5.1 Hz, 1H), 8.21 (dd, J= 5.1, 1.4 Hz, 1H), 7.82 (d, J= 7.9 Hz, 1H), 7.35 (t, J= 7.7 Hz, 2H), 7.26 (dd, J= 7.8, 1.4 Hz, 1H), 7.22-7.15 (m, 1H), 7.12-7.05 (m, 1H), 6.96-6.84 (m, 2H), 4.41 (d, J= 1.2 Hz, 2H), 3.98 (s, 3H), 3.93 (s, 2H), 2.10 (s, 3H), 1.95 (s, 3H). MS: (ES) m/z calculated for C29H28FN404 [M + H]+ 515.2, found 515.5.
Example 80: N-(3"-fluoro-4"-(((2-hydroxyethyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terpheny11-3-yl)pyrimidine-4-carboxamide OMe 0 Me NOH
rYLN
N N Me LJ
[0207] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-yl)pyrimidine-4-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1%
TFA) to give the desired product N-(3"-fluoro-4"-(((2-hydroxyethyl)amino)methyl)-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)pyrimidine-4-carboxamide as a white solid. ITINMR
(400 MHz, CD30D) 8 9.35 (d, J = 1.4 Hz, 1H), 9.09 (d, J = 5.1 Hz, 1H), 8.21 (dd, J = 5.1, 1.4 Hz, 1H), 7.82 (dd, J= 8.1, 1.1 Hz, 1H), 7.34 (t, J = 7.7 Hz, 2H), 7.26 (dd, J
= 7.8, 1.5 Hz, 1H), 7.18 (dd, J = 7.5, 1.5 Hz, 1H), 7.09 (dd, J = 7.8, 1.3 Hz, 1H), 6.96-6.84 (m, 2H), 4.36 (d, J= 1.2 Hz, 2H), 3.98 (s, 3H), 3.88-3.81 (m, 2H), 3.19 (t, J= 5.2 Hz, 2H), 2.10 (s, 3H), 1.95 (s, 3H).
MS: (ES) m/z calculated for C29H30FN403 [M + H]' 501.2, found 501.5.
Example 81: N-(3"-fluoro-4"-((3-hydroxyazetidin-l-yl)methyl)-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terpheny11-3-y1)pyrimidine-4-carboxamide OMe 0 Me rYN OH
N N Me LJ
[0208] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-yl)pyrimidine-4-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1%
TFA) to give the desired product N-(3"-fluoro-4"-((3-hydroxyazetidin-1-yl)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-yl)pyrimidine-4-carboxamide as a white solid. IENMR
(400 MHz, CD30D) 8 9.35 (d, J = 1.4 Hz, 1H), 9.09 (d, J = 5.1 Hz, 1H), 8.21 (dd, J = 5.1, 1.4 Hz, 1H), 7.81 (d, J= 8.1 Hz, 1H), 7.35 (t, J= 7.6 Hz, 2H), 7.30-7.22 (m, 1H), 7.22-7.15 (m, 1H), 7.08 (d, J= 7.4 Hz, 1H), 6.97-6.86 (m, 2H), 4.64-4.49 (m, 3H), 4.46 _______ /1.33 (m, 2H), 4.11-4.01 (m, 2H), 3.98 (s, 3H), 2.09 (s, 3H), 1.96 (s, 3H). MS: (ES) m/z calculated for C301-130FN403 [M + H]' 513.2, found 513.5.
Example 82: 6-((3"-fluoro-4"-(((2-hydroxyethyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terphenyll-3-y1)carbamoyl)nicotinic acid OM e OH
0 Me N
H01.1N Me [0209] The compound was prepared using a procedure similar to the one described in Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product 643"-fluoro-4"-(((2-hydroxyethyl)amino)methyl)-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)carbamoyl)nicotinic acid as a white solid. IENMR (400 MHz, CD30D) 8 9.25 (d, J = 1.4 Hz, 1H), 8.58 (dd, J = 8.1, 2.1 Hz, 1H), 8.33 (d, J= 8.1 Hz, 1H), 7.90-7.81 (m, 1H), 7.34 (t, J = 7.4 Hz, 2H), 7.29-7.15 (m, 2H), 7.07 (d, J = 7.6 Hz, 1H), 6.96-6.84 (m, 2H), 4.36 (s, 2H), 3.99 (s, 3H), 3.88-3.81 (m, 2H), 3.19 (t, J= 5.3 Hz, 2H), 2.11 (s, 3H), 1.97 (s, 3H). MS:
(ES) m/z calculated for C311-131FN305 [M + H]+ 544.2, found 544.5.
Example 83: 1-((3"-(5-aminopyrazine-2-carboxamido)-3-fluoro-5-methoxy-2',2"-dimethy1-11,1':3',1"-terphenyll-4-y1)methyl)azetidine-3-carboxylic acid OMe 0 Me N3 N 25 H2N H Me -[0210] The compound was prepared using a procedure similar to the one described in Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product 1-((3"-(5-aminopyrazine-2-carboxamido)-3-fluoro-5-methoxy-2',2"-dimethyl-[1,1':3',1"-terpheny1]-4-yl)methypazetidine-3-carboxylic acid as a white solid. 1H NMR
(400 MHz, CD30D) 8 8.65 (d, J= 1.4 Hz, 1H), 7.97 (d, J= 1.4 Hz, 1H), 7.82-7.72 (m, 1H), 7.38-7.21 (m, 3H), 7.21-7.14 (m, 1H), 7.06-6.99 (m, 1H), 6.97-6.85 (m, 2H), 4.56 (s, 2H), 4.41 (d, J= 10.8 Hz, 4H), 3.98 (s, 3H), 3.70 (t, J= 10.2 Hz, 1H), 2.06 (s, 3H), 1.96 (s, 3H).
MS: (ES) m/z calculated for C311-131FN504 [M + H]+ 556.2, found 556.5.
Example 84: 1-((3"-(2-aminopyrimidine-4-carboxamido)-3-fluoro-5-methoxy-2',2"-dimethy1-11,1':3',1"-terpheny11-4-yl)methyl)azetidine-3-carboxylic acid OMe 0 Me NN Me LJ

[0211] The compound was prepared using a procedure similar to the one described in Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product 1-((3"-(2-aminopyrimidine-4-carboxamido)-3-fluoro-5-methoxy-2',2"-dimethyl-[1,1':3',1"-terpheny1]-4-yl)methyl)azetidine-3-carboxylic acid as a white solid. 1H NMR (400 MHz, CD30D) 8 8.52 (d, J= 5.1 Hz, 1H), 7.85-7.78 (m, 1H), 7.39-7.21 (m, 4H), 7.21-7.14 (m, 1H), 7.10-7.03 (m, 1H), 6.97-6.85 (m, 2H), 4.56 (s, 2H), 4.45-4.40 (m, 4H), 3.98 (s, 3H), 3.71 (t, J= 11.4 Hz, 1H), 2.09 (s, 3H), 1.96 (s, 3H). MS: (ES) m/z calculated for C311-131FN504 [M +
H]556.2, found 556.5.
Example 85: 1-((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(thiazole-2-carboxamido)-11,1' :3',!' acid OMe 0 Me (NYLN CO2H
H Me [0212] The compound was prepared using a procedure similar to the one described in Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product 1-((3-fluoro-5-methoxy-2',2"-dimethyl-3"-(thiazole-2-carboxamido)41,1':3',1"-terphenyl]-4-yl)methypazetidine-3-carboxylic acid as a white solid. 1-EINMR
(400 MHz, CD30D) 8 8.02 (d, J= 3.1 Hz, 1H), 7.92 (d, J= 3.1 Hz, 1H), 7.66 (dd, J= 7.9, 1.3 Hz, 1H), 7.39-7.21 (m, 3H), 7.18 (dd, J= 7.4, 1.5 Hz, 1H), 7.09 (dd, J= 7.6, 1.3 Hz, 1H), 6.99-6.86 (m, 2H), 4.56 (s, 2H), 4.45-4.40 (m, 4H), 3.98 (s, 3H), 3.74 (bs, 1H), 2.07 (s, 3H), 1.96 (s, 3H). MS:
(ES) m/z calculated for C301-129FN3045 [M + H]+ 546.2, found 546.2.
Example 86: 1-((3-fluoro-5-methoxy-3"-(5-methoxypicolinamido)-2',2"-dimethy1-11,1':3',1"-terphenyll-4-y1)methyl)azetidine-3-carboxylic acid OMe 0 Me Me0 Me [0213] The compound was prepared using a procedure similar to the one described in Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product 1-((3-fluoro-5-methoxy-3"-(5-methoxypicolinamido)-2',2"-dimethy141,1':3',1"-.. terpheny1]-4-yl)methypazetidine-3-carboxylic acid as a white solid. ITINMR
(400 MHz, CD30D) 8 8.36 (dd, J= 2.8, 0.6 Hz, 1H), 8.18 (dd, J= 8.7, 0.7 Hz, 1H), 7.90-7.83 (m, 1H), 7.55 (dd, J= 8.7, 2.9 Hz, 1H), 7.38-7.14 (m, 4H), 7.07-6.99 (m, 1H), 6.97-6.86 (m, 2H), 4.56 (s, 2H), 4.45-4.40 (m, 4H), 3.97 (s, 3H), 3.95 (s, 3H), 3.70 (bs, 1H), 2.09 (s, 3H), 1.96 (s, 3H). MS:
(ES) m/z calculated for C33H33FN305 [M + 570.2, found 570.2.
Example 87: 1-((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(5-methylpicolinamido)-11,1':3',1"-terphenyll-4-y1)methyl)azetidine-3-carboxylic acid OMe 0 Me N3N CO2H
Me LLJ
[0214] The compound was prepared using a procedure similar to the one described in Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product 1-((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(5-methylpicolinamido)41,1':3',1"-terphenyl]-4-yl)methyl)azetidine-3-carboxylic acid as a white solid. 1-EINMR (400 MHz, CD30D) 8 8.54 (dt, J= 2.2, 0.8 Hz, 1H), 8.11 (d, J= 8.7 Hz, 1H), 7.92-7.83 (m, 2H), 7.38-7.14 (m, 4H), 7.07-7.00 (m, 1H), 6.96-6.86 (m, 2H), 4.56 (s, 2H), 4.45-4.40 (m, 4H), 3.98 (s, 3H), 3.70 (bs, 1H), 2.46 (s, 3H), 2.09 (s, 3H), 1.96 (s, 3H). MS: (ES) m/z calculated for C33H33FN304 [M + H]+
554.2, found 554.2.
Example 88: N-(3"-fluoro-4"-(((2-hydroxyethyl)amino)methyl)-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-5-(((2-hydroxyethyl)amino)methyl)picolinamide OMe 0 Me N OH
H N
YL
HOMe [0215] The compound was prepared using a procedure similar to the one described in Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-(((2-hydroxyethyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-5-(((2-hydroxyethyl)amino)methyl)picolinamide as a white solid. 1-EINMR (400 MHz, CD30D) 8 8.82 (s, 1H), 8.31 (d, J= 6.2 Hz, 1H), 8.18 (dd, J= 8.1, 2.2 Hz, 1H), 7.90-7.79 (m, 1H), 7.34 (t, J= 7.7 Hz, 2H), 7.26 (dd, J= 7.7, 1.5 Hz, 1H), 7.18 (dd, J=
7.5, 1.5 Hz, 1H), 7.07-7.03 (m, 1H), 6.96-6.84 (m, 2H), 4.43 (s, 2H), 4.36 (s, 2H), 3.98 (s, 3H), 3.88-3.81 (m, 4H), 3.21 (dt, J= 5.3 Hz, 4H), 2.09 (s, 3H), 1.97 (s, 3H). MS: (ES) m/z calculated for C33H38FN404 [M + 573.28, found 573.5.

Example 89: 4-(((3-fluoro-3"-(5-(((2-hydroxyethyl)amino)methyl)picolinamido)-5-methoxy-2',2"-dimethy1-11,1':3',1"-terpheny11-4-yl)methyl)amino)butanoic acid OMe Me N .r0H

H I
Me LJ
HO
[0216] The compound was prepared using a procedure similar to the one described in Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product 4-(((3-fluoro-3"-(5-(((2-hydroxyethyl)amino)methyl)picolinamido)-5-methoxy-2',2"-dimethyl-[1,1':3',1"-terpheny1]-4-yl)methyl)amino)butanoic acid as a white solid. 1-HNMR (400 MHz, CD30D) 8 8.82 (s, 1H), 8.31 (d, J= 8.1 Hz, 1H), 8.18 (dd, J= 8.1, 2.2 Hz, 1H), 7.84 (d, J
= 8.0 Hz, 1H), 7.34 (t, J= 7.7 Hz, 2H), 7.29-7.22 (m, 1H), 7.21-7.15 (m, 1H), 7.10-7.03 (m, 1H), 6.96-6.84 (m, 2H), 4.43 (s, 2H), 4.33 (s, 2H), 3.98 (s, 3H), 3.88-3.81 (m, 2H), 3.27-3.12 (m, 4H), 2.49 (t, J= 6.9 Hz, 2H), 2.10 (s, 3H), 1.97-2.05 (m, 5H). MS: (ES) m/z calculated for C35H40FN405 [M + H]615.3, found 615.2.
Example 90: 2-(((3-fluoro-3"-(5-(((2-hydroxyethyl)amino)methyl)picolinamido)-5-methoxy-2',2"-dimethy1-11,1':3',1"-terpheny11-4-yl)methyl)amino)ethane-1-sulfonic acid OMe 0 Me N4'0H

H
HO Me [0217] The compound was prepared using a procedure similar to the one described in Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product 2-(((3-fluoro-3"-(5-(((2-hydroxyethyl)amino)methyl)picolinamido)-5-methoxy-2',2"-dimethyl-[1,1':3',1"-terpheny1]-4-yl)methyl)amino)ethane-1-sulfonic acid as a white solid. 11-1 NMR (400 MHz, CD30D) 8 8.82 (s, 1H), 8.31 (d, J= 8.3 Hz, 1H), 8.18 (dd, J=
8.2, 2.2 Hz, 1H), 7.86 (d, J= 8.2 Hz, 1H), 7.34 (t, J= 7.7 Hz, 2H), 7.29-7.22 (m, 1H), 7.17 (dd, J= 8.2, 2.2 Hz 1H), 7.07 (dd, J= 8.2, 2.2 Hz, 1H), 6.96-6.84 (m, 2H), 4.41 (s, 2H), 4.38 (s, 2H), 3.99 (s, 3H), 3.88-3.81 (m, 2H), 3.49 (t, J= 6.2 Hz, 2H), 3.24 (q, J= 7.2 Hz, 2H), 3.15 (t, J= 6.3 Hz, 2H), 2.09 (s, 3H), 1.97 (s, 3H). MS: (ES) m/z calculated for C33H38FN4065 [M +
H]637.2, found 637.2.
Example 91: N-(3"-fluoro-4"-((isopropylamino)methyl)-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terpheny11-3-yl)pyrido13,4-b]pyrazin-5-amine OMe Me ri Me CHO
H2N Me NN NaBH3CN
H
Me OMe )/1:
Me N Me NN
H
Me [0218] A mixture of 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde (24 mg, 0.042 mmol), propan-2-amine (30 mg, 0.51 mmol) and HOAc (90 mg, 1.50 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h.
The mixture was cooled to 0 C and NaBH3CN (45 mg, 0.71 mmol) was added. After stirring for 20 min at room temperature the mixture was concentrated in vacuo . The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to yield N-(3"-fluoro-4"-((isopropylamino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-yl)pyrido[3,4-b]pyrazin-5-amine (TFA salt). 111 NMR (400 MHz, CD30D) 6 9.25 (d, J= 2.0 Hz, 1H), 9.05 (d, J= 2.0 Hz, 1H), 7.79 (d, J= 7.6 Hz, 1H), 7.59 (d, J= 7.6 Hz, 1H), 7.53 (t, J= 7.8 Hz, 1H), 7.40-7.34 (m, 3H), 7.28 (d, J= 7.6 Hz, 1H), 7.24 (d, J= 7.2 Hz, 1H), 6.93 (s, 1H), 6.87 (d, J= 10.0 Hz, 1H), 4.30 (s, 2H), 3.98 (s, 3H), 3.55-3.44 (m, 1H), 2.10 (s, 3H), 2.01 (s, 3H), 1.42 (d, J= 6.8 Hz, 6H).
MS: (ES) m/z calculated C32H33FN50 [M + 522.3, found 522.3.
Example 92: N-(3"-fluoro-4"-((isopropylamino)methyl)-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terphenyll-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide OMe 0 Me OMe 0 Me N Br NQF
1 ).LN
OLbF
Me Pd(dppf)C12, K2CO3 1 Dioxane/H20, 95 C NO Me Me Me Step a Me OMe Me H2N Me 0 Me NMe Na(0Ac)3BH
MeOH:DCE(1:1) 1 rt, 16 h Me Step b Me [0219] Step a: To a solution of N-(3-bromo-2-methylpheny1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide (500 mg, 1.48 mmol), 3-fluoro-5-methoxy-2'-methy1-3'-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)41,1'-biphenyl]-4-carbaldehyde (600 mg, 1.63 mmol), and 2M K2CO3 (1.85 mL, 3.7 mmol) inp-dioxane (10 mL) was added Pd(dppf)C12 complex with dichloromethane (121 mg, 0.148 mmol). The reaction mixture was degassed (N2) for 2 min and stirred under N2 at 95 C for 5 h. The reaction mixture was diluted with Et0Ac, filtered through Celite, washed with brine and dried over MgSO4. The solvent was removed under reduced pressure and the residue was purified by silica gel flash chromatography (5 to 20% to 100%
Et0Ac/hexane) to give N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide. MS: (ES) m/z calculated for C29H25FN204 [M + H]+ 485.2, found 485.2.
[0220] Step b: To a stirred solution of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide (40 mg, 0.082 mmol), and propan-2-amine (10 mg, 0.16 mmol) in MeOH:DCE (2 mL) was added NaBH(OAc)3 (52 mg, 0.24 mmol) and AcOH (5 drops). The reaction mixture was stirred at room temperture for 2 h. The solvent was removed under reduced pressure and the residue was purified by HPLC (0 to 40% to 100% MeCN/H20) to give N-(3"-fluoro-4"-((isopropylamino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide. 1H NMR (400 MHz, CD30D) 8 12.18 (s, 1H), 8.59 (dd, J=
7.3, 2.0 Hz, 1H), 8.13 (d, J= 8.2 Hz, 1H), 7.99 (dd, J= 6.3, 2.0 Hz, 1H), 7.36-7.24 (m, 3H), 7.15 (d, J= 7.2 Hz, 1H), 6.96 (d, J= 7.4 Hz, 1H), 6.93 (s, 1H), 6.86 (d, J=
9.8 Hz, 1H), 6.61 (t, J= 7.5 Hz, 1H), 4.29 (s, 2H), 3.98 (s, 3H), 3.70 (s, 3H), 3.55-3.45 (m, 1H), 2.12 (s, 3H), 1.93 (s, 3H), 1.41 (d, J= 6.3 Hz, 6H). MS: (ES) m/z calculated for C32H35FN303 [M + H]+
528.3, found 528.2.
Example 93: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((5-oxopyrrolidin-3-yl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide OMe idNH
0 Me N
NO Me Me [0221] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-.. [1,1':3',1"-terpheny1]-3-y1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((5-oxopyrrolidin-3-yl)amino)methy1)41,1':3',1"-terphenyl]-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide as a white solid. 1-H NMR (400 MHz, CD30D) 8 12.18 (s, 1H), 8.59 (dd, J= 8.2, 2.4 Hz, 1H), 8.14 (d, J= 8.2 Hz, 1H), 7.98 (dd, J=
6.3, 2.0 Hz, 1H), 7.36-7.24 (m, 3H), 7.16 (d, J= 7.2 Hz, 1H), 6.97 (d, J= 7.4 Hz, 1H), 6.95 (s, 1H), 6.88 (d, J=
9.8 Hz, 1H), 6.61 (t, J= 7.5 Hz, 1H), 4.36 (s, 2H), 4.28-4.20 (m, 1H), 3.99 (s, 3H), 3.87 (dd, J=
11.8, 7.5 Hz, 1H), 3.70 (s, 3H), 3.56 (dd, J= 12.0, 4.4 Hz, 1H), 2.89 (dd, J=
18.0, 9.0 Hz, 1H), 2.54 (dd, J= 17.6, 4.7 Hz, 1H), 2.12 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated for C33H34FN404 [M + 569.3, found 569.3.
Example 94: (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((5-oxopyrrolidin-3-yl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide OMe .6H
0 Me N's N
&N0 Me Me [0222] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((5-oxopyrrolidin-3-yl)amino)methy1)41,1':3',1"-terphenyl]-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide as a white solid. 1H NMIR (400 MHz, CD30D) 8 12.18 (s, 1H), 8.59 (dd, J= 8.2, 2.4 Hz, 1H), 8.14 (d, J= 8.2 Hz, 1H), 7.98 (dd, J=
6.3, 2.0 Hz, 1H), 7.36-7.25 (m, 3H), 7.16 (d, J= 7.8 Hz, 1H), 6.96 (d, J= 7.4 Hz, 1H), 6.95 (s, 1H), 6.88 (d, J=
9.8 Hz, 1H), 6.61 (t, J= 7.5 Hz, 1H), 4.36 (s, 2H), 4.28-4.20 (m, 2H), 3.99 (s, 3H), 3.87 (dd, J=
11.8, 7.5 Hz, 1H), 3.70 (s, 3H), 3.56 (dd, J= 12.0, 4.4 Hz, 1H), 2.90 (dd, J=
18.0, 9.0 Hz, 1H), 2.54 (dd, J= 17.6, 4.7 Hz, 1H), 2.12 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated for C33H34FN404 [M + H]' 569.3, found 569.3.
Example 95: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide OMe 0 Me N4\, 0 N
&N0 Me Me [0223] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide as a white solid. 1H NMR (400 MHz, CD30D) 5 12.18 (s, 1H), 8.57 (d, J= 7.0 Hz, 1H), 8.16 (t, J= 8.2 Hz, 1H), 7.98 (d, J= 6.2 Hz, 1H), 7.36-7.24 (m, 2H), 7.16 (d, J= 7.4 Hz, 1H), 6.98-6.92 (m, 2H), 6.95 (s, 1H), 6.89 (d, J=
9.8 Hz, 1H), 6.60 (t, J= 7.5 Hz, 1H), 4.39 (s, 2H), 4.10-4.05 (m, 1H), 3.99 (s, 3H), 3.70 (s, 3H), 3.26 (dd, J= 6.8, 2.7 Hz, 2H), 2.45-2.35 (m, 3H), 2.13 (s, 3H), 1.94 (s, 3H) 1.93-1.89 (m, 1H).
MS: (ES) m/z calculated for C34H36FN404 [M + H]+ 583.3, found 583.3.
Example 96: (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide OMe N
NO H
0 Me 0 HN
N
Me Me [0224] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide as a white solid. ITINMR (400 MHz, CD30D) 5 12.18 (s, 1H), 8.57 (dd, J= 7.8, 2.4 Hz, 1H), 8.16 (t, J= 8.2 Hz, 1H), 8.01 (dd, J=
6.2, 1.9 Hz, 1H), 7.36-7.24 (m, 3H), 7.16 (d, J= 7.2 Hz, 1H), 6.98 (d, J= 7.4 Hz, 1H), 6.95 (s, 1H), 6.82 (d, J= 9.8 Hz, 1H), 6.60 (t, J= 7.5 Hz, 1H), 4.39 (s, 2H), 4.10-4.00 (m, 1H), 3.99 (s, 3H), 3.70 (s, 3H), 3.30-3.25 (m, 2H), 2.45-2.30 (m, 3H), 2.13 (s, 3H), 1.94 (s, 3H) 1.92-1.85 (m, 1H). MS: (ES) m/z calculated for C34H36FN404 [M + 583.3, found 583.3.

Example 97: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyl((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide OMe 0 Me N F Me Nso Me Me [0225] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by .. HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyl((5-oxopyrrolidin-2-yl)methyl)amino)methy1)41,1':3',1"-terphenyl]-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide as a white solid. 1H NMIR
(400 MHz, CD30D) 5 12.18 (s, 1H), 8.58 (dd, J = 7.8, 2.4 Hz, 1H), 8.15 (t, J= 7.7 Hz, 1H), 7.98 (dd, J=
6.3, 2.0 Hz, 1H), 7.35-7.24 (m, 3H), 7.17 (d, J = 7.4 Hz, 1H), 7.00-6.90 (m, 3H), 6.62 (t, J = 7.5 Hz, 1H), 4.60-4.40 (m, 2H), 4.30-4.25 (m, 1H), 4.01 (s, 3H), 3.70 (s, 3H), 3.55-3.35 (m, 2H), 2.94 (s, 3H), 2.50-2.32 (m, 3H), 2.13 (s, 3H), 1.94 (s, 3H) 1.92-1.85 (m, 1H).
MS: (ES) m/z calculated for C35H38FN404 [M + H]+ 597.3, found 597.3.
Example 98: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((l-methyl-5-oxopyrrolidin-2-yl)methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide OMe Me 0 Me 0 N
&N0 Me Me [0226] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((1-methy1-5-oxopyrrolidin-2-yl)methyl)amino)methy1)41,1':3',1"-terphenyl]-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide as a white solid. 1H NMR
(400 MHz, .. CD30D) 5 12.18 (s, 1H), 8.58 (dd, J= 7.8, 2.4 Hz, 1H), 8.15 (t, J= 8.2 Hz, 1H), 8.01 (dd, J=
6.6, 1.9 Hz, 1H), 7.35-7.24 (m, 3H), 7.16 (d, J= 7.4 Hz, 1H), 6.97 (d, J= 7.4 Hz, 1H), 6.96 (s, 1H), 6.89 (d, J= 9.8 Hz, 1H), 6.62 (t, J= 7.5 Hz, 1H), 4.43 (m, 2H), 4.00 (s, 3H), 3.98-3.90 (m, 1H), 3.70 (s, 3H), 3.46 (dd, J= 7.8, 4.0 Hz, 1H), 3.25-3.20 (m, 1H), 2.85 (s, 3H), 2.60-2.35 (m, 3H), 2.13 (s, 3H), 1.93 (s, 3H), 1.98-1.90 (m, 1H). MS: (ES) m/z calculated for C35H38FN404 .. [M + H]' 597.3, found 597.3.
Example 99: N-(4"-((((2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terpheny11-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 0 Me 0 Me N NH
N F 0 N'.0 0 Me Me [0227] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide using a .. procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(4"-((((2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide as a white solid. 11-1NMR
(400 MHz, CD30D) 8 12.18 (s, 1H), 8.57 (d, J= 7.8 Hz, 1H), 8.12 (t, J= 7.5 Hz, 1H), 7.99 (dd, .. J= 6.7 Hz, 1H), 7.65 (s, 1H), 7.35-7.24 (m, 3H), 7.15 (d, J= 6.2 Hz, 1H), 6.95 (d, J= 7.8 Hz, 1H), 6.91 (s, 1H), 6.84 (d, J= 9.8 Hz, 1H), 6.62 (t, J= 7.0 Hz, 1H), 4.43 (s, 2H), 4.00 (s, 2H), 3.98 (s, 3H), 3.70 (s, 3H), 2.11 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated for C34H36FN505 [M + H]610.3, found 610.2.

Example 100: N-(3"-fluoro-4"-(((1-hydroxy-2-methylpropan-2-yl)amino)methyl)-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terpheny11-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide OMe me Me 0 Me N)c0H
N
Me LLJ
Me [0228] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-(((1-hydroxy-2-methylpropan-2-yl)amino)methyl)-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide as a white solid. 1H NMR (400 MHz, CD30D) 8 12.18 (s, 1H), 8.59 (dd, J= 7.8, 2.4 Hz, 1H), 8.14 (t, J= 8.2 Hz, 1H), 7.99 (d, J= 6.8 Hz, 1H), 7.36-7.24 (m, 3H), 7.15 (d, J= 7.4 Hz, 1H), 6.96 (d, J= 7.4 Hz, 1H), 6.91 (s, 1H), 6.84 (d, J= 9.8 Hz, 1H), 6.60 (t, J= 7.5 Hz, 1H), 4.29 (s, 2H), 3.97 (s, 3H), 3.70 (s, 3H), 3.66 (s, 2H), 2.12 (s, 3H), 1.93 (s, 3H), 1.42 (s, 6H). MS: (ES) m/z calculated for C33H37FN304 [M + H]+
558.3, found 558.2.
Example 101: N-(3"-fluoro-4"-(((2-hydroxyethyl)(methyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terpheny11-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide OMe 0 Me N C)H
Me N
&N0 Me Me [0229] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-(((2-hydroxyethyl)(methyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide as a white solid. ITINMR (400 MHz, CD30D) 8 12.18 (s, 1H), 8.57 (dd, J= 7.8, 2.4 Hz, 1H), 8.16 (t, J= 8.2 Hz, 1H), 7.99 (dd, J=
6.3, 2.0 Hz, 1H), 7.36-7.24 (m, 3H), 7.16 (d, J= 7.4 Hz, 1H), 6.97 (d, J= 7.4 Hz, 1H), 6.96 (s, 1H), 6.89 (d, J= 9.8 Hz, 1H), 6.61 (t, J= 13.7 Hz, 1H), 4.60 (d, J= 13.0 Hz, 1H), 4.37 (d, J=
13.3 Hz, 1H), 3.98 (s, 3H), 3.95-3.85 (m, 2H), 3.70 (s, 3H), 3.45-3.30 (m, 2H), 2.89 (s, 3H), 2.13 (s, 3H), 1.95 (s, 3H). MS: (ES) m/z calculated for C32H35FN304 [M + H]+
544.3, found 544.2.
Example 102: N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((oxetan-3-ylamino)methyl)-11,1':3',1"-terphenyll-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide OMe 0 Me N
&N0 Me Li Me [0230] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((oxetan-3-ylamino)methy1)41,1':3',1"-terphenyl]-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide as a white solid. 1H NMR (400 MHz, CD30D) 8 12.18 (s, 1H), 8.59 (dd, J= 7.3, 2.0 Hz, 1H), 8.13 (t, J= 8.2 Hz, 1H), 7.99 (dd, J= 6.3, 2.0 Hz, 1H), 7.36-7.24 (m, 3H), 7.16 (d, J= 7.4 Hz, 1H), 6.96 (d, J= 7.4 Hz, 1H), 6.92 (s, 1H), 6.88 (d, J= 9.8 Hz, 1H), 6.60 (t, J= 7.5 Hz, 1H), 4.65 (dd, J= 8.2, 5.5 Hz, 2H), 4.55-4.45 (m, 3H), 4.29 (s, 2H), 3.99 (s, 3H), 3.70 (s, 3H), 2.13 (s, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated for C32H33FN304 [M +
542.2, found 542.2.

Example 103: N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((tetrahydrofuran-3-yl)amino)methyl)-11,1':3',1"-terphenyll-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide OMe 0 Me NO
N
Me Me [0231] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((tetrahydrofuran-3-yl)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide as a white solid. 1H NMR (400 MHz, CD30D) 8 12.18 (s, 1H), 8.59 (dd, J= 7.8, 2.4 Hz, 1H), 8.14 (t, J= 8.2 Hz, 1H), 7.98 (dd, J= 6.3, 2.0 Hz, 1H), 7.36-7.24 (m, 3H), 7.16 (d, J= 7.2 Hz, 1H), 6.96 (d, J= 7.4 Hz, 1H), 6.94 (s, 1H), 6.87 (d, J= 9.8 Hz, 1H), 6.61 (t, J= 7.5 Hz, 1H), 4.33 (s, 2H), 4.10-4.05 (m, 2H), 4.04-4.00 (m, 1H), 3.98 (s, 3H), 3.85 (dd, J= 10.4, 5.6 Hz, 1H), 3.73 (dd, J= 8.2, 4.0 Hz, 1H), 3.70 (s, 3H), 2.50-2.41 (m, 1H), 2.12 (s, 3H), 2.10-2.05 (m, 1H), 1.94 (s, 3H). MS: (ES) m/z calculated for C33H35FN304 [M +
H]+ 556.3, found 556.2.
Example 104: N-(4"-(aminomethyl)-3"-fluoro-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terphenyll-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe Me F NHBoc O 0 -0 CI)B
H2N Br HN OH Me HNLN Br _____________ HATU, DMF 0 N 0 Me Pd(dppf)C12, K2CO3,..
MIe Hunig's Base Dioxane/H20, 95 C
Me Step a Step b OMe O Me NHBoc TFA
HN N CH2Cl2, rt 1 h L
Me Step c Me OMe O Me NH2 HN).LN
0 N 0 Me Me [0232] Step a: To a mixture of 3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (0.36 g, 2.35 mmol) and 3-bromo-2-methylaniline (0.43 g, 2.35 mmol) in a vial with DMF
(5.0 mL) was added HATU (1.34 g, 3.52 mmol) and diisopropylethylamine (0.75 g, 5.87 mmol).
The reaction was stirred at room temperature for 16 h. After completion of the reaction, the solvent was removed by half and diluted with water (15 ml) the mixture was stirred for 20 min.
The solid was filtered using plastic funnel, washed with water (10 ml) and dried under vacuum to give N-(3-bromo-2-methylpheny1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.
[0233] Step b: To a mixture of N-(3-bromo-2-methylpheny1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (100 mg, 0.31 mmol), tert-butyl ((3-fluoro-5-methoxy-2'-methy1-3'-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-[1,1'-biphenyl]-4-y1)methyl)carbamate (146 mg, 0.31 mmol) and 2M K2CO3 (0.38 mL, 0.77 mmol) in p-dioxane (4 mL) was added Pd(dppf)C12 complex with dichloromethane (26 mg, 0.032 mmol). The reaction mixture was degassed (N2) for 2 min and stirred under N2 at 95 C for 4 h. The mixture was diluted with Et0Ac, filtered through Celite, washed with brine and dried over MgSO4. The solvent was removed under reduced pressure and the residue was purified by silica gel flash chromatography (5 to 20% to 40% Et0Ac/hexane) to give tert-butyl ((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)-[1,1':3',1"-terpheny1]-4-yl)methyl)carbamate. MS: (ES) m/z calculated for C33H36FN406 [M + H]603.3, found 603.3.
[0234] Step c: To a strirred solution of tert-butyl ((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)-[1,1':3',1"-terpheny1]-4-y1)-methyl)-carbamate (75 mg, 0.123 mmol) in anhydrous dichloromethane (2.5 mL) at room temperature was added TFA (141 mg, 1.23 mmol) dropwise over 5 min. The reaction mixture .. was stirred at room temperature for 2 h. After completion of the reaction, the solvent was removed in vacuo to give as a viscous compound, which was purified by HPLC
(MeCN/H20 with 0.1% TFA) to give N-(4"-(aminomethyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide. 1-E1 NMR
(400 MHz, CD30D) 8 11.19 (s, 1H), 8.41 (s, 1H), 8.06 (d, J= 6.2 Hz, 1H), 7.38-7.21 (m, 3H), 7.15 (dd, J = 7.5, 1.5 Hz, 1H), 6.96 (d, J = 7.2 Hz, 1H), 6.93 (s, 1H), 6.86 (d, J= 8.2 Hz, 1H), 4.22 (s, 2H), 3.97 (s, 3H), 3.36 (s, 3H), 2.10 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated for C281-128FN404 [M + 503.2, found 486.2 [M-17].
Example 105: N-(3"-fluoro-4"-((isopropylamino)-methyl)-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terpheny11-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe Me -B
oMe 0 Me HN ).LN Br ________________ HN)LN
Me Pd(dppf)C12, K2CO3 0 N 0 M e Dioxane/H20, 95 C ONO Me Step a Me OMe Me H2NLMe ) 0 Me N Me Na(0Ac)3BH
MeOH:DCE(1:1) HN)*LN
rt, 16 h 0 N 0 Me Me Step b [0235] Step a: To a mixture of N-(3-bromo-2-methylpheny1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (500 mg, 1.48 mmol), 3-fluoro-5-methoxy-2'-methy1-3'-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-[1,1'-bipheny1]-4-carbaldehyde (939 mg, 2.53 mmol), and 2M K2CO3 (1.85 mL, 3.7 mmol) in p-dioxane (10 mL) was added Pd(dppf)C12 complex with dichloromethane (121 mg, 0.148 mmol). The reaction mixture was degassed (N2) for 2 min and stirred under N2 at 95 C for 5 h. The reaction mixture was diluted with Et0Ac, filtered through Celite, washed with brine and dried over MgSO4. The solvent was removed under reduced presure and the residue was purified by silica gel flash chromatography (5 to 20%
to 40% Et0Ac/hexane) to give N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide. MS: (ES) m/z calculated for C281-125FN305 [M + H]+ 502.2, found 502.2 [0236] Step b: To a stirred solution of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (40 mg, 0.079 mmol) and propan-2-amine (10 mg, 0.16 mmol), in MeOH:DCE (2 mL) was added NaBH(OAc)3 (33 mg, 0.16 mmol) and AcOH (4 drops). The reaction mixture was stirred at room temperture for 2 h. The solvent was removed under reduced pressure and the residue was purified by preparative HPLC (0 to 40% to 100% MeCN/H20) to give N-(3"-fluoro-4"-((isopropylamino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 1-H NMR
(400 MHz, CD30D) 8 11.15 (s, 1H), 8.41 (s, 1H), 8.05 (d, J= 8.0 Hz, 1H), 7.39-7.24 (m, 3H), 7.15 (d, J=
6.2 Hz, 1H), 6.96 (d, J= 7.4 Hz, 1H), 6.94 (s, 1H), 6.86 (d, J= 9.7 Hz, 1H), 4.30 (d, J= 1.5 Hz, 2H), 3.56-3.46 (m, 1H), 3.98 (s, 3H), 3.36 (s, 3H), 2.10 (s, 3H), 1.93 (s, 3H), 1.42 (d, J= 6.5 Hz, 6H). MS: (ES) m/z calculated for C31H34FN404 [M + H]+ 544.3, found 544.2.
Example 106: N-(4"-((dimethylamino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terphenyl1-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe N_Me 0 ri Me HN).LN F Me Me Li Me [0237] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(4"-((dimethylamino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid.
IENMR (400 MHz, CD30D) ö 11.15 (s, 1H), 8.41 (s, 1H), 8.05 (d, J= 8.0 Hz, 1H), 7.39-7.24 (m, 3H), 7.17 (d, J= 6.2 Hz, 1H), 6.96 (d, J= 7.4 Hz, 1H), 6.94 (s, 1H), 6.86 (d, J= 9.7 Hz, 1H), 4.43 (s, 2H), 3.99 (s, 3H), 3.36 (s, 3H), 2.93 (s, 6H), 2.10 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated for C30H32FN404 [M + H]' 531.2, found 531.2.
Example 107: N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(morpholinomethyl)-11,1':3',1"-terphenyll-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me HN)(N F Lo Me Me [0238] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide .. using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(morpholinomethy1)41,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 1-EINMR (400 MHz, CD30D) 8 11.15 (s, 1H), 8.41 (s, 1H), 8.05 (d, J= 8.0 Hz, 1H), 7.39-7.24 (m, 3H), 7.16 (d, J= 6.2 Hz, 1H), 6.96 (d, J= 7.0 Hz, 1H), 6.95 (s, 1H), 6.88 (d, J= 9.7 Hz, 1H), 4.47 (d, J= 1.5 Hz, 2H), 4.06 (d, J= 11.0 Hz, 2H), 3.99 (s, 3H), 3.77 (t, J= 12.5 Hz, 2H), 3.49 (d, J= 12.7 Hz, 4H), 3.36 (s, 3H), 2.10 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated for C32H34FN405 [M + H]572.2, found 572.2.
Example 108: N-(4"-((3-aminopyrrolidin-1-yl)methyl)-3"-fluoro-5"-methoxy-2,2'-.. dimethy1-11,1':3',1"-terpheny11-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me Na_N H2 HNN
0 N 0 Me Me [0239] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(4"-((3-aminopyrrolidin-1-yl)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-.. 1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 1-EINMR (400 MHz, CD30D) 8 11.16 (s, 1H), 8.40 (d, J= 11.2 Hz, 1H), 8.05 (d, J= 7.7 Hz, 1H), 7.39-7.24 (m, 3H), 7.16 (dd, J

= 7.4, 1.5 Hz, 1H), 6.98 (d, J= 7.0 Hz, 1H), 6.95 (s, 1H), 6.85 (d, J= 9.7 Hz, 1H), 4.55-4.50 (m, 2H), 4.45-4.39 (m, 2H), 4.30-4.20 (m, 3H), 3.98 (s, 3H), 3.40-3.17 (m, 5H), 2.10 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated for C32H35FN504 [M + H]+ 572.3, found 572.2.
Example 109: N-(4"-(((2-aminoethyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe N
0 Me NH2 HN )*LN
0 N 0 Me M
e [0240] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(4"-(((2-aminoethyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid.
1-EINMR (400 MHz, CD30D)13 11.15 (s, 1H), 8.42 (s, 1H), 8.05 (d, J= 7.8 Hz, 1H), 7.39-7.24 (m, 3H), 7.16 (d, J= 7.3 Hz, 1H), 6.96 (d, J= 7.0 Hz, 1H), 6.95 (s, 1H), 6.88 (d, J= 9.7 Hz, 1H), 4.41 (s, 2H), 3.98 (s, 3H), 3.77-3.68 (m, 4H), 3.36 (s, 3H), 2.10 (s, 3H), 1.93 (s, 3H). MS:
(ES) m/z calculated for C30H33FN504 [M + 546.2, found 564.2.
Example 110: N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((oxetan-3-ylamino)methyl)-11,1':3',1"-terpheny11-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me N"-C1 HN)LN
0 N 0 Me Me [0241] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((oxetan-3-ylamino)methy1)41,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 1-EINMR (400 MHz, CD30D) 8 11.15 (s, 1H), 8.41 (s, 1H), 8.05 (d, J= 8.2 Hz, 1H), 7.38-7.21 (m, 3H), 7.16 (d, J= 7.3 Hz, 1H), 6.96 (d, J= 7.0 Hz, 1H), 6.94 (s, 1H), 6.88 (d, J= 9.7 Hz, 1H), 4.90 (d, J=
7.0 Hz, 1H), 4.71-4.63 (m, 2H), 4.49-4.41 (m, 2H), 4.29 (s, 2H), 4.00 (s, 3H), 3.36 (s, 3H), 2.10 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated for C31H32FN405 [M + H]+ 559.2, found 559.2.
Example 111: N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((tetrahydrofuran-3-yl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me N"C
HNLN
Me FH

Me [0242] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((tetrahydrofuran-3-yl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 1-EINMR
(400 MHz, CD30D) 8 11.15 (s, 1H), 8.42 (s, 1H), 8.05 (d, J= 8.2 Hz, 1H), 7.38-7.21 (m, 3H), 7.16 (dd, J=

7.3, 1.5 Hz, 1H), 7.01-6.85 (m, 3H), 4.33 (s, 2H), 4.07 (dd, J= 8.6, 3.3 Hz, 2H), 3.99 (s, 3H), 3.86 (dd, J= 10.8, 5.7 Hz, 1H), 3.80-3.67 (m, 1H), 3.36 (s, 3H), 3.30-3.20 (m, 1H), 2.48-2.38 (m, 1H), 2.15-2.05 (m, 4H), 1.93 (s, 3H). MS: (ES) m/z calculated for C32H34FN405 [M + H]+
573.2, found 573.2.
Example 112: N-(3"-fluoro-4"-((((1-hydroxycyclopropyl)methyl)amino)methyl)-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terphenyl1-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me N XOH
H _________________________________________________________ HN
M
0 N 0 e M
e [0243] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-((((1-hydroxycyclopropyl)methyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. lEINMR
(400 MHz, CD30D) 8 11.15 (s, 1H), 8.42 (s, 1H), 8.04 (d, J= 8.1 Hz, 1H), 7.38-7.21 (m, 3H), 7.14 (dd, J= 7.3, 1.5 Hz, 1H), 6.96 (d, J= 7.0 Hz, 1H), 6.93 (s, 1H), 6.85 (d, J= 9.7 Hz, 1H), 4.43 (s, 2H), 3.98 (s, 3H), 3.36 (s, 3H), 3.20 (s, 1H), 2.11-2.08 (m, 4H), 1.93 (s, 3H) 0.89-0.94 (m, 2H), 0.70-0.78 (m, 2H). MS: (ES) m/z calculated for C32H34FN405 [M +
573.2, found 573.2.
Example 113: N-(3"-fluoro-4"-((3-hydroxyazetidin-1-yl)methyl)-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terpheny11-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me HN)LN FOH
Me LiJ
Me [0244] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-((3-hydroxyazetidin-1-yl)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 1-EINMR
(400 MHz, CD30D) 8 11.15 (s, 1H), 8.41 (s, 1H), 8.05 (d, J= 8.2 Hz, 1H), 7.38-7.21 (m, 3H), 7.16 (d, J=
.. 7.3 Hz, 1H), 6.96 (d, J= 7.0 Hz, 1H), 6.94 (s, 1H), 6.88 (d, J= 9.7 Hz, 1H), 4.90 (d, J= 7.0 Hz, 1H), 4.71-4.63 (m, 2H), 4.49-4.41 (m, 2H), 4.29 (s, 2H), 4.00 (s, 3H), 3.36 (s, 3H), 2.10 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated for C31H32FN405 [M + H]+ 559.2, found 559.2.
Example 114: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((5-oxopyrrolidin-yl)methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me N=\, Nclt0 HN.LN
0 N 0 Me Me [0245] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-3-.. methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 1-EINMR (400 MHz, CD30D) 8 11.17 (s, 1H), 8.41 (s, 1H), 8.04 (d, J= 8.2 Hz, 1H), 7.38-7.21 (m, 3H), 7.15 (d, J= 7.3 Hz, 1H), 7.01-6.85 (m, 3H), 4.40 (s, 2H), 4.20-4.10 (m, 1H), 3.98 (s, 3H), 3.36 (s, 3H), 3.20-3.30 (m, 1H), 2.45-2.35 (m, 3H), 2.10 (s, 3H), 1.97-1.87 (m, 4H) 1.90-1.85 (m, 1H).
MS: (ES) m/z calculated for C33H35FN505 [M + H]600.3, found 600.2.
Example 115: (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((5-oxopyrrolidin-yl)methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe N
0 Me 0 HN =Cst HN.LN IIIJ N1 0 N 0 Me Me [0246] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 11-1 NMR (400 MHz, CD30D) 8 11.17 (s, 1H), 8.41 (s, 1H), 8.04 (d, J= 8.2 Hz, 1H), 7.38-7.21 (m, 3H), 7.15 (d, J= 9.0 Hz, 1H), 7.01-6.85 (m, 3H), 4.39 (s, 2H), 4.10-4.05 (m, 1H), 3.99 (s, 3H), 3.36 (s, 3H), 3.30-3.25 (m, 1H), 2.45-2.35 (m, 3H), 2.10 (s, 3H), 1.97-1.89 (m, 4H) 1.92-1.89 (m, 1H). MS: (ES) m/z calculated for C33H35FN505 [M + H]' 600.3, found 600.2.
Example 116: N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((3-oxopiperazin-1-yl)methyl)-11,1':3',1"-terpheny11-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me N
F NH
HN)LN
0 N 0 Me Me [0247] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"43-oxopiperazin-1-y1)methyl)41,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 1-EINMR (400 MHz, CD30D) 8 11.15 (s, 1H), 8.41 (s, 1H), 8.04 (d, J= 7.4 Hz, 1H), 7.38-7.21 (m, 3H), 7.16 (dd, J= 1.5, 7.3 Hz, 1H), 7.01-6.85 (m, 3H), 4.55 (s, 2H), 3.99 (s, 3H), 3.94 (s, 2H), 3.45-3.65 (m, 3H), 3.36 (s, 3H), 3.30-3.20 (m, 1H), 2.10 (s, 3H), 1.95 (s, 3H). MS: (ES) m/z calculated for C32H33FN505 [M + H]' 585.2, found 585.2.
Example 117: (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((5-oxopyrrolidin-3-yl)amino)methyl)-11,1':3',1"-terphenyl1-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me HN N
0 N 0 Me Me [0248] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((5-oxopyrrolidin-3-yl)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid.
1-EINMR (400 MHz, CD30D) 8 11.15 (s, 1H), 8.41 (s, 1H), 8.04 (d, J= 8.2 Hz, 1H), 7.38-7.21 (m, 3H), 7.15 (d, J= 7.3 Hz, 1H), 7.01-6.85 (m, 3H), 4.36 (s, 2H), 4.26-4.20 (m, 1H), 3.99 (s, 3H), 3.87 (dd, J
= 11.3, 7.4 Hz, 1H), 3.56 (dd, J= 11.7, 3.9 Hz, 1H), 3.36 (s, 3H), 2.90 (dd, J= 11.3, 7.4 Hz, 1H), 2.53 (dd, J= 18.0, 5.1 Hz, 1H), 2.10 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated for C32H33FN505 [M + H]+ 586.2, found 586.2.

Example 118: N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(0(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me Nci"
N-HN)LN1r57O
0 N 0 Me Me [0249] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)methyl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 1H NMIR (400 MHz, CD30D) 8 11.17 (s, 1H), 8.41 (s, 1H), 8.04 (d, J= 8.2 Hz, 1H), 7.38-7.21 (m, 3H), 7.15 (d, J = 7.8 Hz, 1H), 7.01-6.85 (m, 3H), 4.49 (s, 2H), 4.32 (s, 2H), 3.98 (s, 3H), 3.36 (s, 3H), 2.09 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated for C31H30FN606 [M +
H]601.2, found 601.2.
Example 119: N-(3"-fluoro-4"-(4(3R,4R)-4-hydroxytetrahydrofuran-3-yl)amino)methyl)-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me Nes H
OH
HN ).(N
0 N 0 Me Me [0250] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-((((3R,4R)-4-hydroxytetrahydrofuran-3-yl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. lEINMR
(400 MHz, CD30D) 8 11.15 (s, 1H), 8.41 (s, 1H), 8.04 (d, J= 8.2 Hz, 1H), 7.38-7.21 (m, 3H), .. 7.15 (d, J= 7.2 Hz, 1H), 7.01-6.85 (m, 3H), 4.88-4.47 (m, 1H), 4.39 (dd, J=
22.0, 13.4 Hz, 2H), 4.20-4.05 (m, 2H), 4.01-3.95 (m, 4H), 3.75-3.70 (m, 1H), 3.60 (dd, J= 9.8, 4.3 Hz, 1H), 3.36 (s, 3H), 2.09 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated for C32H34FN406 [M + H]+ 589.2, found 589.2.
Example 120: N-(3"-fluoro-4"-((((3R,4R)-3-hydroxytetrahydro-2H-pyran-4-yl)amino)methyl)-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terpheny11-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me HNL.LN F oH
Me Me [0251] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-4"-((((3R,4R)-3-hydroxytetrahydro-2H-pyran-4-yl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 1H NMR (400 MHz, CD30D) 8 11.15 (s, 1H), 8.41 (s, 1H), 8.05 (d, J= 7.1 Hz, 1H), 7.38-7.21 (m, 3H), 7.15 (d, J= 7.4 Hz, 1H), 7.01-6.85 (m, 3H), 4.39 (d, J=
13.7 Hz, 1H), 4.29 (d, J= 13.3 Hz, 1H), 4.10-3.96 (m, 2H), 3.98 (s, 3H), 3.60-3.40 (m, 2H), 3.35 (s, 3H), 2.15-2.05 (m, 2H), 2.09 (s, 3H), 1.93 (s, 3H), 1.90-1.85 (m, 2H). MS: (ES) m/z calculated for C33H36FN406 [M + H]603.3, found 603.2.

Example 121: 1-((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)-11,1':3',1"-terpheny11-4-yl)methyl)azetidine-3-carboxylic acid OMe 0 Me ND

Me LiJ
ONO
Me [0252] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step c of Example 1. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product 14(3-fluoro-5-methoxy-2',2"-dimethy1-3"-(3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)41,1':3',1"-terphenyl]-4-yl)methypazetidine-3-carboxylic acid as a white solid. ITINMR
(400 MHz, CD30D) 8 11.15 (s, 1H), 8.41 (s, 1H), 8.05 (d, J= 8.1 Hz, 1H), 7.38-7.21 (m, 3H), 7.16 (d, J=
7.5 Hz, 1H), 7.01-6.85 (m, 3H), 4.56 (s, 2H), 4.42 (t, J= 9.1 Hz, 4H), 3.98 (s, 3H), 3.71 (s, 1H), 3.36 (s, 3H), 2.10 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated for C32H32FN406 [M + H]+
589.2, found 589.2.
Example 122: N-(4"-(aminomethyl)-3"-fluoro-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me NHBoc Me HN Br MeNs.AN Br _____________ _______________________________ 7.-HATU, DMF Me Pd(dppf)C12, K2CO3 MIe Hunig's Base MIe Dioxane/H20, 95 C
Step a Step b OMe TFA, CH2Cl2 0 Me NHBoc rt, 1 h Me,NLN
Me Step c ONO OMe Me 0 Me NH2 Me,NN
Me LLJ
Me [0253] Step a: To a mixture of 1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (0.3 g, 2.35 mmol), 3-bromo-2-methylaniline (0.43 g, 2.35 mmol), in DMF (8 mL) was added HATU (1.34 g, 3.52 mmol) and diisopropylethylamine (0.75 g, 5.87 mmol). The reaction was stirred at room temperature for 16 h. After completion of the reaction, the solvent was removed by half and diluted with water (15 m1). The mixture was stirred for 20 min, then the solid was filtered, washed with water (10 ml) and dried under vacuum to give N-(3-bromo-2-methylpheny1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.
[0254] Step b: To a mixture of N-(3-bromo-2-methylpheny1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (100 mg, 0.31 mmol), tert-butyl ((3-fluoro-5-methoxy-2'-methy1-3'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-y1)41,1'-biphenyl]-4-y1)methyl)carbamate (146 mg, 0.31 mmol) and 2M K2CO3 (0.38 mL, 0.77 mmol) in p-dioxane (4 mL) was added Pd(dppf)C12 complex with dichloromethane (26 mg, 0.032 mmol). The reaction mixture was degassed (N2) for 2 min and stirred under N2 at 95 C for 4 h. The reaction mixture was diluted with Et0Ac, filtered through Celite, washed with brine and dried over MgSO4.
The solvent was removed under reduced pressure and the residue was purified by silica gel flash chromatography (5 to 20% to 60% Et0Ac/hexane) to give tert-butyl ((3"-(1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)-3-fluoro-5-methoxy-2',2"-dimethyl-[1,1':3',1"-terpheny1]-4-yl)methyl)carbamate.
[0255] Step c: To a strirred solution of tert-butyl ((3"-(1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)-3-fluoro-5-methoxy-2',2"-dimethyl-[1,1':3',1"-terpheny1]-4-yl)methyl)carbamate (75 mg, 0.123 mmol) in anhydrous dichloromethane (2.5 mL) at room temperature was added TFA (141 mg, 1.23 mmol) dropwise over 5 min. The reaction mixture was stirred at room temperature for 2 h. After completion of the reaction, the solvent was removed in vacuo to give as a viscous compound, which was purified by HPLC
(MeCN/H20 with 0.1% TFA) to give N-(4"-(aminomethyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide. 1-EINMR
(400 MHz, CD30D) 8 11.16 (s, 1H), 8.63 (s, 1H), 8.05 (d, J= 6.2 Hz, 1H), 7.37-7.21 (m, 3H), 7.15 (d, J= 7.4, 1.5 Hz, 1H), 7.01-6.85 (m, 3H), 4.22 (s, 2H), 3.97 (s, 3H), 3.55 (s, 3H), 3.39 (s, 3H), 2.09 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated for C29H30FN404 [M +
H]+ 517.2, found 500.1 [M-17].
Example 123: (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((6-oxopiperidin-3-yl)amino)methyl)-11,1':3',1"-terphenyll-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe Me OMe Me,NN

0 Me Br _________________________________________ Me,N)LN
Me Pd(dppf)C12, K2CO3 1 N 0 e Me Dioxane/H20, 95 C 0 NO M
Step a Me N
H2fses' H ?Me 0 Me Nµs=NH
Na(0Ac)3BH
Me,N ).LN
MeOH:DCE(1:1) rt, 16 h N
Me Me Step b
126 [0256] Step a: To a mixture of N-(3-bromo-2-methylpheny1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (500 mg, 1.48 mmol), 3-fluoro-5-methoxy-2'-methy1-3'-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-[1,1'-biphenyl]-4-carbaldehyde (939 mg, 2.53 mmol), and 2M K2CO3 (1.85 mL, 3.7 mmol) in p-dioxane (10 mL) was added Pd(dppf)C12 complex with dichloromethane (121 mg, 0.148 mmol). The reaction mixture was degassed (N2) for 2 min and stirred under N2 at 95 C for 5 h. The reaction mixture was diluted with Et0Ac, filtered through Celite, washed with brine and dried over MgSO4. The solvent was removed under reduced pressure and the residue was purified by silica gel flash chromatography (5 to 20% to 40% Et0Ac/hexane) to give N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.
MS: (ES) m/z calculated for C29H27FN305 [M + H]+ 516.2, found 516.2 [0257] Step b: To a stirred solution of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (40 mg, 0.079 mmol) and (R)-5-aminopiperidin-2-one (20 mg, 0.16 mmol) in MeOH:DCE (2 mL) was added NaBH(OAc)3 (45 mg, 0.16 mmol) and AcOH (4 drops). The reaction mixture was stirred at room temperture for 2 h. The solvent was removed under reduced pressure and the residue was purified by preparative HPLC (0 to 40% to 100% MeCN/H20) to give (R)-N-(3" -fluoro-5"-methoxy-2,2'-dimethy1-4"-(((6-oxopiperidin-3-y1)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 11-I
NMR (400 MHz, CD30D) 8 11.16 (s, 1H), 8.63 (s, 1H), 8.05 (d, J= 6.2 Hz, 1H), 7.37-7.21 (m, 3H), 7.15 (d, J= 6.2 Hz, 1H), 7.01-6.85 (m, 3H), 4.41 (dd, J= 13.7, 5.1 Hz, 2H), 4.00 (s, 3H), 3.77-3.55 (m, 2H), 3.54(s, 3H), 3.50-3.45 (m, 1H), 3.38(s, 3H), 3.31-3.29(m, 1H), 2.50 (t, J=
7.2 Hz, 1H), 2.42-2.35 (m, 1H), 2.15-2.05 (m, 1H), 2.09 (s, 3H), 1.93 (s, 3H).
MS: (ES) m/z calculated for C34H37FN505 [M + H]614.3, found 614.2.
Example 124: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((6-oxopiperidin-3-yl)amino)methyl)-11,1':3',1"-terphenyl1-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
127 OMe 0 0 Me Me,N)LN
0 N 0 Me LLJ
Me [0258] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step b of Example 123. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((6-oxopiperidin-3-yl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. ITINMR (400 MHz, CD30D) 8 11.16 (s, 1H), 8.63 (s, 1H), 8.05 (d, J= 6.2 Hz, 1H), 7.37-7.21 (m, 3H), 7.15 (d, J = 6.2 Hz, 1H), 7.01-6.85 (m, 3H), 4.41 (dd, J = 13.7, 5.1 Hz, 2H), 4.00 (s, 3 H), 3.77-3.55 (m, 2H), 3.54 (s, 3H), 3.50-3.45 (m, 1H), 3.38 (s, 3H), 2.50 (t, J = 7.2 Hz, 2H), 2.42-2.35 (m, 1H), 2.12-2.07 (m, 1H), 2.10 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated for C34H37FN505 [M + H]614.3, found 614.2.
Example 125: N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((l-methyl-1H-pyrazol-yl)methyl)-amino)-methyl)-11,1':3',1"-terpheny11-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxamide OMe Me 0 Me N m Me,NLN
0 N 0 Me Me [0259] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step b of Example 123. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((1-methy1-1H-pyrazol-5-yl)methyl)amino)methy1)41,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white
128 solid. 1H NMR (400 MHz, CD30D) 8 11.15 (s, 1H), 8.62 (s, 1H), 8.04 (d, J= 8.1 Hz, 1H), 7.54 (d, J= 2.1 Hz, 1H), 7.38-7.21 (m, 3H), 7.14 (dd, J= 7.4, 1.2 Hz, 1H), 6.96 (d, J= 7.0 Hz, 1H), 6.93 (s, 1H), 6.88 (d, J= 9.7 Hz, 1H), 6.56 (d, J= 2.0 Hz, 1H), 4.49 (s, 2H), 4.40 (s, 2H), 3.97 (s, 3H), 3.92 (s, 3H), 3.55 (s, 3H), 3.38 (s, 3H), 2.10 (s, 3H), 1.93 (s, 3H). MS:
(ES) m/z calculated for C34H36FN604 [M + El]+ 611.3, found 611.2.
Example 126: N-(4"-(((2,5-dioxopyrrolidin-3-yl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terphenyll-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me N
JN H
Me ,N N F 0 0 N 0 Me Me [0260] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step b of Example 123. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(4"-(((2,5-dioxopyrrolidin-3-yl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 1H
NMR (400 MHz, CD30D) 8 11.16 (s, 1H), 8.62 (s, 1H), 8.04 (d, J= 6.2 Hz, 1H), 7.37-7.21 (m, 3H), 7.15 (d, J= 6.2 Hz, 1H), 7.01-6.85 (m, 3H), 4.68-4.59 (m, 2H), 4.43 (d, J= 13.7 Hz, 1H), 3.99 (s, 3H), 3.54 (s, 3H), 3.31 (s, 3H), 3.16 (dd, J= 18.0, 9.0 Hz, 1H), 2.80 (dd, J= 18.0, 5.9 Hz, 1H), 2.09 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated for C33H33FN506 [M + H]614.2, found 614.2.
Example 127: N-(4"-(4(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
129 OMe 0 Me N NH
Me ,N N F Cf"N0 Me ONO
Me [0261] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step b of Example 123. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(4"-((((2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 1-EINMR (400 MHz, CD30D) 8 11.16 (s, 1H), 8.62 (s, 1H), 8.04 (d, J= 8.1 Hz, 1H), 7.65 (s, 1H), 7.38-7.21 (m, 3H), 7.15 (d, J= 6.2 Hz, 1H), 6.96 (d, J= 7.8 Hz, 1H), 6.91 (s, 1H), 6.83 (d, J= 10.2 Hz, 1H), 4.33 (s, 2H), 4.00 (s, 2H), 3.98 (s, 3H), 3.55 (s, 3H), 3.31 (s, 3H), 2.10 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated for C34H34FN606 [M + H]+
641.2, found 641.2.
Example 128: N-(4"-(4(1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl)-amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terphenyll-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me N Me Me ,N N F sZeN0 M e Me LtJ
Me [0262] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Step b of Example 123 The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(4"-((((1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-
130 tetrahydropyrimidine-5-carboxamide as a white solid. 1-H NMR (400 MHz, CD30D) 11.16 (s, 1H), 8.62 (s, 1H), 8.07 (d, J= 8.2 Hz, 1H), 7.83 (s, 1H), 7.38-7.21 (m, 3H), 7.15 (d, J= 6.2 Hz, 1H), 6.95 (d, J= 7.8 Hz, 1H), 6.92 (s, 1H), 6.84 (d, J= 10.2 Hz, 1H), 4.34 (s, 2H), 4.03 (s, 2H), 3.98 (s, 3H), 3.55 (s, 3H), 3.38 (s, 3H), 3.30 (s, 6H), 2.10 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated for C36H38FN606 [M + H]+ 669.3, found 669.2.
Example 129: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((5-oxopyrrolidin-3-yl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide 0 Mel, K2CO3, DMF 0 ,NA Me'N'N OMe ______________________ 12N
HCI, AcOH Me,N-N
HN OH rt, 60 C OH
0 N 0 Step a ON 0 Step b 0 N 0 H M1e M1e OMe H2N . Br 0 F
Me MeNõN lei N Br LJ
____________________ ,..- ______________________________________ _ HATU, DMF 0 N 0 H
Me Pd(dppf)C12, K2CO3 Hunig's Base I Dioxane/H20, 95 C
Me Step c Step d OMe =,,NH
0 Me 0 H2 HCIN
MeõNj( N N F
H Na(0Ac)3BH, DMF

Me rt, 16 h 0 I
Me Step e OMe idNH
0 Me N
MeNõN).L
N F H
H
0 N 0 Me Me [0263] Step a: To a stirred solution of 3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylic acid (380 mg, 2.4 mmol) in anhydrous DMF (7 mL) was added methyl iodide (1.2 mL, 19 mmol), and potassium carbonate (2.0 g, 14 mmol) at room temperature. After stirring at 60 C
131 for 2 h, the mixture was poured into water (25 mL) and extracted with 60 mL of CHC13:2-propanol (2:1). The crude material was purified by silica gel chromatography (45 to 60%
Et0Ac/hexane) to give desired product methyl 2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylate.
[0264] Step b : To a vial containing methyl 2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylate (284 mg, 1.4 mmol) was added acetic acid (2 mL) and 12 M HC1 (2 mL) at room temperature. The mixture was heated at 60 C for 2 h, then concentrated under reduced pressure and dried in vacuo. The residue, 2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylic acid was used in the following step without purification.
[0265] Step c: To a mixed solution of 2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylic acid (238 mg, 1.28 mmol) and 3-bromo-2-methylaniline (287 mg, 1.54 mmol) in DMF (6.0 mL) was added HATU (730 mg, 1.92 mmol) and diisopropylethylamine (330 mg, 2.56 mmol). The reaction was stirred at room temperature for 16 h. After completion of the reaction, the solvent was removed by half and diluted with water (15 ml) the mixture was stirred for 20 min. The solid was filtered, washed with water (10 ml), and dried under vacuum to give N-(3-bromo-2-methylpheny1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide as a white solid.
[0266] Step d: To a mixture of N-(3-bromo-2-methylpheny1)-1-methy1-2-oxo-1,2-dihydropyridine-3-carboxamide (450 mg, 1.27 mmol), 3-fluoro-5-methoxy-2'-methy1-3'-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)41,1'-biphenyl]-4-carbaldehyde (550 mg, 1.27 mmol), and K2CO3 (500 mg, 3.17 mmol) in p-dioxane/H20 (9:1 mL) was added Pd(dppf)C12 complex with dichloromethane (120mg, 0.127 mmol). The reaction mixture was degassed (N2) for 2 min and stirred under N2 at 95 C for 5 h. The reaction mixture was diluted with Et0Ac, filtered through Celite, washed with brine and dried over MgSO4. The solvent was removed under reduced pressure and the residue was purified by silica gel flash chromatography (20%
to 100%
Et0Ac/hexane) to give N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide.
MS: (ES) m/z calculated for C281-126FN405[M + H]+ 517.2, found 517.2.
132 [0267] Step e: To a stirred solution of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (125 mg, 0.32 mmol), and (S)-4-aminopyrrolidin-2-one-hydrochloride (23 mg, 0.155 mmol), in MeOH:DCE (1:1 mL) was added diisopropylethylamine (25 mg, 0.231 mmol), .. NaBH(OAc)3 (49 mg, 0.231 mmol) and AcOH (5 drops). The reaction mixture was stirred at room temperture for 3 h. The solvent was removed under reduced pressure and the residue was purified by preparative HPLC (0% to 40%-100% MeCN/H20) to give (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((5-oxopyrrolidin-3-yl)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide as a white solid. 11-1 NMR (400 MHz, CD30D) 8 11.08 (s, 1H), 8.07 (d, J= 8.2 Hz, 1H), 7.37-7.29 (m, 2H), 7.24 (d, J= 7.8 Hz, 1H), 7.16 (d, J= 8.2 Hz, 1H), 7.01 (d, J= 7.8 Hz, 1H), 6.95 (s, 1H), 6.88 (d, J= 9.8 Hz, 1H), 4.36 (s, 2H), 4.26 __ /1.20 (m, 1H), 3.99 (s, 3H), 3.87 (dd, J= 11.7, 7.8 Hz, 1H), 3.77 (s, 3H), 3.56 (dd, J= 11.4, 4.0 Hz, 1H), 3.38 (s, 3H), 2.92 (dd, J= 18.6, 4.7 Hz, 1H), 2.52 (dd, J=
18.0, 4.7 Hz, 1H), 2.11 (s, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated for C32H34FN605 [M +
H]+ 601.3, found 601.2.
Example 130: (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((5-oxopyrrolidin-3-yl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide OMe .6H
0 Me N's MeõN
N N
0 N 0 Me Me [0268] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-.. carboxamide and (S)-4-aminopyrrolidin-2-one-hydrochloride-carboxamide using a procedure similar to the one described in Step e of Example 129. The product was purified by HPLC
(MeCN/H20 with 0.1% TFA) to give the desired product (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((5-oxopyrrolidin-3-yl)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-2,4-dimethyl-3,5-
133 dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide as a white solid. 1-EINMR (400 MHz, CD30D) 8 11.07 (s, 1H), 8.05 (t, J= 7.8 Hz, 1H), 7.37-7.29 (m, 2H), 7.24 (d, J= 8.2 Hz, 1H), 7.16 (d, J= 7.4 Hz, 1H), 7.01 (d, J= 7.8 Hz, 1H), 6.94 (s, 1H), 6.88 (d, J=
9.3 Hz, 1H), 4.36 (s, 2H), 4.26-4.20 (m, 1H), 3.99 (s, 3H), 3.92-3.85 (m, 1H), 3.77 (s, 3H), 3.60-3.50 (m, 1H), 3.38 (s, 3H), 2.92 (dd, J= 18.0, 9.0 Hz, 1H), 2.60-2.52 (m, 1H), 2.11 (s, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated for C32H34FN605 [M + H]601.3, found 601.2.
Example 131: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((5-oxopyrrolidin-yl)methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide OMe 0 Me Me õN
N N
0 N 0 Me Me [0269] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide and (5)-5-(aminomethyl)pyrrolidin-2-one-hydrochloride using a procedure similar to the one described in Step e of Example 129. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide as a white solid. ITINMR (400 MHz, CD30D) 8 11.08 (s, 1H), 8.07 (t, J= 7.8 Hz, 1H), 7.37-7.26 (m, 2H), 7.24 (d, J= 8.2 Hz, 1H), 7.16 (d, J=
7.8 Hz, 1H), 7.01 (d, J= 7.2 Hz, 1H), 6.95 (s, 1H), 6.88 (d, J= 9.4 Hz, 1H), 4.40 (s, 2H), 4.10-4.02 (m, 1H), 4.00 (s, 3H), 3.77 (s, 3H), 3.39 (s, 3H), 3.30-3.25 (m, 2H), 2.46-2.34 (m, 3H), 2.11 (s, 3H), 1.94 (s, 3H), 1.92-1.89 (m, 1H). MS: (ES) m/z calculated for C32H36FN605 [M +
H]' 615.3, found 615.2.
Example 132: (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((5-oxopyrrolidin-yl)methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide
134 OMe N
0 Me Hi .1 _t 0 MeõN
N N
0 N 0 Me Me [0270] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide and (R)-5-(aminomethyl)pyrrolidin-2-one-hydrochloride using a procedure similar to the one described in Step e of Example 129. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide as a white solid. 1H NMIR (400 MHz, CD30D) 8 11.08 (s, 1H), 8.07 (t, J= 8.2 Hz, 1H), 7.37-7.26 (m, 2H), 7.24 (d, J= 8.2 Hz, 1H), 7.16 (d, J=
7.8 Hz, 1H), 7.01 (d, J= 7.8 Hz, 1H), 6.95 (s, 1H), 6.88 (d, J= 9.0 Hz, 1H), 4.39 (s, 2H), 4.05-4.00 (m, 1H), 3.99 (s, 3H), 3.77 (s, 3H), 3.38 (s, 3H), 3.30-3.20 (m, 2H), 2.46-2.34 (m, 3H), 2.11 (s, 3H), 1.94 (s, 3H), 1.92-1.89 (m, 1H). MS: (ES) m/z calculated for C32H36FN605 [M +
H]+615.3, found 615.2.
Example 133: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyl((5-oxopyrrolidin-2-y1)-methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide OMe 0 Me .4,r,õNto MeõN Me 1-N N
0 N 0 Me Me [0271] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide and 1-(4-fluoropheny1)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-b]pyridine using a procedure similar to the one described in Step e of Example 129. The product was purified by
135 HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyl((5-oxopyrrolidin-2-yl)methyl)amino)methy1)41,1':3',1"-terphenyl]-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide as a white solid. 11-1 NMR (400 MHz, CD30D) 8 11.08 (s, 1H), 8.07 (t, J= 8.5 Hz, 1H), 7.37-7.22 (m, 3H), 7.17 (d, J
= 7.1 Hz, 1H), 7.01 (d, J= 8.2 Hz, 1H), 6.99 (s, 1H), 6.93 (d, J= 9.7 Hz, 1H), 4.65-4.55 (m, 1H), 4.50-4.42 (m, 2H), 4.30-4.20 (m, 2H), 4.01 (s, 3H), 3.77 (s, 3H), 3.38 (s, 3H), 2.94 (s, 3H), 2.55-2.30 (m, 3H), 2.11 (s, 3H), 1.95 (s, 3H), 1.90-1.85 (m, 1H). MS: (ES) m/z calculated for C34H38FN605 [M + H]+ 629.3, found 629.2.
Example 134: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((6-oxopiperidin-3-yl)amino)methyl)-11,1':3',1"-terphenyll-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide OMe 0 Me Me'N'N N
0 N 0 Me Me [0272] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide and (S)-5-aminopiperidin-2-one using a procedure similar to the one described in Step e of Example 129. The product was purified by HPLC (MeCN/H20 with 0.1%
TFA) to give the desired product (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"4(6-oxopiperidin-3-y1)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide as a white solid. 1-EINMR (400 MHz, CD30D) 5 11.09 (s, 1H), 8.07 (t, J
= 7.8 Hz, 1H), 7.37-7.26 (m, 2H), 7.24 (d, J= 7.0 Hz, 1H), 7.16 (d, J= 7.8 Hz, 1H), 7.01 (d, J=
7.8 Hz, 1H), 6.95 (s, 1H), 6.88 (d, J= 9.7 Hz, 1H), 4.41 (dd, J= 18.4, 12.9 Hz, 2H), 3.99 (s, 3H), 3.77 (s, 3H), 3.75-3.70 (m, 1H), 3.50-3.45 (m, 1H), 3.38 (s, 3H), 2.50 (t, J=
6.2 Hz, 2H), 2.45-2.35 (m, 2H), 2.11 (s, 3H), 2.15-2.05 (m, 1H), 1.94 (s, 3H). MS: (ES) m/z calculated for C33H36FN605 [M + H]615.3, found 615.2.
136 Example 135: (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((6-oxopiperidin-3-yl)amino)methyl)-11,1':3',1"-terphenyll-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide OMe 0 Me KrNsNH
MeõN)-L
N N
Me LLJ Me [0273] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide and (R)-5-aminopiperidin-2-one using a procedure similar to the one described in Step e of Example 129. The product was purified by HPLC (MeCN/H20 with 0.1%
TFA) to give the desired product (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((6-oxopiperidin-3-yl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide as a white solid. 1-EINMR (400 MHz, CD30D) 6 11.09 (s, 1H), 8.06 (t, J
= 8.2 Hz, 1H), 7.37-7.26 (m, 2H), 7.24 (d, J = 7.0 Hz, 1H), 7.15 (d, J = 7.2 Hz, 1H), 7.01 (d, J =
7.8 Hz, 1H), 6.94 (s, 1H), 6.88 (d, J = 10.1 Hz, 1H), 4.40 (dd, J= 12.6, 5.4 Hz, 2H), 3.99 (s, 3H), 3.77 (s, 3H), 3.75-3.65 (m, 2H), 3.50-3.45 (m, 1H), 3.38 (s, 3H), 2.50 (t, J=
7.1 Hz, 2H), 2.45-2.35 (m, 1H), 2.11 (s, 3H), 2.10-2.00 (m, 1H), 1.94 (s, 3H). MS: (ES) m/z calculated for C33H36FN605 [M + H]615.3, found 615.2.
Example 136: (1S,2R)-2-(((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido13,4-blpyrazin-5-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)cyclopentan-1-ol OMe H2N's Me CHO OH
NY(N NaBH(OAc)3 LN H
Me OMe Me -NN5)F
H OH
H
Me
137 [0274] A mixture of 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde (23 mg, 0.041 mmol), (1S,2R)-2-aminocyclopentan-1-01 hydrochloride (30 mg, 0.22 mmol), Et3N (15 mg, 0.15 mmol) and HOAc (75 mg, 1.25 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C and NaBH(OAc)3 .. (70 mg, 0.33 mmol) was added. After stirring for 30 min at room temperature the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1%
TFA) to yield (1S,2R)-2-(((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terphenyl]-4-y1)methyl)amino)cyclopentan-1-ol (TFA salt).
1H NMR (400 MHz, CD30D) 8 9.25 (d, J = 2.0 Hz, 1H), 9.06 (d, J = 2.0 Hz, 1H), 7.78 (d, J=
7.6 Hz, 1H), 7.60-7.51 (m, 2H), 7.41-7.34 (m, 3H), 7.28 (dd, J = 7.6, 1.2 Hz, 1H), 7.23 (dd, J= 7.2, 1.2 Hz, 1H), 6.92 (s, 1H), 6.86 (dd, J= 9.6, 1.2 Hz, 1H), 4.44-4.28 (m, 3H), 3.97 (s, 3H), 3.52-3.44 (m, 1H), 2.18-2.07 (m, 1H), 2.10 (s, 3H), 2.02 (s, 3H), 2.00-1.77 (m, 4H), 1.62-1.74 (m, 1H). MS:
(ES) m/z calculated C34H35FN502 [M + H]+ 564.3, found 564.3.
Example 137: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(42-(5-oxopyrrolidin-yl)ethyl)amino)methyl)-11,1':3',1"-terphenyll-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide OMe 0 Me MeõN
N N
0 N 0 Me Me [0275] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide and (5)-5-(2-aminoethyppyrrolidin-2-one-hydrochloride using a procedure similar to the one described in Step e of Example 129. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((2-(5-oxopyrrolidin-2-yl)ethyl)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide as a white solid. ITINMR (400 MHz, CD30D) 8 11.08 (s, 1H), 8.07 (t, J= 8.7 Hz, 1H), 7.37-7.26 (m, 2H), 7.24 (d, J = 7.0 Hz, 1H), 7.15 (d, J =
138 7.8 Hz, 1H), 7.01 (d, J= 7.8 Hz, 1H), 6.94 (s, 1H), 6.87 (d, J= 10.2 Hz, 1H), 4.34 (s, 2H), 3.98 (s, 3H), 3.77 (s, 3H), 3.80-3.70 (m, 2H), 3.38 (s, 3H), 3.25-3.10 (m, 2H), 2.40-2.30 (m, 3H), 2.12 (s, 3H), 2.10-1.95 (m, 1H), 1.94 (s, 3H), 1.85-1.75 (m, 1H). MS: (ES) m/z calculated for C34H38FN605 [M + H]+ 629.3, found 629.2.
Example 138: N-(4"-(((3-amino-3-oxopropyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide OMe 0 0 N Me NH2 Me õ
N N
0 N 0 Me iLi M
e [0276] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide and 3-aminopropanamide using a procedure similar to the one described in Step e of Example 129. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product N-(4"-(((3-amino-3-oxopropyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide as a white solid. 1-EINMR (400 MHz, CD30D) 8 11.09 (s, 1H), 8.08 (t, J= 7.4 Hz, 1H), 7.37-7.26 (m, 2H), 7.25 (d, J= 6.6 Hz, 1H), 7.15 (d, J= 7.1 Hz, 1H), 7.01 (d, J= 7.2 Hz, 1H), 6.93 (s, 1H), 6.86 (d, J= 10.2 Hz, 1H), 4.35 (s, 2H), 3.99 (s, 3H), 3.77 (s, 3H), 3.38 (s, 3H), 3.34-3.30 (m, 2H), 2.70 (d, J= 12.0 Hz, 2H), 2.11 (s, 3H), 1.94 (s, 3H). MS:
(ES) m/z calculated for C31H34FN605 [M + 589.3, found 589.2.
Example 139: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((3-oxoisoxazolidin-yl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide
139 OMe 0, 0 Me NICA
Me N õNA 0 N NH
0 N 0 Me Me [0277] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide and (S)-4-aminoisoxazolidin-3-one using a procedure similar to the one described in Step e of Example 129. The product was purified by HPLC (MeCN/H20 with 0.1%
TFA) to give the desired product (S)-N-(3 "-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((3-oxoisoxazolidin-4-yl)amino)methyl)-[1,1':3',1"-terpheny1]-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide as a white solid. 1-HNMR (400 MHz, CD30D) 8 11.08 (s, 1H), 8.07 (t, J
= 7.8 Hz, 1H), 7.37-7.26 (m, 2H), 7.24 (d, J = 8.2 Hz, 1H), 7.16 (d, J= 7.2 Hz, 1H), 7.01 (d, J=
7.8 Hz, 1H), 6.94 (s, 1H), 6.85 (d, J = 9.7 Hz, 1H), 4.73 (s, 2H), 4.70-4.61 (m, 1H), 4.39 (d, J=
10.7 Hz, 2H), 3.98 (s, 3H), 3.77 (s, 3H), 3.38 (s, 3H), 2.11 (s, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated for C31H32FN606 [M + H]603.2, found 603.2.
Example 140: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((2-oxopiperidin-3-yl)amino)methyl)-11,1':3',1"-terphenyll-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide OMe 0 Me H II
NH
MeõN)L 0 N N
0 N 0 Me iti Me [0278] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide and (S)-3-aminopiperidin-2-one-hydrochloride using a procedure similar to the one described in Step e of Example 129. The product was purified by HPLC (MeCN/H20 with 0.1%
TFA) to give the desired product (S)-N-(3 "-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((2-
140 oxopiperidin-3-yl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide as a white solid. 1H NMIR (400 MHz, CD30D) 8 11.08 (s, 1H), 8.07 (t, J= 8.2 Hz, 1H), 7.37-7.26 (m, 2H), 7.15 (d, J= 7.2 Hz, 1H), 7.01 (d, J= 8.2 Hz, 1H), 6.92 (s, 1H), 6.85 (d, J= 10.5 Hz, 1H), 4.49 (d, J= 13.2 Hz, 1H), 4.40 (d, J= 13.1 Hz, 1H), 4.05-3.90 (m, 1H), 3.99 (s, 3H), 3.77 (s, 3H), 3.38 (s, 3H), 3.37-3.15 (m, 2H), 2.45-2.38 (m, 1H), 2.12 (s, 3H), 2.01-1.97 (m, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated for C33H36FN605 [M + H]615.3, found 615.2.
Example 141: (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((2-oxopiperidin-3-yl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide OMe 0 Me H II

Me Me [0279] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide and (R)-3-aminopiperidin-2-one-hydrochloride using a procedure similar to the one described in Step e of Example 129. The product was purified by HPLC (MeCN/H20 with 0.1%
TFA) to give the desired product (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((2-oxopiperidin-3-yl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide as a white solid. 1H NMIR (400 MHz, CD30D) 8 11.08 (s, 1H), 8.07 (t, J= 8.2 Hz, 1H), 7.37-7.26 (m, 2H), 7.15 (d, J= 7.2 Hz, 1H), 7.01 (d, J= 8.2 Hz, 1H), 6.92 (s, 1H), 6.85 (d, J= 10.5 Hz, 1H), 4.47 (d, J= 13.5 Hz, 1H), 4.37 (d, J= 12.6 Hz, 1H), 4.10-3.90 (m, 1H), 3.99 (s, 3H), 3.77 (s, 3H), 3.38 (s, 3H), 3.35-3.05 (m, 2H), 2.45-2.38 (m, 1H), 2.15-2.10 (m, 1H), 2.12 (s, 3H), 1.90-2.00 (m, 2H), 1.94 (s, 3H). MS:
(ES) m/z calculated for C33H36FN605 [M + H]+ 615.3, found 615.2.
141 Example 142: (S)-N-(4"-(((2,6-dioxopiperidin-3-yl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terphenyl1-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide OMe 0 r Me MeõN 0 N N
Me LLJ
ONO
Me [0280] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide and 3-aminopiperidine-2,6-dione hydrochloride using a procedure similar to the one described in Step e of Example 129. The product was purified by HPLC
(MeCN/H20 with 0.1% TFA) to give the desired product (S)-N-(4"-(((2,6-dioxopiperidin-3-yl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide as a white solid. 1H NMIR (400 MHz, CD30D) 8 11.08 (s, 1H), 8.06 (t, J= 8.2 Hz, 1H), 7.33-7.26 (m, 3H), 7.15 (d, J= 7.0 Hz, 1H), 7.00 (d, J= 8.2 Hz, 1H), 6.93 (s, 1H), 6.87 (d, J= 10.1 Hz, 1H), 4.55 (d, J= 14.1 Hz, 1H), 4.50-4.42 (m, 2H), 3.99 (s, 3H), 3.77 (s, 3H), 3.38 (s, 3H), 2.85-2.79 (m, 2H), 2.50-2.42 (m, 1H), 2.30-2.20 (m, 1H), 2.11 (s, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated for C33H34FN606 [M + H]+
629.2, found 629.1.
Example 143: N-(4"-((((2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terpheny11-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide OMe 0 Me N/NH
Me N - NJL. N F CoN0 0 N 0 Me Me [0281] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-
142 carboxamide and 5-(aminomethyl)pyrimidine-2,4(1H,3H)-dione hydrochloride using a procedure similar to the one described in Step e of Example 129. The product was purified by HPLC
(MeCN/H20 with 0.1% TFA) to give the desired product N-(4"-((((2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)methyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide as a white solid. 1H NMR (400 MHz, CD30D) 8 11.08(s, 1H), 8.07 (t, J= 7.8 Hz, 1H), 7.65 (s, 1H), 7.30 (dd, J= 17.2, 7.8 Hz, 2H), 7.24 (d, J= 7.4 Hz, 1H), 7.14 (d, J= 7.0 Hz, 1H), 7.00 (d, J=
7.8 Hz, 1H), 6.90 (s, 1H), 6.83 (d, J= 9.8 Hz, 1H), 4.33 (s, 2H), 4.00 (s, 2H), 3.98 (s, 3H), 3.77 (s, 3H), 3.38 (s, 3H), 2.11 (s, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated for C33H33FN706 [M +
H]642.2, found 642.1.
Example 144: N-(4"-(((2,4-dioxohexahydropyrimidin-5-yl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terpheny11-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide OMe NO
NNH
0 Me H N( MeõN 0 N N
Me Lii Me [0282] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide and 5-aminodihydropyrimidine-2,4(1H,31])-dione using a procedure similar to the one described in Step e of Example 129. The product was purified by HPLC
(MeCN/H20 with 0.1% TFA) to give the desired product N-(4"4(2,4-dioxohexahydropyrimidin-5-yl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide as a white solid. 1-EINMR (400 MHz, .. CD30D) 8 11.08 (s, 1H), 8.06 (t, J= 8.0 Hz, 1H), 7.39-7.22 (m, 3H), 7.15 (d, J= 7.0 Hz, 1H), 7.00 (d, J= 6.2 Hz, 1H), 6.93 (s, 1H), 6.87 (d, J= 10.1 Hz, 1H), 4.66-4.58 (m, 1H), 4.55-4.42 (m, 2H), 3.99 (s, 3H), 3.86-3.75 (m, 4H), 3.55 (t, J= 12.2 Hz, 1H), 3.38 (s, 3H), 2.12 (s, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated for C32H33FN706 [M + H]630.2, found 630.2.
143 Example 145: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((5-oxopyrrolidin-3-yl)amino)methyl)-11,1':3',1"-terphenyl1-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe ipeNH
0 Me Me,N-LN
Me Me [0283] To a solution of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (46 mg, 0.089 mmol) in 1:1 MeOH:DCE (2 mL) was added (S)-4-aminopyrrolidin-2-one (28 mg, 0.28 mmol). After stirring at room temperature for 75 min, sodium triacetoxyborohydride (82 mg, 0.39 mmol) was added. The reaction mixture was concentrated in vacuo and the crude residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to obtain the (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((5-oxopyrrolidin-3-y1)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA salt). 1H
NMR (400 MHz, CD30D) 11.17 (s, 1H), 8.63 (s, 1H), 8.06 (d, J= 7.9 Hz, 1H), 7.38-7.21 (m, 3H), 7.16 (d, J= 7.7 Hz, 1H), 7.00-6.86 (m, 3H), 4.37 (s, 2H), 4.23 (m, 1H), 4.00 (s, 3H), 3.88 (dd, J=
11.7, 7.6 Hz, 1H), 3.60-3.55 (m, 1H), 3.55 (s, 3H), 3.39 (s, 3H), 2.91 (dd, J=
17.8, 8.8 Hz, 1H), 2.55 (dd, J= 17.8, 4.7 Hz, 1H), 2.09 (s, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated for C33H35FN505 [M+H] 600.3, found 600.3.
Example 146: (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((5-oxopyrrolidin-3-yl)amino)methyl)-11,1':3',1"-terphenyll-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
144 OMe NH
0 Me N' NANN
0 N 0 Me Me [0284] The compound was prepared from N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Example 145. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((5-oxopyrrolidin-3-yl)amino)methy1)41,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide as a white solid. 1H NMR (400 MHz, CD30D) 8 11.16 (s, 1H), 8.63 (s, 1H), 8.06 (d, J= 8.2 Hz, 1H), 7.38-7.21 (m, 3H), 7.16 (d, J= 7.5 Hz, 1H), 7.00-6.86 (m, 3H), 4.37 (s, 2H), 4.23 (m, 1H), 4.00 (s, 3H), 3.88 (dd, J=
11.7, 7.6 Hz, 1H), 3.60-3.55 (m, 1H), 3.55 (s, 3H), 3.39 (s, 3H), 2.91 (dd, J=
17.8, 8.8 Hz, 1H), 2.55 (dd, J= 17.8, 4.7 Hz, 1H), 2.09 (s, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated for C33H35FN505 [M+H] 600.3, found 600.2.
Example 147: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyl(5-oxopyrrolidin-3-y1)amino)methyl)-11,1':3',1"-terphenyll-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe NH
0 Me Me rViN)(N
0 N 0 Me Me [0285] To a solution of (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4" -(((5-oxopyrrolidin-3-yl)amino)methyl)-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (87 mg, 0.15 mmol) in 1:1 MeOH:DCE (2 mL) was added 37% aqueous formalin solution (210 mg, 2.6 mmol). After stirring at room temperature for 30
145 min, sodium triacetoxyborohydride (128 mg, 0.60 mmol) was added. After stirring an additional 18 h, the solvent was removed under reduced pressure and the residue was purified by HPLC
(MeCN/H20 with 0.1% TFA) to give the desired product (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyl(5-oxopyrrolidin-3-y1)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide. 1-EINMR (400 MHz, CD 30D) 8 11.16 (s, 1H), 8.63 (s, 1H), 8.06 (d, J= 7.7 Hz, 1H), 7.39-7.23 (m, 3H), 7.21-7.13 (m, 1H), 7.01-6.90 (m, 3H), 4.47 (s, 2H), 4.43-4.35 (m, 1H), 4.01 (s, 3H), 3.93 (bs, 1H), 3.75 (dd, J=
11.6, 5.1 Hz, 1H), 3.55 (s, 3H), 3.39 (s, 3H), 2.97-2.88 (m, 1H), 2.91 (s, 3H), 2.81 (d, J= 6.0 Hz, 1H), 2.10 (s, 3H), 1.95 (s, 3H). MS: (ES) m/z calculated for C34H37FN505 [M+H]
614.3, found 614.2.
Example 148: (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyl(5-oxopyrrolidin-3-y1)amino)methyl)-11,1':3',1"-terphenyl1-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe .6H
0 Me Me,NLN F
0 N 0 Me Me [0286] The compound was prepared from (R)-N -(3" -flu o r 0-5" -m eth oxy -2 ,2' -dim ethyl- 4" #(5 -oxopyrrolidin-3-yDamino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Example 147. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to give (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyl(5-oxopyrrolidin-3-y1)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide. 1-E1 NMR
(400 MHz, CD30D) 8 11.16 (s, 1H), 8.63 (s, 1H), 8.06 (d, J= 7.7 Hz, 1H), 7.39-7.23 (m, 3H), 7.21-7.13 (m, 1H), 7.01-6.90 (m, 3H), 4.47 (s, 2H), 4.43-4.35 (m, 1H), 4.01 (s, 3H), 3.93 (bs, 1H), 3.75 (dd, J= 11.6, 5.1 Hz, 1H), 3.55 (s, 3H), 3.39 (s, 3H), 2.97-2.88 (m, 1H), 2.91 (s, 3H), 2.81 (d, J= 6.0 Hz, 1H), 2.10 (s, 3H), 1.95 (s, 3H). MS: (ES) m/z calculated for C34H37FN505 [M+H] 614.3, found 614.2.
146 Example 149: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(0(5-oxopyrrolidin-2-yl)methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe N 0 Me Me,NLN
iCt Me Me [0287] To a solution of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (46 mg, 0.089 mmol) in 1:1 MeOH:DCE (2 mL) was added (S)-5-aminomethylpyrrolidin-2-one hydrochloride (57 mg, 0.38 mmol) and diisopropylethylamine (0.066 mL, 0.38 mmol). The mixture was stirred for 1 h at room temperature, at which point sodium triacetoxyborohydride (111 mg, 0.52 mmol) was added. After stirring at room temperature for 2 d, the solvent was removed under reduced pressure and the residue was purified by HPLC (MeCN/H20 with 0.1%
TFA) to give the desired product (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((5-oxopyrrolidin-2-yOmethyl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide. 1H NMIR (400 MHz, CD30D) ö 11.17 (s, 1H), 8.63 (s, 1H), 8.06 (d, J= 7.7 Hz, 1H), 7.38-7.21 (m, 3H), 7.16 (d, J= 7.4 Hz, 1H), 7.00-6.86 (m, 3H), 4.40 (s, 2H), 4.08-4.03 (m, 1H), 4.00 (s, 3H), 3.55 (s, 3H), 3.39 (s, 3H), 3.26 (dd, J= 6.2, 2.0 Hz, 2H), 2.46-2.34 (m, 3H), 2.09 (s, 3H), 1.94 (s, 4H). MS: (ES) m/z calculated for C34H37FN505 [M+H] 614.3, found 614.3.
Example 150: (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(4(5-oxopyrrolidin-2-yl)methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
147 OMe N
0 Me NH 'Cto MeNLN
I11 jJZIIXT
0 N 0 Me Me [0288] The compound was prepared from of N-(3 "-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl- [1,1' :3',1"-terphenyl] -3 -y1)-1,3 -dimethy1-2,4-di oxo-1,2,3,4-tetrahydropyrimi dine-5 -carboxamide using a procedure similar to the one described in Example 149. The reaction mixture was purified by HPLC (MeCN/H20 with 0.1% TFA) to give (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide. 1-HNMR (400 MHz, CD30D) 8 11.17 (s, 1H), 8.63 (s, 1H), 8.06 (d, J= 7.7 Hz, 1H), 7.38-7.21 (m, 3H), 7.16 (d, J=
7.4 Hz, 1H), 7.00-6.86 (m, 3H), 4.40 (s, 2H), 4.08-4.03 (m, 1H), 4.00 (s, 3H), 3.55 (s, 3H), 3.39 (s, 3H), 3.26 (dd, J= 6.2, 2.0 Hz, 2H), 2.46-2.34 (m, 3H), 2.09 (s, 3H), 1.94 (s, 4H). MS: (ES) m/z calculated for C34H37FN5 05 [M+H] 614.3, found 614.2.
Example 151: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyl((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me :3/4N-to Me,NN
Me 1 ONO
Me [0289] To a solution of N-(3 "-fluoro-4"-formy1-5"-methoxy-2,2'-dimethy141,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (46 mg, 0.089 mmol) in 1:1 MeOH:DCE (2 mL) was added (5S)-5-[(methylamino)methyl]pyrrolidin-2-one hydrochloride (58 mg, 0.35 mmol) and diisopropylethylamine (0.061 mL, 0.35 mmol).
After stirring at room temperature for 1 h, sodium triacetoxyborohydride (78 mg, 0.37 mmol) was added and the reaction mixture was stirred for an additional 2 d. The solvents were removed under reduced pressure and the residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to
148 give (S)-N-(3 "-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyl((5-oxopyrrolidin-2-yl)methyl)amino)methy1)41,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide. 1H NMR (400 MHz, CD30D) 8 8.63 (s, 1H), 8.08 (d, J=
7.5 Hz, 1H), 7.34 (t, J= 7.6 Hz, 1H), 7.30-7.25 (m, 2H), 7.17 (dd, J= 7.4, 1.5 Hz, 1H), 7.02-6.92 (m, 3H), 4.49 (bs, 2H), 4.27 (bs, 1H), 4.01 (s, 3H), 3.55 (s, 3H), 3.44 (bs, 2H), 3.38 (s, 3H) 2.95 (s, 3H), 2.53-2.33 (m, 3H), 2.10 (s, 3H), 1.95 (s, 3H), 1.94 (bs, 1H).
MS: (ES) m/z calculated for C35H39FN505 [M+H] 628.3, found 628.3.
Example 152: (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyl((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe N
0 Me N 0 Me ,N )LN 1 7-le ONO Me Me [0290] This compound was prepared from (R)-N-(3 "-fluoro-5"-methoxy-2,2'-dimethy1-4"-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide using a procedure similar to the one described in Example 147. The residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to give (R)-N -(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyl((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.
1H NMR (400 MHz, CD30D) 8 11.17 (s, 1H), 8.63 (s, 1H), 8.08 (d, J= 7.5 Hz, 1H), 7.34 (t, J=
7.6 Hz, 1H), 7.30-7.25 (m, 2H), 7.17 (dd, J = 7.4, 1.5 Hz, 1H), 7.02-6.92 (m, 3H), 4.49 (bs, 2H), 4.27 (bs, 1H), 4.01 (s, 3H), 3.55 (s, 3H), 3.44 (bs, 2H), 3.38 (s, 3H) 2.95 (s, 3H), 2.53-2.33 (m, 3H), 2.10 (s, 3H), 1.95 (s, 3H), 1.94 (bs, 1H). MS: (ES) m/z calculated for [M+H] 628.3, found 628.3.
Example 153: (S)-4-(43-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido13,4-blpyrazin-5-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)pyrrolidin-2-one
149 OMe 101 Me CHO

N CI
H2N Br Me psLi ________________________________ N N Br _______________________ Cs2CO3, DMSO
H Pd(dppf)C12=CH2C12 60 C, 42 h Me 2M K2CO3, dioxane, 90 C
Step a Step b OMe edNH
CHO
Me H2N
NN Na(0Ac)3BH
H MeOH:DCE (1:1) Me 0 Step c OMe vedNH
Me NN
H
Me [0291] Step a: In a 100-mL round bottom flask was combined 5-chloropyrido[3,4-b]pyrazine (1.1 g, 6.6 mmol), 3-bromo-2-methylaniline (2.9 g, 16 mmol), cesium carbonate (6.6 g, 20 mmol) and DMSO (25 mL). The mixture was stirred at 60 C for 42 h. After cooling to room temperature, the reaction mixture was poured into water (100 mL) and extracted with 20% THF
in Et0Ac (3 x 200 mL). The combined extracts were concentrated and the residue was purified by silica gel flash chromatography (6 to 25% Et0Ac/hexane) to obtain N-(3-bromo-2-methylphenyl)pyrido[3,4-b]pyrazin-5-amine.
[0292] Step b: To a mixture of N-(3-bromo-2-methylphenyl)pyrido[3,4-b]pyrazin-5-amine (700 mg, 2.2 mmol), 3-fluoro-5-methoxy-2'-methy1-3'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-y1)-[1,1'-bipheny1]-4-carbaldehyde (1.0 g, 2.7 mmol) and 2 M K2CO3(2.5 mL, 5.0 mmol) in p-dioxane (10 mL) was added Pd(dppf)C12 complex with dichloromethane (300 mg, 0.37 mmol).
The mixture degassed with N2 and then stirred at 90 C for 2 h. After cooling to room temperature, the mixture was diluted with ethyl acetate and water. The organic phase was concentrated and purified by silica gel flash chromatography (16 to 100%
Et0Ac/hexane, then 10% Me0H/DCM) followed by a second silica gel flash chromatography (4 to 6%
Et0Ac/DCM)
150 to give the desired product, 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)41,1':3',1"-terphenyl]-4-carbaldehyde.
[0293] Step c: In a 40-mL round bottom flask was combined 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)41,1':3',1"-terphenyl]-4-carbaldehyde (44 mg, 0.092 mmol), (S)-4-amino-2-pyrrolidinone (54 mg, 0.54 mmol), and 1:1 MeOH:DCE
(2 mL).
The mixture was heated until fully dissolved, then stirred for 30 min at room temperature.
Sodium triacetoxyborohydride (82 mg, 0.39 mmol) was added and the mixture was stirred for another 1.5 h. The solvent was removed under reduced pressure and the residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to give (S)-44(3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)41,1':3',1"-terpheny1]-4-y1)methyl)amino)pyrrolidin-2-one.
NMR (400 MHz, CD30D) 6 9.23 (d, J= 2.0 Hz, 1H), 9.04 (d, J= 2.0 Hz, 1H), 7.80 (d, J= 7.1 Hz, 1H), 7.65-7.58 (m, 1H), 7.57-7.48 (m, 1H), 7.42-7.20 (m, 5H), 6.98-6.86 (m, 2H), 4.37 (s, 2H), 4.27-4.19 (m, 1H), 3.99 (s, 3H), 3.88 (dd, J= 11.6, 7.6 Hz, 1H), 3.58 (dd, J= 11.6, 3.9 Hz, 1H), 2.90 (dd, J= 17.8, 8.8 Hz, 1H), 2.56 (dd, J= 17.8, 4.7 Hz, 1H), 2.10 (s, 3H), 2.01 (s, 3H).
MS: (ES) m/z calculated for C33H32FN602 [M+1-1]+ 563.3, found 563.3.
Example 154: (S)-54(03-fluoro-5-methoxy-2',2"-dimethyl-3"-(pyrido[3,4-blpyrazin-5-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)methyl)pyrrolidin-2-one OMe Me N Nc_lt0 N N
H
Me [0294] The compound was prepared from 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde and (S)-5-aminomethylpyrrolidin-2-one hydrochloride using a procedure similar to the one described in Step c of Example 153. The product was purified by HPLC (MeCN/H20 with 0.1% TFA) to obtain (S)-5-((((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)41,1':3',1"-terphenyl]-4-y1)methyl)amino)methyl)pyrrolidin-2-one. NMR (400 MHz, CD30D) 6 9.24 (d, J=
2.0 Hz, 1H), 9.05 (d, J= 2.0 Hz, 1H), 7.79 (d, J= 7.1 Hz, 1H), 7.64-7.49 (m, 2H), 7.42-7.33 (m, 3H), 7.26 (ddd, J= 19.6, 7.6, 1.5 Hz, 2H), 6.98-6.85 (m, 2H), 4.40 (s, 2H), 4.10-4.02 (m, 1H), 3.99
151 (s, 3H), 3.28-3.23 (m, 2H), 2.48-2.32 (m, 3H), 2.10 (s, 3H), 2.02 (s, 3H), 1.96-1.87 (m, 1H).
MS: (ES) m/z calculated for C34H34FN602 [M+H]P 577.3, found 577.2.
Example 155: (S)-4-(02"-chloro-3-fluoro-5-methoxy-2'-methyl-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)pyrrolidin-2-one OMe = Me JLXCHO
'B
H2N Br O

CI
I
CI _____________________________ NN Br _______________________ Cs2CO3 II H
CI Pd(dppf)C12,CH2C12 DMSO, 60 C, 19 h 2M K2CO3, dioxane, 90 C
Step a Step b OMe CH O 4.6H
Me H2N
NN Na(0Ac)3BH
H LLJCI MeOH:DCE (1:1) 0 Step c OMe iedNH
Me NN
H
CI
[0295] Step a: A mixture of 5-chloropyrido[3,4-b]pyrazine (250 mg, 1.5 mmol), 3-bromo-2-chloroaniline (800 mg, 3.9 mmol) and cesium carbonate (900 mg, 2.8 mmol) in DMSO (2.5 mL) was stirred at 60 C for 19 h. Upon completion of the reaction, the mixture was cooled and diluted with ethyl acetate and water. The organic phase was separated and purified by silica gel flash chromatography (4 to 34% DCM/hexane) followed by a second silica gel flash chromatography purification (2 to 10% Me0H/DCM) to provide N-(3-bromo-2-chlorophenyl)pyrido[3,4-b]pyrazin-5-amine.
[0296] Step b: To a mixture of N-(3-bromo-2-chlorophenyl)pyrido[3,4-b]pyrazin-5-amine (320 mg, 0.94 mmol), 3-fluoro-5-methoxy-2'-methy1-3'-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)41,1'-biphenyl]-4-carbaldehyde (400 mg, 1.1 mmol), and 2 M K2CO3 (1.5 mL, 3.0 mmol)
152 in dioxane (4 mL) was added Pd(dppf)C12 complex with dichloromethane (220 mg, 0.27 mmol).
The mixture was degassed with N2 and stirred at 90 C for 75 min. Upon completion of the reaction, the mixture was diluted with ethyl acetate and water. The organic phase was separated, dried and concentrated and the resulting residue was purified by silica gel flash chromatography (4 to 30% Et0Ac/hexane followed by 2 to 5% Me0H/DCM) to provide 2"-chloro-3-fluoro-5-methoxy-2'-methy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)41,1':3',1"-terphenyl]-4-carbaldehyde.
[0297] Step c: To a solution of 2"-chloro-3-fluoro-5-methoxy-2'-methy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde (40 mg, 0.084 mmol) in 1:1 MeOH:DCE (2 mL) was added (S)-4-aminopyrolidin-2-one (40 mg, 0.40 mmol). The mixture was stirred at room temperature for 1.5 h and sodium triacetoxyborohydride (123 mg, 0.58 mmol) was added. The mixture was stirred for an additional 20 min. The solvent was removed under reduced pressure and the residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product (S)-4-(((2"-chloro-3-fluoro-5-methoxy-2'-methy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terphenyl]-4-y1)methyl)amino)pyrrolidin-2-one. 111NMR (400 MHz, CD30D) 6 9.11 (d, J= 1.9 Hz, 1H), 8.93 (d, J= 1.9 Hz, 1H), 8.82-8.74(m, 1H), 8.27 (d, J
= 6.3 Hz, 1H), 7.51 (t, J= 7.9 Hz, 1H), 7.38 (dd, J= 9.2, 6.8 Hz, 2H), 7.33-7.21 (m, 2H), 7.12 (dd, J= 7.5, 1.5 Hz, 1H), 6.98-6.87 (m, 2H), 4.37 (s, 2H), 4.24 (m, 1H), 4.00 (s, 3H), 3.88 (dd, J
= 11.7, 7.6 Hz, 1H), 3.57 (dd, J= 11.6, 3.9 Hz, 1H), 2.91 (dd, J= 17.8, 8.8 Hz, 1H), 2.55 (dd, J=
17.8, 4.6 Hz, 1H), 2.03 (s, 3H). MS: (ES) m/z calculated for C32H29FC1N602 [M
+ H]+ 583.2, found 583.1.
Example 156: 3-(((2"-chloro-3-fluoro-5-methoxy-2'-methyl-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)-2,2-dimethylpropanamide OMe 0 Me N NH2 NN 25 H Me Me II H
CI
[0298] This compound was prepared from 2"-chloro-3-fluoro-5-methoxy-2'-methy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)41,1':3',1"-terphenyl]-4-carbaldehyde and 3-amino-2,2-dimethylpropanamide using a procedure similar to the one described in Step c of Example 155.
153 The reaction mixture was purified by by HPLC (MeCN/H20 with 0.1% TFA) to give the desired product 3-(((2"-chloro-3-fluoro-5-methoxy-2'-methy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-yl)methyl)amino)-2,2-dimethylpropanamide. 1-HNMR (400 MHz, CD30D) 5 9.11 (d, J= 1.9 Hz, 1H), 8.94 (d, J= 1.9 Hz, 1H), 8.72 (d, J= 8.2 Hz, 1H), 8.28-8.21 (m, 1H), 7.51 (t, J= 7.9 Hz, 1H), 7.42-7.21 (m, 4H), 7.18-7.11 (m, 1H), 6.94 (s, 1H), 6.91-6.83 (m, 1H), 4.34 (s, 2H), 4.02 (s, 3H), 3.14 (s, 2H), 2.04 (s, 3H), 1.34 (s, 6H).
MS: (ES) m/z calculated for C33H33FC1N602 [M + H]+ 599.2, found 599.1.
Example 157: (S)-5-(4(2"-chloro-3-fluoro-5-methoxy-2'-methyl-3"-(pyrido13,4-b1pyrazin-5-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)methyl)pyrrolidin-2-one OMe Me N=%..,cfs....t10 NN
H
CI
[0299] This compound was prepared from 2"-chloro-3-fluoro-5-methoxy-2'-methy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde and (S)-(aminomethyl)pyrrolidin-2-one hydrochloride using a procedure similar to the one described in Step c of Example 155. The reaction mixture was purified by HPLC (MeCN/H20 with 0.1%
TFA) to obtain (S)-5-((((2"-chloro-3-fluoro-5-methoxy-2'-methy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terphenyl]-4-y1)methyl)amino)methyl)pyrrolidin-2-one.
NMR (400 MHz, CD30D) 9.13 (d, J= 1.9 Hz, 1H), 8.95 (d, J= 1.9 Hz, 1H), 8.66 (d, J= 8.3 Hz, 1H), 8.22 (d, J= 6.4 Hz, 1H), 7.53 (t, J= 7.9 Hz, 1H), 7.38 (dd, J= 11.7, 7.0 Hz, 2H), 7.33-7.22 (m, 2H), 7.21-7.14 (m, 1H), 6.98-6.86 (m, 2H), 4.40 (s, 2H), 4.09-4.03 (m, 1H), 4.00 (s, 3H), 3.28-3.24 (m, 2H), 2.48-2.34 (m, 3H), 2.04 (s, 3H), 1.95-1.88 (m, 1H). MS: (ES) m/z calculated for C33H3iFC1N602 [M + 597.2, found 597.2.
Example 158: (S)-N-(2-chloro-3"-fluoro-5"-methoxy-2'-methyl-4"-(((5-oxopyrrolidin-3-yl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
154 OMe 0 Me CHO Me,N
kCI

0 OMe 0 N 0 Me CHO Me H2N Br H2N
pyr, THF
Pd(dppf)C12,CH2C12 CI
Step b 2M K2CO3, dioxane, 90 C Me Step a A

OMe CHO
0 Me H2N
Me,N)LN
Na(0Ac)3BH
CI 1:1 MeOH:DCE

Me Step c OMe ed 0 Me Me,NLN
NH
C LLJ

Me [0300] Step a: To a mixture of 3-bromo-2-chloroaniline (240 mg, 1.2 mmol), 3-fluoro-5-methoxy-2'-methy1-3'-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)41,1'-biphenyl]-4-carbaldehyde (370 mg, 1.0 mmol), and 2 M K2CO3 (1.5 mL, 3.0 mmol) in dioxane (8 mL) was added Pd(dppf)C12 complex with dichloromethane (120 mg, 0.15 mmol). The mixture was degassed with N2 and stirred at 90 C for 2.5 h. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate and water, the organic phase was separated and purified by silica gel flash chromatography to obtain 3"-amino-3-fluoro-5-methoxy-2',2"-dimethyl-[1,1':3',1"-terpheny1]-4-carbaldehyde.
[0301] Step b: To a solution 1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carbonyl chloride in THF (4 mL) was added a solution of 3"-amino-3-fluoro-5-methoxy-2',2"-dimethyl-[1,1':3',1"-terpheny1]-4-carbaldehyde (200 mg, 0.54 mmol) and pyridine (0.12 mmol, 1.5 mmol).
The mixture was sonicated, briefly heated, and left to stand at room temperature for 4 d. The solvents were removed to give N-(2-chloro-3"-fluoro-4"-formy1-5"-methoxy-2'-methyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.
155 [0302] Step c: A mixture of the crude aldehyde N-(2-chloro-3"-fluoro-4"-formy1-5"-methoxy-2'-methyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (ca. 0.11 mmol) and (S)-4-aminopyrrolidin-2-one (36 mg, 0.36 mmol) in 1:1 MeOH:DCE (1.4 mL) was briefly heated, sonnicated and then stirred at room temperature for 15 min. Sodium triacetoxyborohydride (81 mg, 0.38 mmol) was added and the mixture was stirred at room temperature for an additional 15 min. The solvents were removed under reduced pressure and the residue was purified by by HPLC (MeCN/H20 with 0.1% TFA) to obtain (S)-N-(2-chloro-3"-fluoro-5"-methoxy-2'-methy1-4"-(((5-oxopyrrolidin-3-y1)amino)methyl)-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide. 1-E1 NMR
(400 MHz, CD30D) 8 11.68 (s, 1H), 8.66 (s, 1H), 8.50 (d, J= 8.5 Hz, 1H), 7.44-7.24 (m, 3H), 7.19 (d, J= 7.6 Hz, 1H), 7.09-7.02 (m, 1H), 6.97-6.85 (m, 2H), 4.37 (s, 2H), 4.23 (s, 1H), 3.99 (s, 3H), 3.88 (dd, J= 11.7, 7.7 Hz, 1H), 3.61-3.58 (m, 1H), 3.55 (s, 3H), 3.38 (s, 3H), 2.91 (dd, J
= 17.6, 9.1 Hz, 1H), 2.56 (dd, J= 17.7, 4.6 Hz, 1H), 1.98 (s, 3H). MS: (ES) m/z calculated for C32H32FC1N505 [M + H]+ 620.2, found 620.1.
Example 159: N-(4"-(((3-amino-2,2-dimethy1-3-oxopropyl)amino)methyl)-2-chloro-3"-fluoro-5"-methoxy-2'-methyl-11,1':3',1"-terphenyll-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 0 Me N NH2 Me,N)LN H Me Me M
e [0303] This compound was prepared from N-(2-chloro-3"-fluoro-4"-formy1-5"-methoxy-2'-methyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide and 3-amino-2,2-dimethylpropanamide using a procedure similar to the one described in Step c of Example 158. The crude residue was purified by by HPLC
(MeCN/H20 with 0.1% TFA) to obtain N-(4"4(3-amino-2,2-dimethy1-3-oxopropyl)amino)methyl)-2-chloro-3"-fluoro-5"-methoxy-2'-methyl-[1,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide. 1H NMR (400 MHz, CD30D)43 11.63 (s, 1H), 8.61 (s, 1H), 8.45 (dd, J= 8.3, 1.6 Hz, 1H), 7.39-7.20 (m, 3H), 7.17-7.10 (m, 1H), 7.01 (dd, J = 7.2, 1.6
156 Hz, 1H), 6.88 (s, 1H), 6.85-6.77 (m, 1H), 4.28 (s, 2H), 3.96 (s, 3H), 3.50 (s, 3H), 3.33 (s, 3H), 3.09 (s, 2H), 1.93 (s, 3H), 1.29 (s, 6H). MS: (ES) m/z calculated for C33H36FC1N505 [M + H]+
636.2, found 636.3.
Example 160: (S)-N-(2-chloro-3"-fluoro-5"-methoxy-2'-methy1-4"-(0(5-oxopyrrolidin-2-yl)methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide OMe 0 Me N ly0 Me ,N )LN

Me [0304] This compound was prepared from N-(2-chloro-3"-fluoro-4"-formy1-5"-methoxy-2'-methyl-E1,1':3',1"-terpheny1]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide and (S)-5-(aminomethyl)pyrrolidin-2-one using a procedure similar to the one described in Step c of Example 158. The crude residue was purified by HPLC
(MeCN/H20 with 0.1% TFA) to obtain (S)-N-(2-chloro-3"-fluoro-5"-methoxy-2'-methy1-4"-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide. 1H NMR (400 MHz, CD30D) 8 11.61 (s, 1H), 8.59 (s, 1H), 8.47-8.40 (m, 1H), 7.37-7.18 (m, 3H), 7.12 (d, J= 7.6 Hz, 1H), 6.99 (d, J= 7.7 Hz, 1H), 6.91-6.78 (m, 2H), 4.33 (s, 2H), 4.03-3.95 (m, 1H), 3.93 (s, 3H), 3.48 (s, 3H), 3.31 (s, 3H), 3.25-3.16 (m, 2H), 2.39-2.27 (m, 3H), 1.92 (s, 3H), 1.89-1.81 (m, 1H). MS:
(ES) m/z calculated for C33H34C1FN505 [M + H]' 634.2, found 634.1.
Example 161: (S)-N-(2-chloro-3"-fluoro-5"-methoxy-2'-methy1-4"-(((6-oxopiperidin-3-yl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
157 OMe 0 Me NoNH
Me,N).LN

Me [0305] This compound was prepared from N-(2-chloro-3"-fluoro-4"-formy1-5"-methoxy-2'-methyl-E1,1':3',1"-terpheny1]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide and (S)-5-aminopiperidin-2-one using a procedure similar to the one described in Step c of Example 158. The crude residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to obtain (S)-N-(2-chloro-3"-fluoro-5"-methoxy-2'-methy1-4"-(((6-oxopiperidin-yl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide. 1H NMR (400 MHz, CD30D) 8 11.61 (s, 1H), 8.59 (s, 1H), 8.44 (d, J= 8.3 Hz, 1H), 7.37-7.18 (m, 3H), 7.16-7.09 (m, 1H), 7.03-6.95 (m, 1H), 6.90-6.78 (m, 2H), 4.42-4.29 (m, 2H), 3.93 (s, 3H), 3.73-3.64 (m, 2H), 3.48 (s, 3H), 3.45-3.36 (m, 1H), 3.31 (s, 3H), 2.44 (t, J= 6.9 Hz, 2H), 2.32 (bs, 1H), 2.10-1.97 (m, 1H), 1.92 (s, 3H). MS:
(ES) m/z calculated for C33H34C1FN505 [M + H]+ 634.2, found 634.2.
Example 162: N-(2'-chloro-3"-fluoro-4"-((((3R,4R)-3-hydroxytetrahydro-2H-pyran-yl)amino)methyl)-5"-methoxy-2-methyl-11,1':3',1"-terpheny11-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
158 OMe ; 0, 0 is C:0 Br S OMe Br CHO B¨B1 0"O
CI CI
______________________________________ i..-__________________________________ ).-\i F Br Br F
PdOPPDC12(CH2C12) c K2CO3 KOAc Step a Step b Me, (1:11 0 OMe NN Br OMe H
Me 0 CI
CHO
\\ HO C 0 NO YO CI
Me Me,NN
F
H
Me Pd(dppf)C12(CH2C12)0N 0 M1e Step c 0 OMe 0 H2N% , 0 CI
z OH Me, ).L H OH
NaBH3CN H
Me ONO
Step d Me 103061 Step a: A mixture of 2-fluoro-6-methoxy-4-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-yl)benzaldehyde (511 mg, 1.82 mmol), 1,3-dibromo-2-chlorobenzene (750 mg, 2.77 mmol), K2CO3 (756 mg, 5.48 mmol) and Pd(dppf)C12 complex with dichloromethane (200 mg, 0.24 mmol) in dioxane (9 mL) and water (1.3 mL) was stirred under N2 at 95 C for 8 h. The mixture was cooled to room temperature and purified by silica gel flash chromatography (0 to 100%
Et0Ac/hexanes) to afford 3'-bromo-2'-chloro-3-fluoro-5-methoxy-[1,1'-bipheny1]-carbaldehyde. MS: (ES) m/z calculated for Ci4H9BrC1F02Na [M + Na]+ 365.0, found 365Ø
103071 Step b: A mixture of 3'-bromo-2'-chloro-3-fluoro-5-methoxy-[1,1'-bipheny1]-4-carbaldehyde (330 mg, 0.96 mmol), 4,4,4',4',5,5,5',5'-octamethy1-2,2'-bi(1,3,2-dioxaborolane) (270 mg, 1.06 mmol), KOAc (236 mg, 2.40 mmol), and Pd(dppf)C12 complex with dichloromethane (120 mg, 0.15 mmol) in dioxane (5 mL) was stirred under N2 at 95 C for 5 h.
The mixture was cooled to room temperature and purified by silica gel flash chromatography (0
159 to 100% Et0Ac/hexanes) to afford 2'-chloro-3-fluoro-5-methoxy-3'-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)41,1'-bipheny1]-4-carbaldehyde. MS: (ES) m/z calculated for C2oH22BC1F04 [M + H]391.1, found 391Ø
[0308] Step c: A mixture of 2'-chloro-3-fluoro-5-methoxy-3'-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)[1,1'-bipheny1]-4-carbaldehyde (80 mg, 0.20 mmol), N-(3-bromo-2-methylpheny1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (70 mg, 0.20 mmol), K2CO3 (100 mg, 0.72 mmol) and Pd(dppf)C12 complex with dichloromethane (45 mg, 0.055 mmol) in dioxane (3 mL) and water (0.45 mL) was stirred under N2 at 95 C for 2.5 h.
The mixture was cooled to room temperature and purified by silica gel flash chromatography (0 to 100% Et0Ac/hexanes) to afford N-(2'-chloro-3"-fluoro-4"-formy1-5"-methoxy-2-methyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.
MS: (ES) m/z calculated for C28H23C1FN305 [M + H]+ 536.1, found 536.1.
[0309] Step d: A mixture of N-(2'-chloro-3"-fluoro-4"-formy1-5"-methoxy-2-methyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (20 mg, 0.037 mmol), (3R,4R)-4-aminotetrahydro-2H-pyran-3-ol hydrochloride (12 mg, 0.078 mmol), Et3N (15 mg, 0.15 mmol) and HOAc (90 mg, 1.5 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C and NaBH3CN (45 mg, 0.71 mmol) was added.
After stirring for 3 min at 0 C the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to give N-(2'-chloro-3"-fluoro-4"-((((3R,4R)-3-hydroxytetrahydro-2H-pyran-4-yl)amino)methyl)-5"-methoxy-2-methyl-[1,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA
salt). 1-EINMR
(400 MHz, CD30D) 8 8.62 (s, 1H), 8.11 (d, J= 7.2 Hz, 1H), 7.49 (t, J= 7.4 Hz, 1H), 7.43 (dd, J
= 7.2, 2.0 Hz, 1H), 7.34 (dd, J= 7.6, 2.0 Hz, 1H), 7.29 (t, J= 8.0 Hz, 1H), 7.03 (s, 1H), 7.05-6.97 (m, 2H), 4.41 (d, J= 13.2 Hz, 1H), 4.33 (d, J= 13.2 Hz, 1H), 4.07 (s, 1H), 3.99 (s, 3H), 4.04-3.94 (m, 2H), 3.55 (s, 3H), 3.60-3.42 (m, 3H), 3.39 (s, 3H), 2.13 (s, 3H), 2.17-2.05 (m, 1H), 1.90-1.85 (m, 1H). MS: (ES) m/z calculated C33H35C1FN406 [M + H]637.2, found 637.2.
Example 163: (S)-N-(2'-chloro-3"-fluoro-5"-methoxy-2-methyl-4"-(((6-oxopiperidin-3-yl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
160 OMe CHO

Me,N
0 N 0 Me NaBH3CN
MIe OMe Me ,N ).LN
0 N 0 Me Me [0310] A mixture of N-(2'-chloro-3"-fluoro-4"-formy1-5"-methoxy-2-methy141,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (20 mg, 0.037 mmol), (S)-5-aminopiperidin-2-one hydrochloride (10 mg, 0.066 mmol), Et3N (15 mg, 0.15 mmol) and HOAc (75 mg, 1.25 mmol) in Et0H (1.5 mL) was heated at 70 C
for 0.5 h.
The mixture was cooled to 0 C and NaBH3CN (45 mg, 0.71 mmol) was added. After stirring for 3 min at 0 C the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to give (S)-N-(2'-chloro-3"-fluoro-5"-methoxy-2-methy1-4"-(((6-oxopiperidin-3-yl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA salt). 1H NMIR (400 MHz, CD30D) 8 11.17 (s, 1H), 8.63 (s, 1H), 8.09 (d, J= 7.6 Hz, 1H), 7.49 (t, J= 7.4 Hz, 1H), 7.43 (dd, J= 7.6, 1.6 Hz, 1H), 7.34 (dd, J= 7.2, 2.0 Hz, 1H), 7.29 (t, J= 8.0 Hz, 1H), 7.05 (s, 1H), 6.97-7.20 (m, 2H), 4.47-4.37 (m, 2H), 4.01 (s, 3H), 3.80-3.72 (m, 2H), 3.55 (s, 3H), 3.50-3.42 (m, 1H), 3.39 (s, 3H), 2.53-2.47 (m, 2H), 2.44-2.34 (m, 1H), 2.13 (s, 3H), 2.14-2.02 (m, 1H).
MS: (ES) m/z calculated C33H34C1FN505 [M + H]+ 634.2, found 634.2.
Example 164: N-(4"-(((3-amino-2,2-dimethy1-3-oxopropyl)amino)methyl)-2'-chloro-3"-fluoro-5"-methoxy-2-methyl-11,1':3',1"-terphenyll-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
161 OMe Me Me Me,N)LN
Me NaBH3CN
0 N 0 OMe Me Me,N,õ)LN
H Me Me 0 N 0 Me Me [0311] A mixture of N-(2'-chloro-3"-fluoro-4"-formy1-5"-methoxy-2-methy141,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (25 mg, 0.046 mmol), 3-amino-2,2-dimethylpropanamide (25 mg, 0.021 mmol) and HOAc (120 mg, 2.0 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C and NaBH3CN (40 mg, 0.63 mmol) was added. After stirring for 3 min at 0 C the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1%
TFA) to give N-(4"-(((3-amino-2,2-dimethy1-3-oxopropyl)amino)methyl)-2'-chloro-3"-fluoro-5"-methoxy-2-methyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA salt). 1-HNMR (400 MHz, CD30D) 6 8.56 (s, 1H), 8.05 (d, J= 8.0 Hz, 1H), 7.43-7.34 (m, 2H), 7.19-7.27 (m, 2H), 6.93 (d, J= 7.2 Hz, 1H), 6.87 (s, 1H), 6.79 (d, J= 9.6, 1H), 5.43 (s, 1H), 3.92 (s, 2H), 3.88 (s, 3H), 3.49 (s, 3H), 3.32 (s, 3H), 2.69 (s, 2H), 2.07 (s, 3H), 1.14 (s, 6H). MS: (ES) m/z calculated C33H36C1FN505 [M
+ H]636.2, found 636.2.
Example 165: (S)-N-(2'-chloro-3"-fluoro-5"-methoxy-2-methyl-4"-(((5-oxopyrrolidin-3-yl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
162 OMe CHO iedNH

Me,NAN F

Me NaBH3CN I
OMe Me iedNH

Me,NAN
0 N 0 Me Me [0312] A mixture of N-(2'-chloro-3"-fluoro-4"-formy1-5"-methoxy-2-methy141,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (19 mg, 0.035 mmol), (S)-4-aminopyrrolidin-2-one (10 mg, 0.010 mmol) and HOAc (60 mg, 1.0 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C
and NaBH3CN
(40 mg, 0.63 mmol) was added. After stirring for 3 min at 0 C the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to give (S)-N-(2'-chloro-3"-fluoro-5"-methoxy-2-methy1-4"-(((5-oxopyrrolidin-3-yl)amino)methy1)41,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA salt).
1-EINMR (400 MHz, CD30D) 6 11.10 (s, 1H), 8.56 (s, 1H), 8.05 (dd, J= 7.2, 7.2 Hz, 1H), 7.46-7.35 (m, 2H), 7.28 (d, J = 7.2 Hz, 1H), 7.23 (t, J= 7.8 Hz, 1H), 6.99 (s, 1H), 6.96-6.90 (m, 2H), 4.31 (s, 2H), 4.18 (bs, 1H), 3.94 (s, 3H), 3.78-3.86 (m, 1H), 3.60-3.40 (m, 1H), 3.48 (s, 3H), 3.32 (s, 3H), 2.85-2.80 (m, 1H), 2.50 (d, J= 18.0, 4.0 Hz, 1H), 2.06 (s, 3H).
MS: (ES) m/z calculated C32H32C1FN505 [M + H]+ 620.2, found 620.1.
Example 166: (S)-N-(2'-chloro-3"-fluoro-5"-methoxy-2-methyl-4"-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
163 OMe CHO H2N--"NO

Me,NLN
0 N 0 Me NaBH3CN I
Mie OMe 0 CI N=11,c :t1 0 rµlieN)LN
0 N 0 Me Me [0313] A mixture of N-(2'-chloro-3"-fluoro-4"-formy1-5"-methoxy-2-methy141,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (22 mg, 0.040 mmol), (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride (15 mg, 0.10 mmol), Et3N (15 mg, 0.15 mmol) and HOAc (75 mg, 1.25 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h.
The mixture was cooled to 0 C, and NaBH3CN (45 mg, 0.71 mmol) was added.
After stirring for 3 min at 0 C the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to give (S)-N-(2'-chloro-3"-fluoro-5"-methoxy-2-methy1-4"-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA salt). 1-EINMR (400 MHz, CD30D) 8 11.08 (s, 1H), 8.54 (s, 1H), 8.02 (t, J= 7.0 Hz, 1H), 7.43-7.32 (m, 2H), 7.25 (d, J= 6.8 Hz, 1H), 7.20 (t, J= 8.0 Hz, 1H), 6.97 (s, 1H), 6.93-6.88 (m, 2H), 4.32 (s, 2H), 4.10-3.93 (m, 1H), 3.92 (s, 3H), 3.46 (s, 3H), 3.29 (s, 3H), 3.20-3.15 (m, 2H), 2.40-2.24 (m, 3H), 2.04 (s, 3H), 1.90-1.78 (m, 1H). MS: (ES) m/z calculated C33H34C1FN505 [M + H]634.2, found 634.2.
Example 167: (S)-5-((((2'-chloro-3-fluoro-5-methoxy-2"-methyl-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)methyl)pyrrolidin-2-one
164 OMe CHO
\O CI OMe CHO
N N CI
NN NN
Br _________________________________________ H
Me Pd(dppf)C12(CH2C12) H
Me Step a OMe NaBH(OAc)3 311- NN
Step b H
Me [0314] Step a: A mixture of 2'-chloro-3-fluoro-5-methoxy-3'-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)41,1'-bipheny1]-4-carbaldehyde (86 mg, 0.22 mmol), N-(3-bromo-2-methylphenyl)pyrido[3,4-b]pyrazin-5-amine (70 mg, 0.22 mmol), K2CO3 (92 mg, 0.67 mmol) and Pd(dppf)C12 complex with dichloromethane (45 mg, 0.049 mmol) in dioxane (3 mL) and water (0.45 mL) was stirred under N2 at 95 C for 2 h. The mixture was cooled to room temperature and purified by silica gel flash chromatography (0 to 100%
Et0Ac/hexanes) to afford 2'-chloro-3-fluoro-5-methoxy-2"-methy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)41,1':3',1"-terpheny1]-4-carbaldehyde. MS: (ES) m/z calculated for C281-121C1FN402 [M +
H]499.1, found 499Ø
[0315] Step b: A mixture of 2'-chloro-3-fluoro-5-methoxy-2"-methy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde (20 mg, 0.040 mmol), (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride (11 mg, 0.073 mmol), Et3N (15 mg, 0.15 mmol) and HOAc (90 mg, 1.5 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C and NaBH(OAc)3(50 mg, 0.24 mmol) was added. After stirring for 5 min at 0 C
the mixture was concentrated in vacuo. The obtained residue was purified by HPLC
(MeCN/H20 with 0.1% TFA) to yield (S)-5-((((2'-chloro-3-fluoro-5-methoxy-2"-methy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-yl)methyl)amino)methyl)pyrrolidin-2-one (TFA salt). 1H NMR (400 MHz, CD30D) 8 9.01 (d, J= 2.0 Hz, 1H), 8.86 (d, J
= 2.0 Hz, 1H), 8.14 (d, J= 5.6 Hz, 1H), 8.03 (d, J= 7.2, 1H), 7.50-7.40 (m, 2H), 7.40-7.32 (m, 2H), 7.20
165 (d, J= 6.0 Hz, 1H), 7.05 (d, J= 6.8 Hz, 1H), 6.91 (s, 1H), 6.83 (dd, J= 10.0, 1.6 Hz, 1H), 3.91 (s, 3H), 3.90 (s, 2H), 3.88-3.78 (m, 1H), 2.73-2.60 (m, 2H), 2.38-2.20 (m, 3H), 2.13 (s, 3H), 1.82-1.70 (m, 1H). MS: (ES) m/z calculated C33H3iC1FN602 [M + H]+ 597.2, found 597.2.
Example 168: (S)-4-4(2'-chloro-3-fluoro-5-methoxy-2"-methyl-3"-(pyrido13,4-blpyrazin-5-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)pyrrolidin-2-one OMe NH
CHO

N 1)LN
H
Me NaBH(OAc)3 0 OMe NH
CI
N(N
H
Me [0316] A mixture of 2'-chloro-3-fluoro-5-methoxy-2"-methyl-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde (26 mg, 0.052 mmol), (S)-4-aminopyrrolidin-2-one (15 mg, 0.15 mmol) and HOAc (75 mg, 1.25 mmol) in Et0H (1.5 mL) was heated at 70 C
for 0.5 h. The mixture was cooled to 0 C and NaBH(OAc)3 (45 mg, 0.21 mmol) was added.
After stirring for 5 min at 0 C the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to yield (S)-4-(((2'-chloro-3-fluoro-5-methoxy-2"-methyl-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-yl)methyl)amino)pyrrolidin-2-one (TFA salt). ITINMR (400 MHz, CD30D) 8 9.24 (d, J= 2.0 Hz, 1H), 9.05 (d, J= 2.0 Hz, 1H), 7.79 (d, J= 7.2 Hz, 1H), 7.63 (dd, J= 7.9, 1.4 Hz, 1H), 7.58-7.51 (m, 2H), 7.48 (dd, J= 7.7, 1.9 Hz, 1H), 7.44-7.37 (m, 3H), 7.05 (s, 1H), 6.90 (dd, J= 10.4, 1.2 Hz, 1H), 4.37 (s, 2H), 4.28-4.20 (m, 1H), 4.00 (s, 3H), 3.86-3.83 (m, 1H), 3.58 (dd, J= 11.6, 3.6 Hz, 1H), 2.94-2.86 (m, 1H), 2.57 (dd, J= 18.0, 4.8 Hz, 1H), 2.15 (s, 3H).
MS: (ES) m/z calculated C32H29C1FN602 [M + 583.2, found 583.2.
Example 169: (3R,4R)-4-0(2'-chloro-3-fluoro-5-methoxy-2"-methyl-3"-(pyrido13,4-b] pyrazin-5-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)tetrahydro-2H-pyran-3-ol
166 OMe \µ' -CI OH
N -YLN NaBH(OAc)3 LN H
Me OMe CI
z NYLN H OH
H
Me [0317] A mixture of 2'-chloro-3-fluoro-5-methoxy-2"-methy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde (20 mg, 0.04 mmol), (3R,4R)-4-aminotetrahydro-2H-pyran-3-ol (13 mg, 0.085 mmol), Et3N (15 mg, 0.15 mmol) and HOAc (90 mg, 1.5 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C
and NaBH(OAc)3 (45 mg, 0.21 mmol) was added. After stirring for 5 min at 0 C and mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to yield (3R,4R)-4-(((2'-chloro-3-fluoro-5-methoxy-2"-methy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-yl)methyl)amino)tetrahydro-2H-pyran-3-ol (TFA salt).
1-EINMR (400 MHz, CD30D) 6 9.24 (d, J= 2.0 Hz, 1H), 9.05 (d, J= 2.0 Hz, 1H), 7.78 (d, J=
7.2 Hz, 1H), 7.63 (d, J= 7.2, 1.4 Hz, 1H), 7.58-7.51 (m, 2H), 7.48 (dd, J= 7.6, 2.0 Hz, 1H), 7.43-7.37 (m, 3H), 7.03 (s, 1H), 6.98 (dd, J= 9.6 Hz, 1H), 4.41 (d, J= 13.6 Hz, 1H), 4.32 (d, J=
13.2 Hz, 1H), 4.08 (s, 3H), 4.10-3.94 (m, 3H), 3.60-3.40 (m, 3H), 2.15 (s, 3H), 2.20-2.00 (m, 1H), 1.95-1.91 (m, 1H). MS: (ES) m/z calculated C33H31C1FN502 [M ¨ OH, + H]+ 583.2, found 583.1.
Example 170: (S)-N-(2,2'-dichloro-3"-fluoro-5"-methoxy-4"-((((5-oxopyrrolidin-yl)methyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
167 OMe CHO
CI
OMe CHO

Me, (I:?
NN Br ____________________ )1'KlieLN
CI Pd(dpp9C12(CH2C12) Me K2CO3 0 N 0 MI e Step a OMe H2N NCto 0 CI rc.s.1 0 ______________________ )1. Me,N)LN
NaBH3CN
CI

Step b Me [0318] Step a: A mixture of 2'-chloro-3-fluoro-5-methoxy-3'-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)41,1'-bipheny1]-4-carbaldehyde (110 mg, 0.28 mmol), N-(3-bromo-2-chloropheny1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (110 mg, 0.30 mmol), K2CO3 (116 mg, 0.84 mmol) and Pd(dppf)C12 complex with dichloromethane (45 mg, 0.055 mmol) in dioxane (3 mL) and water (0.45 mL) was stirred under N2 at 95 C for 3 h.
The mixture was cooled to room temperature and purified by silica gel flash chromatography (0 to 100% Et0Ac/hexanes) to afford N-(2,2'-dichloro-3"-fluoro-4"-formy1-5"-methoxy-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide. MS: (ES) m/z calculated for C27H21C12FN305 [M + H]+ 556.1, found 556Ø
[0319] Step b: A mixture of N-(2,2'-dichloro-3"-fluoro-4"-formy1-5"-methoxy-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (20 mg, 0.036 mmol), (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride (12 mg, 0.080 mmol), Et3N
(15 mg, 0.15 mmol) and HOAc (90 mg, 1.5 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C and NaBH3CN (45 mg, 0.71 mmol) was added.
After stirring for 3 min at 0 C and mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to give (S)-N-(2,2'-dichloro-3"-fluoro-5"-methoxy-4"-((((5-oxopyrrolidin-2-yl)methyl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA salt). 1H NMIR (400 MHz, CD30D) ö 11.57 (s, 1H), 8.54 (s, 1H), 8.42 (d, J= 8.4 Hz, 1H), 7.42-7.35 (m, 2H), 7.32-7.24 (m, 2H), 7.00-6.93
168 (m, 2H), 6.88 (d, J= 9.6 Hz, 1H), 4.29 (s, 2H), 3.98-3.90 (m, 1H), 3.90 (s, 3H), 3.44 (s, 3H), 3.27 (s, 3H), 3.20-3.12 (m, 2H), 2.36-2.20 (m, 3H), 2.07-1.95 (m, 1H). MS:
(ES) m/z calculated C32H31C12FN502 [M + H]+ 654.0, found 654Ø
Example 171: (3R,4R)-4-0(3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido13,4-blpyrazin-5-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)tetrahydro-2H-pyran-3-ol OMe H2Nµ
ri CHO
Me OH
NN NaBH(OAc)3 LN H
Me OMe Me H
OH
H
Me [0320] A mixture of 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde (20 mg, 0.041 mmol), (3R,4R)-4-aminotetrahydro-2H-pyran-3-ol (10 mg, 0.065 mmol), Et3N (15 mg, 0.15 mmol) and HOAc (75 mg, 1.25 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C
and NaBH(OAc)3 (45 mg, 0.21 mmol) was added. After stirring for 5 min at 0 C and mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to yield (3R,4R)-44(3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-y1)methyl)amino)tetrahydro-2H-pyran-3-ol (TFA salt). 1-EINMR (400 MHz, CD30D) 5 9.23 (d, J= 1.6 Hz, 1H), 9.04 (s, 1H), 7.80 (d, J= 7.2 Hz, 1H), 7.60 (d, J= 7.2 Hz, 1H), 7.52 (t, J= 7.6, 2.0 Hz, 1H), 7.40-7.33 (m, 3H), 7.28 (d, J= 7.2 Hz, 1H), 7.23 (d, J= 7.2 Hz, 1H), 6.92 (s, 1H), 6.86 (d, J= 10 Hz, 1H), 4.41 (d, J=13.2 Hz, 1H), 4.31 (d, J= 12.8 Hz, 1H), 4.07 (s, 1H), 3.98 (s, 5H), 3.57 (d, J= 12.4 Hz, 1H), 3.60-3.42 (m, 2H), 2.20-2.04 (m, 1H), 2.12 (s, 3H), 2.02 (s, 3H), 1.86-1.80 (m, 1H). MS: (ES) m/z calculated C34H35FN503 [M +
580.3, found 580.2.
Example 172: (3R,4R)-4-0(3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido13,4-blpyrazin-8-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)tetrahydro-2H-pyran-3-ol
169 OMe CHO
\O Me 0"
H2N el Br Me NrBr Pd2(dba)3, BINAP Br NrN
Pd(dppf)C12(CH2C12) H
NaOtBu Me Step a Step b OMe Me OH
NrN NaBH(OAc)3 LN H
Me LJ Step c OMe Me -NN H OH
H
Me [0321] Step a: A mixture of 8-bromopyrido[3,4-b]pyrazine (450 mg, 2.14 mmol), 3-bromo-2-methylaniline (437 mg, 2.35 mmol), NaOtBu (514 mg, 5.35 mmol), Pd2(dba)3 (195 mg, 0.21 mmol) and racemic BINAP (266 mg, 0.43 mmol) in toluene (8 mL) was stirred under N2 at 100 C for 4 h. The mixture was cooled to room temperature and purified by silica gel flash chromatography (0 to 100% Et0Ac in hexanes) to afford N-(3-bromo-2-methylphenyl)pyrido[3,4-b]pyrazin-8-amine. MS: (ES) m/z calculated for Ci4Hi2BrN4 [M + H]+
315.0, found 315Ø
[0322] Step b: A mixture of N-(3-bromo-2-methylphenyl)pyrido[3,4-b]pyrazin-8-amine (480 mg, 1.52 mmol), 3-fluoro-5-methoxy-2'-methy1-3'-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)-[1,1'-biphenyl]-4-carbaldehyde (540 mg, 1.45 mmol), K2CO3 (600 mg, 4.35 mmol) and Pd(dppf)C12 complex with dichloromethane (142 mg, 0.17 mmol) in dioxane (7 mL) and water (1.0 mL) was stirred under N2 at 95 C for 1.5 h. The mixture was cooled to room temperature and purified by silica gel flash chromatography (0 to 100% Et0Ac/hexanes) to afford 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-8-ylamino)41,1':3',1"-terphenyl]-4-carbaldehyde.
170 [0323] Step c: A mixture of 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-8-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde (25 mg, 0.051 mmol), (3R,4R)-4-aminotetrahydro-2H-pyran-3-ol (12 mg, 0.078 mmol), Et3N (15 mg, 0.15 mmol) and HOAc (75 mg, 1.25 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C and NaBH(OAc)3 (45 mg, 0.21 mmol) was added. After stirring for 5 min at 0 C and mixture was concentrated in vacuo. The obtained residue was purified by HPLC
(MeCN/H20 with 0.1% TFA) followed by silica gel flash chromatography (0 to 100% Me0H in DCM) to yield (3R,4R)-4-(((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-8-ylamino)-[1,1':3',1"-terpheny1]-4-yl)methyl)amino)tetrahydro-2H-pyran-3-ol (TFA salt).
1-HNIVIR (400 MHz, CD30D) 8 9.04 (s, 2H), 8.74 (s, 1H), 7.94 (s, 1H), 7.46 (d, J= 8.4 Hz, 1H), 7.40-7.28 (m, 2H), 7.23 (d, J= 7.2 Hz, 1H), 7.17 (d, J= 7.6 Hz, 1H), 7.08 (d, J= 7.6 Hz, 1H), 6.81 (s, 1H), 6.74 (d, J= 10.4 Hz, 1H), 3.91 (s, 3H), 4.06-3.82 (m, 5H), 3.54-3.38 (m, 2H), 2.96 (d, J= 10.4 Hz, 1H), 2.03 (s, 3H), 1.98 (s, 3H), 1.94-1.82 (m, 1H), 1.72 (d, J= 12.4 Hz, 1H). MS: (ES) m/z calculated C34H35FN503 [M + H]+ 580.3, found 580.2.
Example 173: (S)-5-(43-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido13,4-blpyrazin-8-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)piperidin-2-one OMe ifl CHO
Me H2NNH
NN NaBH(OAc)3 I
H
Me OMe Me rN NH
NrN
H Me [0324] A mixture of 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-8-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde (25 mg, 0.052 mmol), (S)-5-aminopiperidin-2-one (15 mg, 0.10 mmol) and HOAc (60 mg, 1.0 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C and NaBH(OAc)3 (45 mg, 0.21 mmol) was added. After stirring for 5 min at 0 C the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) followed by silica gel flash chromatography (0 to 100%
171 Me0H in DCM) to yield (S)-54(3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-8-ylamino)41,1':3',1"-terphenyl]-4-y1)methyl)amino)piperidin-2-one (TFA salt).
IENMR (400 MHz, CD30D) ö 9.03 (s, 2H), 8.74 (s, 1H), 7.94 (s, 1H), 7.45 (d, J= 8.0 Hz, 1H), 7.40-7.28 (m, 2H), 7.23 (d, J= 6.8 Hz, 1H), 7.16 (d, J= 7.6 Hz, 1H), 7.08 (d, J= 8.0 Hz, 1H), 6.80 (s, 1H), 6.73 (d, J=10.0 Hz, 1H), 3.96 (s, 2H), 3.91 (s, 3H), 3.51 (dd, J= 12.4, 3.6 Hz, 1H), 3.20-3.10 (m, 1H), 3.04 (bs, 1H), 2.50-2.40 (m, 1H), 2.38-2.27 (m, 1H), 2.13-2.03 (m, 1H), 2.03 (s, 3H), 1.98 (s, 3H), 1.86-1.74 (m, 1H). MS: (ES) m/z calculated C34H34FN602 [M +
H]577.3, found 577.2.
Example 174: (S)-4-(((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido13,4-blpyrazin-8-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)pyrrolidin-2-one OMe ri NH

Me NN NaBH(OAc)3 0 H
Me OMe idN
I Me H
NNJF
H
Me [0325] A mixture of 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-8-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde (25 mg, 0.052 mmol), (S)-5-aminopiperidin-2-one (15 mg, 0.10 mmol) and HOAc (45 mg, 0.75 mmol) in Et0H (1.5 mL) was heated at 70 C
for 0.5 h.
The mixture was cooled to 0 C and NaBH(OAc)3(45 mg, 0.21 mmol) was added.
After stirring for 5 min at 0 C the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) followed by silica gel flash chromatography (0 to 100%
Me0H in DCM) to yield (S)-44(3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-8-ylamino)41,1':3',1"-terphenyl]-4-y1)methyl)amino)pyrrolidin-2-one (TFA salt).
IENMR (400 MHz, CD30D) 8 9.03 (s, 2H), 8.73 (s, 1H), 7.94 (s, 1H), 7.45 (d, J= 8.0 Hz, 1H), 7.40-7.28 (m, 2H), 7.23 (d, J= 7.2 Hz, 1H), 7.16 (d, J= 7.6 Hz, 1H), 7.08 (d, J= 7.6 Hz, 1H), 6.80 (s, 1H), 6.73 (d, J= 9.6 Hz, 1H), 3.92 (s, 2H), 3.90 (s, 3H), 3.70-3.58 (m, 2H), 3.30-3.23 (m, 1H), 2.65-
172 2.56 (m, 1H), 2.24 (dd, J= 17.2, 4.8 Hz, 1H), 2.03 (s, 3H), 1.98 (s, 3H). MS:
(ES) m/z calculated C33H32FN602 [M + H]+ 563.3, found 563.3.
Example 175: (S)-5-(0(3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-blpyrazin-8-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)methyl)pyrrolidin-2-one OMe H2N :5 .!_ Me CHO
I
NrN NaBH(OAc)3 1 LN H
Me OMe I Me HN
NN
H
Me [0326] A mixture of 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-8-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde (30 mg, 0.065 mmol), (S)-5-(aminomethyl)pyrrolidin-2-one hydrochloride (15 mg, 0.15 mmol), Et3N (15 mg, 0.15 mmol) and HOAc (75 mg, 1.25 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C
and NaBH(OAc)3 (45 mg, 0.21 mmol) was added. After stirring for 5 min at 0 C the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) followed by silica gel flash chromatography (0 to 100% Me0H in DCM) to yield (S)-5-((((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-8-ylamino)-[1,1':3',1"-terpheny1]-4-yl)methyl)amino)methyl)pyrrolidin-2-one (TFA salt). 1-EINMR (400 MHz, CD30D) ö
9.04 (s, 1H), 8.74 (s, 1H), 7.94 (s, 1H), 7.46 (d, J= 8.4 Hz, 1H), 7.40-7.29 (m, 2H), 7.23 (d, J= 7.2 Hz, 1H), 7.18 (d, J= 6.8 Hz, 1H), 7.08 (d, J= 7.6 Hz, 1H), 6.84 (s, 1H), 6.77 (d, J= 9.6 Hz, 1H), 5.48 (s, 1H), 4.08 (s, 2H), 3.93 (s, 3H), 3.94-3.89 (m, 1H), 2.94-2.82 (m, 2H), 2.40-2.25 (m, 3H), 2.03 (s, 3H), 1.99 (s, 3H), 1.94-1.88 (m, 1H). MS: (ES) m/z calculated C34H34FN602 [M +
H]' 577.3, found 577.2.
Example 176: N-(3"-fluoro-4"-(0(3R,4S)-4-hydroxytetrahydrofuran-3-yl)amino)methyl)-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
173 OMe 0 Me CHO H2Nµ
MN'j(N OH
0 N 0 e NaBH3CN I
M
MIe OMe 0 Me N
OH
0 N 0 Me Me [0327] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (25 mg, 0.048 mmol), (3S,4R)-4-aminotetrahydrofuran-3-ol (20 mg, 0.020 mmol) and HOAc (75 mg, 1.25 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C
and NaBH3CN
(40 mg, 0.63 mmol) was added. After stirring for 3 min at 0 C the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to give N-(3"-fluoro-4"-((((3R,4S)-4-hydroxytetrahydrofuran-3-yl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA salt). 1H NMR (400 MHz, CD30D) 11.14 (s, 1H), 8.61 (s, 1H), 8.07 (dd, J=
7.2, 7.2 Hz, 1H), 7.36-7.22 (m, 3H), 7.15 (d, J= 6.8 Hz, 1H), 6.98-6.92 (m, 2H), 6.87 (d, J
= 9.6 Hz, 1H), 4.53 (bs, 1H), 4.48-4.34 (m, 2H), 4.20-4.08 (m, 2H), 4.20-3.98 (m, 1H), 3.99 (s, 3H), 3.71 (s, 1H), 3.60 (dd, J= 9.6, 4 Hz, 1H), 3.54 (s, 3H), 3.37 (s, 3H), 2.09 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated C33H36FN406 [M + H]603.3, found 603.2.
Example 177: N-(4"-(((4-amino-4-oxobutyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide
174 OMe CHO 0 Me H2N.rNH2 MeõN).L 0 N N
Meft) NaBH3CN ___ Jr 0 N 0 OMe Me 0 Me irN
Me N õNj=L N F

Me LLJ
ONO
Me [0328] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (22 mg, 0.042 mmol), 4-aminobutanamide hydrochloride (15 mg, 0.11 mmol), Et3N (15 mg, 0.15 mmol) and HOAc (90 mg, 1.5 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C, and NaBH3CN (40 mg, 0.63 mmol) was added. After stirring for 5 min at 0 C
the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to yield N-(4"-(((4-amino-4-oxobutyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (TFA salt). 1H NMR (400 MHz, CD30D) ö 8.08 (d, J= 8.0 Hz, 1H), 7.36-7.28 (m, 2H), 7.25 (d, J = 8.0 Hz, 1H), 7.16 (d, J= 7.6 Hz, 1H), 7.02 (d, J= 7.2 Hz, 1H), 6.92 (s, 1H), 6.86 (d, J= 9.6 Hz, 1H), 4.31 (s, 2H), 3.98 (s, 3H), 3.77 (s, 3H), 3.38 (s, 3H), 3.15 (t, J = 7.0 Hz, 2H), 2.43 (t, J = 6.6 Hz, 2H), 2.11 (s, 3H), 2.03-1.94 (m, 2H), 1.94 (s, 3H). MS:
(ES) m/z calculated C32H36FN605 [M + H]603.3, found 603.2.
Example 178: N-(4"-(((3-amino-2,2-dimethy1-3-oxopropyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terphenyll-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide
175 OMe 0 Me (;CHO H2N
Me Me N N
Me NaBH3CN
0 N 0 OMe 0 Me 0 Me rY N

MeõN H
Me Me N N
0 N 0 Me iLJ
Me [0329] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (22 mg, 0.042 mmol), 3-amino-2,2-dimethylpropanamide (30 mg, 0.26 mmol) and HOAc (90 mg, 1.5 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C
and NaBH3CN
(40 mg, 0.63 mmol) was added. After stirring for 5 min at 0 C the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) followed by silica gel flash chromatography (0 to 100% Me0H in DCM) to yield N-(4"-(((3-amino-2,2-dimethy1-3-oxopropyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (TFA salt). 1H
NMR (400 MHz, CD30D) 6 8.09 (d, J= 8.4 Hz, 1H), 7.36-7.27 (m, 2H), 7.24 (d, J=
8.0 Hz, 1H), 7.12 (d, J= 7.6 Hz, 1H), 7.01 (d, J= 7.2 Hz, 1H), 6.80 (s, 1H), 6.72 (d, J= 9.6 Hz, 1H), 3.93 (s, 2H), 3.91 (s, 3H), 3.77 (s, 3H), 3.37 (s, 3H), 2.70 (s, 2H), 2.12 (s, 3H), 1.93 (s, 3H), 1.18 (s, 6H). MS: (ES) m/z calculated C33H38FN605 [M + H]617.3, found 617.3.
Example 179: N-(4"-(((2-amino-2-oxoethyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide
176 OMe 0 Me CHO H2Nõ---y0 Me,N,N)LN
NaBH3CN
0 N 0 Me OMe Me 0 Me N

H I
Me,N,N).L N NH2 Me ONO
Me [0330] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (23 mg, 0.044 mmol), 2-aminoacetamide hydrochloride (30 mg, 0.27 mmol), Et3N (20 mg, 0.20 mmol) and HOAc (120 mg, 2.0 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C, and NaBH3CN (40 mg, 0.63 mmol) was added. After stirring for 5 min at 0 C
and the mixture was concentrated in vacuo. The obtained residue was purified by HPLC
(MeCN/H20 with 0.1% TFA) to yield N-(4"-(((2-amino-2-oxoethyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (TFA salt). 1H NMIR (400 MHz, CD30D) 6 11.08 (s, 1H), 8.07 (t, J = 7.6 Hz, 1H), 7.38-7.28 (m, 2H), 7.25 (d, J = 8.4 Hz, 1H), 7.16 (d, J= 8.0 Hz, 1H), 7.02 (d, J
= 7.2 Hz, 1H), 6.93 (s, 1H), 6.87 (d, J = 10.0 Hz, 1H), 4.38 (s, 2H), 3.98 (s, 3H), 3.82 (s, 2H), 3.78 (s, 3H), 3.38 (s, 3H), 2.12 (s, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated C30H32FN605 [M
+H]P 575.2, found 575.1.
Example 180: N-(3"-fluoro-4"-((isopropylamino)methyl)-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide
177 OMe Me 0 Me CHO
MeõN H2N Me N N
NaBH3CN
Me OMe Me Me 0 Me NMe Me õN
N N
LS LL F H
0 N 0 Me Me [0331] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (23 mg, 0.044 mmol), propan-2-amine (60 mg, 1.0 mmol) and HOAc (120 mg, 2.0 mmol) in Et0H
(1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C and NaBH3CN (40 mg, 0.63 mmol) was added. After stirring for 5 min at 0 C the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to yield N-(3"-fluoro-4"-((isopropylamino)methyl)-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (TFA salt). 1H NMIR
(400 MHz, CD30D) 8.08 (d, J= 8.0 Hz, 1H), 7.37-7.27(m, 2H), 7.24 (d, J= 7.6 Hz, 1H), 7.15 (d, J= 7.6 Hz, 1H), 7.01 (d, J= 7.2 Hz, 1H), 6.92 (s, 1H), 6.86 (d, J= 10.0 Hz, 1H), 4.30 (s, 2H), 3.98 (s, 3H), 3.77 (s, 3H), 3.50 (m, 1H), 3.38 (s, 3H), 2.11 (s, 3H), 1.93 (s, 3H), 1.43 (s, 3H), 1.41 (s, 3H). MS: (ES) m/z calculated C31H35FN504 [M + H]+ 560.3, found 560.2.
Example 181: N-(3"-fluoro-4"-((((3S,4R)-4-hydroxytetrahydrofuran-3-yl)amino)methyl)-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terpheny11-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
178 OMe 0 Me H2NeL:5 CHO
Me ,N OH
0 N 0 Me NaBH3CN I
OMe /0\
Me 0 Me H OH
Me,N )LN
0 N 0 Me Me [0332] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (25 mg, 0.048 mmol), (3R,4S)-4-aminotetrahydrofuran-3-ol (15 mg, 0.015 mmol) and HOAc (60 mg, 1.0 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C
and NaBH3CN
(45 mg, 0.71 mmol) was added. After stirring for 3 min at 0 C the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to yield N-(3"-fluoro-4"-((((3S,4R)-4-hydroxytetrahydrofuran-3-yl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA salt). 1-EINMR (400 MHz, CD30D) 6 11.15 (s, 1H), 8.61 (s, 1H), 8.07 (t, J =
7.2 Hz, 1H), 7.36-7.22 (m, 3H), 7.15 (d, J = 6.8 Hz, 1H), 6.98-6.92 (m, 2H), 6.87 (d, J= 9.6 Hz, 1H), 4.53 (bs, 1H), 4.48-4.34 (m, 2H), 4.20-4.08 (m, 2H), 4.02-3.98 (m, 1H), 3.99 (s, 3H), 3.71 (s, 1H), 3.60 (dd, J= 9.6, 4.4 Hz, 1H), 3.54 (s, 3H), 3.37 (s, 3H), 2.09 (s, 3H), 1.93 (s, 3H). MS:
(ES) m/z calculated C33H36FN406 [M + H]+ 603.2, found 603.2.
Example 182: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyl(5-oxopyrrolidin-3-y1)amino)methyl)-11,1':3',1"-terphenyll-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
179 HN)LN

Br OM e 0 N 0 Me iedNH Me \C) Me Pd(dpp1)C12(CH2C12) 0-B F Me OMe v6H
0 Me Me HN
Me ftJ
Me [0333] A mixture of (S)-44(3-fluoro-5-methoxy-2'-methy1-3'-(4,4,5,5-tetramethy1-1,3,2-dioxaborolan-2-y1)41,1'-biphenyl]-4-yl)methyl)(methyl)amino)pyrrolidin-2-one (40 mg, 0.085 mmol), N-(3-bromo-2-methylpheny1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (29 mg, 0.085 mmol), K2CO3 (41 mg, 0.30 mmol) and Pd(dppf)C12 complex with dichloromethane (25 mg, 0.030 mmol) in dioxane (2 mL) and water (0.30 mL) was stirred under N2 at 95 C for 4 h. The mixture was cooled to room temperature and purified by silica gel flash chromatography (0 to 100% Me0H in DCM) follwed by HPLC (MeCN/H20 with 0.1%
TFA) to yield (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-((methyl(5-oxopyrrolidin-3-y1)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA salt). 1H NMIR (400 MHz, CD30D) 5 11.15 (s, 1H), 8.41 (s, 1H), 8.05 (d, J
= 8.0 Hz, 1H), 7.38-7.22 (m, 3H), 7.16 (d, J= 8.0 Hz, 1H), 6.98 (s, 1H), 6.96-6.90 (m, 2H), 4.50-4.32 (m, 3H), 4.00 (s, 3H), 3.92 (bs, 1H), 3.78-3.71 (m, 1H), 3.35 (s, 3H), 2.94-2.88 (m, 1H), 2.90 (s, 3H), 2.78 (dd, J= 17.2, 6.0 Hz, 1H), 2.10 (s, 3H), 1.94 (s, 3H).
MS: (ES) m/z calculated C33H35FN505 [M + H]+ 600.3, found 600.2.
Example 183: N-(3"-fluoro-4"-((((3R,4S)-4-hydroxytetrahydrofuran-3-yl)amino)methyl)-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
180 ro, OMe CHO
0 Me H2Nµµ.
OH
HN
Me NaBH3CN I

OMe Me 0 Me Nes.CC:) HN ).LN F
OH
0 N 0 Me Me [0334] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (23 mg, 0.046 mmol), (3S,4R)-4-aminotetrahydrofuran-3-ol (12 mg, 0.012 mmol) and HOAc (60 mg, 1.0 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C
and NaBH3CN
(45 mg, 0.71 mmol) was added. After stirring for 3 min at 0 C the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to yield N-(3"-fluoro-4"-((((3R,4S)-4-hydroxytetrahydrofuran-3-yl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA salt). 1-EINMR (400 MHz, CD30D) 6 11.13 (s, 1H), 8.40 (s, 1H), 8.06 (t, J =
7.2 Hz, 1H), 7.35-7.22 (m, 3H), 7.14 (d, J = 7.2 Hz, 1H), 6.98-6.92 (m, 2H), 6.87 (d, J= 10.4 Hz, 1H), 4.53 (bs, 1H), 4.48-4.34 (m, 2H), 4.19-4.08 (m, 2H), 4.20-3.97 (m, 1H), 3.99 (s, 3H), 3.71 (s, 1H), 3.60 (dd, J = 9.6, 4.0 Hz, 1H), 3.34 (s, 3H), 2.09 (s, 3H), 1.93 (s, 3H). MS: (ES) .. m/z calculated C32H34FN406 [M + H]589.3, found 589.3.
Example 184: N-(3"-fluoro-4"-((((3S,4R)-4-hydroxytetrahydrofuran-3-yl)amino)methyl)-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terpheny11-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
181 OMe CHO
0 Me H2N
oH
HNN
NaBH3CN
Me ie OMe M
0 Me H OH
HNLN
0 N 0 Me Me [0335] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (23 mg, 0.046 mmol), (3R,4S)-4-aminotetrahydrofuran-3-ol (12 mg, 0.012 mmol) and HOAc (60 mg, 1.0 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C
and NaBH3CN
(45 mg, 0.71 mmol) was added. After stirring for 3 min at 0 C the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to yield N-(3"-fluoro-4"-((((3S,4R)-4-hydroxytetrahydrofuran-3-yl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA salt). 1-EINMR (400 MHz, CD30D) 6 11.13 (s, 1H), 8.40 (s, 1H), 8.06 (t, J=
7.4 Hz, 1H), 7.35-7.22 (m, 3H), 7.14 (d, J= 7.2 Hz, 1H), 6.98-6.91 (m, 2H), 6.87 (d, J= 10 Hz, 1H), 4.54 (bs, 1H), 4.48-4.34 (m, 2H), 4.19-4.08 (m, 2H), 4.20-3.97 (m, 1H), 3.99 (s, 3H), 3.71 (bs, 1H), 3.60 (dd, J= 10, 4.4 Hz, 1H), 3.33 (s, 3H), 2.08 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated C32H34FN406 [M + H]+ 589.2, found 589.2.
Example 185: N-(4"-(((4-amino-4-oxobutyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
182 OMe 0 Me Me,N )*LN
Me NaBH3CN
Me 0 N 0 OMe N 0 Me Me,NLN F

Me LtJ
Me [0336] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (28 mg, 0.054 mmol), 4-aminobutanamide hydrochloride (15 mg, 0.11 mmol), Et3N (15 mg, 0.15 mmol) and HOAc (90 mg, 1.5 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C
and NaBH3CN (45 mg, 0.71 mmol) was added. After stirring for 5 min at 0 C the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1%
TFA) to yield N-(4"-(((4-amino-4-oxobutyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA salt). 1H NMR (400 MHz, CD30D) 8 11.15 (s, 1H), 8.61 (s, 1H), 8.07 (t, J=
7.2 Hz, 1H), 7.36-7.22 (m, 3H), 7.15 (d, J= 7.6 Hz, 1H), 6.96 (d, J= 7.6 Hz, 1H), 6.92 (s, 1H), 6.85 (d, J=
10 Hz, 1H), 4.31 (s, 2H), 3.98 (s, 3H), 3.54 (s, 3H), 3.37 (s, 3H), 3.15 (t, J= 5.8 Hz, 2H), 2.43 (t, J= 6.6 Hz, 2H), 2.09 (s, 3H), 2.03-1.94 (m, 2H), 1.93 (s, 3H). MS: (ES) m/z calculated C33H37FN505 [M + H]602.3, found 602.2.
Example 186: N-(4"-(44-amino-4-oxobutyl)aminOmethyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terpheny11-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
183 OMe 0 Me 2N

HN'LN H
0 N 0 Me NaBH3CN
OMe Me Me N
rNH2 0 N 0 Me Me [0337] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (25 mg, 0.050 mmol), 4-aminobutanamide hydrochloride (15 mg, 0.11 mmol), Et3N (15 mg, 0.15 mmol) and HOAc (90 mg, 1.5 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C
and NaBH3CN (45 mg, 0.71 mmol) was added. After stirring for 5 min at 0 C the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1%
TFA) to yield N-(4"-(((4-amino-4-oxobutyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA salt). 1H NMR (400 MHz, CD30D) 8 11.14 (s, 1H), 8.41 (s, 1H), 8.06 (t, J=
7.4 Hz, 1H), 7.36-7.22 (m, 3H), 7.15 (d, J= 6.8 Hz, 1H), 6.96 (d, J= 7.6 Hz, 1H), 6.92 (s, 1H), 6.86 (d, J=
10.0 Hz, 1H), 4.31 (s, 2H), 3.98 (s, 3H), 3.35 (s, 3H), 3.16 (t, J= 7.0 Hz, 2H), 2.44 (t, J= 6.6 Hz, 2H), 2.09 (s, 3H), 2.04-1.94 (m, 2H), 1.93 (s, 3H). MS: (ES) m/z calculated C32H35FN505 [M +
H]+ 588.3, found 588.2.
Example 187: N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((2-(2-oxopyrrolidin-1-yl)ethyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide
184 OMe CHO
0 Me MeõN

Me NaBH3CN I

Me OMe 0 Me N
Me õN
N N
0 N 0 Me Me [0338] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-2,4-dimethyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (10 mg, 0.019 mmol), 1-(2-aminoethyl)pyrrolidin-2-one (25 mg, 0.020 mmol) and HOAc (75 mg, 1.25 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C
and NaBH3CN
(40 mg, 0.63 mmol) was added. After stirring for 5 min at 0 C the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to yield N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"4(2-(2-oxopyrrolidin-1-y1)ethyl)amino)methyl)-[1,1':3',1"-terpheny1]-3-y1)-2,4-dimethy1-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (TFA salt). 1H NMR (400 MHz, CD30D) 6 11.08 (s, 1H), 8.07 (t, J=
7.8 Hz, 1H), 7.38-7.28 (m, 2H), 7.25 (d, J = 7.6 Hz, 1H), 7.16 (d, J= 7.6 Hz, 1H), 7.02 (d, J= 7.2 Hz, 1H), 6.93 (s, 1H), 6.87 (d, J= 10.0 Hz, 1H), 4.39 (s, 2H), 3.99 (s, 3H), 3.78 (s, 3H), 3.65 (t, J= 5.6 Hz, 2H), 3.52 (t, J= 7.2 Hz, 2H), 3.39 (s, 3H), 3.35-3.30 (m, 2H), 2.46-2.37 (m, 2H), 2.12 (s, 3H), 2.15-2.06 (m, 2H), 1.94 (s, 3H). MS: (ES) m/z calculated C34H38FN605 [M +
H]629.3, found 629.2.
Example 188: N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((2-(2-oxopyrrolidin-1-yl)ethyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide
185 OMe Me CHO

N*LN
kN0 H NaBH(OAc)3 Me OMe Me 0 Me N
kN0 H
Me Me [0339] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide (30 mg, 0.061 mmol), 1-(2-aminoethyl)pyrrolidin-2-one (30 mg, 0.024 mmol) and HOAc (75 mg, 1.25 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C and NaBH(OAc)3 (50 mg, 0.23 mmol) was added. After stirring for 5 min at 0 C the mixture was concentrated in vacuo.
The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to yield N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((2-(2-oxopyrrolidin-1-ypethyl)amino)methyl)-[1,1':3',1"-terpheny1]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide (TFA
salt). ITINMR
(400 MHz, CD30D) 8 11.41 (s, 1H), 8.92 (s, 1H), 8.67 (s, 1H), 8.12 (t, J= 7.4 Hz, 1H), 7.37-7.23 (m, 3H), 7.16 (d, J= 8.0 Hz, 1H), 6.99 (d, J= 7.6 Hz, 1H), 6.94 (s, 1H), 6.88 (d, J=10Hz, 1H), 4.39 (s, 2H), 3.99 (s, 3H), 3.66 (s, 3H), 3.67-3.62 (m, 2H), 3.52 (t, J=
7.0 Hz, 2H), 3.36-3.30 (m, 2H), 2.42 (t, J= 8.2 Hz, 2H), 2.12 (s, 3H), 2.15-2.04 (m, 2H), 1.94 (s, 3H). MS: (ES) m/z calculated C34H37FN504 [M + H]598.3, found 598.2.
Example 189: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((2-(5-oxopyrrolidin-2-yl)ethyl)amino)methyl)-11,1':3',1"-terphenyll-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
186 OMe -oe-10 CHO
0 Me Me ,N
0 N 0 Me NaBH3CN I

OMe -oeid Me 0 Me Me,N )=LN
0 N 0 Me Me [0340] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (25 mg, 0.048 mmol), (S)-5-(2-aminoethyl)pyrrolidin-2-one hydrochloride (15 mg, 0.091 mmol), Et3N
(15 mg, 0.15 mmol) and HOAc (90 mg, 1.5 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C and NaBH3CN (50 mg, 0.78 mmol) was added. After stirring for 5 min at 0 C the mixture was concentrated in vacuo. The obtained residue was purified by silica gel flash chromatography (0 to 100% Me0H in DCM) followed by HPLC (MeCN/H20 with 0.1% TFA) to yield (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"4(2-(5-oxopyrrolidin-2-y1)ethyl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA salt). 1H NMIR (400 M1Hz,CD30D) 8 11.16 (s, 1H), 8.62 (s, 1H), 8.07 (t, J= 7.4 Hz, 1H), 7.36-7.22 (m, 3H), 7.16 (d, J= 7.6 Hz, 1H), 6.98-6.92 (m, 2H), 6.88 (d, J= 10.0 Hz, 1H), 4.34 (s, 2H), 3.98 (s, 3H), 3.80-3.72 (m, 1H), 3.55 (s, 3H), 3.38 (s, 3H), 3.24-3.10 (m, 2H), 2.40-2.30 (m, 2H), 2.09 (s, 3H), 2.00-1.90 (m, 3H), 1.94 (s, 3H), 1.84-1.74 (m, 1H). MS: (ES) m/z calculated C35H39FN505 [M + H]628.3, found 628.2.
Example 190: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((2-(5-oxopyrrolidin-2-yl)ethyl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
187 OMe CHO
0 Me HN .L N
NaBH3CN I
0 N 0 Me Me OMe ;ON
0 Me 0 N 0 Me Me [0341] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (25 mg, 0.050 mmol), (5)-5-(2-aminoethyl)pyrrolidin-2-one hydrochloride (15 mg, 0.091 mmol), Et3N (15 mg, 0.15 mmol) and HOAc (90 mg, 1.5 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C and NaBH3CN (50 mg, 0.78 mmol) was added. After stirring for 5 min at 0 C
the mixture was concentrated in vacuo. The obtained residue was purified by HPLC
(MeCN/H20 with 0.1% TFA) followed by silica gel flash chromatography (0 to 100% Me0H in DCM) to yield (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"#(2-(5-oxopyrrolidin-yl)ethyl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA salt). 1-HNMR (400 MHz, CD30D) 8 8.42 (s, 1H), 8.07 (dd, J= 8.0, 1.2 Hz, 1H), 7.34-7.22 (m, 3H), 7.14 (dd, J= 7.2, 1.2 Hz, 1H), 6.95 (dd, J =
8.0, 1.2 Hz, 1H), 6.88 (s, 1H), 6.81 (dd, J= 9.6, 1.6 Hz, 1H), 4.17 (s, 2H), 3.95 (s, 3H), 3.78-3.70 (m, 1H), 3.34 (s, 3H), 3.05-2.94 (m, 2H), 2.37-2.26 (m, 3H), 2.09 (s, 3H), 1.93 (s, 3H), 1.92-1.72 (m, 3H). MS: (ES) m/z calculated C34H37FN505 [M + H]614.3, found 614.2.
Example 191: N-(4"-(((3-amino-3-oxopropyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
188 OMe 0 CHO
0 Me NaBH3CN I
M
ONO e OMe 0 Me A 0 Me N

Me,N,AN
Me LiJ
ONO
Me [0342] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (25 mg, 0.048 mmol), 3-aminopropanamide (30 mg, 0.37 mmol) and HOAc (60 mg, 1.0 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C and NaBH3CN (50 mg, 0.78 mmol) was added. After stirring for 5 min at 0 C the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to yield N-(4"-(((3-amino-3-oxopropyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA salt). 1H
NMR (400 MHz, CD30D) 11.16 (s, 1H), 8.62 (s, 1H), 8.07 (t, J = 7.4 Hz, 1H), 7.36-7.22 (m, 3H), 7.15 (dd, J = 7.6, 0.8 Hz, 1H), 6.96 (dd, J = 7.6, 0.8 Hz, 1H), 6.93 (s, 1H), 6.86 (dd, J= 10.0, 0.8 Hz, 1H), 4.35 (s, 2H), 4.00 (s, 3H), 3.55 (s, 3H), 3.38 (s, 3H), 3.36-3.28 (m, 2H), 2.71 (t, J= 6.4 Hz, 2H), 2.09 (s, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated C32H35FN505 [M + H]+
588.3, found 588.2.
Example 192: N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((2-(2-oxopyrrolidin-1-yl)ethyl)amino)methyl)-11,1':3',1"-terphenyll-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
189 OMe 0 Me Me,NAN CHO H2N
0 N 0 Me NaBH3CN
OMe Me 0 Me Me,N)LN
0 N 0 Me Me [0343] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (23 mg, 0.044 mmol), .. 1-(2-aminoethyl)pyrrolidin-2-one (25 mg, 0.20 mmol) and HOAc (60 mg, 1.0 mmol) in Et0H
(1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C and NaBH3CN (45 mg, 0.63 mmol) was added. After stirring for 5 min at 0 C the mixture was concentrated in vacuo.
The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to yield N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((2-(2-oxopyrrolidin-1-ypethyl)amino)methyl)-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA salt).
1H NMR (400 MHz, CD30D) 6 11.16 (s, 1H), 8.63 (s, 1H), 8.06 (t, J= 8.0 Hz, 1H), 7.36-7.22 (m, 3H), 7.16 (dd, J= 7.6, 1.2 Hz, 1H), 6.97 (dd, J= 6.8, 1.2 Hz, 1H), 6.94 (s, 1H), 6.87 (dd, J=
10.4, 1.2 Hz, 1H), 4.38 (s, 2H), 3.99 (s, 3H), 3.65 (t, J= 5.6 Hz, 2H), 3.55 (s, 3H), 3.55-3.50 (m, 2H), 3.34-3.00 (m, 2H), 3.88 (s, 3H), 2.45-2.34 (m, 2H), 2.15-2.06 (m, 2H), 2.09 (s, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated C35H39FN505 [M + H]628.3, found 628.2.
Example 193: N-(4"-((((1H-imidazol-2-yl)methyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terpheny11-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
190 OMe 0 Me CHO H2N
HN ).LN
Me NaBH3CN I

MIe OMe 0 Me N
HNLN
0 N 0 Me Me [0344] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (25 mg, 0.050 mmol), (1H-imidazol-2-yl)methanamine hydrochloride (28 mg, 0.16mmol), Et3N (25 mg, 0.25 mmol) and HOAc (120 mg, 2.0 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C and NaBH3CN (45 mg, 0.71 mmol) was added. After stirring for 25 min at room temperature the mixture was concentrated in vacuo. The obtained residue was purified by HPLC
(MeCN/H20 with 0.1% TFA) to yield N-(4"-((((1H-imidazol-2-yl)methyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA salt). 1-HNMR (400 MHz, CD30D) ö 11.15 (s, 1H), 8.41 (s, 1H), 8.04 (t, J= 7.2 Hz, 1H), 7.41 (s, 2H), 7.35-7.22 (m, 3H), 7.15 (dd, J = 7.2, 1.6 Hz, 1H), 6.97 (dd, J= 7.2, 0.8 Hz, 1H), 6.88 (s, 1H), 6.82 (dd, J= 10.0, 1.2 Hz, 1H), 4.40 (s, 2H), 4.29 (s, 2H), 3.93 (s, 3H), 3.36 (s, 3H), 2.10 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated C32H32FN604 [M + H]' 583.2, found 583.2.
Example 194: N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((tetrahydro-2H-pyran-4-yl)aminOmethyl)-11,1':3',1"-terpheny11-3-yOpyrido[3,4-b]pyrazin-5-amine
191 OMe CHO
Me H2N
NN NaBH(OAc)3 LN H
Me OMe Me N) NN
H
Me [0345] A mixture of 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde (25 mg, 0.052 mmol), tetrahydro-2H-pyran-4-amine (18 mg, 0.18 mmol)and HOAc (60 mg, 1.0 mmol) in Et0H (1.5 mL) was heated at 70 C
for 0.5 h.
The mixture was cooled to 0 C and NaBH(OAc)3(45 mg, 0.21 mmol) was added.
After stirring for 5 min at 0 C the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to yield N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((tetrahydro-2H-pyran-4-yl)amino)methy1)41,1':3',1"-terphenyl]-3-y1)pyrido[3,4-b]pyrazin-5-amine (TFA salt). 1H NMR (400 MHz, CD30D) 8 9.23 (d, J= 2.0 Hz, 1H), 9.04 (d, J= 2.0 Hz, 1H), 7.80 (d, J= 7.2 Hz, 1H), 7.61 (d, J= 7.6 Hz, 1H), 7.53 (t, J= 7.8 Hz, 1H), 7.40-7.34 (m, 3H), 7.28 (dd, J= 8.0, 1.2 Hz, 1H), 7.23 (d, J= 7.2 Hz, 1H), 6.94 (s, 1H), 6.88 (d, J =10 .0 Hz, 1H), 4.36 (s, 2H), 4.06 (dd, J= 11.2, 4.4 Hz, 2H), 3.98 (s, 3H), 3.52-3.44 (m, 3H), 2.18-2.12 (m, 2H), 2.10 (s, 3H), 2.01 (s, 3H), 1.80-1.68 (m, 2H). MS: (ES) m/z calculated C34H35FN502 [M +
H]564.3, found 564.2.
Example 195: N-(4"-(((3-amino-3-oxopropyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethy1-11,1':3',1"-terpheny11-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
192 OMe 0 0 rii Me CHO

HN).LN
Me NaBH3CN

ie OMe M
A
0 Me N

Me LLJ
Me [0346] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (25 mg, 0.050 mmol), 3-aminopropanamide hydrochloride (30 mg, 0.24 mmol), Et3N (20 mg, 0.20 mmol) and HOAc (105 mg, 1.75 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C and NaBH3CN (45 mg, 0.79 mmol) was added. After stirring for 5 min at 0 C the mixture was concentrated in vacuo. The obtained residue was purified by HPLC
(MeCN/H20 with 0.1% TFA) to yield N-(4"4(3-amino-3-oxopropyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terpheny1]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA salt). 1H NMR (400 MHz, CD30D) 6 11.14 (s, 1H), 8.41 (s, 1H), 8.06 (t, J=
6.8 Hz, 1H), 7.35-7.23 (m, 3H), 7.15 (dd, J= 7.2, 1.2 Hz, 1H), 6.96 (d, J= 8.0 Hz, 1H), 6.93 (s, 1H), 6.87 (d, J= 10.0 Hz, 1H), 4.35 (s, 2H), 3.99 (s, 3H), 3.35 (s, 3H), 3.34-3.30 (m, 2H), 2.71 (t, J= 6.4 Hz, 2H), 2.09 (s, 3H), 1.93 (s, 3H). MS: (ES) m/z calculated C31H33FN505 [M + H]+
574.2, found 574.2.
Example 196: N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((2-(2-oxopyrrolidin-1-yl)ethyl)amino)methyl)-11,1':3',1"-terphenyll-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
193 OMe HN N JJ,fJCHO
0 Me L
Me NaBH3CN

Me OMe 0 Me HN)LN
0 N 0 Me Me [0347] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (24 mg, 0.046 mmol), 1-(2-aminoethyl)pyrrolidin-2-one (30 mg, 0.23 mmol) and HOAc (60 mg, 1.0 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C and NaBH3CN
(45 mg, 0.63 mmol) was added. After stirring for 5 min at 0 C the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to yield N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((2-(2-oxopyrrolidin-1-y1)ethyl)amino)methyl)41,1':3',1"-terphenyl]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA
salt). 1-HNMR
(400 MHz, CD30D) 11.15 (s, 1H), 8.41 (s, 1H), 8.06 (t, J= 7.6 Hz, 1H), 7.36-7.23 (m, 3H), 7.15 (d, J= 7.6 Hz, 1H), 6.98 (d, J= 7.6 Hz, 1H), 6.93 (s, 1H), 6.87 (d, J=
10.4 Hz, 1H), 4.38 (s, 2H), 3.99 (s, 3H), 3.65 (t, J= 5.6 Hz, 2H), 3.52 (t, J= 7.2 Hz, 2H), 3.35 (s, 3H), 3.34-3.30 (m, 2H), 2.42 (t, J= 8.0 Hz, 2H), 2.15-2.16 (m, 2H), 2.10 (s, 3H), 1.94 (s, 3H).
MS: (ES) m/z calculated C34H37FN505 [M + H]614.3, found 614.2.
Example 197: N-(4"-(4(1H-pyrazol-5-y1)methyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terpheny11-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
194 OMe CHO
0 Me H2N
HN
Me NaBH3CN
0 N 0 OMe Me 0 Me H
N
HN).LN
0 N 0 Me Me [0348] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (25 mg, 0.048 mmol), (1H-pyrazol-5-yl)methanamine hydrochloride (25 mg, 0.19 mmol), Et3N (15 mg, 0.15 mmol) and HOAc (90 mg, 1.5 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C and NaBH3CN (45 mg, 0.70 mmol) was added. After stirring for 5 min at 0 C
the mixture was concentrated in vacuo. The obtained residue was purified by HPLC
(MeCN/H20 with 0.1% TFA) to yield N-(4"-((((1H-pyrazol-5-yl)methyl)amino)methyl)-3"-fluoro-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA salt). 1-HNMR (400 MHz, CD30D) ö 11.15 (s, 1H), 8.41 (s, 1H), 8.06 (t, J= 7.4 Hz, 1H), 7.75 (d, J= 2.4 Hz, 1H), 7.35-7.22 (m, 3H), 7.15 (d, J=
7.2 Hz, 1H), 6.96 (d, J= 7.6 Hz, 1H), 6.90 (s, 1H), 6.84 (d, J= 9.6 Hz, 1H), 6.50 (d, J= 2.4 Hz, 1H), 4.30 (s, 4H), 3.95 (s, 3H), 3.36 (s, 3H), 2.10 (s, 3H), 1.93 (s, 3H). MS:
(ES) m/z calculated C32H32FN604 [M + H]' 583.2, found 583.2.
Example 198: (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((2-oxopyrrolidin-3-yl)amino)methyl)-11,1':3',1"-terphenyll-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
195 OMe 0 0 Me CHO H2N,,,a NH
HN)*LN
Me NaBH3CN

Me OMe N
Z..21H
s=
0 Me Nµ
HNN
0 N 0 Me Me [0349] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-3-methy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (22 mg, 0.042 mmol), (5)-3-aminopyrrolidin-2-one hydrochloride (15 mg, 0.11 mmol), Et3N (15 mg, 0.15 mmol) and HOAc (90 mg, 1.5 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C and NaBH3CN (50 mg, 0.78 mmol) was added. After stirring for 5 min at 0 C
the mixture was concentrated in vacuo. The obtained residue was purified by HPLC
(MeCN/H20 with 0.1% TFA) to yield (S)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((2-oxopyrrolidin-3-yl)amino)methy1)41,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA salt). 1-EINMR (400 MHz, CD30D) 8 11.15 (s, 1H), 8.41 (s, 1H), 8.06 (t, J= 7.6 Hz, 1H), 7.23-7.36 (m, 3H), 7.16 (d, J = 7.6 Hz, 1H), 6.97 (d, J =
7.6 Hz, 1H), 6.93 (s, 1H), 6.87 (d, J = 10.0 Hz, 1H), 4.63 (d, J= 13.6 Hz, 1H), 4.39 (d, J= 12.8 Hz, 1H), 4.24-4.18 (m, 1H), 3.99 (s, 3H), 3.50-3.40 (m, 2H), 3.36 (s, 3H), 2.67-2.58 (m, 1H), 2.28-2.16 (m, 1H), 2.10 (s, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated C32H33FN505 [M + H]+
586.2, found 586.2.
Example 199: (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((2-oxopyrrolidin-3-yl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
196 OMe CHO H2Na"-aNH
0 Me HN-LN
Me NaBH3CN

Me OMe NH
0 Me HN.LN
0 N 0 Me Me [0350] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (23 mg, 0.044 mmol), (R)-3-aminopyrrolidin-2-one hydrochloride (15 mg, 0.11 mmol), Et3N (15 mg, 0.15 mmol) and HOAc (90 mg, 1.5 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C and NaBH(OAc)3(60 mg, 0.28 mmol) was added. After stirring for 25 min at room temperature the mixture was concentrated in vacuo . The obtained residue was purified by HPLC (MeCN/H20 with 0.1% TFA) to yield (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((2-oxopyrrolidin-3-yl)amino)methy1)41,1':3',1"-terphenyl]-3-y1)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (TFA salt). 1-HNMR (400 MHz, CD30D) ö 11.15 (s, 1H), 8.41 (s, 1H), 8.06 (t, J= 7.4 Hz, 1H), 7.36-7.23 (m, 3H), 7.16 (d, J= 7.6 Hz, 1H), 6.97 (d, J =
7.6 Hz, 1H), 6.93 (s, 1H), 6.87 (d, J = 10.4 Hz, 1H), 4.63 (d, J= 13.6 Hz, 1H), 4.39 (d, J= 12.8 Hz, 1H), 4.24-4.18 (m, 1H), 3.99 (s, 3H), 3.50-3.40 (m, 2H), 3.36 (s, 3H), 2.67-2.58 (m, 1H), 2.28-2.16 (m, 1H), 2.10 (s, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated C32H33FN505 [M + H]+
586.2, found 586.2.
Example 200: (1S,2S)-2-(03-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido13,4-blpyrazin-5-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)cyclopentan-l-ol
197 OMe 100 Me OH
N)LN NaBH(OAc)3 Me OMe Me H
OH
H
Me [0351] A mixture of 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde (25 mg, 0.045 mmol), (1S,2S)-2-aminocyclopentan-1-01 .. hydrochloride (15 mg, 0.11 mmol), Et3N (15 mg, 0.15 mmol) and HOAc (90 mg, 1.5 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C
and NaBH(OAc)3 (60 mg, 0.28 mmol) was added. After stirring for 30 min at room temperature the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1%
TFA) to yield (1S,2S)-2-(((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-yl)methyl)amino)cyclopentan-1-ol (TFA salt).
1H NMR (400 MHz, CD30D) 6 9.23 (d, J= 2.0 Hz, 1H), 9.04 (d, J= 2.0 Hz, 1H), 7.80 (d, J=
7.2 Hz, 1H), 7.61 (d, J= 7.6 Hz, 1H), 7.53 (t, J= 7.6 Hz, 1H), 7.34-7.40 (m, 3H), 7.28 (dd, J=
7.6, 1.2 Hz, 1H), 7.23 (dd, J= 7.2, 1.2 Hz, 1H), 6.93 (s, 1H), 6.87 (d, J= 10.0 Hz, 1H), 4.49 (d, J= 13.2 Hz, 1H), 4.34 (d, J= 13.2 Hz, 1H), 4.30-4.22 (m, 1H), 3.98 (s, 3H), 3.45-3.38 (m, 1H), 2.33-2.23 (m, 1H), 2.10 (s, 3H), 2.10-2.00 (m, 1H), 2.01 (s, 3H), 1.90-1.62 (m, 4H). MS: (ES) m/z calculated C34H35FN502 [M + H]+ 564.3, found 564.2.
Example 201: (R)-4-(43-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido13,4-blpyrazin-5-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)pyrrolidin-2-one
198 OMe Me CHO
H2NNs NN NaBH(OAc)3 1 H
Me OMe .dNH
ri Me NN
H
Me [0352] A mixture of 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde (23 mg, 0.041 mmol), (R)-4-aminopyrrolidin-2-one hydrochloride (18 mg, 0.13 mmol), Et3N (15 mg, 0.15 mmol) and HOAc (90 mg, 1.5 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C
and NaBH(OAc)3 (60 mg, 0.28 mmol) was added. After stirring for 20 min at room temperature the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1%
TFA) to yield (R)-4-(((3-fluoro-5-methoxy-2',2"-dimethyl-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-yl)methyl)amino)pyrrolidin-2-one (TFA salt). 1-EINMR
(400 MHz, CD30D) 5 9.24 (d, J= 2.0 Hz, 1H), 9.05 (d, J= 2.4 Hz, 1H), 7.79 (d, J= 7.2 Hz, 1H), 7.60 (dd, J
= 7.6, 1.2 Hz, 1H), 7.53 (t, J= 7.6 Hz, 1H), 7.40-7.34 (m, 3H), 7.28 (dd, J=
8.0, 1.6 Hz, 1H), 7.24 (dd, J= 7.6, 1.2 Hz, 1H), 6.94 (s, 1H), 6.88 (dd, J= 9.6, 1.2 Hz, 1H), 4.37 (s, 2H), 4.28-4.20 (m, 1H), 3.99 (s, 3H), 3.91-3.85 (m, 1H), 3.62-3.57 (m, 1H), 2.94-2.86 (m, 1H), 2.58 (dd, J
= 17.2, 4.4 Hz, 1H), 2.10 (s, 3H), 2.02 (s, 3H). MS: (ES) m/z calculated C33H32FN602 [M + H]+
563.3, found 563.3.
Example 202: (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((5-oxopyrrolidin-3-yl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide
199 OMe Me CHO NH

NkN
kN0 H NaBH(OAc)3 1 Me 0 OMe Me dNH
0 Me Nr N.LN
kN0 H
Me Me [0353] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-1-methy1-6-oxo-1,6-dihydropyrimidine-5-carboxamide (22 mg, 0.045 mmol), (R)-4-aminopyrrolidin-2-one hydrochloride (15 mg, 0.11 mmol), Et3N (15 mg, 0.15 mmol) and HOAc (90 mg, 1.5 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C and NaBH(OAc)3 (50 mg, 0.23 mmol) was added. After stirring for 20 min at room temperature the mixture was concentrated in vacuo. The obtained residue was purified by HPLC
(MeCN/H20 with 0.1% TFA) to yield (R)-N-(3"-fluoro-5"-methoxy-2,2'-dimethy1-4"-(((5-oxopyrrolidin-3-yl)amino)methy1)41,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide (TFA salt). 1-HNMR (400 MHz, CD30D) 8 11.41 (s, 1H), 8.91 (s, 1H), 8.67 (s, 1H), 8.12 (t, J= 7.6 Hz, 1H), 7.36-7.23 (m, 3H), 7.17 (dd, J = 7.6, 1.6 Hz, 1H), 6.99 (dd, J= 8.0, 0.8 Hz, 1H), 6.95 (s, 1H), 6.89 (dd, J= 10.0, 1.2 Hz, 1H), 4.37 (s, 2H), 4.27-4.20 (m, 1H), 4.00 (s, 3H), 3.91-3.85 (m, 1H), 3.66 (s, 3H), 3.60-3.55 (m, 1H), 2.95-2.87 (m, 1H), 2.56 (dd, J= 18.0, 4.8 Hz, 1H), 2.11 (s, 3H), 1.94 (s, 3H). MS: (ES) m/z calculated C32H33FN504 [M + H]+ 570.2, found 570.2.
Example 203: (R)-5-((((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido13,4-blpyrazin-5-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)methyl)pyrrolidin-2-one
200 OMe Me 1LCHO Ny0 N)LN NaBH(OAc)3 LN H
Me OMe Me C.t0 N
NN
H
Me [0354] A mixture of 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde (23 mg, 0.035 mmol), (R)-5-(aminomethyl)pyrrolidin-2-one hydrochloride (20 mg, 0.13 mmol), Et3N (15 mg, 0.15 mmol) and HOAc (90 mg, 1.5 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C
and NaBH(OAc)3(50 mg, 0.24 mmol) was added. After stirring for 20 min at room temperature the mixture was concentrated in vacuo. The obtained residue was purified by HPLC
(MeCN/H20 with 0.1% TFA) to yield (R)-5-((((3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-yl)methyl)amino)methyl)pyrrolidin-2-one (TFA salt). 1H
NMR (400 MHz, CD30D) 6 9.24 (d, J= 2.0 Hz, 1H), 9.05 (d, J= 2.4 Hz, 1H), 7.79 (d, J= 7.2 Hz, 1H), 7.60 (dd, J= 7.6, 1.2 Hz, 1H), 7.53 (t, J= 7.8 Hz, 1H), 7.40-7.34 (m, 3H), 7.28 (dd, J=
8.0, 1.2 Hz, 1H), 7.24 (dd, J= 8.0, 0.8 Hz, 1H), 6.94 (s, 1H), 6.88 (dd, J=
9.6, 1.6 Hz, 1H), 4.40 (s, 2H), 4.11-4.04 (m, 1H), 3.99 (s, 3H), 3.28-3.24 (m, 2H), 2.46-2.33 (m, 3H), 2.10 (s, 3H), 2.02 (s, 3H), 1.98-1.85 (m, 1H). MS: (ES) m/z calculated C34H34FN602 [M +H]P 577.3, found 577.2.
Example 204: N-(3"-fluoro-4"-(4(1S,2S)-2-hydroxycyclopentyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-11,1':3',1"-terpheny11-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide
201 OMe .90 0 Me CHO H2N
OH
NN
0 H Me NaBH(OAc)3 Ie OMe M
0 Me H OH

Me uii Me [0355] A mixture of N-(3"-fluoro-4"-formy1-5"-methoxy-2,2'-dimethy141,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide (23 mg, 0.047 mmol), (1S,2S)-2-aminocyclopentan-1-ol hydrochloride (25 mg, 0.18 mmol), Et3N (15 mg, 0.15 mmol) and HOAc (90 mg, 1.5 mmol) in Et0H (1.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C and NaBH(OAc)3 (50 mg, 0.23 mmol) was added. After stirring for 20 min at room temperature the mixture was concentrated in vacuo . The obtained residue was purified by HPLC
(MeCN/H20 with 0.1% TFA) to yield N-(3"-fluoro-4"-((((lS,2S)-2-hydroxycyclopentyl)amino)methyl)-5"-methoxy-2,2'-dimethyl-[1,1':3',1"-terphenyl]-3-y1)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carboxamide (TFA salt). 1H NMIR (400 MHz, CD30D) 8 8.91 (s, 1H), 8.67 (s, 1H), 8.12 (dd, J= 8.4, 1.2 Hz, 1H), 7.36-7.22 (m, 3H), 7.16 (dd, J= 7.6, 1.6 Hz, 1H), 6.99 (dd, J= 7.2, 0.8 Hz, 1H), 6.93 (s, 1H), 6.87 (dd, J= 10.4, 1.2 Hz, 1H), 4.49 (d, J= 13.2 Hz, 1H), 4.33 (d, J= 13.6 Hz, 1H), 4.29-4.22 (m, 1H), 3.99 (s, 3H), 3.65 (s, 3H), 3.45-3.38 (m, 1H), 2.33-2.23 (m, 1H), 2.12 (s, 3H), 2.10-2.01 (m, 1H), 1.94 (s, 3H), 1.90-1.75 (m 2H), 1.75-1.62 (m, 2H). MS: (ES) m/z calculated C33H36FN402 [M + H]+ 571.3, found 571.2.
Example 205: (1S,2R)-2-(((3-fluoro-5-methoxy-2',2"-dimethy1-3"-((1,2,3,4-tetrahydropyrido[3,4-blpyrazin-5-yl)amino)-11,1':3',1"-terpheny11-4-yl)methyl)amino)cyclopentan-l-ol
202 OMe Hisr CHO
Me oH
NLN
NaBH3CN
LN H
Me OMe Me HNN
NH Me [0356] A mixture of 3-fluoro-5-methoxy-2',2"-dimethy1-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde (22 mg, 0.046 mmol), (1S,2R)-2-aminocyclopentan-1-01 hydrochloride (25 mg, 0.18 mmol), Et3N (0.040 mL, 0.23 mmol) and HOAc (90 mg, 1.5 mmol) in Et0H (2.5 mL) was heated at 70 C for 0.5 h. The mixture was cooled to 0 C
and NaBH3CN
(45 mg, 0.71 mmol) was added. After stirring for 20 min at room temperature the mixture was concentrated in vacuo. The obtained residue was purified by HPLC (MeCN/H20 with 0.1%
TFA) to yield (1S,2R)-2-(((3-fluoro-5-methoxy-2',2"-dimethy1-3"-((1,2,3,4-tetrahydropyrido[3,4-b]pyrazin-5-yl)amino)41,1':3',1"-terphenyl]-4-y1)methyl)amino)cyclopentan-1-ol (TFA salt). 1-E1 NMR (400 MHz, CD30D) 6 7.39-7.31 (m, 2H), 7.25 (d, J = 6.8 Hz, 1H), 7.20-7.10 (m, 4H), 6.91 (s, 1H), 6.85 (d, J= 9.6 Hz, 1H), 6.34 (d, J= 7.2 Hz, 1H), 4.42-4.28 (m, 3H), 3.97 (s, 3H), 3.52-3.42 (m, 3H), 3.35-3.28 (m, 2H), 2.18-2.05 (m, 1H), 2.01 (s, 3H), 1.97 (s, 3H), 1.95-1.77 (m, 4H), 1.74-1.62 (m, 1H). MS: (ES) m/z calculated C34H39FN502 [M + H]568.3, found 568.3.
Example 206: N-(2,2'-dichloro-3"-fluoro-4"-((((3S,4S)-3-hydroxytetrahydro-211-pyran-4-yl)amino)methyl)-5"-methoxy-11,1':3',1"-terphenyll-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
203 OMe CHO HCI

Me,NLN F
OH
0 N 0 CI Li NaBH3CN
Mie OMe 0 CI N'Th?
Me,N-)LN OH
C

Me [0357] A mixture of N-(2,2'-dichloro-3"-fluoro-4"-formy1-5"-methoxy-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (25 mg, 0.045 mmol), (3S,4S)-4-aminotetrahydro-2H-pyran-3-ol hydrogen chloride (12 mg, 0.078 mmol), TEA (60 mg, 0.60 mmol) and HOAc (120 mg, 2.0 mmol) in Et0H (2 mL) was heated at 70 C
for 0.5 h.
The mixture was cooled to 0 C and NaBH3CN (40 mg, 0.56 mmol) was added. After stirring for 5 min at 0 C the mixture was concentrated in vacuo . The residue was purified by HPLC
(MeCN/H20 with 0.1% TFA) to yield N-(2,2'-dichloro-3"-fluoro-4"-((((3S,4S)-3-hydroxytetrahydro-2H-pyran-4-yl)amino)methyl)-5"-methoxy-[1,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide. 1-EINMR (400 MHz, CD 30D) 8 11.69 (s, 1H), 8.66 (s, 1H), 8.53 (dd, J= 8.4, 1.6 Hz, 1H), 7.53-7.45 (m, 2H), 7.43-7.35 (m, 2H), 7.08 (dd, J= 7.6, 1.6 Hz, 1H), 7.03 (s, 1H), 6.98 (dd, J= 9.6, 1.2 Hz, 1H), 4.41 (d, J= 13.2 Hz, 1H), 4.30 (d, J= 13.2 Hz, 1H), 4.10-3.95 (m, 4H), 3.99 (s, 3H), 3.60-3.54 (m, 1H), 3.55 (s, 3H), 3.52-3.42 (m, 2H), 3.39 (s, 3H), 2.17-2.05 (m, 1H), 1.90-1.82 (m, 1H).
MS: (ES) m/z calculated C32H32C12FN406 [M + H]+ 657.2, found 657Ø
Example 207: N-(2,2'-dichloro-3"-fluoro-4"-((((3R,4R)-3-hydroxytetrahydro-211-pyran-4-yl)amino)methyl)-5"-methoxy-11,1':3',1"-terphenyll-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
204 OMe CHO H2N's =) HCI

OH
C

NaBH3CN
Mie OMe z Me,N)LN F
H OH
CI

Me 103581 A mixture of N-(2,2'-dichloro-3"-fluoro-4"-formy1-5"-methoxy-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (200 mg, 0.36 mmol), (3R,4R)-4-aminotetrahydro-2H-pyran-3-ol hydrogen chloride (66 mg, 0.43 mmol), TEA (0.12 mL, 0.86 mmol) and HOAc (0.10 mL, 1.7 mmol) in Et0H (4 mL) and DCM (4 mL) was heated at 70 C for 1 h. The mixture was cooled to 0 C and NaBH3CN (36 mg, 0.57 mmol) was added.
After stirring for 10 min at 0 C the mixture was quenched with sat. NaHCO3 and extracted with DCM. The organic layer was separated, dried over Na2SO4, concentrated in vacuo and purified by silica gel chromatography eluting with 0-100% Et0Ac/DCM followed by 0-50%
Me0H/Et0Ac to obtain a white solid. The solid was treated with HC1 (1 mL, 1M/ether) in Me0H (4 mL) and DCM (4 mL) at 0 C followed by concentrating in vacuo to afford the HC1 salt of N-(2,2'-dichloro-3"-fluoro-4"-((((3R,4R)-3-hydroxytetrahydro-2H-pyran-yl)amino)methyl)-5"-methoxy-[1,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide. NMR (400 MHz, CD30D) ö 11.68 (s, 1H), 8.66 (s, 1H), 8.53 (d, J= 8.4, 1H), 7.53-7.45 (m, 2H), 7.43-7.35 (m, 2H), 7.08 (dd, J=
8.0, 1.2 Hz, 1H), 7.03 (s, 1H), 6.98 (dd, J = 9.6, 1.2 Hz, 1H), 4.42 (d, J= 13.6 Hz, 1H), 4.32 (d, J= 12.8 Hz, 1H), 4.10-3.95 (m, 4H), 4.00 (s, 3H), 3.60-3.54 (m, 1H), 3.55 (s, 3H), 3.52-3.42 (m, 2H), 3.38 (s, 3H), 2.17-2.05 (m, 1H), 1.90-1.83 (m, 1H). MS: (ES) m/z calculated C32H32C12FN406 [M + H]+
657.2, found 657.2.
Example 208: (S)-N-(2,2'-dichloro-3"-fluoro-5"-methoxy-4"-(((5-oxopyrrolidin-3-yl)amino)methyl)-11,1':3',1"-terpheny11-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
205 OMe 0 CHO
0 CI ,O6H
Me,N.LN H2N
CI NaBH3CN 0 M OMe Me e6 H
Me'rsiLN

Me [0359] A mixture of N-(2,2'-dichloro-3"-fluoro-4"-formy1-5"-methoxy-[1,1':3',1"-terpheny1]-3-y1)-1,3-dimethy1-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (3.90 g, 7.0 mmol), (S)-4-aminopyrrolidin-2-one (0.70 g, 7.0 mmol) and HOAc (0.84 mL, 14 mmol) in Et0H
(30 mL) and DCM (60 mL) was heated at 70 C for 1 h. The mixture was cooled to 0 C
and NaBH3CN
(656 mg, 10.5 mmol) was added. After stirring for 30 min at 0 C the mixture was quenched with sat. NaHCO3 and extracted with DCM. The organic layer was separated, dried over Na2SO4, concentrated in vacuo and purified by silica gel chromatography eluting with 0-100%
Et0Ac/DCM followed by 0-80% Me0H/Et0Ac to yield a white solid. It was treated with HC1 (14 mL, 1M/ether) in Me0H (40 mL) and DCM (40 mL) at 0 C followed by concentrating in vacuo to yield the HC1 salt of (S)-N-(2,2'-dichloro-3"-fluoro-5"-methoxy-4"4(5-oxopyrrolidin-3-yl)amino)methyl)-[1,1':3',1"-terphenyl]-3-y1)-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide. 1-E1 NMR (400 MHz, CD30D) ö 11.69 (s, 1H), 8.66 (s, 1H), 8.53 (d, J= 8.4 Hz, 1H), 7.54-7.45 (m, 2H), 7.43-7.35 (m, 2H), 7.08 (dd, J= 7.6, 1.2 Hz, 1H), 7.06 (s, 1H), 7.00 (d, J= 10 Hz, 1H), 4.37 (s, 2H), 4.28-4.20 (m, 1H), 4.01 (s, 3H), 3.92-3.85 (m, 1H), 3.60-3.55 (m, 1H), 3.55 (s, 3H), 3.38 (s, 3H), 2.95-2.87 (m, 1H), 2.56 (dd, J=
17.6, 4.8 Hz, 1H). MS: (ES) m/z calculated C32H29C12FN505 [M + H]+ 640.2, found 640Ø
Example 209: Synthesis of 1-((2',2"-dichloro-3-fluoro-5-methoxy-3"-(pyrido 13,4-131pyrazin-5-ylamino)-11,1':3',1"-terpheny11-4-yl)methyl)-3-methylazetidine-3-carboxylic acid
206 OMe CI ________________________________________________________ COOH
Me NYLN
II H
CI NaCNBH3 DCE/Et0H
0 C, 10 min OMe CI
\A--COOH
NN F Me H
CI
[0360] To a stirred solution of 2',2"-dichloro-3-fluoro-5-methoxy-3"-(pyrido[3,4-b]pyrazin-5-ylamino)-[1,1':3',1"-terpheny1]-4-carbaldehyde (40 mg, 0.077 mmol) and 3-methylazetidine-3-carboxylic acid (18 mg, 0.154 mmol) in dichloroethane (2 mL) and ethanol (1 mL) was added triethylamine (2 drops) then followed by acetic acid (2 drops). The reaction mixture was stirred at 70 C for 1 hr. The mixture was then cooled to 0 C and NaCNBH3 (10 mg, 0.154 mmol) was added slowly. The mixture was stirred at 0 C for 10 minutes. The mixture was passed through syringe filter and then purified by preparative HPLC (0 to 40% to 100%
Acetonitrile/H20) to give 1-((2',2"-dichloro-3-fluoro-5-methoxy-3"-(pyrido[3,4-b]pyrazin-5-ylamino)41,1':3',1"-terpheny1]-4-yl)methyl)-3-methylazetidine-3-carboxylic acid. 1H NMIR (400 MHz, CD30D) 8 9.11 (s, 1H), 8.93 (d, J= 1.8 Hz, 1H), 8.80 (d, J= 8.5 Hz, 1H), 8.26 (d, J=
6.3 Hz, 1H), 7.57 ¨
7.36 (m, 5H), 7.20 ¨ 7.13 (m, 1H), 7.09 ¨ 6.98 (m, 2H), 4.56 (d, J= 17.3 Hz, 4H), 4.13 (d, J=
11.1 Hz, 2H), 4.00 (s, 3H), 3.34 ¨ 3.28 (m, 13H), 3.25 (s, 1H), 1.60 (s, 3H).
MS: (ES) m/z calculated for C32H26C12FN503 [M + H]618.2, found 618.2.
Characterization Conditions Reverse phase HPLC conditions used for determination of retention times in Table 1:
Column: ZORBAX (SB-C18 2.1 x 50 mm, 5 pm) Mobile phase A: 95% H20, 5% MeCN (with 0.1% Formic Acid) Mobile phase B: 5% H20, 95% MeCN (with 0.1% Formic Acid) Flow rate: 1.0 mL/min Gradient: 0 to 100% phase B in 4.5 min (for Method A) or 20 to 100% B in 3.5 min (for Method B)
207 Biological Example: Enzyme-Linked Immunosorbent Assay ¨ ELISA
[0361] 96 Well plates were coated with 111g/mL of human PD-Li (obtained from R&D) in PBS overnight at 4 C. The wells were then blocked with 2% BSA in PBS (W/V) with 0.05 %
TWEEN-20 for 1 hour at 37 C. The plates were washed 3 times with PBS/0.05%

and the compounds were serial diluted (1:5) in dilution medium and added to the ELISA plates.
Human PD-1 and biotin 0.31.tg/mL (ACRO Biosystems) were added and incubated for 1 hour at 37 C then washed 3 times with PBS/0.05% TWEEN-20. A second block was performed with 2% BSA in PBS (W/V)/0.05% TWEEN-20 for 10 min at 37 C and the plates were washed 3 times with PBS/0.05% TWEEN-20. Streptavidin¨HRP was added for 1 hour at 37 C
then the plates were washed 3 times with PBS/0.05% TWEEN-20. TMB substrate was added and reacted for 20 min at 37 C. A stop solution (2 N aqueous H2504) was added. The absorbance was read at 450 nm using a micro-plate spectrophotometer. The results are shown in Table 1: IC50 values are provided as follows: from 1000 to 10,000 nM (+); from 10 up to 1000 nM
(++); less than 10 nM (+++).
Table 1 Cmpd. ELISA m/z HPLC
HPLC
Structure No. ICso (nM) [m+Fir RT (min) Method 1.001 -TOH +++ 617.2 2.9 A
1.002 G---I H
40, 617.2 2.9 A
1.003 C--P3 639.2 2.1
208 1.004 -0-' ------0 ------I`m H
618.3 2.1 B
H

1.005 a.
. Ft 618.3 2.1 B
H i ' 1.006 a' y ,.... , ... re' i H
657.0 2.9 A
=-.. ',..
Ft I
Cil'ist" 0 I
1.007 0---' -----y---' F li 654.0 2.7 A
1.008 r :f Ft 1 0 H 657.0 2.8 A
=-.
H
I
1.009 ----..- --., 'L-------"
1 I "
V. 634.3 2.4 B
H
CI

1.010 , 637.2 2.6 B
I
1.011 637.2 3.0 A
'..... N. `.. OH
H
209 1.012 -617.3 2.2 B

1.013 SH 617.3 2.2 B
ot,r= , H

1.014 -f -----) ....--II
... I H µSH 658.2 2.6 B
----.
H
CI
1.015 r );=JH
641.1 2.1 B
H 1 .
)0 1.016 .3 OH 621.3 2.2 B
's-r. =-=..
i 1.017 ,-,--H '6' H 637.2 2.8 A
HI ....õ
1.018 -----, --..0 --. +++ 634.2 2.7 A
'..
H
..---1.019 0 ---=----,.. s ---::-...,, -,--1---k---'"-N----", I I i H 597.2 2.4 B
...-- ,--= ' ...-->--, 7. F
H I
210 1.020 i,9 ON
H 604.3 2.2 B
1 H i I
`--....õ...,"
1.021 H
N ...". rit I = 11 k :1-,- rk., H 1 )------L..2 -IS ..`"4:1 Nie-µ:=`, N.-----...,.--= =-=:. ,F 618.3 2.1 B
i 1 i 1.022 -, il i I I H ++ 599.1 2.5 B
--- --- .
..--1.023 ,0 '9 0.41-1 , -..
583.1 2.2 B
F

1.024 0 a +++ 583.2 2.6 A
, =-.. F
1.025 H . 601.1 2.6 A
te-k=----..--11- 8H
, ---, 11 ,i H I
1.026 1,.....,17-0 --, e-L-----""
II H
--- +++ 634.2 2.1 B
c) '=-===-=i, , H .
6:
]
1.027 '4 C:
r li 1 il ii 1 h i ...) 597.2 2.7 A
.7", ..","....... ',.-..1 ..-- r
211 1.028 ,:3 H
IN F
581.3 2.0 B
F
1.1õ.........:2N H
1.029 N F 1-1.1r)N1-12 583.3 2.5 B
F
U H
1.030 -, H
h,.....(7=0 +++ 634.1 2.3 B
I
1.031 --L.----- --......-a 1 fa ? :i "13 L_;., +++ 654.0 2.8 A
1.032 --.0 (--.7\--C
636.1 2.5 B
I
1.033 .
if-XIC
+++ 620.3 2.4 B
H
I
1.034 I
636.2 2.9 A
0%jN o H
1.035 ,P

if" 1 V
H
620.1 2.7 A
H r I
1.036 v--) ---634.2 2.8 A
212 1.037 H.
-.-... ----' +++ 618.2 2.3 B

1.038 ..-nso 587.3 2.0 B
F
'11-f I

1.039 -eCb -,.

587.3 2.0 B
N. F
H
I
1.040 o ,-,-----, I I H 6 H 580.2 2.8 A
N N F
II H I
-.., 1.041 ,..),,,, Ni---.,!---' I H ' 580.2 2.9 A
.----- '6H
0 . \ F
I I H I
..,-"' 1.042 0 o--1 I H 577.2 2.8 A
H I
1.043 a o-' -141H +++ 563.3 2.8 A
N `F

µ-'-:;--' 1.044 ,0 ,r.dis --...
I I H 604.2 2.1 B
..,.
--, . H
I
213 1.045 H
'H
-----1 H 630.2 2.7 A
`,..
N-...

1.046 H
1,114 H 629.1 2.8 A

1.047 ,0 -, d.4..
H
620.1 2.2 B
g - F

1.048 IH
C1-7......L.1 ......, , " 'k.,T_ Nri''' M '&)'--) f 577.2 2.8 A
.....
K....--=.õ-zy 4, ..... ,kõ.õ -..õ.......A.õ. -1.049 CO
H
H \
573.3 2.4 B
H
: 0 1.050 r---\,, 1---../
H
573.3 2.2 B
H
1.051 \
598.3 1.9 B
IsrXICL'IN, --- / F
lc H
'-= 11 1.052 0--- ------.0 --...,--------, ..-- I H
li 601.3 2.7 B
\
---......7---
214 1.053 ce.....--j---, H
+++ 587.3 2.5 B
H I
o i 1.054 C , ....,... IL 1., J ......, +++ 642.2 2.7 A
of-4"-n-' .--.1-.) . ' C=.=:,4 i 1.055 0 615.3 2.1 B
--..,., -..., ...... ,.... ,.., H I
1.056 I ril .- ."'"I I- H Pr'') .sy,. . .3.,1 ....z.I.A.k.,.. ......F tõ 629.3 2.1 B
1.057 -H
OH 603.2 2.8 A
"...., `,.., : H
... o 1.058 OMe yO
0 ./.
I II h F 629.1 2.8 A
H

1.059 OMe iTh F N.,õ.......iNH
...õ,õ..1:1 615.2 2.5 A

1.060 Ofvte r-i . .. -.. 615.2 2.9 A
Od' H
I
215 1.061 OMB
i-o)4H
IIV- ---\\..

629.2 2.8 A
i 1.062 ...-=
.,,,_ H i ...r.,..r If -1.---.1i ...1,.....õ---,,,F .... +++ 603.2 2.8 A
0"---v---so 1.063 9--- *
1 (5.:...ii ri. `If ,-= '''''' 617.3 2.9 A

1.064 ii 575.1 2.9 A
F
H
I
1.065 ..,. I 11 ...,.
H
F 560.2 3.0 A
1.066 0 .---I

F C)H 587.3 2.1 B
1.067 ---.
I , H
41 +++ 628.2 2.2 B
--... -, ---- .--- F H
1.068 ....,..--, .............õ,h 'c C li i ( I' L.)--:
-LA ....õ,...,,,,,, 615.2 2.7 A
k
216 1.069 H
615.2 2.7 A
-.
H

1.070 OMe == 63 li 0 Nkni 14`"
H 601.2 2.6 A
1.071 '--0 ---%
+++ 614.2 2.1 B
H"=-,-. ..--- 1 H
1.072 ..------,, ,--L-1 1 , i H '0E-I 603.2 2.9 A
H I
I
1.073 0 Ce....
.C.--,t=IH
600.2 2.8 A
H I
."-..7'.

1.074 0 r_Az k H
I
583.3 2.3 B
I
1.075 I I H I
OH 618.3 2.4 B
=-.....
H
217 1.076 We i I H
-----. OH 618.2 2.7 A
I
1.077 OPvle H
9 ----1 .--"L-------*"-+++ 629.2 2.7 A
1.078 -" H 589.3 2.6 A
1-ceit'H
I
1.079 -1 Nr0 H
I '....1 589.2 2.7 A

1.080 0------.(=-= ..-- H2 I H
616.3 2.2 B

'''=a ....' 1.081 -H2 602.2 2.8 A
1.082 ...i,3 ,.11 õ Jr, ),.
r.- +++ 628.2 2.8 A
1,krlYkr 115-----,)--F
1.083 ---H
I-i 588.2 2.7 A
Htst'.1 C:i'Ll .. 0 H
218 1.084 ,0 r 6.
9 , fli--Y
I 584.3 2.0 B
*--,.. .õ..,.....t. --...., ,........õF
kt:TX.LI-E
--...,...,-i-1.085 o--- P
..-------"m ---- Ii -,.., 602.3 2.2 B

1.086 .....c.......,,,....¨õ...L., -+++ 614.2 2.7 A
H
1.087 . F.r. .- j----,, q .
Ft i 571.3 2.4 B
I........ ' H
1.088 OPRe HO
il 629.2 2.6 A
-...

1.089 0.
i---- -r ...,), & +++ 615.2 2.6 A
6.51.... . V . ',....0 1.090 13 e-;-.1 i r';'-i-i----tr---'-mR, +++ 589.2 2.7 A
---T",,---...--,õõ)--,,,--:-..1.),,..i)....-õ,,, i 1.091 0--1-k i H
558.3 2.2 B
: H
4.7.b
219 1.092 0, ----."-', ---..
I I i H
+++ 629.2 2.8 A
H

I
1.093 o cy' ni o ...-N
614.3 2.1 B
N..
CPI' H
I
1.094 CIC
H
600.3 2.1 B
H

I
1.095 Clo4H
',. 628.3 2.2 B
H
0-" 0 1.096 pi 0 1 .----1 i H 600.3 2.1 B
07.,.."
H I ,,,,,,,-=

1.097 ONle 0'NH
-'''''''',.."--=". ''''N - i -"--.. ',.
F 0'Pr"...L.0 610.2 2.8 A
I H H
I
1.098 1,...y...---... --.. .1 , i rk-a, 1 ii ff. I ) "
ti'"1-- lirT ry ----.F .... 598.3 2.2 B
N'Akr) '-',-;.;
1.099 -- c:,,r-, R H
598.2 2.8 A
icrk,..0 H
I
220 1.100 0--- 0 +++ 614.2 2.8 A
Ft 1.101 0----11 II 604.3 2.3 B
N.
--.""
1.102 ...-- r,----yo i I H
'-`-, 584.3 2.0 B
I H
I
1.103 0 it 11 584.3 2.0 B
--, ---.
11, Ft 1 ...-1.104 j 11) 1 .A r %, ',.-.. -.
,-....õ...,,.... ..tr"krykr,,..., ,F - +++ 615.2 2.7 A
1.105 0 ome 6H
0 ....". ; ....". te-i I i I 1 1-1 601.2 2.6 A
N, N.
t_...= 1",.. "..L;
1.106 0 N...4( Ms H
H 629.2 2.6 A
...--.

1.107 H
614.2 2.7 A
H
11!10
221 1.108 p H 628.2 2.8 A
'Nu '.-7:=)'.1.-N1 .
i 1.109 p HO
:1-17-Xtill :
i H 614.2 2.7 A
i 1.110 .4., +++ 614.2 2.7 A
:'''''''Ll=I'..k-'" ,:-.) 1.111 OMe 00 H .61-1 603.2 2.7 A
c.'-ri-IP
H
I ,,...
I
Me 1.112 OMe NH
H 1 i 611.1 2.8 A
----:th 7 ' 1.113 .--Ft `,.. 611.2 2.1 B
---. o 1.114 cs-' .....y.,-,11,_ ,:y=4.11 .....-1,-"=-,;-....- -,,,, 588.2 2.7 A
.r."-1,,,A:kr, ' '=:-...:::' 1.115 ?
-li ii 628.2 2.8 A
222 1.116 H
N
H I i'l 560.3 2.6 B
L.31,1 11 l 7"
1.117 0 ..-".
1 / H \OH
570.2 2.9 A
/ H
l`,4e 1.118 H
628.2 2.9 A
H

1.119 c.---H
I 1 4 *
..- ++ 583.2 2.6 A
HI ...õ.
/
1.120 4.1 r,,,,-.1.1 i r...4=!--ir..-.),r---yrti,),=.) ++ 601.2 2.8 A
Faf =====:- li cfl'k-le""'"=-'r) '`-r---.)-1 1.121 ?
0Me NH
0 ...""
/ H 614.2 2.8 A
1.122 ,r^....--H 592.3 2.3 B
\ F
II H I
..--- .-=
1.123 , -,.. '----N--) 564.2 2.7 A
--=-..
il I H /
223 1.124 0 9---" ..õ"....,.....t --.-.,--------1 I i i H 592.3 2.0 B
--.. '`..
N s=--, ,..-1.125 0 H
0--- ,..c ...-1-------N r I I I H 563.3 2.1 B
-F

1.126 -,.., 1/1 ---3--, H
.......N., `F
++ 614.2 1.8 BC.)*:
I
1.127 0 dfli 9 ,....
Ft 600.2 1.9 B
. s... F
H

1.128 g ----------I ---..
..'" 574.2 2.7 A
H
t=I'-0 N.,;;') I
1.129 -,..
me0 I õ...- bi4 +++ 601.3 2.3 B
I
1.130 . 0, H
------H 563.3 2.0 B
I H I
N
"N..õ,.--------
224 1.131 0 H
614.2 2.8 A
I
1.132 H
) ++ 598.3 2.3 B
. 1 1H
I
1.133 ---, OH
H
i +++ 589.3 2.2 B
..". F
1-t 1.134 0--H
0 .-----=-", . ----.... --,.. +++ 583.2 2.8 A
H I
I
1.135 H
II hi '-.. ++ 586.2 2.7 A
1.136 H 6 +++ 589.2 2.7 A
hi F
H
I
1.137 ---,_ {...) i 1 I Ft 601.3 2.2 B
N., H

i
225 1.138 0, H
e_.--II a H
586.2 2.7 A
0 j....14........,...b H
==.,2-4-I
1.139 b 557.3 2.0 B
--- '--, '--F
cc H I I
'=-=,..õ,;,;-' I
1.140 -1:-....-----.

557.3 2.4 B
1.141 ,9 ,., 614.2 2.7 A
---- 2-- ,--'=
H ..",.

1.142 0 569.3 3.3 A
i H I I
),le 1.143 9 .61H
P
H 586.2 2.9 A
HNI--y-r= - F
H
I
1.144 ---....- -::-..
-.:.------"--14 -1.-----1"-- - --...
11 ZIF1 564.2 2.7 A
..,
226 1.145 0----1 r f,`,. ,) r, [...:,,f_cH
0 ' +++ 583.2 3.0 A
a I
Me 1.146 fi' L'--- 1 -,.,..,......1......õ. ,,....,,....õ,,..... c,..._ ...,.... ,,,c, 669.2 3.1 A
6-.4,..7.--k-k, 1.147 - --1------^t'D 4e H H 601.3 1.6 B
f H

1.148 9 'sx) d'JH

../ 614.2 1.9 B
ci:Lt") 4 1.149 ,7,-, "4, ....... .====... =;=-. -.---Cz.,..---F 0---)--,:rt- kt,. +++ 641.2 3.1 A

1.150 Otie ......_ H
`-...
558.2 3.1 A
i 1 H

1.151 , 0 , ka-, ,,..õ AH
f,= 1 H
559.3 2.4 B
--H ---, -.. 'T

1.152 ,.

... 628.3 2.0 B
-",,N =,,, H
227 1.153 p o--- r----c 563.3 2.8 A
.--"
F
LIE h 1.154 0 , ----e.
+++ 570.2 2.9 A
H i I
614.2 2.5 B
H
1.156 ome +++ 597.2 3.0 A
H

1.157 OMe H

I 1 H Li =''' '''s--. --Ale----'' \ F 583.2 3.0 A
H I
1.158 ?w, i.... ¨ ....,.., )1 L.¨, +++ 600.2 2.9 A
o r:::,='-il i r.>" y T, .r \?.....) ot--1.159 OMe r-iy, r,,,f1 i c----r- cto 577.3 3.2 A
IT' -...y.-- -tr''''r- -Ti---k-,,,-- ------,.
1.160 , cr---H
OH
\ Nr---- 571.2 3.2 A
F
I H
I
228 1.161 0--o H
OH 571.2 3.2 A
rAI-Nr -1- F

I
1.162 * r"
587.2 2.3 B
F
' "=::`,õ-=,,,, I
1.163 ,r---. .-...,---' i "---,------No -----, \

1 I-I OH 557.3 2.6 A
----L-N-^-'-' ' ..:;,=",,F
L,... 0 1.164 OMe 544.2 3.2 A
1.165 Me Cr>
9 -.-:------,-, 1 I. i1 õ---......=y------,,0== , Z5li 570.2 3.2 A
- --'-':--'"Lt.r""'''z=------- õ-_-.1,,, ¨ F
: 1-1 1.166 0----, x0H
573.3 2.5 B

I
1.167 0 Me H

597.2 3.1 A
229 1.168 OMe r N--H
556.2 3.1 A
F

..--".

1.169 01,,le P-----tp H
542.2 3.2 A
.õ...--...............r.õ----.1.4,-- s-,..
F

1.170 OMe 0W---'-___LL I ..--=-- H
528.2 3.2 A
1.171 cme 49 569.3 3.0 A
F
4IIIPP-7.

I
1.172 --N.

H lam +++ 571.2 3.2 A
1.173 . H
HNõ---=:=,..j-1. ' OH 568.3 2.6 A
H I
1.174 -, "----- F ' 275.2 2.2 B
H
C , I
230 1.175 0 '' F --- 628.2 2.5 B
.--"' I
1.176 .----I H
545.3 2.2 B

1.177 -....
LP
573.3 2.1 B
H I

1.178 -, ------..--., --1.4.-----,-,,,n-,..
H I
H bi-t +++ 601.2 2.6 B

1.179 "--0 `=1\1--- H
561.2 2.7 B
H y F

1.180 Okle , ...., ......,n i (...... ,ti- , , H
,94 1 OH 564.3 2.9 A
1.181 ONie 1 I 1 I H 522.3 3.0 A
ryi-H
-.. ----N '`--,--i-
231 1.182 ONle 0 N y 570.2 3.0 A
(I, H
, I
1.183 01+,4 e I
586.2 3.0 A
H N.
H

I
1.184 ---H
553.2 3.1 A
H / I I
i 1.185 -I I H
569.3 3.1 A
i4 1.186 0"---H
.
I=

...--. I H .... ) 584.3 2.2 B
H 01 `F
I
1.187 .
.---"' ---- 614.2 2.1 B
H I
-,..0 `=-..
I
1.188 . .---( Lzmi Nr"
' 1-3 600.3 1.9 B

----.. .---
232 1.189 i Nr---j-- 110 ...----, 1 ir'''. 612.3 2.3 B
ILN'''o H
1.190 -OH
.)",...,...õ....
H
569.3 2.9 A
Ei 1 1.191 V ... 0 .---- .---I I H 1{5H
µ",. 595.3 2.9 A
ii 1.192 !A
i 622.3 2.8 A

1.193 9---- 1-1 -,---608.3 2.8 A
o 1.194 -H
Ll' ++ 600.3 2.0 B
Li, H
I
1.195 i ..-1\p, 3,. ,I .1, y. A '-i L, +++ 598.3 2.2 B
ri ;iv yi `Y, - NF

1.196 ,0 _,FI<NH
I I H 594.2 3.1 A
--k.."---- ----- ''F' N
H I
I
233 1.197 .--õlei:7 r "--. i 0 ..--543.3 2.3 B
/
1.198 ri -) H
555.3 2.9 B
,--1.199 ..-- -0 ( I H '.
"N, ' 11-1 571.3 2.5 B
"N F
I
1.200 , ri--,,,õ --,:-.: : li- --k-i------tr----y-k.
+++ 577.2 2.1 B
A A ri,õ.....:1,.õ.1.. ...k .......:1. $4 L......./-te,.. -.1 14 c ir ..... ssc t!--.,:f----k 1.201 a ,0 +++ 600.2 3.0 A
-1-"--01.----fe-0 1.202 ---11):7 H
541.3 2.8 B
'N. F
H

I
1.203 H
..--".

"N. 545.3 2.4 B

1.204 , - H
H
545.3 2.3 B

I
234 1.205 cr.--H
I H
559.3 2.5 B
H

1.206 ci:
H
--*". ====*.. )1 -...we' 563.3 1.9 B
...."" F
isrY"''H 1 1.207 a OH
I i I H 538.2 2.0 B
...-' i H I i 1.208 , 538.2 2.0 B
F
Li 1.209 9 CSH
fe"
+++ 570.2 2.6 B
H
't 1.210 H
H
533.3 1.9 B
1.211 H
t. ---584.5 2.2 B
Ir....' 0 H
I
1.212 r----NH
..k-J
..---ii Ft -N, 558.3 2.2 B
H -N, H
235 1.213 -.. N--1---/ -re'N
Nril....ti ...--, I H 550.2 2.0 B
---- F
i H 11 >:.., .-1.214 0141e OH
I. H
573.2 3.1 A
icii'. 1 F

1.215 0---H
555.3 2.9 A
H
I
1.216 OMe 1-----.0 I i H
-N. 559.3 2.8 A
N.
H

I
1.217 ...- l.,,. ..,,,,"---,---' : H
6H 601.3 2.6 B
HIT"'s.`11/ 'I "N F
.r..: I 1 ../
1.218 II 1 i H 'PH
587.3 2.3 B
H
I
1.219 ----.-----:"---N
I
--, , ++ 637.3 3.7 A
N , F
. H 1 I
1.220 -561.2 3.0 A
H N
H

I
236 1.221 ,y,-, ,,,, ,., = , I , H

.7 F 531.2 2.3 B
1.222 H
. s',..
i 1 H
561.3 2.3 B
Hisf.1 -F
Cl.'N H
1.223 cr--561.2 3.0 A
1.224 ..
¨\0 -,. +++ 573.2 3.0 A
H I
cd^Nte=k..0 N,,..j.' 1.225 !
= -I, ii Hisr't F +++ 561.2 2.1 B
i 1.226 ---.

...-"" 561.2 2.1 B
H
i 1.227 .----G --- , i I \
+++ 558.2 2.8 A

1.228 0 ..---,1*---',-.. 572.3 2.8 A
I
237 1.229 ,.., ,-.....,,,,00-1---ii 586.3 2.0 B
L H ii F
ek'0 .7 1.230 H
.7 i i I H
600.3 2.1 B
11'N' H
I
1.231 \------'"OH 536.2 2.0 B

1.232 H
=-". ;
H
575.3 2.3 B
rjs, 34 I
...."' I
1.233 I i H
.7 575.3 2.5 B
H \ F
Ft I
1.234 ,-..-- -.

\ .7 546.2 2.8 A
H NN \
H I
1,.^0 N.N......./-1.235 .õ--a .---1,,, I I .=
573.2 3.1 A
H I

1.236 --- N.
il II H
'N. 7 545.3 2.4 B
H
238 1.237 9----- --- , --. -... = ++ 612.3 2.1 B
H
H

1.238 .......le.,....õ......OH
',.. =
I H 524.3 2.2 B
'`.
--1.239 ii----=,,--ki 1,--.ssz) , ri r .-3 li 537.2 2.1 B
...k.,..--- , )1,, ( ,..-?.`,,, T --I.
.....,,,,,...,õ
1.240 H
11 'N li i 538.2 1.9 B
k.,_,,...1'-' H -=<,,,,,, 1.241 -...--- --- , .... Nr i --. +++ 531.2 3.2 A
H-. I , --H
H I
...'"
1.242 -.
-,,-, 1., .
R
627.3 2.2 B
HVAYY 1 ) i e 1 1.243 0--'-N ..--"N
F CO,H 564.3 3.0 B
',.. , 1.244 0.---++ 569.3 2.6 A
.--=". ,H
.---1.245 , ",..
F 02H 564.3 2.4 A
239 1.246 õ

++ 563.3 3.5 B
ki 1.1--".
ir 1.247 ---.., 589.2 2.5 B
H
\ ' 1.248 0--' ---, 110 \----\N"c0214 ++ 563.3 3.9 B
-=.õ.,..iN H 1 1.249 ++ 552.2 2.9 A
1.250 N Op 580.2 3.6 A
H
Mel 1.251 I i 1 --- ,--574.2 2.1 B
----1.252 -.
N. = 1-6 I H
_./
560.2 2.1 B
FE F
1.253 0--Nla,c0 H 564.2 3.2 A
..--'
240 1.254 ?"-- ii --. I ,...):,`, 'F 596.3 2.2 B
Ft I
I
1.255 07 ,..."
t, -1,,.......,NH

H
584.3 2.1 B

I H
I
1.256 n11 1cç ++ 562.2 3.6 A
! H i 1.257 -, \ .
.--- 44 641.3 2.1 B
HN".
Ft I
1.258 0---564.3 2.9 B
' \ F
I H
1.259 -500.1 3.0 A
H I
.---".

I
1.260 H
;0,'LLAK-''kj 595.2 2.8 A
H I

1.261 ---..
I H
..-." H 561.2 2.1 B
H I I
-"-, 0 ' I
241 1.262 0--I .,.., --..--I
EasCO,H 562.3 2.1 B
. N. ,..
H ,,_. F
-;--1.263 Me fln r----i 1 ac 563.3 3.2 A
I H I
1.264 HN---11*-------14 --..., I .õi Irj.:\,,c) ++ 581.3 0.8 B
---"
..., 1.265 V

....,-.1,, F cqH 595.2 2.8 A
H I
I
1.266 .
I i H
N \ 559.3 2.2 B
,,,._7="==
I' 1.267 Cr--_OH
I i I Ft i 545.3 2.1 B
---.. ==-. F
1.268 I I I
"N N 573.3 2.1 B
N,..
I H
i 0 1.269 -H
.../
I H
N 625.3 2.1 B
.--.0 I
242 ../.' 547.2 2.8 A
i o 1.271 -, 11 I '1`0.0 ,-559.2 2.8 A
F
I. 0 1.272 1 r. 1_I 11:-'a ..i.õ-- ..,...:,.._,... ...õ--. =F 1:0,11 571.2 2.5 A
1 il H
1.273 -+++ 564.2 2.7 A
[I N H I
1.274 11 1 i 486.1 2.6 A
. H
1.275 0----,H 598.2 2.8 A
H

i 1.276 0--LL-LC
1.---\
CO)1 600.2 1.5 B
1) NH
1.277 0--0 .N. a*CO,H
CkIjoCE3 1 600.3 2.1 .. B
...--rj
243 1.278 --- ; ---- ----, +++ 593.3 2.4 A
F
H
I
1.279 0---0 --- 1,------^ir 572.3 2.6 A
F
H )1/
!tie 1.280 --i 594.2 2.7 A
Ft 1 1.281 , ..-,--- , i I H 1 OH
558.3 2.3 B
'-..... '--.
r'.I") ===,....7.
1.282 ,-,----I. -.., ."--tr'--Aoi-;
1-;
558.3 2.4 B
, o 1.283 0---ra.
HI,1"-' OOP 587.3 2.6 A
I
1.284 -:'-. -==
..õ _.,...._,_. ii 'sr\
,,....õ
¨ MK- F caH 592.2 3.2 A

I
1.285 9,'E
---j- --. .-, Er I .r.71 ....r..r 627.3 2.5 A
244 1.286 '-'1-:=-rfoi I i ' 513.2 2.6 A
I H I

1.287 --,...
(LNN ---- 593.3 3.0 A
II icr,....0 1.288 cr.' 1,LL`
512.3 1.8 B
QYj 1.289 =-= '7'1 .----- ---'"---CLAW' 0 588.3 2.1 B
rq-- ----o I
1.290 r ----. I-MCI' 544.3 2.1 B

1.291 , 3.--o =-==3--') ic, i iq H
C.,..A
I 513.2 2.0 B
cy 1.292 0.---' i 1 571.2 1.7 B
245 1.293 0,---{).1,,, . Na..
572.3 1.9 B
(1,3 r.1 I
.---V
1.294 .7 * I H2 i 472.2 2.3 A
:
'` , NN F
I H
-,---' 1.295 .õ--I 484.2 2.4 A
..---I H I
1.296 ii i 529.2 2.4 A
H

-.
1.297 ..--0 ------ 1-'-::---- 4H_ Il ++ 472.9 2.1 B

N OH
1.298 OMe H, :
t ""=-. F 483.1 2.5 A

1.299 9---.--7 1 ----m-12 cyCil-''- +++
500.3 2.5 A

s" 7
246 1.300 F 530.2 2.7 B
H I
'...0 1.301 cr' ...--II
570.3 2.5 B
F
CLH
1.302 I, {i etz)., 1 '2-;c4112 + 497.1 2.7 A
'11 -;----1.303 --,--1/4----,,----""-NH., õ..
..----if 74., ---------1õ--73,- -...:-., --õ, .....õ..yr-511.2 3.0 A

1.304 0----489.1 2.4 A
HO
H
1.305 0.14te 9 1 ''''= K2 557.3 2.4 A

..
HO
1.306 Okl e 1, Cr'tµi. I F 527.2 2.6 A
F
.-.....,..4:-
247 1.307 9-_--0 . NH2 i 514.2 2.4 A
-===""

1.308 OMe Hy, õ.....õ.õ..õ.õ.(3-1.2 522.3 1.7 B . 1 ...H
1.309 0 0 --- ; ---L-----mt 1 +++ 515.1 2.5 A
--. ' ---Et 1.310 Me 513.2 2.4 A
I
1.311 otvle 486.2 2.5 A
õ----1.312 465.1 2.0 A
...-- ' õ
1.313 0--o ===-s, s'NI-3, 1 465.1 1.9 A
L
-.) H I

1.314 V
0 .N112 522.2 2.1 A
H
1.315 9Me 0 n, NH2 478.3 1.5 B
F
1., H 1
248 Okle 1.316 0 ---:----;s ---"---------NH2 I 509.3 1.6 B
iio =-.. ' .,... ---...
F
,.,,,-,-----1.317 Me . It i 482.1 2.4 A
====..
H2 =,,,,.,>""

1.318 y -... = ,-----i'z,-------., .. N.\---\To I 1 , ++ 563.3 2.3 A
---- ...--= '''''''''---""`F

..----N .-"---, 1.319 9--.-..-- ----NH, I 464.2 2.0 A
--....
ofsq,,, 1.320 9 i';`-'-ii ri= Ny ist- %
:. : , .,.. +++ 556.5 2.5 A
,j..... J. U.., j )2 ..---)k..,F `-- -"C.O,H
T r y )---ki N--1.321 555.2 2.7 .. A
----=
1 ti t ..... =
1.322 ...-1, F Hi 501.4 2.4 A
ra H

1.323 0----INk,,--i NH2 , I I _., 465.4 2.0 A
-- ' `----=-'-.:'.=,,--"---'F T , H
-,_--6
249 1.324 Ohrle H 508.3 1.7 B
1.325 ONle ' 1 NH2 463.3 1.5 B
HN.,.....,....-1.326 0--ta,c,,,, +++ 571.5 2.5 A
--.. -..
ii H 1 HO.,,,,A,,,,....; N "*.-1.327 .----.
i-- ,t ro,o,, ...- 556.5 2.5 A
1 g, NR, 1.328 OMe I
549.3 1.6 B
=-.
- H i 1.329 OMe OH
r:02H
I 1 1 H 565.3 1.4 B
, c,'`,...
. "-... --F
H i ,...--"--:' 1.330 Okle \------ 547.3 1.5 B
1.331 i 1 1 528.4 3.2 A

.."'"
1.332 Otvle I
-. ,---ta..c 02H 556.5 2.5 A
'-..
' '-`, H,
250 1.333 ON%
CH
I i H
544.5 2.5 A
---.. F

1.334 Olvie ...õ--........õõOH

F:
558.5 2.8 A
FE
....õOyaj a 1.335 0----1 514.3 2.6 A
'`... ' ,T, \
OH ri..----'-'N F
H
U.-. -T.----1.336 . 0 q E
H 551.3 3.1 A

1.337 OMe \- 513.5 2.6 A
11., N...., N..:i.-:
1.338 OMe OH
0 XI H 501.5 2.5 A
rf-nrjLii I CN F
ist,,,,,:;.}==- ; :, ,..--1.339 CMe -*---":.--"----Nnr"Nce .,1-1 I I H - 515.5 2.6 A
=-=.. ---`,-. ----..

1.340 OMe \--3\----C , 555.3 2.4 B
\
irk--T)-LH 1 N
251 1.341 ++ 533.3 3.2 A
Fi i CSH
1.342 9,----0=::-::''',.--'.'"if-j1,,i, IN, jj= . I., .R. \_1,, +++ 570.5 2.6 A
eõ--k........... ..- Ns.- II._ ..........., ,z11 1.343 Okle ,OH
L , 0 --,--- '''le.':".:'C 0,,FE
I I H 560.3 2.3 B
-.., .---:-..õ--,------ --.., F

N--.. ---,%-q ....-1.344 ----o-q ---- , I ,-....õ

++ 470.5 2.8 A
--õ,....,:-=,,N ...----1.345 OMB
0 ....--- s's. --''N''CO2H

',.. 542.7 2.6 A
1 H I '''' F
,4.-,-,.--1.346 OMe I 1 546.2 2.9 =--, ..--A

1.347 OMe I H F 556.3 2.7 A

1.348 ?m,, j,. .., p 11 j: ..t. j ..1:._., \ 'C Op 544.2 2.5 B
r-fry k NI("---)1'F 30,r4 1,...,..:::= I Z.!. ,..:
...c., 1.349 OMe 530.1 2.5 A
252 1.350 OMe 546.0 2.6 A
H I
1.351 OMe 570.2 2.8 A
\ ----- 02H
'N. N...
1.352 0Me I I
"N. 483.1 2.6 A
\ \ F
I H I
H..., .-='.
b 1.353 011,4e 497.1 2.9 A
I Fi NI ..., =
, :
1.354 OMe 0 568.3 3.3 B
I H I I
......,..:..N ,----1.355 OMe 0 1 1 -',. )1,..
rl OH
568.3 2.6 B

'N. F '''''..---1.356 0-7 I 11 I 551.1 2.5 A
\
1.357 ONle I I I 541.2 2.6 A
.N. F
1.358 . ) :-...... ......1 -1-, It t., 1. .-05, ++ 568.3 2.9 B
q kI 11 T Ti ,ki ,,, ,n 1 :
õ N
253 1.359 ',--...
-----; ..--)k ----11 1 .1., 1 ..J.!.1 ..1. 11-21. ,os ++ 558.0 2.9 A
r,...., -11.= ....y ......., .F I
1.360 OMe H O
(. 554.3 2.3 B

1.361 ONle 458.1 2.5 A
N 1 Ij. 1 F
. -....----------, -----=-'' 1.362 OMe Fi 0 II H 594.3 2.7 B

1.363 Me 0 -:-<:).'1 NH, 463.2 2.5 A
H I
1.364 --,, Di 01-1 ++ 555.2 2.2 B
I H I
õ...''',:.=,,,õ_,N N.
1.365 D ¨ i Ci CO.,H +++ 560.1 2.8 A
,,-= ... N
-.....--,,, 1.366 OMe 0 ----.0 .....nCO,H
554.3 2.3 B
... ..-...N
-,..,:..-1.367 GMe I I
541.2 2.6 A
\
'\ 2R
I H
N...,....;õ1,3
254 1.368 OMe I
0 ...--++ 554.3 2.4 B
1.369 OMe 1 I 574.0 3.0 A
I H I I
1.370 9.--.47-'-= --)\'"".....----\, 01 ++ 544.0 2.9 A
1.371 ONle 554.1 2.9 A
1"YtH 11 Nµ F
1.372 OH
OMe T
0 ..-=.----Z N"-.'''i 578.3 2.6 B

1.373 OH
OMe 578.3 2.7 B
1.374 OMe 1 , 467.1 2.6 A
-,..õ.õ....------.....----=-,--3---\F
irS"rTh'F`i N.. ,...11 .,....2 1.375 \---V ++ 526.1 2.8 A
ti,---
255
256 PCT/US2020/032904 1.376 rzOH
OMe lot. 1 .-------------`,-"'"'"N`-'1'.) I

OH 530.3 2.6 B
1.377 OMe CO,H
!
O Olt 1 568.3 2.6 B
1.378 OMe O -.;------7."--i -N,------------141-12 1 1 +++ 458.1 2.3 A
H I
1.379 OH
H
H 560.2 2.7 A
H
\-2-- ' 1.380 co,H
r-,-O I-- -'.'".L=Z'N'i%("C.--"- 1 568.2 3.1 A
Thti I
1.381 0----i I
til''CO,H 540.2 2.8 A
' \

1.382 OMe ? -.-----:\ '11,, ====^,7-, N -,..,,. 471.1 2.8 A
L :t -,r 1.383 OMe 457.0 2.4 A
'¨'-',------'`
L H
I

1.384 Otvie 01 1 rib U., 1 457.0 2.3 A
,--------1 -1,r .."----------Z.-:,------"=---;"5? F
H . I
1.385 V
I i H 514.2 2.8 A
---... ---, F
1.386 Mole 471.0 2.5 A
F
NH, 1.387 --..0 0 -------"'''.:::"= ------------'N'N1-12 eNit,, ,. I H
I
....õ.õ,, 457.0 2.1 B
1.388 0---.,t. An \-3- +++ 512.1 2.8 A
'''=W ---,-----.,--, F '"03-1 1.389 Mle ..---- I "...t..-............isr,....s....70H
I i H
515.1 2.1 A
--' NH, 1.390 ONie H
1 1 H 515.1 2.1 A
---.. ----1.391 ....t., ..-1. irk:, .L i,.:1 +++ 530.0 2.1 B
'--t,r-ir-
257 1.392 õ----õ..................&-N
463.2 2.1 A
H I , 1.393 OtVie '. K2 506.2 2.0 A
'11-I I
HO
1.394 0---462.1 2.0 A
F
H
'N
H
1.395 ,,,...,,,, ....k.,,,õ.......,..f.shi , ++ 550.2 2.0 A
r- ---..,--=
,-Ø----,--k) H 1 i. 11 1 ....,,,,,.., 1.396 OH
Ft 500.0 2.3 B
-,--....,;,.... ' 1.397 ONte OH
0 - \
I H 506.1 2.4 A
rH
. 1 .
1.398 , 1 I Ft s.., 579.2 1.4 B
1.399 q ,.. jt =
---i'ke------N--------.1,,,,i-: 1.1 637.2 2.2 A
, ., r.
1.400 ...5..... II ) 1-1 ' +++ 609.2 1.4 B
,.,.....õ...,..- .......p.
,t----: H I:, II
' -..,,....-
258 1.401 ....L ......, ....., ...-..., L f.. I .0 7,' - - '14 +++ 615.2 2.2 A
rki-- 7-kt--õTr--,_:õ( -,, 1.402 .-/
I Ar H
689.1 2.3 A
HQ) 1.403 '9 A , -i-., (.:--:-="-ii i...- ....õr" ,,,,,i..-_.......¨_,,......ji ..9",, 1 ...it ........1, h +++ 607.2 1.6 B
=-' y. `-' `F
.., 1.404 c.,si6 .4.,..--,,...---....AH
".in..... ..- I 'I t4 +++ 573.2 2.2 A
=:-...õ-..õ.A.,..,. ,,,õ..
ti 1 1 [0362] Using the methods described in the Examples above, the compounds in Table 2 were prepared & tested for biological activity using the ELISA method described above. The ICso values are provided as follows: from 1000 to 10,000 nM (+); from 10 up to 1000 nM (++); less than 10 nM (+++).
Table 2 Cmpd ELISA m/z HPLC HPLC
No. Structure ICso (nM) [m+Fi] RT (min) Method 2.001 c:K
H
F

654.5 3.3 B
H
(31,110 I
2.002 0 a +++ 666.2 3.6 A
F N ..........>
H
L I H

I
259 2.003 1 NK.,====''Lli 669.2 3.4 B
o H I
I
2.004 ario +++ 669.0 3.3 B
F
Cil I
I
2.005 I
683.2 3.2 B
)H OH
I

I
2.006 c) re.).Lo a F NH
++ 674.3 2.9 A
-......¨ \
2.007 e o o a \ /
660.2 2.8 A
oo H 1 I
2.008 c) o& CI
rs----COOH
+++ 655.1 3.4 A
F
H
I

2.009 1 Na 1,,........1-0H 655.0 3.3 B
F

I
260 2.010 1 0.....,0 \NI F OH 655.0 3.4 B
o H 1 I
2.011 e N).Lo +++ 626.2 2.7 A
F

H
I
2.012 e N.Lo a +++ 646.2 2.4 A
F

I
2.013 1 nii +++ 663.2 3.4 A

I
2.014 e r,rA) Na-COOH 601.2 3.1 A
F
H
ONO

2.015 I
\rsi/A F
649.2 3.2 A
oJ. o H
I
2.016 607.2 3.1 A
oj. 0 H
I
261 2.017 c) rst.).Lo CI
r c0OH +++ 635.2 3.0 A
2.018 F +++ 635.2 3.0 A
c)lacH
2.019 +++ 649.2 3.3 A
F
2.020 F +++ 621.2 2.9 A
cH
2.021 +++ 635.2 3.1 A
2.022 F +++ 657.2 2.72 2.023 FNIP
F () +++ 637.2 3.05 H H

2.024 rcY
F () +++ 651.2 3.13
262 2.025 r?
+++ 671.1 3.15 B
cd. 0 H
I
I
2.026 r'Al'N
+++ 640.2 2.0 A
I

I
2.027 e-...........,N H
I
H
+++ 640.2 2.2 A
0). H
I
I
2.028 el,,,)s1H
I
H +++ 624.2 2.3 A
H Nr. F
I
2.029 recj OH +++ 643.2 2.2 A
H
I

2.030 H ' OH +++ 643.2 2.1 A
Cd. 0 H
I
I
2.031 +++ 620.2 2.1 A
H F
H
I
263 2.032 0 H
I
H
+++ 620.2 2.0 A
1:11 H
I
2.033 õ.4o 1 eL)H
H 606.2 1.9 A

I
2.034 reci OH 623.2 2.0 A
H
I
2.035 I
H
6H 623.2 2.0 A

I
2.036 o NeCri e..)Lo CI
H
+++ 668.2 2.95 B
F
H

I
2.037 H
OH 671.3 3.03 B
\ Nr F

I
I
2.038 NH
Niy)L0 CI
H
++ 648.3 2.88 B
F
H

I
2.039 I
H i OH 651.3 2.98 B
c\& F
H

I
264 2.040 0 NedNH
+++ 591.2 1.93 A

2.041 IIH
+++ 604.3 2.06 A
2.042 N10) H
OH +++ 607.2 1.96 A
CH

2.043 Co +++ 621.3 2.60 A
2.044 rY
NH, +++ 694.3 2.88 H
2.045 +++ 609.3 2.3 A
c)I :
2.046 F ra'000H +++ 621.2 2.3 A
o H
265 2.047 COON
I
+++ 649.3 2.4 A

I
2.048 re 0 I
H i OH +++ 633.3 2.94 B
OistH
I
2.049 \ N OH +++ 620.2 2.76 B
cd. 0 H
I
2.050 I
HIP
+++ 635.3 2.69 A
cd" 0 H
I
2.051 .0 " OH +++ 621.3 2.9 B
H

I
2.052 H
OH +++ 621.3 3.0 B
Cd 0 H
I
2.053 , r-C?
OH +++ 621.3 2.9 B
F
CdH
I
266 2.054 ne H
OH 619.3 2.88 c3 o H
2.055 dNH
++ 654.2 2.13 A
cc&H
2.056 OH
+++ 607.2 2.3 A
:&H

2.057 NIJOH
+++ 609.3 2.3 A
2.058 595.2 2.1 A

2.059 634.3 2.23 A
o H
2.060 H
621.3 2.4 A
267 2.061 .6H
++ 634.3 2.18 A

2.062 I OH 651.3 2.92 0)NH

2.063 599.2 2.6 A

2.064 579.2 2.95 2.065 e)" 627.2 2.5 A
Ce 0 I
2.066 627.2 2.4 A
o H
2.067 Ne0 +++ 621.3 2.99
268 2.068 0 Nr.dNH
I
I +++ 654.2 1.94 A
Cd 0 H
I
I
2.069 ea 1 I +++ 635.3 2.56 A
F
ONCH
I
2.070 ..II
I
H
OH +++ 657.2 2.3 A
H
CI
I
2.071 1 nr0 H
+++ 657.2 2.3 A

2.072 0 N$NH
I
I +++ 634.3 1.93 A
F
CdNICH
I
2.073 I
H "
tH +++ 643.2 2.2 A
F
I
CdNaaCH
I
2.074 H
OH +++ 643.2 2.2 A
ii& F
H
I

I
269 2.075 õ.q I
H
OH 643.2 2.2 A
F
H
I
I
2.076 1 Nr0 " 6 +++ 643.2 2.2 A
F
).H
I
I
2.077 Nr0 H
OH 637.1 2.9 B
F
I
2.078 H
OH 637.0 2.0 A
F
c)NH
I
I
2.079 H
F
FICC...0 +++ 638.1 2.8 B
F
OXH
I
2.080 H
+++ 621.2 2.50 A
F
H
I
2.081 o (3 dNH
H 640.2 2.48 B
H I
I
270 2.082 I
H ' OH 657.3 2.87 B
I
I
2.083 NO I
H
+++ 621.2 2.87 B
F
OjtH
I
2.084 o o 1 N
Ns H 620.3 1.97 A
H
I
2.085 o r<r NH2 ++ 622.0 2.80 B

I
2.086 I
H
OH 637.2 2.06 A
F
H
I
2.087 1 eCO
H
+++ 607.0 2.84 B
F
c:X.0LII
I
2.088 NiLo a N,"0 H ' OH 637.3 1.91 A
F
271 2.089 H A
OH +++ 637.3 2.34 A
\NI7 2.090 OH +++ 623.3 2.73 2.091 H
+++ 641.1 2.8 CH
2.092 er) +++ 623.1 2.83 2.093 OH +++ 623.3 2.85 Cd'N 0 H
2.094 .C) OH +++ 623.3 2.80 2.095 NrC, H E
OH +++ 621.3 2.15 A
C)H
272 2.096 Ne0 H E
OH 617.3 2.11 A
JH
2.097 OH 617.3 2.64 A
c):1H
2.098 .. Co +++ 607.0 2.83 cH
2.099 OH 621.3 2.43 A
cc'yLo 2.100 648.2 2.4 A
C) 0 2.101 ......... H
rst +++ 634.1 2.68 2.102 Nr"
OH 637.0 2.79 OX-)CH
273 2.103 r9 OH 637.5 2.5 A
F
Cd'.H
I
I
2.104 rcl OH 637.3 2.90 B
F
I
2.105 rci OH 621.3 2.16 A
F
NC:C.:H
I
2.106 1 Nr 0) H ' 8H 641.2 2.42 A
F
I
2.107 .....--,..ro NLto CI
H
+++ 654.0 2.68 B
F
0). H
I
I
2.108 I it'H'I'NFI, +++ 656.1 2.93 B
F
H
0;: I
I
2.109 N I
NtnI COOH
+++ 618.2 3.9 A
F
H
274 2.110 N CI IsK.C/
H s +++ 608.2 2.8 A
'OH
F
N H I
2.111 e +++ 570.2 1.9 A
NOrIH F
..,.- N
2.112 e +++ 572.2 1.8 A
F
UN H
2.113 o 0 ---......'N I

n,L +++ 599.3 2.9 B
F
U H
2.114 NI:) ---.....-.-------, N CI
H F OH +++ 600.3 1.8 A
U H
2.115 N CI C?
1.1 tH +++ 586.2 2.0 A
F
IU "
2.116 Nr,,,..........õNH
N CI
H +++ 597.2 1.6 A
F
u H
[0363] Particular embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Upon reading the foregoing, description, variations of the disclosed embodiments may become apparent to individuals working in the art, and it is expected that those skilled artisans may employ such variations as appropriate.
Accordingly, it is intended that the invention be practiced otherwise than as specifically
275 described herein, and that the invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law.
Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
[0364] All publications, patent applications, accession numbers, and other references cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.
276

Claims (38)

WHAT IS CLAIMED IS:
1. A compound of Formula (I):
or a pharmaceutically acceptable salt, prodrug or bioisostere thereof, wherein:
R1a, R1b, Rlc and ¨ ld are each independently selected from the group consisting of H, halogen, C1-3 alkyl, C1-3 haloalkyl, C1-3 alkoxy and CN;
Xl is C1-3 alkylene, optionally substituted with one or two C1-2 alkyl or CO2H;
R2a and R2b are each independently selected from the group consisting of H, C1-8 alkyl, C1-8 hal oal kyl, -Y, -X2-C(0)2Ra, -X2-0Ra, -x24\lltaRb, _x2_CONRaRb, _x2_so2Ra, -X2-SO2NRaRb, -X2-SO3Ra and ¨X2-Y wherein each X2 is C1.6 alkylene and any C1-8 alkyl or C1-6 alkylene, is optionally further substituted with one or two members independently selected from OH, SO2NH2, CONH2, C(0)NHOH, P03H2, COO-C1-8 alkyl or CO2H, and each Y is selected from the group consisting of C3-6 cycloalkyl, C4-8 heterocyclyl and 5-to 6-membered heteroaryl, each of which is optionally further substituted with one to four substituents independently selected from the group consisting of oxo, OH, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 hydroxyalkoxy, SO2NH2, CONH2, C(0)NHOH, P03H2, COO-C1-8 alkyl, SO3H and CO2H;
or R2a and R2b are combined to form a 4- to 10-membered ring or spirocyclic ring, optionally having one or two additional ring vertices selected from 0, N or S;
wherein the ring formed by combining R2a and R2b, is substituted with 0 to 4 substituents independently selected from the group consisting of oxo, C1-8 alkyl, C1-8 haloalkyl, Cl-8 hydroxyalkyl, -X3-C(0)2Ra, -X3-0Ra, -X3-NRaRb, -X3-CONRaRb, -X3-SO2Ra, -X3-SO2NRaRb, and ¨X3-SO3Ra; wherein X3 is a bond or C1-6 alkylene;
R3 and R4 are each independently selected from the group consisting of F, Cl, CN, CH3, OCH3, CH2CH3 and CF3;

the subscript n is 0, 1, 2 or 3;
each R3 is independently selected from the group consisting of H, F, c1, c13 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 haloalkoxy, C2-3 alkenyl and CN;
R6, R7 and le are each independently selected from the group consisting of H, F, ci, CN, CH3, OcH3, cH2cH3 and cF3;
A is a member selected from the group consisting of ¨N(Ra)-, ¨c(=0)N(Ra)-, ¨S(0)N(Ra)-, and ¨S(0)2N(Ra)-;
Z is selected from the group consisting of:
i) a monocyclic, bicyclic, or spirocyclic non-aromatic heterocyclic ring, optionally substituted with one or two oxo groups and optionally substituted with up to four IV
and/or Rb;
ii) a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three Rc; and iii) a fused bicyclic heteroaryl ring, optionally substituted with one to three Rc;
wherein when A is ¨N(Ra)-, then Z is a fused bicyclic heteroaryl ring optionally substituted with one to three Rc;
each It' is independently selected from the group consisting of H, c1-6 alkyl, C3-6 cycloalkyl, c1-6 haloalkyl, c 1-6 hydroxyalkyl, c1-6 alkylene-c02H, c 1-6 alkylene-SO3H;
each Rb is independently selected from the group consisting of H, c1-6 alkyl, C3-6 cycloalkyl, c16 haloalkyl, c1.6 hydroxyalkyl, c1.6 alkylene-c02H, and c1.6 alkylene-SO3H, each of which is optionally further substituted with one or two members independently selected from OH, SO2NH2, cONH2, C(0)NHOH, P03H2, COO-C1-8 alkyl and cO2H;
and IV and Rb, when attached to the same nitrogen atom, are optionally combined to form a 4- to 8-membered ring or spirocyclic ring, optionally substituted with halogen, OH, SO2NH2, cONH2, C(0)NHOH, P03H2, COO-C1-8 alkyl or cO2H;
each Rc is independently selected from the group consisting of H, halogen, cN, c16 alkyl, c1-6 haloalkyl, -Y1, _ X C(0)2Ra, -0-X4-C(0)2Ra, -X4-0Ra, -x4 _NRaRb _x4_ coNRaRb, -0-X4-CONRaRb, -VI-S02Ra, -VI-SO2NRaRb, -VI-S03Ra, and -N(Ra)-x4_c(o)2Ra, wherein each X4 is a bond or c1_6 alkylene, and each Y1 is selected from the group consisting of C3-6 cycloalkyl and C4-8 heterocyclyl; and optionally two Rc on adjacent ring vertices are combined to form a fused 5- or 6-membered heterocyclic ring.
2. A compound of Formula (I):
or a pharmaceutically acceptable salt, prodrug or bioisostere thereof, wherein:
R1a, Rlb, Rlc and ¨ ld are each independently selected from the group consisting of H, halogen, Cl-3 alkyl, C1-3 haloalkyl, C1-3 alkoxy and CN;
Xl is Cl-3 alkylene, optionally substituted with one or two C1-2 alkyl or CO2H;
R2a and R2b are each independently selected from the group consisting of H, C1-8 alkyl, C1-8 hal oal kyl, -Y, -X2-C(0)2Ra, -X2-0Ra, -)(24\TRaRb, _x2_CONRaRb, _x2_so2Ra, -x2-SO2NRaRb, -x2-S03Ra and ¨X2-Y wherein each X2 is C1.6 alkylene and any C1-8 alkyl or C1-6 alkylene, is optionally further substituted with one or two members independently selected from OH, SO2NH2, CONH2, C(0)NHOH, P03H2, COO-C1-8 alkyl or CO2H, and each Y is selected from the group consisting of C3-6 cycloalkyl, C4-8 heterocyclyl and 5-to 6-membered heteroaryl, each of which is optionally further substituted with one to four substituents independently selected from the group consisting of oxo, OH, C1-4 alkyl, C1-4 haloalkyl, C1_4 hydroxyalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 hydroxyalkoxy, SO2NH2, CONH2, C(0)NHOH, P03H2, COO-C1-8 alkyl, SO3H and CO2H;
or R2a and R2b are combined to form a 4- to 9-membered ring or spirocyclic ring, optionally having one or two additional ring vertices selected from 0, N or S;
wherein the ring formed by combining R2a and R2b, is substituted with 0 to 4 substituents independently selected from the group consisting of oxo, C1-8 alkyl, C1-8 haloalkyl, Cl-g hydroxyalkyl, -X3-C(0)2Ra, -X3-0Ra, -X3-NRaRb, -X3-CONRaRb, -X3-SO2Ra, -X3-SO2NRaRb, and ¨X3-SO3Ra; wherein X3 is a bond or C1-6 alkylene;
R3 and R4 are each independently selected from the group consisting of F, Cl, CN, CH3, OCH3, CH2CH3 and CF3;
the subscript n is 0, 1, 2 or 3;

each R3 is independently selected from the group consisting of H, F, c1, c13 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 haloalkoxy, C2-3 alkenyl and CN;
R6, R7 and le are each independently selected from the group consisting of H, F, ci, CN, CH3, OcH3, cH2cH3 and cF3;
A is a member selected from the group consisting of ¨N(Ra)-, ¨c(=0)N(Ra)-, ¨S(0)N(Ra)-, and ¨S(0)2N(Ra)-;
Z is selected from the group consisting of:
i) a monocyclic, bicyclic, or spirocyclic non-aromatic heterocyclic ring, optionally substituted with one or two oxo groups and optionally substituted with up to four IV
and/or Rb;
ii) a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three Rc; and iii) a fused bicyclic heteroaryl ring, optionally substituted with one to three Rc;
wherein when A is ¨N(Ra)-, then Z is a fused bicyclic heteroaryl ring optionally substituted with one to three Rc;
each IV is independently selected from the group consisting of H, c16 alkyl, C3-6 cycloalkyl, c16 haloalkyl, c 1-6 hydroxyalkyl, c1-6 alkylene-c02H, c 1-6 alkylene-SO3H;
each Rb is independently selected from the group consisting of H, c1-6 alkyl, C3-6 cycloalkyl, c16 haloalkyl, c1.6 hydroxyalkyl, c1.6 alkylene-c02H, and c1.6 alkylene-SO3H, each of which is optionally further substituted with one or two members independently selected from OH, SO2NH2, cONH2, C(0)NHOH, P03H2, C00-C1-8 alkyl and cO2H;
and IV and Rb, when attached to the same nitrogen atom, are optionally combined to form a 4- to 8-membered ring or spirocyclic ring, optionally substituted with halogen, OH, SO2NH2, cONH2, C(0)NHOH, P03H2, C00-C1-8 alkyl or cO2H;
each Rc is independently selected from the group consisting of H, halogen, cN, c16 alkyl, c1-6 haloalkyl, -Y1, _ X C(0)2Ra, -0-X4-C(0)2Ra, -X4-0Ra, -x4 _NRaRb _x4_ coNRaRb, -0-X4-CONRaRb, -VI-802Ra, -V1-802NRaRb, -VI-803Ra, and -N(Ra)-x4_c(o)2Ra, wherein each X4 is a bond or c1_6 alkylene, and each Y1 is selected from the group consisting of C3-6 cycloalkyl and C4-8 heterocyclyl; and optionally two Rc on adjacent ring vertices are combined to form a fused 5- or 6-membered heterocyclic ring.
3. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof haying formula (Ia):
4. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof haying formula (Ib):
5. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof haying formula (Ic):
6. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof haying formula (Id):
7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof wherein the group lea is OCH3 and leb is F.
8. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof wherein A is ¨C(=0)N(Ra)-, and Z is selected from the group consisting of:
i) a 5- or 6-membered non-aromatic heterocyclic ring, optionally substituted with one or two oxo groups and optionally substituted with up to four IV
and/or Rb; and ii) a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three It'.
9. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof wherein Z is a non-aromatic heterocyclic ring having a formula selected from the group consisting of:
10. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof wherein Z is a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three It', and said heterocyclic ring is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, oxazolyl, thiazolyl, and pyrazolyl.
11. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein Z is a non-aromatic heterocyclic ring selected from the group consisting of piperidinyl, morpholinyl, tetrahydropyranyl, and tetrahydrofuranyl, each of which is optionally substituted with up to four IV and/or Rb.
12. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein A is ¨N(Ita)-, and Z is a fused bicyclic heteroaryl ring, optionally substituted with one to three It'.
13. The compound of claim 1 or 12, or a pharmaceutically acceptable salt thereof wherein Z is a fused bicyclic heteroaryl ring having a formula selected from the group consisting of:
14. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof wherein R2a and R2b are each H.
15. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof wherein R2a and R2b are combined to form a 4- to 9-membered ring or spirocyclic ring, optionally having one or two additional ring vertices selected from 0, N or S;
wherein said ring or spirocyclic ring is substituted with 0 to 4 substituents independently selected from the group consisting of oxo, C1-8 alkyl, C1-8 haloalkyl, C1-8 hydroxyalkyl, -X2-C(0)2Ra, -X2-0Ra, - x2 _NRaRb _x2_C ONRaRb, _x2_ s 02Ra, _x2_ s 02NRaRb and ¨X2-SO3Ra;
wherein X2 is a bond or C1-6 alkylene.
16. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof wherein ¨N(R2a)(R2b) is selected from the group consisting of:
17. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof wherein ¨N(R2a)(R2b) is selected from the group consisting of:

18. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof wherein ¨N(10)(R2b) is selected from the group consisting of:

19. The compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof wherein lea is H or C1-8 alkyl; and R2b is ¨Y or ¨X2-Y.
20. The compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, wherein the compound is an optically pure or enriched isomer.
21. The compound of claim 19, or a pharmaceutically acceptable salt thereof wherein Y is selected from the group consisting of C3-6 cycloalkyl and C4-8heterocyclyl, each of which is optionally further substituted with one to four substituents independently selected from the group consisting of oxo, OH, C1-4 alkyl, C1-4 haloalkyl, C1-4hydroxyalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C1-4hydroxyalkoxy, SO2NH2, CONH2, C(0)NHOH, P03H2, COO-C1-8alkyl, and CO2H.
22. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof wherein A is ¨C(=0)N(Ra)- and Z is a 5- or 6-membered non-aromatic heterocyclic ring, optionally substituted with one or two oxo groups and optionally substituted with IV and/or Rb.
23. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof wherein A is ¨C(=0)N(Ra)- and Z is a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three It'.
24. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof wherein A is ¨C(=0)N(Ra)-; Z is a 5- or 6-membered non-aromatic heterocyclic ring, optionally substituted with one or two oxo groups and optionally substituted with IV and/or Rb;
and each of Ric, R6, R7 and le is H.
25. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof wherein A is ¨C(=0)N(Ra)-; Z is a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three Rc; and each of R1c, R6, R7 and le is H.
26. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof wherein A is ¨C(=0)N(Ra)-; Z is a 5- or 6-membered non-aromatic heterocyclic ring, optionally substituted with one or two oxo groups and optionally substituted with IV and/or Rb;
and said non-aromatic heterocyclic ring is selected from the group consisting of piperidinyl, morpholinyl, tetrahydropyranyl, and tetrahydrofuranyl.
27. The compound of claim 1 or claim 2, or a pharmaceutically acceptable salt thereof wherein A is ¨C(=0)N(Ra)-; Z is a monocyclic 5- or 6-membered heteroaryl ring, optionally substituted with one to three Rc; and said heterocyclic ring is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, oxazolyl, thiazolyl, and pyrazolyl.
28. A pharmaceutical composition comprising a compound of any one of claims 1 to 27, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
29. The pharmaceutical composition of claim 28, further comprising one or more additional therapeutic agents.
30. The pharmaceutical composition of claim 29, wherein the one or more additional therapeutic agent is selected from the group consisting of an antimicrobial agent, an antiviral agent, a cytotoxic agent, a gene expression modulatory agent, a chemotherapeutic agent, an anti-cancer agent, an anti-angiogenic agent, an immunotherapeutic agent, an anti-hormonal agent, an anti-fibrotic agent, radiotherapy, a radiotherapeutic agent, an anti-neoplastic agent, and an anti-proliferation agent.
31. A method of modulating an immune response mediated by the PD-1 signaling pathway in a subject, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 27, or a pharmaceutically acceptable salt thereof or a composition of any one of claims 28 to 30.
32. A method of enhancing, stimulating, modulating and/or increasing the immune response in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 27, or a pharmaceutically acceptable salt thereof or a composition of any one of claims 28 to 30.
33. A method of inhibiting growth, proliferation, or metastasis of cancer cells in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 27, or a pharmaceutically acceptable salt thereof or a composition of any one of claims 28 to 30.
34. A method of treating a subject suffering from or susceptible to a disease or disorder mediated by the PD-1 signaling pathway, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1 to 27, or a pharmaceutically acceptable salt thereof or a composition of any one of claims 28 to 30.
35. The method of any one of claims 31 to 34, wherein the subject suffers from a disease or disorder selected from the group consisting of an infectious disease, a bacterial infectious disease, a viral infectious disease a fungal infectious disease, a solid tumor, a hematological malignancy, an immune disorder, an inflammatory disease, and cancer.
36. The method of claim 34, wherein the disease or disorder is selected from the group consisting of melanoma, glioblastoma, esophagus tumor, nasopharyngeal carcinoma, uveal melanoma, lymphoma, lymphocytic lymphoma, primary CNS lymphoma, T-cell lymphoma, diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, prostate cancer, castration-resistant prostate cancer, chronic myelocytic leukemia, Kaposi's sarcoma fibrosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, angiosarcoma, lymphangiosarcoma, synoviomaõ meningioma, leiomyosarcoma, rhabdomyosarcoma, sarcoma of soft tissue, sarcoma, sepsis, biliary tumor, basal cell carcinoma, thymus neoplasm, cancer of the thyroid gland, cancer of the parathyroid gland, uterine cancer, cancer of the adrenal gland, liver infection, Merkel cell carcinoma, nerve tumor, follicle center lymphoma, colon cancer, Hodgkin's disease, non-Hodgkin's lymphoma, leukemia, chronic or acute leukemias including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma, ovary tumor, myelodysplastic syndrome, cutaneous or intraocular malignant melanoma, renal cell carcinoma, small-cell lung cancer, lung cancer, mesothelioma, breast cancer, squamous non-small cell lung cancer (SCLC), non-squamous NSCLC, colorectal cancer, ovarian cancer, gastric cancer, hepatocellular carcinoma, pancreatic carcinoma, pancreatic cancer, Pancreatic ductal adenocarcinoma, squamous cell carcinoma of the head and neck, cancer of the head or neck, gastrointestinal tract, stomach cancer, HIV, Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, herpes viruses, papillomaviruses, influenza, bone cancer, skin cancer, rectal cancer, cancer of the anal region, testicular cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the urethra, cancer of the penis, cancer of the bladder, cancer of the kidney, cancer of the ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, epidermoid cancer, abestosis, carcinoma, adenocarcinoma, papillary carcinoma, cystadenocarcinoma, bronchogenic carcinoma, renal cell carcinoma, transitional cell carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, wilm's tumor, pleomorphic adenoma, liver cell papilloma, renal tubular adenoma, cystadenoma, papilloma, adenoma, leiomyoma, rhabdomyoma, hemangioma, lymphangioma, osteoma, chondroma, lipoma and fibroma.
37. The method of any one of claims 31 to 36, further comprising administering to the subject a therapeutically effective amount of one or more additional therapeutic agents.
38. The method of claim 37, wherein the one or more additional therapeutic agents is selected from the group consisting of an antimicrobial agent, an antiviral agent, a cytotoxic agent, a gene expression modulatory agent, a chemotherapeutic agent, an anti-cancer agent, an anti-angiogenic agent, an immunotherapeutic agent, an anti-hormonal agent, an anti-fibrotic agent, radiotherapy, a radiotherapeutic agent, an anti-neoplastic agent, and an anti-proliferation agent.
CA3139526A 2019-05-15 2020-05-14 Triaryl compounds for treatment of pd-l1 diseases Pending CA3139526A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962848114P 2019-05-15 2019-05-15
US62/848,114 2019-05-15
PCT/US2020/032904 WO2020232256A1 (en) 2019-05-15 2020-05-14 Triaryl compounds for treatment of pd-l1 diseases

Publications (1)

Publication Number Publication Date
CA3139526A1 true CA3139526A1 (en) 2020-11-19

Family

ID=73289294

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3139526A Pending CA3139526A1 (en) 2019-05-15 2020-05-14 Triaryl compounds for treatment of pd-l1 diseases

Country Status (13)

Country Link
US (2) US11266643B2 (en)
EP (1) EP3968996A4 (en)
JP (1) JP2022531970A (en)
KR (1) KR20220009420A (en)
CN (1) CN114340633A (en)
AU (1) AU2020276277A1 (en)
BR (1) BR112021022659A2 (en)
CA (1) CA3139526A1 (en)
IL (1) IL287843A (en)
MA (1) MA55974A (en)
MX (1) MX2021013819A (en)
SG (1) SG11202112310TA (en)
WO (1) WO2020232256A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7185532B2 (en) 2016-06-27 2022-12-07 ケモセントリックス，インコーポレイティド immunomodulatory compounds
AU2018306619B2 (en) 2017-07-28 2022-06-02 Chemocentryx, Inc. Immunomodulator compounds
CN111225665B (en) 2017-08-08 2023-12-08 凯莫森特里克斯股份有限公司 Macrocyclic immunomodulators
EP3755311A4 (en) 2018-02-22 2021-11-10 ChemoCentryx, Inc. Indane-amines as pd-l1 antagonists
JP2022536845A (en) 2019-06-20 2022-08-19 ケモセントリックス，インコーポレイティド Compounds for treating PD-L1 diseases
JP2022539830A (en) 2019-07-10 2022-09-13 ケモセントリックス，インコーポレイティド Indane as a PD-L1 inhibitor
PE20221764A1 (en) 2019-10-16 2022-11-11 Chemocentryx Inc HETEROARYL-BIPHENYL AMINES FOR THE TREATMENT OF PD-L1 DISEASES
US11713307B2 (en) * 2019-10-16 2023-08-01 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
WO2021093817A1 (en) * 2019-11-15 2021-05-20 杭州和正医药有限公司 Immunomodulatory compounds, composition and application thereof
WO2021136354A1 (en) * 2020-01-03 2021-07-08 上海翰森生物医药科技有限公司 Biphenyl derivative inhibitor, preparation method therefor and use thereof
CN116472045A (en) * 2020-06-23 2023-07-21 坎莫森特里克斯公司 Methods of treating cancer using heteroaryl biphenyl amide derivatives
US20230031213A1 (en) * 2021-06-18 2023-02-02 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1
WO2023114365A1 (en) * 2021-12-16 2023-06-22 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1
CN115010658B (en) * 2022-05-11 2023-06-27 南方医科大学 Compound and preparation method and application thereof
WO2024018403A1 (en) * 2022-07-21 2024-01-25 Arbutus Biopharma Corporation Substituted imidazoamide compounds, and methods using same

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
CA2647819C (en) 2006-03-31 2012-12-11 Novartis Ag Phenylcyclohexyl derivatives as dgat1 inhibitors
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
KR102276644B1 (en) 2013-09-04 2021-07-13 브리스톨-마이어스 스큅 컴퍼니 Compounds useful as immunomodulators
RS57559B1 (en) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
SG11201601682RA (en) 2013-09-06 2016-04-28 Aurigene Discovery Tech Ltd 1,2,4-oxadiazole derivatives as immunomodulators
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3377488T2 (en) 2015-11-19 2023-02-28 Incyte Corp Heterocyclic compounds as immunomodulators
EP3390361B1 (en) 2015-12-17 2022-03-16 Incyte Corporation N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators
SG11201805300QA (en) 2015-12-22 2018-07-30 Incyte Corp Heterocyclic compounds as immunomodulators
EP3190103A1 (en) 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibitors of the pd-1/pd-l1 protein/protein interaction
ES2906460T3 (en) 2016-05-06 2022-04-18 Incyte Corp Heterocyclic compounds as immunomodulators
EP3466944B1 (en) 2016-05-23 2022-06-15 Institute of Materia Medica, Chinese Academy of Medical Sciences Nicotinyl alcohol ether derivative, preparation method therefor, and pharmaceutical composition and uses thereof
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3028685A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Heterocyclic compounds as immunomodulators
JP7185532B2 (en) 2016-06-27 2022-12-07 ケモセントリックス，インコーポレイティド immunomodulatory compounds
CA3029857C (en) 2016-07-05 2023-07-04 Guangzhou Maxinovel Pharmaceuticals Co., Ltd Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
US10590105B2 (en) 2016-07-08 2020-03-17 Bristol-Meyers Squibb Company 1,3-dihydroxy-phenyl derivatives useful as immunomodulators
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2941716T3 (en) 2016-08-29 2023-05-25 Incyte Corp Heterocyclic compounds as immunomodulators
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2018045142A1 (en) 2016-09-02 2018-03-08 Polaris Pharmaceuticals, Inc. Immune checkpoint inhibitors, compositions and methods thereof
WO2018118848A1 (en) 2016-12-20 2018-06-28 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
ES2934230T3 (en) 2016-12-22 2023-02-20 Incyte Corp Benzooxazole derivatives as immunomodulators
HRP20221216T1 (en) 2016-12-22 2022-12-23 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
CA3047991A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018121560A1 (en) 2016-12-29 2018-07-05 深圳微芯生物科技有限责任公司 Urea compound and preparation method and application thereof
CN108395443B (en) 2017-02-04 2021-05-04 广州丹康医药生物有限公司 Cyclic compounds inhibiting programmed death receptor ligand 1 and uses thereof
WO2018183171A1 (en) 2017-03-27 2018-10-04 Bristol-Myers Squibb Company Substituted isoquionline derivatives as immunomudulators
JOP20180040A1 (en) 2017-04-20 2019-01-30 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
WO2018196768A1 (en) 2017-04-26 2018-11-01 南京圣和药业股份有限公司 Heterocyclic compound serving as pd-l1 inhibitor
CN108863963B (en) 2017-05-08 2022-05-27 南京圣和药物研发有限公司 Heterocyclic compounds as PD-L1 inhibitors
EP3669872A4 (en) 2017-08-18 2021-05-05 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Compound having pd-l1 inhibitory activity, preparation method therefor and use thereof
EP3692053A1 (en) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunomodulators
CN109665968B (en) 2017-10-16 2022-02-22 四川科伦博泰生物医药股份有限公司 Fused ring compound, preparation method and application thereof
CN109678796B (en) 2017-10-19 2023-01-10 上海长森药业有限公司 PD-1/PD-L1 small molecule inhibitor and preparation method and application thereof
CN109721527B (en) 2017-10-27 2024-03-12 广州丹康医药生物有限公司 Novel anti-PD-L1 compound, application thereof and composition containing same
CN111386265A (en) 2017-11-06 2020-07-07 朱比连特普罗德尔有限责任公司 Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
CN109956898B (en) 2017-12-22 2021-03-26 上海海雁医药科技有限公司 Immunomodulator, preparation method and medical application thereof
US11384048B2 (en) 2017-12-29 2022-07-12 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application
JP7214752B2 (en) 2018-01-23 2023-01-30 ブリストル－マイヤーズ スクイブ カンパニー 2,8-Diacyl-2,8-diazaspiro[5.5]undecane compounds useful as immunomodulators
CN111448189A (en) 2018-02-05 2020-07-24 上海和誉生物医药科技有限公司 Biaryl derivative, preparation method and pharmaceutical application thereof
TWI796596B (en) 2018-02-13 2023-03-21 美商基利科學股份有限公司 Pd-1/pd-l1 inhibitors
JP7326306B2 (en) 2018-03-01 2023-08-15 ブリストル－マイヤーズ スクイブ カンパニー Compounds Useful as Immunomodulators
BR112020018610A2 (en) 2018-03-13 2020-12-29 Jubilant Prodel LLC COMPOUNDS OF FORMULA I, FORMULA II, FORMULA III, FORMULA IV, FORMULA V, FORMULA VI, OR ITS POLYMORPHOS, STEREOISOMERS, TAUTOMERS, PROPHARMACES, SOLVATES AND PHARMACEUTICAL MALES OF THE MESOUSLY MESOUS MOSES; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; AND METHOD FOR THE TREATMENT AND / OR PREVENTION OF VARIOUS DISEASES, INCLUDING CANCER AND INFECTIOUS DISEASES
WO2019174533A1 (en) 2018-03-13 2019-09-19 广东东阳光药业有限公司 Small molecule pd-1/pd-l1 inhibitor and use thereof in drugs
FI3774791T3 (en) 2018-03-30 2023-03-21 Incyte Corp Heterocyclic compounds as immunomodulators
US20210040118A1 (en) 2018-04-03 2021-02-11 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN112752756A (en) 2018-05-11 2021-05-04 因赛特公司 Tetrahydro-imidazo [4,5-c ] pyridine derivatives as PD-L1 immunomodulators
WO2020011209A1 (en) 2018-07-11 2020-01-16 上海和誉生物医药科技有限公司 Immunosuppressive agent, preparation method therefor and pharmaceutical use thereof
US20220119411A1 (en) 2018-07-12 2022-04-21 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
KR20230159715A (en) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 inhibitors
WO2020015717A1 (en) 2018-07-19 2020-01-23 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
CN112566900B (en) 2018-07-19 2024-04-26 贝达药业股份有限公司 Immunomodulator, composition and preparation method thereof
US20210347785A1 (en) 2018-08-01 2021-11-11 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Preparation and application of aromatic compound having immunoregulatory function
CN109336857A (en) 2018-11-13 2019-02-15 南方医科大学 A kind of flavones and its application containing substituted biphenyl
CN109438263A (en) 2018-11-28 2019-03-08 南方医科大学 A kind of naphthalene and its application containing substituted biphenyl
CN109503546A (en) 2019-01-10 2019-03-22 南方医科大学 A kind of two methyl phenyl ethers anisole of resorcinol and its application
CN109776377B (en) 2019-02-01 2021-08-24 沈阳药科大学 Indoline compound and preparation method and application thereof
CN109776445B (en) 2019-03-28 2022-12-06 中国药科大学 Benzoxadiazole compound, preparation method and medical application thereof
CN110200959A (en) 2019-05-30 2019-09-06 天津科技大学 A kind of application of flavone compound
CN110128415B (en) 2019-05-31 2022-03-25 沈阳药科大学 Indoline compound used as immunomodulator and preparation method thereof
JP2022536845A (en) 2019-06-20 2022-08-19 ケモセントリックス，インコーポレイティド Compounds for treating PD-L1 diseases

Also Published As

Publication number Publication date
CN114340633A (en) 2022-04-12
US20200383979A1 (en) 2020-12-10
JP2022531970A (en) 2022-07-12
KR20220009420A (en) 2022-01-24
IL287843A (en) 2022-01-01
WO2020232256A1 (en) 2020-11-19
EP3968996A4 (en) 2022-12-28
MX2021013819A (en) 2022-02-10
SG11202112310TA (en) 2021-12-30
US20230044941A1 (en) 2023-02-09
BR112021022659A2 (en) 2022-03-29
AU2020276277A1 (en) 2021-12-09
MA55974A (en) 2022-03-23
EP3968996A1 (en) 2022-03-23
US11266643B2 (en) 2022-03-08

Similar Documents

Publication Publication Date Title
CA3139526A1 (en) Triaryl compounds for treatment of pd-l1 diseases
AU2017289038B2 (en) Immunomodulator compounds
AU2018313744C1 (en) Macrocyclic immunomodulators
US11485708B2 (en) Compounds for treatment of PD-L1 diseases
US11713307B2 (en) Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
US11866429B2 (en) Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220922

EEER Examination request

Effective date: 20220922

EEER Examination request

Effective date: 20220922

EEER Examination request

Effective date: 20220922

EEER Examination request

Effective date: 20220922

EEER Examination request

Effective date: 20220922